CORRECTED VERSION

(19) World Intellectual Property Organization

International Bureau

(43) International Publication Date 25 September 2003 (25.09.2003)





(10) International Publication Number WO 2003/078662 A1

(51) International Patent Classification: C12N 15/10 (2006.01) G01N 33/574 (2006.01) C12Q 1/68 (2006.01)

(21) International Application Number:

PCT/US2003/007713

(22) International Filing Date: 12 March 2003 (12.03.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/364,890 13 March 2002 (13.03.2002) US 60/412,049 18 September 2002 (18.09.2002) US

- (71) Applicant (for all designated States except US): GE-NOMIC HEALTH [US/US]; 301 Penobscot Drive, Redwood City, CA 94063 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BAKER, Joffre, B. [US/US]; P.O. Box 371212, Montara, CA 94937 (US). CRONIN, Maureen, T. [US/US]; 771 Anderson Drive, Los Altos, CA 94024 (US). KIEFER, Michael, C. [US/US]; 401 Wright Court, Clayton, CA 94517 (US). SHAK, Steve [US/US]; 1133 Cambridge Road, Burlingame, CA 94010 (US). WALKER, Michael, G. [US/US]; 1475 Flamingo Way, Sunnyvale, CA 94087 (US).

- (74) Agent: DREGER, Ginger, R.; Heller Ehrman White & McAuliffe, 275 Middlefield Road, Menlo Park, CA 94025-3506 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (48) Date of publication of this corrected version:

27 September 2007


(15) Information about Correction:

see PCT Gazette No. 39/2007 of 27 September 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES

(57) Abstract: The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. Th invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.



GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES

Background of the Invention

Cross-Reference

5

10

15

20

25

30

This application claims the benefit under 35 U.S.C. 119(h) of provisional applications serial nos. 60/412,049, filed September 18, 2002 and 60/364,890, filed March 13, 2002, the entire disclosures which are herby incorporated by reference.

Field of the Invention

The present invention relates to gene expression profiling in biopsied tumor tissues. In particular, the present invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. In addition, the invention provides a set of genes the expression of which is important in the diagnosis and treatment of breast cancer.

Oncologists have a number of treatment options available to them, including different combinations of chemotherapeutic drugs that are characterized as "standard of care," and a number of drugs that do not carry a label claim for a particular cancer, but for which there is evidence of efficacy in that cancer. Best likelihood of good treatment outcome requires that patients be assigned to optimal available cancer treatment, and that this assignment be made as quickly as possible following diagnosis.

Currently, diagnostic tests used in clinical practice are single analyte, and therefore do not capture the potential value of knowing relationships between dozens of different markers. Moreover, diagnostic tests are frequently not quantitative, relying on immunohistochemistry. This method often yields different results in different laboratories, in part because the reagents are not standardized, and in part because the interpretations are subjective and cannot be easily quantified. RNA-based tests have not often been used because of the problem of RNA degradation over time and the fact that it is difficult to obtain fresh tissue samples from patients for analysis. Fixed paraffin-embedded tissue is more readily available and methods have been established to detect RNA in fixed tissue. However, these methods typically do not allow for the study of large numbers of genes (DNA or RNA) from small amounts of material. Thus, traditionally fixed tissue has been rarely used other than for immunohistochemistry detection of proteins.

Recently, several groups have published studies concerning the classification of various cancer types by microarray gene expression analysis (see, e.g. Golub *et al.*, *Science* 286:531-537

SUBSTITUTE SHEET (RULE 26)

(1999); Bhattacharjae et al., Proc. Natl. Acad. Sci. USA 98:13790-13795 (2001); Chen-Hsiang et al., Bioinformatics 17 (Suppl. 1):S316-S322 (2001); Ramaswamy et al., Proc. Natl. Acad. Sci. USA 98:15149-15154 (2001)). Certain classifications of human breast cancers based on gene expression patterns have also been reported (Martin et al., Cancer Res. 60:2232-2238 (2000); West et al., Proc. Natl. Acad. Sci. USA 98:11462-11467 (2001); Sorlie et al., Proc. Natl. Acad. Sci. USA 98:10869-10874 (2001); Yan et al., Cancer Res. 61:8375-8380 (2001)). However, these studies mostly focus on improving and refining the already established classification of various types of cancer, including breast cancer, and generally do not provide new insights into the relationships of the differentially expressed genes, and do not link the findings to treatment strategies in order to improve the clinical outcome of cancer therapy.

5

10

15

20

25

30

Although modern molecular biology and biochemistry have revealed more than 100 genes whose activities influence the behavior of tumor cells, state of their differentiation, and their sensitivity or resistance to certain therapeutic drugs, with a few exceptions, the status of these genes has not been exploited for the purpose of routinely making clinical decisions about drug treatments. One notable exception is the use of estrogen receptor (ER) protein expression in breast carcinomas to select patients to treatment with anti-estrogen drugs, such as tamoxifen. Another exceptional example is the use of ErbB2 (Her2) protein expression in breast carcinomas to select patients with the Her2 antagonist drug Herceptin® (Genentech, Inc., South San Francisco, CA).

Despite recent advances, the challenge of cancer treatment remains to target specific treatment regimens to pathogenically distinct tumor types, and ultimately personalize tumor treatment in order to maximize outcome. Hence, a need exists for tests that simultaneously provide predictive information about patient responses to the variety of treatment options. This is particularly true for breast cancer, the biology of which is poorly understood. It is clear that the classification of breast cancer into a few subgroups, such as ErbB2⁺ subgroup, and subgroups characterized by low to absent gene expression of the estrogen receptor (ER) and a few additional transcriptional factors (Perou *et al.*, *Nature* 406:747-752 (2000)) does not reflect the cellular and molecular heterogeneity of breast cancer, and does not allow the design of treatment strategies maximizing patient response.

Summary of the Invention

The present invention provides (1) sensitive methods to measure mRNA levels in biopsied tumor tissue, (2) a set of approximately 190 genes, the expression of which is important in the diagnosis of breast cancer, and (3) the significance of abnormally low or high expression

for the genes identified and included in the gene set, through activation or disruption of biochemical regulatory pathways that influence patient response to particular drugs used or potentially useful in the treatment of breast cancer. These results permit assessment of genomic evidence of the efficacy of more than a dozen relevant drugs.

The present invention accommodates the use of archived paraffin-embedded biopsy material for assay of all markers in the set, and therefore is compatible with the most widely available type of biopsy material. The invention presents an efficient method for extraction of RNA from wax-embedded, fixed tissues, which reduces cost of mass production process for acquisition of this information without sacrificing quality of the analysis. In addition, the invention describes a novel highly effective method for amplifying mRNA copy number, which permits increased assay sensitivity and the ability to monitor expression of large numbers of different genes given the limited amounts of biopsy material. The invention also captures the predictive significance of relationships between expressions of certain markers in the breast cancer marker set. Finally, for each member of the gene set, the invention specifies the oligonucleotide sequences to be used in the test.

In one aspect, the invention concerns a method for predicting clinical outcome for a patient diagnosed with cancer, comprising

determining the expression level of one or more genes, or their expression products, selected from the group consisting of p53BP2, cathepsin B, cathepsin L, Ki67/MiB1, and thymidine kinase in a cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set,

wherein a poor outcome is predicted if:

5 ·

10

15

20

25

30

- (a) the expression level of p53BP2 is in the lower 10th percentile; or
- (b) the expression level of either cathepsin B or cathepsin L is in the upper 10th percentile; or
- (c) the expression level of any either Ki67/MiB1 or thymidine kinase is in the upper 10^{th} percentile.

Poor clinical outcome can be measured, for example, in terms of shortened survival or increased risk of cancer recurrence, e.g. following surgical removal of the cancer.

In another embodiment, the inventor concerns a method of predicting the likelihood of the recurrence of cancer, following treatment, in a cancer patient, comprising determining the expression level of p27, or its expression product, in a cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference

cancer tissue set, wherein an expression level in the upper 10th percentile indicates decreased risk of recurrence following treatment.

In another aspect, the invention concerns a method for classifying cancer comprising, determining the expression level of two or more genes selected from the group consisting of Bcl2, hepatocyte nuclear factor 3, ER, ErbB2, and Grb7, or their expression products, in a cancer tissue, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set, wherein (i) tumors expressing at least one of Bcl2, hepatocyte nuclear factor 3, and ER, or their expression products, above the mean expression level in the reference tissue set are classified as having a good prognosis for disease free and overall patient survival following treatment; and (ii) tumors expressing elevated levels of ErbB2 and Grb7, or their expression products, at levels ten-fold or more above the mean expression level in the reference tissue set are classified as having poor prognosis of disease free and overall patient survival following treatment.

5

10

15

20

25

30

All types of cancer are included, such as, for example, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer. The foregoing methods are particularly suitable for prognosis/classification of breast cancer.

In all previous aspects, in a specific embodiment, the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample. While all techniques of gene expression profiling, as well as proteomics techniques, are suitable for use in performing the foregoing aspects of the invention, the gene expression levels are often determined by reverse transcription polymerase chain reaction (RT-PCR).

If the source of the tissue is a formalin-fixed, paraffin embedded tissue sample, the RNA is often fragmented.

The expression data can be further subjected to multivariate analysis, for example using the Cox Proportional Hazards model.

In a further aspect, the invention concerns a method for the preparation of nucleic acid from a fixed, wax-embedded tissue specimen, comprising:

- (a) incubating a section of the fixed, wax-embedded tissue specimen at a temperature of about 56 °C to 70 °C in a lysis buffer, in the presence of a protease, without prior dewaxing, to form a lysis solution;
 - (b) cooling the lysis solution to a temperature where the wax solidifies; and
 - (c) isolating the nucleic acid from the lysis solution.

The lysis buffer may comprise urea, such as 4M urea.

15

20

25

30

In a particular embodiment, incubation in step (a) of the foregoing method is performed at about 65°C.

In another particular embodiment, the protease used in the foregoing method is proteinase 5 K.

In another embodiment, the cooling in step (b) is performed at room temperature.

In a further embodiment, the nucleic acid is isolated after protein removal with 2.5 M NH₄OAc.

The nucleic acid can, for example, be total nucleic acid present in the fixed, wax-10 embedded tissue specimen.

In yet another embodiment, the total nucleic acid is isolated by precipitation from the lysis solution, following protein removal, with 2.5 M NH₄OAc. The precipitation may, for example, be performed with isopropanol.

The method described above may further comprise the step of removing DNA from the total nucleic acid, for example by DNAse treatment.

The tissue specimen may, for example, be obtained from a tumor, and the RNA may be obtained from a microdissected portion of the tissue specimen enriched for tumor cells.

All types of tumor are included, such as, without limitation, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer, in particular breast cancer..

The method described above may further comprise the step of subjecting the RNA to gene expression profiling. Thus, the gene expression profile may be completed for a set of genes comprising at least two of the genes listed in Table 1.

Although all methods of gene expression profiling are contemplated, in a particular embodiment, gene expression profiling is performed by RT-PCR which may be preceded by an amplification step.

In another aspect, the invention concerns a method for preparing fragmented RNA for gene expression analysis, comprising the steps of:

- (a) mixing the RNA with at least one gene-specific, single-stranded DNA scaffold under conditions such that fragments of the RNA complementary to the DNA scaffold hybridize with the DNA scaffold;
- (b) extending the hybridized RNA fragments with a DNA polymerase to form a DNA-DNA duplex; and

(c) removing the DNA scaffold from the duplex.

5

10

15

20

25

. 30

In a specific embodiment, in step (b) of this method, the RNA may be mixed with a mixture of single-stranded DNA templates specific for each gene of interest.

The method can further comprise the step of heat-denaturing and reannealing the duplexed DNA to the DNA scaffold, with or without additional overlapping scaffolds, and further extending the duplexed sense strand with DNA polymerase prior to removal of the scaffold in step (c).

The DNA templates may be, but do not need to be, fully complementary to the gene of interest.

In a particular embodiment, at least one of the DNA templates is complementary to a specific segment of the gene of interest.

In another embodiment, the DNA templates include sequences complementary to polymorphic variants of the same gene.

The DNA template may include one or more dUTP or rNTP sites. In this case, iin step (c) the DNA template may be removed by fragmenting the DNA template present in the DNA-DNA duplex formed in step (b) at the dUTP or rNTP sites.

In an important embodiment, the RNA is extracted from fixed, wax-embedded tissue specimens, and purified sufficiently to act as a substrate in an enzyme assay. The RNA purification may, but does not need to, include an oligo-dT based step.

In a further aspect, the invention concerns a method for amplifying RNA fragments in a sample comprising fragmented RNA representing at least one gene of interest, comprising the steps of:

- (a) contacting the sample with a pool of single-stranded DNA scaffolds comprising an RNA polymerase promoter at the 5' end under conditions such that the RNA fragments complementary to the DNA scaffolds hybridize with the DNA scaffolds;
- (b) extending the hybridized RNA fragments with a DNA polymerase along the DNA scaffolds to form DNA-DNA duplexes;
 - (c) amplifying the gene or genes of interest by in vitro transcription; and
 - (d) removing the DNA scaffolds from the duplexes.

An exemplary promoter is the T7 RNA polymerase promoter, while an exemplary DNA polymerase is DNA polymerase I.

In step (d) the DNA scaffolds may be removed, for example, by treatment with DNase I.

In a further embodiment, the pool of single-stranded DNA scaffolds comprises partial or complete gene sequences of interest, such as a library of cDNA clones.

In a specific embodiment, the sample represents a whole genome or a fraction thereof. In a preferred embodiment, the genome is the human genome.

In another aspect, the invention concerns a method of preparing a personalized genomics profile for a patient, comprising the steps of:

(a) subjecting RNA extracted from a tissue obtained from the patient to gene expression analysis;

5

10

15

20

25

30

- (b) determining the expression level in such tissue of at least two genes selected from the gene set listed in Table 1, wherein the expression level is normalized against a control gene or genes, and is compared to the amount found in a cancer tissue reference set;
- (c) and creating a report summarizing the data obtained by the gene expression analysis.

The tissue obtained from the patient may, but does not have to, comprise cancer cells. Just as before, the cancer can, for example, be breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, or brain cancer, breast cancer being particularly preferred.

In a particular embodiment, the RNA is obtained from a microdissected portion of breast cancer tissue enriched for cancer cells. The control gene set may, for example, comprise S-actin, and ribosomal protein LPO.

The report prepared for the use of the patient or the patient's physician, may include the identification of at least one drug potentially beneficial in the treatment of the patient.

Step (b) of the foregoing method may comprise the step of determining the expression level of a gene specifically influencing cellular sensitivity to a drug, where the gene can, for example, be selected from the group consisting of aldehyde dehydrogenase 1A1, aldehyde dehydrogenase 1A3, amphiregulin, ARG, BRK, BCRP, CD9, CD31, CD82/KAI-1, COX2, c-abl, c-kit, c-kit L, CYP1B1, CYP2C9, DHFR, dihydropyrimidine dehydrogenase, EGF, epiregulin, ER-alpha, ErbB-1, ErbB-2, ErbB-3, ErbB-4, ER-beta, farnesyl pyrophosphate synthetase, gamma-GCS (glutamyl cysteine synthetase), GATA3, geranyl geranyl pyrophosphate synthetase, Grb7, GST-alpha, GST-pi, HB-EGF, hsp 27, human chorionic gonadotropin/CGA, IGF-1, IGF-2, IGF1R, KDR, LIV1, Lung Resistance Protein/MVP, Lot1, MDR-1, microsomal epoxide hydrolase, MMP9, MRP1, MRP2, MRP3, MRP4, PAI1, PDGF-A, PDGF-B, PDGF-C, PDGF-D, PGDFR-alpha, PDGFR-beta, PLAGa (pleiomorphic adenoma 1), PREP prolyl endopeptidase, progesterone receptor, pS2/trefoil factor 1, PTEN, PTB1b, RAR-alpha, RAR-beta2, Reduced

Folate Carrier, SXR, TGF-alpha, thymidine phosphorylase, thymidine synthase, topoisomerase II-alpha, topoisomerase II-beta, VEGF, XIST, and YB-1.

In another embodiment, step (b) of the foregoing process includes determining the expression level of multidrug resistance factors, such as, for example, gamma-glutamyl-cysteine synthetase (GCS), GST- α , GST- π , MDR-1, MRP1-4, breast cancer resistance protein (BCRP), lung cancer resistance protein (MVP), SXR, or YB-1.

5

10

15

20

25

30

In another embodiment, step (b) of the foregoing process comprises determination of the expression level of eukaryotic translation initiation factor 4E (EIF4E).

In yet another embodiment, step (b) of the foregoing process comprises determination of the expression level of a DNA repair enzyme.

In a further embodiment, step (b) of the foregoing process comprises determination of the expression level of a cell cycle regulator, such as, for example, c-MYC, c-Src, Cyclin D1, Ha-Ras, mdm2. p14ARF, p21WAF1/CI, p16INK4a/p14, p23, p27, p53, PI3K, PKC-epsilon, or PKC-delta.

In a still further embodiment, step (b) of the foregoing process comprises determination of the expression level of a tumor suppressor or a related protein, such as, for example, APC or Ecadherin.

In another embodiment, step (b) of the foregoing method comprises determination of the expression level of a gene regulating apoptosis, such as, for example, p53, BC12, Bcl-x1, Bak, Bax, and related factors, NFκ-B, CIAP1, CIAP2, survivin, and related factors, p53BP1/ASPP1, or p53BP2/ASPP2.

In yet another embodiment, step (b) of the foregoing process comprises determination of the expression level of a factor that controls cell invasion or angiogenesis, such as, for example, uPA, PAI1, cathepsin B, C, and L, scatter factor (HGF), c-met, KDR, VEGF, or CD31.

In a different embodiment, step (b) of the foregoing method comprises determination of the expression level of a marker for immune or inflammatory cells or processes, such as, for example, Ig light chain λ , CD18, CD3, CD68. Fas(CD95), or Fas Ligand.

In a further embodiment, step (b) of the foregoing process comprises determination of the expression level of a cell proliferation marker, such as, for example, Ki67/MiB1, PCNA, Pin1, or thymidine kinase.

In a still further embodiment, step (b) of the foregoing process comprises determination of the expression level of a growth factor or growth factor receptor., such as, for example, IGF1, IGF2, IGFBP3, IGF1R, FGF2, CSF-1, CSF-1R/fms, SCF-1, IL6 or IL8.

In another embodiment, step (b) of the foregoing process comprises determination of the expression level of a gene marker that defines a subclass of breast cancer, where the gene marker can, for example, be GRO1 oncogene alpha, Grb7, cytokeratins 5 and 17, retinol binding protein 4, hepatocyte nuclear factor 3, integrin subunit alpha 7, or lipoprotein lipase.

In a still further aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to 5-fluorouracil (5-FU) or an analog thereof, comprising the steps of:

5

10

20

25

30

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis;
- (b) determining the expression level in the tissue of thymidylate synthase mRNA, wherein the expression level is normalized against a control gene or genes, and is compared to the amount found in a reference breast cancer tissue set; and
- (c) predicting patient response based on the normalized thymidylate synthase mRNA level.
- Step (d) of the foregoing method can further comprise determining the expression level of dihydropyrimidine phosphorylase.

In another embodiment, step (b) of the method can further comprise determining the expression level of thymidine phosphorylase.

In yet another embodiment, a positive response to 5-FU or an analog thereof is predicted if: (i) normalized thymidylate synthase mRNA level determined in step (b) is at or below the 15th percentile; or (ii) the sum of normalized expression levels of thymidylate synthase and dihydropyrimidine phosphorylase determined in step (b) is at or below the 25th percentile; or (iii) the sum of normalized expression levels of thymidylate synthase, dihydropyrimidine phosphorylase, plus thymidine phosphorylase determined in step (b) is at or below the 20th percentile..

In a further embodiment, in step (b) of the foregoing method the expression level of c-myc and wild-type p53 is determined. In this case, a positive response to 5-FU or an analog thereof is predicted, if the normalized expression level of c-myc relative to the normalized expression level of wild-type p53 is in the upper 15th percentile.

In a still further embodiment, in step (b) of the foregoing method, expression level of NFκB and cIAP2 is determined. In this particular embodiment, resistance to 5-FU or an analog thereof is typically predicted if the normalized expression level of NFκB and cIAP2 is at or above the 10th percentile.

In another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to methotrexate or an analog thereof, comprising the steps of:

(a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and

5

10

15

20

25

30 -

(b) predicting decreased patient sensitivity to methotrexate or analog if (i) DHFR levels are more than tenfold higher than the average expression level of DHFR in the control gene set, or (ii) the normalized expression levels of members of the reduced folate carrier (RFC) family are below the 10th percentile.

In yet another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to an anthracycline or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting patient resistance or decreased sensitivity to the anthracycline or analog if (i) the normalized expression level of topoisomerase $II\alpha$ is below the 10^{th} percentile, or (ii) the normalized expression level of topoisomerase $II\beta$ is below the 10^{th} percentile, or (iii) the combined normalized topoisomerase $II\alpha$ or $II\beta$ expression levels are below the 10^{th} percentile.

In a different aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a docetaxol, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting reduced sensitivity to docetaxol if the normalized expression level of CYP1B1 is in the upper 10th percentile.

The invention further concerns a method for predicting the response of a patient diagnosed with breast cancer to cyclophosphamide or an analog thereof, comprising

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting reduced sensitivity to the cyclophosphamide or analog if the sum of the expression levels of aldehyde dehydrogenase 1A1 and 1A3 is more than tenfold higher than the average of their combined expression levels in the reference tissue set.

In a further aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to anti-estrogen therapy, comprising

(a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set that contains both specimens negative for and positive for estrogen receptor- α (ER α) and progesterone receptor- α (PR α); and

5

15

20

25

30

(b) predicting patient response based upon the normalized expression levels of ERα or PRα, and at least one of microsomal epoxide hydrolase, pS2/trefoil factor 1, GATA3 and
 10 human chorionic gonadotropin.

In a specific embodiment, lack of response or decreased responsiveness is predicted if (i) the normalized expression level of microsomal epoxide hydrolase is in the upper 10^{th} percentile; or (ii) the normalized expression level of pS2/trefoil factor 1, or GATA3 or human chorionic gonaostropin is at or below the corresponding average expression level in said breast cancer tissue set, regardless of the expression level of ER α or PR α in the breast cancer tissue obtained from the patient.

In another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a taxane, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting reduced sensitivity to taxane if (i) no or minimal XIST expression is detected; or (ii) the normalized expression level of GST- π or propyl endopeptidase (PREP) is in the upper 10th percentile; or (iii) the normalized expression level of PLAG1 is in the upper 10th percentile.

The invention also concerns a method for predicting the response of a patient diagnosed with breast cancer to cisplatin or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting resistance or reduced sensitivity if the normalized expression level of ERCC1 is in the upper 10th percentile.

The invention further concerns a method for predicting the response of a patient diagnosed with breast cancer to an ErbB2 or EGFR antagonist, comprising the steps of:

(a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and

(b) predicting patient response based on the normalized expression levels of at least one of Grb7, IGF1R, IGF1 and IGF2.

5

10

15

20

25

30

In particular embodiment, a positive response is predicted if the normalized expression level of Grb7 is in the upper 10th percentile, and the expression of IGF1R, IGF1 and IGF2 is not elevated above the 90th percentile.

In a further particular embodiment, a decreased responsiveness is predicted if the expression level of at least one of IGF1R, IGF1 and IGF2 is elevated.

In another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a bis-phosphonate drug, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response if the breast cancer tissue obtained from the patient expresses mutant Ha-Ras and additionally expresses farnesyl pyrophosphate synthetase or geranyl pyrophosphone synthetase at a normalized expression level at or above the 90th percentile.

In yet another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to treatment with a cyclooxygenase 2 inhibitor, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response if the normalized expression level of COX2 in the breast cancer tissue obtained from the patient is at or above the 90th percentile.

The invention further concerns a method for predicting the response of a patient diagnosed with breast cancer to an EGF receptor (EGFR) antagonist, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response to an EGFR antagonist, if (i) the normalized expression level of EGFR is at or above the 10th percentile, and (ii) the normalized expression

level of at least one of epiregulin, TGF- α , amphiregulin, ErbB3, BRK, CD9, MMP9, CD82, and Lot1 is above the 90^{th} percentile.

In another aspect, the invention concerns a method for monitoring the response of a patient diagnosed with breast cancer to treatment with an EGFR antagonist, comprising monitoring the expression level of a gene selected from the group consisting of epiregulin, TGF-α, amphiregulin, ErbB3, BRK, CD9, MMP9, CD82, and Lot1 in the patient during treatment, wherein reduction in the expression level is indicative of positive response to such treatment.

5

10

15

20

25

30

In yet another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a drug targeting a tyrosine kinase selected from the group consisting of abl, c-kit, PDGFR-α, PDGFR-β and ARG, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set;
- (b) determining the normalized expression level of a tyrosine kinase selected from the group consisting of abl, c-kit, PDGFR- α , PDGFR- β and ARG, and the cognate ligand of the tyrosine kinase, and if the normalized expression level of the tyrosine kinase is in the upper 10^{th} percentile,
- (c) determining whether the sequence of the tyrosine kinase contains any mutation, wherein a positive response is predicted if (i) the normalized expression level of the tyrosine kinase is in the upper 10th percentile, (ii) the sequence of the tyrosine kinase contains an activating mutation, or (iii) the normalized expression level of the tyrosine kinase is normal and the expression level of the ligand is in the upper 10th percentile.

Another aspect of the invention is a method for predicting the response of a patient diagnosed with breast cancer to treatment with an anti-angiogenic drug, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response if (i) the normalized expression level of VEGF is in the upper 10th percentile and (ii) the normalized expression level of KDR or CD31 is in the upper 20th percentile.

A further aspect of the invention is a method for predicting the likelihood that a patient diagnosed with breast cancer develops resistance to a drug interacting with the MRP-1 gene coding for the multidrug resistance protein P-glycoprotein, comprising the steps of:

(a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis to determine the expression level of PTP1b, wherein the expression level is normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and

(b) concluding that the patient is likely to develop resistance to said drug if the normalized expression level of the MRP-1 gene is above the 90th percentile.

5

10

15

20

25

30

The invention further relates to a method for predicting the likelihood that a patient diagnosed with breast cancer develops resistance to a chemotherapeutic drug or toxin used in cancer treatment, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) determining the normalized expression levels of at least one of the following genes: MDR1, SGT α , GST π , SXR, BCRP YB-1, and LRP/MVP, wherein the finding of a normalized expression level in the upper 4th percentile is an indication that the patient is likely to develop resistance to the drug.

Also included herein is a method for measuring the translational efficiency of VEGF mRNA in a breast cancer tissue sample, comprising determining the expression levels of the VEGF and EIF4E mRNA in the sample, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a higher normalized EIF4E expression level for the same VEGF expression level is indicative of relatively higher translational efficiency for VEGF.

In another aspect, the invention provides a method for predicting the response of a patient diagnosed with breast cancer to a VEGF antagonist, comprising determining the expression level of VEGF and EIF4E mRNA normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a VEGF expression level above the 90th percentile and an EIF4E expression level above the 50th percentile is a predictor of good patient response.

The invention further provides a method for predicting the likelihood of the recurrence of breast cancer in a patient diagnosed with breast cancer, comprising determining the ratio of p53:p21 mRNA expression or p53:mdm2 mRNA expression in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein an above normal ratio is indicative of a higher risk

of recurrence. Typically, a higher risk of recurrence is indicated if the ratio is in the upper 10th percentile.

In yet another aspect, the invention concerns a method for predicting the likelihood of the recurrence of breast cancer in a breast cancer patient following surgery, comprising determining the expression level of cyclin D1 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein an expression level in the upper 10th percentile indicates increased risk of recurrence following surgery. In a particular embodiment of this method, the patient is subjected to adjuvant chemotherapy, if the expression level is in the upper 10th percentile.

5

10

15

20

25

30

Another aspect of the invention is a method for predicting the likelihood of the recurrence of breast cancer in a breast cancer patient following surgery, comprising determining the expression level of APC or E-cadherin in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein an expression level in the upper 5th percentile indicates high risk of recurrence following surgery, and heightened risk of shortened survival.

A further aspect of the invention is a method for predicting the response of a patient diagnosed with breast cancer to treatment with a proapoptotic drug comprising determining the expression levels of BCl2 and c-MYC in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein (i) a BCl2 expression level in the upper 10th percentile in the absence of elevated expression of c-MYC indicates good response, and (ii) a good response is not indicated if the expression level c-MYC is elevated, regardless of the expression level of BCl2.

A still further aspect of the invention is a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) determining the normalized expression levels of NFkB and at least one gene selected from the group consisting of cIAP1, cIAP2, XIAP, and Survivin,

wherein a poor prognosis is indicated if the expression levels for NFκB and at least one of the genes selected from the group consisting of cIAP1, cIAP2, XIAP, and Survivin is in the upper 5th percentile.

The invention further concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of p53BP1 and p53BP2 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor outcome is predicted if the expression level of either p53BP1 or p53BP2 is in the lower 10th percentile.

5

10

15

20

25

30

The invention additionally concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of uPA and PAI1 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein (i) a poor outcome is predicted if the expression levels of uPA and PAI1 are in the upper 20th percentile, and (ii) a decreased risk of recurrence is predicted if the expression levels of uPA and PAI1 are not elevated above the mean observed in the breast cancer reference set. In a particular embodiment, poor outcome is measured in terms of shortened survival or increased risk of cancer recurrence following surgery. In another particular embodiment, uPA and PAI1 are expressed at normal levels, and the patient is subjected to adjuvant chemotherapy following surgery.

Another aspect of the invention is a method for predicting treatment outcome in a patient diagnosed with breast cancer, comprising determining the expression levels of cathepsin B and cathepsin L in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor outcome is predicted if the expression level of either cathepsin B or cathepsin L is in the upper 10th percentile. Just as before, poor treatment outcome may be measured, for example, in terms of shortened survival or increased risk of cancer recurrence.

A further aspect of the invention is a method for devising the treatment of a patient diagnosed with breast cancer, comprising the steps of

- (a) determining the expression levels of scatter factor and c-met in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, and
- (b) suggesting prompt aggressive chemotherapeutic treatment if the expression levels of scatter factor and c-met or the combination of both, are above the 90th percentile.

A still further aspect of the invention is a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of VEGF, CD31, and KDR in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein

a poor treatment outcome is predicted if the expression level of any of VEGF, CD31, and KDR is in the upper 10th percentile.

Yet another aspect of the invention is a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of Ki67/MiB1, PCNA, Pin1, and thymidine kinase in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor treatment outcome is predicted if the expression level of any of Ki67/MiB1, PCNA, Pin1, and thymidine kinase is in the upper 10th percentile.

5

10

15

20

25

30

The invention further concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression level of soluble and full length CD95 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein the presence of soluble CD95 correlates with poor patient survival.

The invention also concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of IGF1, IGF1R and IGFBP3 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor treatment outcome is predicted if the sum of the expression levels of IGF1, IGF1R and IGFBP3 is in the upper 10th percentile.

The invention additionally concerns a method for classifying breast cancer comprising, determining the expression level of two or more genes selected from the group consisting of Bcl12, hepatocyte nuclear factor 3, LIV1, ER, lipoprotein lipase, retinol binding protein 4, integrin α7, cytokeratin 5, cytokeratin 17, GRO oncogen, ErbB2 and Grb7, in a breast cancer tissue, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein (i) tumors expressing at least one of Bcl1, hepatocyte nuclear factor 3, LIV1, and ER above the mean expression level in the reference tissue set are classified as having a good prognosis for disease free and overall patient survival following surgical removal; (ii) tumors characterized by elevated expression of at least one of lipoprotein lipase, retinol binding protein 4, integrin α7 compared to the reference tissue set are classified as having intermediate prognosis of disease free and overall patient survival following surgical removal; and (iii) tumors expressing either elevated levels of cytokeratins 5 and 17, and GRO oncogen at levels four-fold or greater above the mean expression level in the reference tissue set, or ErbB2 and Grb7 at levels ten-fold or more above the mean expression level in the reference

tissue set are classified as having poor prognosis of disease free and overall patient survival following surgical removal.

Another aspect of the invention is a panel of two or more gene specific primers selected from the group consisting of the forward and reverse primers listed in Table 2.

5

10

15

20

25

30

Yet another aspect of the invention is a method for reverse transcription of a fragmented RNA population in RT-PCR amplification, comprising using a multiplicity of gene specific primers as the reverse primers in the amplification reaction. In a particular embodiment, the method uses between two and about 40,000 gene specific primers in the same amplification reaction. In another embodiment, the gene specific primers are about 18 to 24 bases, such as about 20 bases in length. In another embodiment, the Tm of the primers is about 58-60 °C. The primers can, for example, be selected from the group consisting of the forward and reverse primers listed in Table 2.

The invention also concerns a method of reverse transcriptase driven first strand cDNA synthesis, comprising using a gene specific primer of about 18 to 24 bases in length and having a Tm optimum between about 58 °C and about 60 °C. In a particular embodiment, the first strand cDNA synthesis is followed by PCR DNA amplification, and the primer serves as the reverse primer that drives the PCR amplification. In another embodiment, the method uses a plurality of gene specific primers in the same first strand cDNA synthesis reaction mixture. The number of the gene specific primers can, for example, be between 2 and about 40,000.

In a different aspect, the invention concerns a method of predicting the likelihood of long-term survival of a breast cancer patient without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising determining the expression level of one or more prognostic RNA transcripts or their product in a breast cancer tissue sample obtained from said patient, normalized against the expression level of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products, wherein the prognostic transcript is the transcript of one or more genes selected from the group consisting of: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, DIABLO, CDH1, HIF1α, IGFBP3, CTSB, and Her2, wherein overexpression of one or more of FOXM1, PRAME, STK15, Ki-67, CA9, NME1, SURV, TFRC, YB-1, RPS6KB1, Src, Chk1, CCNB1, Chk2, CDC25B, CYP3A4, EpCAM, VEGFC, hENT1, BRCA2, EGFR, TK1, VDR, EPHX1, IF1A, Contig51037, CDH1, HIF1α,

IGFBP3, CTSB, Her2, and pENT1 indicates a decreased likelihood of long-term survival without breast cancer recurrence, and the overexpression of one or more of Bcl2, CEGP1, GSTM1, PR, BBC3, GATA3, DPYD, GSTM3, ID1, EstR1, p27, XIAP, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, pS2, WISP1, HNF3A, NFKBp65, and DIABLO indicates an increased likelihood of long-term survival without breast cancer recurrence.

5

10

15

20

25

30

In a particular embodiment of this method, the expression level of at least 2, preferably at least 5, more preferably at least 10, most preferably at least 15 prognostic transcipts or their expression products is determined.

When the breast cancer is invasive breast carcinoma, including both estrogen receptor (ER) overexpressing (ER positive) and ER negative tumors, the analysis includes determination of the expression levels of the transcripts of at least two of the following genes, or their expression products: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, Src, CA9, Contig51037, RPS6K1 and Her2.

When the breast cancer is ER positive invasive breast carcinoma, the analysis includes dtermination of the expression levels of the transcripts of at least two of the following genes, or their expression products: PRAME, Bcl2, FOXM1, DIABLO, EPHX1, HIF1A, VEGFC, Ki-67, IGF1R, VDR, NME1, GSTM3, Contig51037, CDC25B, CTSB, p27, CDH1, and IGFBP3.

Just as before, it is preferred to determine the expression levels of at least 5, more preferably at least 10, most preferably at least 15 genes, or their respective expression products.

In a particular embodiment, the expression level of one or more prognostic RNA transcripts is determined, where RNA may, for example, be obtained from a fixed, wax-embedded breast cancer tissue specimen of the patient. The isolation of RNA can, for example, be carried out following any of the procedures described above or throughout the application, or by any other method known in the art.

In yet another aspect, the invention concerns an array comprising polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2, immobilized on a solid surface.

In a particular embodiment, the array comprosies polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, CDH1, HIF1 α , IGFBP3, CTSB, Her2 and DIABLO.

In a further aspect, the invention concerns a method of predicting the likelihood of longterm survival of a patient diagnosed with invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:

- (1) determining the expression levels of the RNA transcripts or the expression
 5 products of genes of a gene set selected from the group consisting of
 - (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
 - (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
 - (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
- 10 (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
 - (e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
 - (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
- 15 (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
 - (h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27,NFKBp65;
 - (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
 - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
 - (l) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
- 25 (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
- (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1,
 VEGFC; and
 - (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS

in a breast cancer tissue sample obtained from said patient, normalized against the expression levels of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products;

(2) subjecting the data obtained in step (a) to statistical analysis; and

5

10

20

(3) determining whether the likelihood of said long-term survival has increased or decreased.

In a still further aspect, the invention concerns a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-positive invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:

- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
- (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 15 (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
 - (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
- 25 (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - (i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
 - (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- 30 (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
 - (l) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
 - (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;

(n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;

- (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
- (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
- 5 (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
 - (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;
 - (t) VDR, Bel2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
- 10 (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
 - (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
 - (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
 - (x). FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
- 15 (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, EBXO5, CA9, CYP, KRT18; and
 - (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF;
 - (2) subjecting the data obtained in step (1) to statistical analysis; and
- 20 (3) determining whether the likelihood of said long-term survival has increased or decreased.

In a different aspect, the invention concerns an array comprising polynucleotides hybridizing to a gene set selected from the group consisting of:

- (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
- 25 (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
 - (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
 - (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
- 30 (e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
 - (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
 - (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;

(h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;

- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
- 5 (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
 - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
 - (l) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
 - (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
 - (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC; and
- 15 (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS,

immobilized on a solid surface.

10

25

In an additional aspect, the invention concerns an array comprising polynucleotides hybridizing to a gene set selected from the group consisting of:

- 20 (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2:
- 30 (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
 - (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;

(i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;

- (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
- (l) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
- 5 (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
 - (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
- 10 (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
 - (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
 - (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;
- 15 (t) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
 - (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
 - (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
 - (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
- 20 (x) FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
 - (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, FBXO5, CA9, CYP, KRT18; and
 - (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF,
- 25 immobilized on a solid surface.

30

In all aspects, the polynucleotides can be cDNAs ("cDNA arrays") that are typically about 500 to 5000 bases long, although shorter or longer cDNAs can also be used and are within the scope of this invention. Alternatively, the polynucleotides can be oligonucleotides (DNA microarrays), which are typically about 20 to 80 bases long, although shorter and longer oligonucleotides are also suitable and are within the scope of the invention. The solid surface can, for example, be glass or nylon, or any other solid surface typically used in preparing arrays, such as microarrays, and is typically glass.

Brief Description of the Drawings

Figure 1 is a chart illustrating the overall workflow of the process of the invention for measurement of gene expression. In the Figure, FPET stands for "fixed paraffin-embedded tissue," and "RT-PCR" stands for "reverse transcriptase PCR." RNA concentration is determined by using the commercial RiboGreen™ RNA Quantitation Reagent and Protocol.

Figure 2 is a flow chart showing the steps of an RNA extraction method according to the invention alongside a flow chart of a representative commercial method.

Figure 3 is a scheme illustrating the steps of an improved method for preparing fragmented mRNA for expression profiling analysis.

Figure 4 illustrates methods for amplification of RNA prior to RT-PCR.

Figure 5 illustrates an alternative scheme for repair and amplification of fragmented mRNA.

Figure 6 shows the measurement of estrogen receptor mRNA levels in 40 FPE breast cancer specimens via RT-PCR. Three 10 micron sections were used for each measurement. Each data point represents the average of triplicate measurements.

Figure 7 shows the results of the measurement of progesterone receptor mRNA levels in 40 FPE breast cancer specimens via RT-PCR performed as described in the legend of Figure 6 above.

Figure 8 shows results from an IVT/RT-PCR experiment.

Figure 9 is a representation of the expression of 92 genes across 70 FPE breast cancer specimens. The y-axis shows expression as cycle threshold times. These genes are a subset of the genes listed in Table 1.

Table 1 shows a breast cancer gene list.

Table 2 sets forth amplicon and primer sequences used for amplification of fragmented 25 mRNA.

Table 3 shows the Accession Nos. and SEQ ID NOS of the breast cance genes examined.

Detailed Description of the Preferred Embodiment

A. Definitions

5

10

15

20

30

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton *et al.*, Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY 1994), and March, Advanced Organic Chemistry Reactions, Mechanisms

and Structure 4th ed., John Wiley & Sons (New York, NY 1992), provide one skilled in the art with a general guide to many of the terms used in the present application.

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

5

10

15

20

25

30

The term "microarray" refers to an ordered arrangement of hybridizable array elements, preferably polynucleotide probes, on a substrate.

The term "polynucleotide," when used in singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. In addition, the term "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. The term "polynucleotide" specifically includes DNAs and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases, are included within the term "polynucleotides" as defined herein. In general, the term "polynucleotide" embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells.

The term "oligonucleotide" refers to a relatively short polynucleotide, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available. However, oligonucleotides can be made by a variety of other methods, including *in vitro* recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms.

5

10

15

20

.25

30

The terms "differentially expressed gene," "differential gene expression" and their synonyms, which are used interchangeably, refer to a gene whose expression is activated to a higher or lower level in a subject suffering from a disease, specifically cancer, such as breast cancer, relative to its expression in a normal or control subject. The terms also include genes whose expression is activated to a higher or lower level at different stages of the same disease. It is also understood that a differentially expressed gene may be either activated or inhibited at the nucleic acid level or protein level, or may be subject to alternative splicing to result in a different. polypeptide product. Such differences may be evidenced by a change in mRNA levels, surface expression, secretion or other partitioning of a polypeptide, for example. Differential gene expression may include a comparison of expression between two or more genes, or a comparison of the ratios of the expression between two or more genes, or even a comparison of two differently processed products of the same gene, which differ between normal subjects and subjects suffering from a disease, specifically cancer, or between various stages of the same disease. Differential expression includes both quantitative, as well as qualitative, differences in the temporal or cellular expression pattern in a gene or its expression products among, for example, normal and diseased cells, or among cells which have undergone different disease events or disease stages. For the purpose of this invention, "differential gene expression" is considered to be present when there is at least an about two-fold, preferably at least about fourfold, more preferably at least about six-fold, most preferably at least about ten-fold difference between the expression of a given gene in normal and diseased subjects, or in various stages of disease development in a diseased subject.

The phrase "gene amplification" refers to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line. The duplicated region (a stretch of amplified DNA) is often referred to as "amplicon." Usually, the amount of the messenger RNA (mRNA) produced, *i.e.*, the level of gene expression, also increases in the proportion of the number of copies made of the particular gene expressed.

The term "prognosis" is used herein to refer to the prediction of the likelihood of cancerattributable death or progression, including recurrence, metastatic spread, and drug resistance, of
a neoplastic disease, such as breast cancer. The term "prediction" is used herein to refer to the
likelihood that a patient will respond either favorably or unfavorably to a drug or set of drugs,
and also the extent of those responses. The predictive methods of the present invention can be
used clinically to make treatment decisions by choosing the most appropriate treatment
modalities for any particular patient. The predictive methods of the present invention are
valuable tools in predicting if a patient is likely to respond favorably to a treatment regimen, such

wightenings

as surgical intervention, chemotherapy with a given drug or drug combination, and/or radiation therapy.

The term "increased resistance" to a particular drug or treatment option, when used in accordance with the present invention, means decreased response to a standard dose of the drug or to a standard treatment protocol.

5

10

15

20

25

30

The term "decreased sensitivity" to a particular drug or treatment option, when used in accordance with the present invention, means decreased response to a standard dose of the drug or to a standard treatment protocol, where decreased response can be compensated for (at least partially) by increasing the dose of drug, or the intensity of treatment.

"Patient response" can be assessed using any endpoint indicating a benefit to the patient, including, without limitation, (1) inhibition, to some extent, of tumor growth, including slowing down and complete growth arrest; (2) reduction in the number of tumor cells; (3) reduction in tumor size; (4) inhibition (i.e., reduction, slowing down or complete stopping) of tumor cell infiltration into adjacent peripheral organs and/or tissues; (5) inhibition (i.e. reduction, slowing down or complete stopping) of metastasis; (6) enhancement of anti-tumor immune response, which may, but does not have to, result in the regression or rejection of the tumor; (7) relief, to some extent, of one or more symptoms associated with the tumor; (8) increase in the length of survival following treatment; and/or (9) decreased mortality at a given point of time following treatment.

The term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. In tumor (e.g., cancer) treatment, a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents, e.g., radiation and/or chemotherapy.

The term "tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.

The "pathology" of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnormal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.

5

10

15

20

-25

30

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., <u>Current Protocols in Molecular Biology</u>, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, typically: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x

Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

In the context of the present invention, reference to "at least one," "at least two," "at least five," etc. of the genes listed in any particular gene set means any one or any and all combinations of the genes listed.

The terms "splicing" and "RNA splicing" are used interchangeably and refer to RNA processing that removes introns and joins exons to produce mature mRNA with continuous coding sequence that moves into the cytoplasm of an eukaryotic cell.

In theory, the term "exon" refers to any segment of an interrupted gene that is represented in the mature RNA product (B. Lewin. *Genes IV* Cell Press, Cambridge Mass. 1990). In theory the term "intron" refers to any segment of DNA that is transcribed but removed from within the transcript by splicing together the exons on either side of it. Operationally, exon sequences occur in the mRNA sequence of a gene as defined by Ref. Seq ID numbers. Operationally, intron sequences are the intervening sequences within the genomic DNA of a gene, bracketed by exon sequences and having GT and AG splice consensus sequences at their 5' and 3' boundaries.

B. <u>Detailed Description</u>

5

10

15

20

25

30

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", 2nd edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology", 4th edition (D.M. Weir & C.C. Blackwell, eds., Blackwell Science Inc., 1987); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987); and "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994).

1. Gene Expression Profiling

In general, methods of gene expression profiling can be divided into two large groups: methods based on hybridization analysis of polynucleotides, and methods based on sequencing of polynucleotides. The most commonly used methods known in the art for the quantification of mRNA expression in a sample include northern blotting and *in situ* hybridization (Parker & Barnes, *Methods in Molecular Biology* 106:247-283 (1999)); RNAse protection assays (Hod,

Biotechniques 13:852-854 (1992)); and reverse transcription polymerase chain reaction (RT-PCR) (Weis et al., Trends in Genetics 8:263-264 (1992)). Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE), and gene expression analysis by massively parallel signature sequencing (MPSS).

2. Reverse Transcriptase PCR (RT-PCR)

5

10

15

20

25

30

Of the techniques listed above, the most sensitive and most flexible quantitative method is RT-PCR, which can be used to compare mRNA levels in different sample populations, in normal and tumor tissues, with or without drug treatment, to characterize patterns of gene expression, to discriminate between closely related mRNAs, and to analyze RNA structure.

The first step is the isolation of mRNA from a target sample. The starting material is typically total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines, respectively. Thus RNA can be isolated from a variety of primary tumors, including breast, lung, colon, prostate, brain, liver, kidney, pancreas, spleen, thymus, testis, ovary, uterus, etc., tumor, or tumor cell lines, with pooled DNA from healthy donors. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples.

General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., Current Protocols of Molecular Biology, John Wiley and Sons (1997). Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp and Locker, Lab Invest. 56:A67 (1987), and De Andrés et al., BioTechniques 18:42044 (1995). In particular, RNA isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns. Other commercially available RNA isolation kits include MasterPure™ Complete DNA and RNA Purification Kit (EPICENTRE®, Madison, WI), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumor can be isolated, for example, by cesium chloride density gradient centrifugation.

As RNA cannot serve as a template for PCR, the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction. The two most commonly used reverse transcriptases are avilo myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus

reverse transcriptase (MMLV-RT). The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, CA, USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.

5

10

15

20

25

30

Although the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5'-3' nuclease activity but lacks a 3'-5' proofreading endonuclease activity. Thus, TaqMan® PCR typically utilizes the 5'-nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5' nuclease activity can be used. Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.

TaqMan® RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700TM Sequence Detection SystemTM (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany). In a preferred embodiment, the 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700TM Sequence Detection SystemTM. The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

5'-Nuclease assay data are initially expressed as Ct, or the threshold cycle. As discussed above, fluorescence values are recorded during every cycle and represent the amount of product

amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (C₁).

To minimize errors and the effect of sample-to-sample variation, RT-PCR is usually performed using an internal standard. The ideal internal standard is expressed at a constant level among different tissues, and is unaffected by the experimental treatment. RNAs most frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and β-actin.

A more recent variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan® probe). Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. For further details see, e.g. Held *et al.*, *Genome Research* 6:986-994 (1996).

3. <u>Microarrays</u>

5

10

15

20

25

30

Differential gene expression can also be identified, or confirmed using the microarray technique. Thus, the expression profile of breast cancer-associated genes can be measured in either fresh or paraffin-embedded tumor tissue, using microarray technology. In this method, polynucleotide sequences of interest are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest. Just as in the RT-PCR method, the source of mRNA typically is total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of primary tumors or tumor cell lines. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.

In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA clones are applied to a substrate in a dense array. Preferably at least 10,000 nucleotide sequences are applied to the substrate. The microarrayed genes, immobilized on the microchip at 10,000 elements each, are suitable for hybridization under stringent conditions. Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed

element allows for assessment of corresponding mRNA abundance. With dual color fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93(2):106-149 (1996)). Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, or Incyte's microarray technology.

The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumor types.

4. <u>Serial Analysis of Gene Expression (SAGE)</u>

5

10

15

20

25

30

Serial analysis of gene expression (SAGE) is a method that allows the simultaneous and quantitative analysis of a large number of gene transcripts, without the need of providing an individual hybridization probe for each transcript. First, a short sequence tag (about 10-14 bp) is generated that contains sufficient information to uniquely identify a transcript, provided that the tag is obtained from a unique position within each transcript. Then, many transcripts are linked together to form long serial molecules, that can be sequenced, revealing the identity of the multiple tags simultaneously. The expression pattern of any population of transcripts can be quantitatively evaluated by determining the abundance of individual tags, and identifying the gene corresponding to each tag. For more details see, e.g. Velculescu *et al.*, *Science* 270:484-487 (1995); and Velculescu *et al.*, *Cell* 88:243-51 (1997).

5. Gene Expression Analysis by Massively Parallel Signature Sequencing (MPSS)

This method, described by Brenner et al., Nature Biotechnology 18:630-634 (2000), is a sequencing approach that combines non-gel-based signature sequencing with in vitro cloning of millions of templates on separate 5 µm diameter microbeads. First, a microbead library of DNA templates is constructed by in vitro cloning. This is followed by the assembly of a planar array of the template-containing microbeads in a flow cell at a high density (typically greater than 3 x 10⁶ microbeads/cm²). The free ends of the cloned templates on each microbead are analyzed simultaneously, using a fluorescence-based signature sequencing method that does not require DNA fragment separation. This method has been shown to simultaneously and accurately

provide, in a single operation, hundreds of thousands of gene signature sequences from a yeast cDNA library.

6. <u>General Description of the mRNA Isolation</u>, <u>Purification and Amplification</u> <u>Methods of the Invention</u>

5

10

15

20

25

30

The steps of a representative protocol of the invention, including mRNA isolation, purification, primer extension and amplification are illustrated in Figure 1. As shown in Figure 1, this representative process starts with cutting about 10 µm thick sections of paraffin-embedded tumor tissue samples. The RNA is then extracted, and protein and DNA are removed, following the method of the invention described below. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR. Finally, the data are analyzed to identify the best treatment option(s) available to the patient on the basis of the characteristic gene expression pattern identified in the tumor sample examined. The individual steps of this protocol will be discussed in greater detail below.

7. <u>Improved Method for Isolation of Nucleic Acid from Archived Tissue Specimens</u>

As discussed above, in the first step of the method of the invention, total RNA is extracted from the source material of interest, including fixed, paraffin-embedded tissue specimens, and purified sufficiently to act as a substrate in an enzyme assay. Despite the availability of commercial products, and the extensive knowledge available concerning the isolation of nucleic acid, such as RNA, from tissues, isolation of nucleic acid (RNA) from fixed, paraffin-embedded tissue specimens (FPET) is not without difficulty.

In one aspect, the present invention concerns an improved method for the isolation of nucleic acid from archived, e.g. FPET tissue specimens. Measured levels of mRNA species are useful for defining the physiological or pathological status of cells and tissues. RT-PCR (which is discussed above) is one of the most sensitive, reproducible and quantitative methods for this "gene expression profiling". Paraffin-embedded, formalin-fixed tissue is the most widely available material for such studies. Several laboratories have demonstrated that it is possible to successfully use fixed-paraffin-embedded tissue (FPET) as a source of RNA for RT-PCR (Stanta et al., Biotechniques 11:304-308 (1991); Stanta et al., Methods Mol. Biol. 86:23-26 (1998); Jackson et al., Lancet 1:1391 (1989); Jackson et al., J. Clin. Pathol. 43:499-504 (1999); Finke et al., Biotechniques 14:448-453 (1993); Goldsworthy et al., Mol. Carcinog. 25:86-91 (1999); Stanta and Bonin, Biotechniques 24:271-276 (1998); Godfrey et al., J. Mol. Diagnostics 2:84 (2000); Specht et al., J. Mol. Med. 78:B27 (2000); Specht et al., Am. J. Pathol. 158:419-429 (2001)). This allows gene expression profiling to be carried out on the most commonly available

source of human biopsy specimens, and therefore potentially to create new valuable diagnostic and therapeutic information.

The most widely used protocols utilize hazardous organic solvents, such as xylene, or octane (Finke et al., supra) to dewax the tissue in the paraffin blocks before nucleic acid (RNA and/or DNA) extraction. Obligatory organic solvent removal (e.g. with ethanol) and rehydration steps follow, which necessitate multiple manipulations, and addition of substantial total time to the protocol, which can take up to several days. Commercial kits and protocols for RNA extraction from FPET [MasterPure™ Complete DNA and RNA Purification Kit (EPICENTRE®, Madison, WI); Paraffin Block RNA Isolation Kit (Ambion, Inc.) and RNeasy™ Mini kit (Qiagen, Chatsworth, CA)] use xylene for deparaffinization, in procedures which typically require multiple centrifugations and ethanol buffer changes, and incubations following incubation with xylene.

5

10

15

20

25

30

The present invention provides an improved nucleic acid extraction protocol that produces nucleic acid, in particular RNA, sufficiently intact for gene expression measurements. The key step in the nucleic acid extraction protocol herein is the performance of dewaxing without the use of any organic solvent, thereby eliminating the need for multiple manipulations associated with the removal of the organic solvent, and substantially reducing the total time to the protocol. According to the invention, wax, e.g. paraffin is removed from wax-embedded tissue samples by incubation at 65-75 °C in a lysis buffer that solubilizes the tissue and hydrolyzes the protein, following by cooling to solidify the wax.

Figure 2 shows a flow chart of an RNA extraction protocol of the present invention in comparison with a representative commercial method, using xylene to remove wax. The times required for individual steps in the processes and for the overall processes are shown in the chart. As shown, the commercial process requires approximately 50% more time than the process of the invention.

The lysis buffer can be any buffer known for cell lysis. It is, however, preferred that oligo-dT-based methods of selectively purifying polyadenylated mRNA not be used to isolate RNA for the present invention, since the bulk of the mRNA molecules are expected to be fragmented and therefore will not have an intact polyadenylated tail, and will not be recovered or available for subsequent analytical assays. Otherwise, any number of standard nucleic acid purification schemes can be used. These include chaotrope and organic solvent extractions, extraction using glass beads or filters, salting out and precipitation based methods, or any of the purification methods known in the art to recover total RNA or total nucleic acids from a biological source.

Lysis buffers are commercially available, such as, for example, from Qiagen, Epicentre, or Ambion. A preferred group of lysis buffers typically contains urea, and Proteinase K or other protease. Proteinase K is very useful in the isolation of high quality, undamaged DNA or RNA, since most mammalian DNases and RNases are rapidly inactivated by this enzyme, especially in the presence of 0.5 - 1% sodium dodecyl sulfate (SDS). This is particularly important in the case of RNA, which is more susceptible to degradation than DNA. While DNases require metal ions for activity, and can therefore be easily inactivated by chelating agents, such as EDTA, there is no similar co-factor requirement for RNases.

Cooling and resultant solidification of the wax permits easy separation of the wax from the total nucleic acid, which can be conveniently precipitated, e.g. by isopropanol. Further processing depends on the intended purpose. If the proposed method of RNA analysis is subject to bias by contaminating DNA in an extract, the RNA extract can be further treated, e.g. by DNase, post purification to specifically remove DNA while preserving RNA. For example, if the goal is to isolate high quality RNA for subsequent RT-PCR amplification, nucleic acid precipitation is followed by the removal of DNA, usually by DNase treatment. However, DNA can be removed at various stages of nucleic acid isolation, by DNase or other techniques well known in the art.

10

15

20

25

30

While the advantages of the nucleic acid extraction protocol of the invention are most apparent for the isolation of RNA from archived, paraffin embedded tissue samples, the wax removal step of the present invention, which does not involve the use of an organic solvent, can also be included in any conventional protocol for the extraction of total nucleic acid (RNA and DNA) or DNA only. All of these aspects are specifically within the scope of the invention.

By using heat followed by cooling to remove paraffin, the process of the present invention saves valuable processing time, and eliminates a series of manipulations, thereby potentially increasing the yield of nucleic acid. Indeed, experimental evidence presented in the examples below, demonstrates that the method of the present invention does not compromise RNA yield.

8. <u>5'-multiplexed Gene Specific Priming of Reverse Transcription</u>

RT-PCR requires reverse transcription of the test RNA population as a first step. The most commonly used primer for reverse transcription is oligo-dT, which works well when RNA is intact. However, this primer will not be effective when RNA is highly fragmented as is the case in FPE tissues.

The present invention includes the use of gene specific primers, which are roughly 20 bases in length with a Tm optimum between about 58 °C and 60 °C. These primers will also serve as the reverse primers that drive PCR DNA amplification.

Another aspect of the invention is the inclusion of multiple gene-specific primers in the same reaction mixture. The number of such different primers can vary greatly and can be as low as two and as high as 40,000 or more. Table 2 displays examples of reverse primers that can be successfully used in carrying out the methods of the invention. Figure 9 shows expression data obtained using this multiplexed gene-specific priming strategy. Specifically, Figure 9 is a representation of the expression of 92 genes (a subset of genes listed in Table 1) across 70 FPE breast cancer specimens. The y-axis shows expression as cycle threshold times.

5

10

15

20

25

30

An alternative approach is based on the use of random hexamers as primers for cDNA synthesis. However, we have experimentally demonstrated that the method of using a multiplicity of gene-specific primers is superior over the known approach using random hexamers.

9. <u>Preparation of Fragmented mRNA for Expression Profiling Assays</u>

It is of interest to analyze the abundance of specific mRNA species in biological samples, since this expression profile provides an index of the physiological state of that sample. mRNA is notoriously difficult to extract and maintain in its native state, consequently, mRNA recovered from biological sources is often fragmented or somewhat degraded. This is especially true of human tissue specimen which have been chemically fixed and stored for extended periods of time.

In one aspect, the present invention provides a means of preparing the mRNA extracted from various sources, including archived tissue specimens, for expression profiling in a way that its relative abundance is preserved and the mRNA's of interest can be successfully measured. This method is useful as a means of preparing mRNA for analysis by any of the known expression profiling methods, including RT-PCR coupled with 5' exonuclease of reporter probes (TaqMan® type assays), as discussed above, flap endonuclease assays (Cleavase® and Invader® type assays), oligonucleotide hybridization arrays, cDNA hybridization arrays, oligonucleotide ligation assays, 3' single nucleotide extension assays and other assays designed to assess the abundance of specific mRNA sequences in a biological sample.

According to the method of the invention, total RNA is extracted from the source material and sufficiently purified to act as a substrate in an enzyme assay. The extraction procedure, including a new and improved way of removing the wax (e.g. paraffin) used for embedding the tissue samples, has been discussed above. It has also been noted that it is preferred that oligo-dT based methods of selectively purifying polyadenylated mRNA not be used to isolate RNA for this invention since the bulk of the mRNA is expected to be fragmented, will not be polyadenylated

5

10

15

. 20

25

30

and, therefore, will not be recovered and available for subsequent analytical assays if an oligo-dT based method is used.

A diagram of an improved method for repairing fragmented RNA is shown in Figure 3. The fragmented RNA purified from the tissue sample is mixed with universal or gene-specific, single-stranded, DNA templates for each mRNA species of interest. These templates may be full length DNA copies of the mRNA derived from cloned gene sources, they may be fragments of the gene representing only the segment of the gene to be assayed, they may be a series of long oligonucleotides representing either the full length gene or the specific segment(s) of interest. The template can represent either a single consensus sequence or be a mixture of polymorphic variants of the gene. This DNA template, or scaffold, will preferably include one or more dUTP or rNTP sites in its length. This will provide a means of removing the template prior to carrying out subsequent analytical steps to avoid its acting as a substrate or target in later analysis assays. This removal is accomplished by treating the sample with uracil-DNA glycosylase (UDG) and heating it to cause strand breaks where UDG has generated abasic sites. In the case of rNTP's, the sample can be heated in the presence of a basic buffer (pH ~10) to induce strand breaks where rNTP's are located in the template.

The single stranded DNA template is mixed with the purified RNA, the mixture is denatured and annealed so that the RNA fragments complementary to the DNA template effectively become primers that can be extended along the single stranded DNA templates. DNA polymerase I requires a primer for extension but will efficiently use either a DNA or an RNA primer. Therefore in the presence of DNA polymerase I and dNTP's, the fragmented RNA can be extended along the complementary DNA templates. In order to increase the efficiency of the extension, this reaction can be thermally cycled, allowing overlapping templates and extension products to hybridize and extend until the overall population of fragmented RNA becomes represented as double stranded DNA extended from RNA fragment primers.

Following the generation of this "repaired" RNA, the sample should be treated with UDG or heat-treated in a mildly based solution to fragment the DNA template (scaffold) and prevent it from participating in subsequent analytical reactions.

The product resulting from this enzyme extension can then be used as a template in a standard enzyme profiling assay that includes amplification and detectable signal generation such as fluorescent, chemiluminescent, colorimetric or other common read outs from enzyme based assays. For example, for TaqMan® type assays, this double stranded DNA product is added as the template in a standard assay; and, for array hybridization, this product acts as the cDNA

template for the cRNA labeling reaction typically used to generate single-stranded, labeled RNA for array hybridization.

This method of preparing template has the advantage of recovering information from mRNA fragments too short to effectively act as templates in standard cDNA generation schemes. In addition, this method acts to preserve the specific locations in mRNA sequences targeted by specific analysis assays. For example, TaqMan® assays rely on a single contiguous sequence in a cDNA copy of mRNA to act as a PCR amplification template targeted by a labeled reporter probe. If mRNA strand breaks occur in this sequence, the assay will not detect that template and will underestimate the quantity of that mRNA in the original sample. This target preparation method minimizes that effect from RNA fragmentation.

The extension product formed in the RNA primer extension assay can be controlled by controlling the input quantity of the single stranded DNA template and by doing limited cycling of the extension reaction. This is important in preserving the relative abundance of the mRNA sequences targeted for analysis.

This method has the added advantage of not requiring parallel preparation for each target sequence since it is easily multiplexed. It is also possible to use large pools of random sequence long oligonucleotides or full libraries of cloned sequences to extend the entire population of mRNA sequences in the sample extract for whole expressed genome analysis rather than targeted gene specific analysis.

10. <u>Amplification of mRNA Species Prior to RT-PCR</u>

5

10

15

20

25

30

Due to the limited amount and poor quality of mRNA that can be isolated from FPET, a new procedure that could accurately amplify mRNAs of interest would be very useful, particularly for real time quantitation of gene expression (TaqMan®) and especially for quantitatively large number (>50) of genes >50 to 10,000.

Current protocols (e.g. Eberwine, *Biotechniques* 20:584-91 (1996)) are optimized for mRNA amplification from small amount of total or poly A⁺ RNA mainly for microarray analysis. The present invention provides a protocol optimized for amplification of small amounts of fragmented total RNA (average size about 60-150 bps), utilizing gene-specific sequences as primers, as illustrated in Figure 4.

The amplification procedure of the invention uses a very large number, typically as many as 100 - 190,000 gene specific primers (GSP's) in one reverse transcription run. Each GSP contains an RNA polymerase promoter, e.g. a T7 DNA-dependent RNA polymerase promoter, at the 5' end for subsequent RNA amplification. GSP's are preferred as primers because of the small size of the RNA. Current protocols utilize dT primers, which would not adequately

represent all reverse transcripts of mRNAs due to the small size of the FPET RNA. GSP's can be designed by optimizing usual parameters, such as length, Tm, etc. For example, GSP's can be designed using the Primer Express® (Applied Biosystems), or Primer 3 (MIT) software program. Typically at least 3 sets per gene are designed, and the ones giving the lowest Ct on FPET RNA (best performers) are selected.

5

10

20

25

30

Second strand cDNA synthesis is performed by standard procedures (see Figure 4, Method 1), or by GSP_f primers and Taq pol under PCR conditions (e.g., 95 °C, 10 min (Taq activation) then 60 °C, 45 sec). The advantages of the latter method are that the second gene specific primer, SGF_f adds additional specificity (and potentially more efficient second strand synthesis) and the option of performing several cycles of PCR, if more starting DNA is necessary for RNA amplification by T7 RNA polymerase. RNA amplification is then performed under standard conditions to generate multiple copies of cRNA, which is then used in a standard TaqMan® reaction.

Although this process is illustrated by using T7-based RNA amplification, a person skilled in the art will understand that other RNA polymerase promoters that do not require a primer, such as T3 or Sp6 can also be used, and are within the scope of the invention.

11. <u>A method of Elongation of Fragmented RNA and Subsequent Amplification</u>

This method, which combines and modifies the inventions described in sections 9 and 10 above, is illustrated in Figure 5. The procedure begins with elongation of fragmented mRNA. This occurs as described above except that the scaffold DNAs are tagged with the T7 RNA polymerase promoter sequence at their 5' ends, leading to double-stranded DNA extended from RNA fragments. The template sequences need to be removed after *in vitro* transcription. These templates can include dUTP or rNTP nucleotides, enabling enzymatic removal of the templates as described in section 9, or the templates can be removed by DNaseI treatment.

The template DNA can be a population representing different mRNAs of any number. A high sequence complexity source of DNA templates (scaffolds) can be generated by pooling RNA from a variety of cells or tissues. In one embodiment, these RNAs are converted into double stranded DNA and cloned into phagemids. Single stranded DNA can then be rescued by phagemid growth and single stranded DNA isolation from purified phagemids.

This invention is useful because it increases gene expression profile signals two different ways: both by increasing test mRNA polynucleotide sequence length and by *in vitro* transcription amplification. An additional advantage is that it eliminates the need to carry out reverse transcription optimization with gene specific primers tagged with the T7 RNA polymerase promoter sequence, and thus, is comparatively fast and economical.

This invention can be used with a variety of different methods to profile gene expression, e.g., RT-PCR or a variety of DNA array methods. Just as in the previous protocol, this approach is illustrated by using a T7 promoter but the invention is not so limited. A person skilled in the art will appreciate, however, that other RNA polymerase promoters, such as T3 or Sp6 can also be used.

12. <u>Breast Cancer Gene Set, Assayed Gene Subsequences, and Clinical Application of Gene Expression Data</u>

_.5

10

15

20

25

30

An important aspect of the present invention is to use the measured expression of certain genes by breast cancer tissue to match patients to best drugs or drug combinations, and to provide prognostic information. For this purpose it is necessary to correct for (normalize away) both differences in the amount of RNA assayed and variability in the quality of the RNA used. Therefore, the assay measures and incorporates the expression of certain normalizing genes, including well known housekeeping genes, such as GAPDH and Cyp1. Alternatively. normalization can be based on the mean or median signal (Ct) of all of the assayed genes or a large subset thereof (global normalization approach). On a gene-by-gene basis, measured normalized amount of a patient tumor mRNA is compared to the amount found in a breast cancer tissue reference set. The number (N) of breast cancer tissues in this reference set should be sufficiently high to ensure that different reference sets (as a whole) behave essentially the same way. If this condition is met, the identity of the individual breast cancer tissues present in a particular set will have no significant impact on the relative amounts of the genes assayed. Usually, the breast cancer tissue reference set consists of at least about 30, preferably at least about 40 different FPE breast cancer tissue specimens. Unless noted otherwise, normalized expression levels for each mRNA/tested tumor/patient will be expressed as a percentage of the expression level measured in the reference set. More specifically, the reference set of a sufficiently high number (e.g. 40) tumors yields a distribution of normalized levels of each mRNA species. The level measured in a particular tumor sample to be analyzed falls at some percentile within this range, which can be determined by methods well known in the art. Below, unless noted otherwise, reference to expression levels of a gene assume normalized expression relative to the reference set although this is not always explicitly stated.

The breast cancer gene set is shown in Table 1. The gene Accession Numbers, and the SEQ ID NOs for the forward primer, reverse primer and amplicon sequences that can be used for gene amplification, are listed in Table 2. The basis for inclusion of markers, as well as the clinical significance of mRNA level variations with respect to the reference set, is indicated below. Genes are grouped into subsets based on the type of clinical significance indicated by

their expression levels: A. Prediction of patient response to drugs used in breast cancer treatment, or to drugs that are approved for other indications and could be used off-label in the treatment of breast cancer. B. Prognostic for survival or recurrence of cancer.

C. <u>Prediction of Patient Response to Therapeutic Drugs</u>

5

10

15

20

25

30

1. Molecules that specifically influence cellular sensitivity to drugs

Table 1 lists 74 genes (shown in italics) that specifically influence cellular sensitivity to potent drugs, which are also listed. Most of the drugs shown are approved and already used to treat breast cancer (e.g., anthracyclines; cyclophosphamide; methotrexate; 5-FU and analogues). Several of the drugs are used to treat breast cancer off-label or are in clinical development phase (e.g., bisphosphonates and anti-VEGF mAb). Several of the drugs have not been widely used to treat breast cancer but are used in other cancers in which the indicated target is expressed (e.g., Celebrex is used to treat familial colon cancer; cisplatin is used to treat ovarian and other cancers.)

Patient response to 5FU is indicated if normalized thymidylate synthase mRNA amount is at or below the 15th percentile, or the sum of expression of thymidylate synthase plus dihydropyrimidine phosphorylase is at or below the 25th percentile, or the sum of expression of these mRNAs plus thymidine phosphorylase is at or below the 20th percentile. Patients with dihydropyrimidine dehydrogenase below 5th percentile are at risk of adverse response to 5FU, or analogs such as Xeloda.

When levels of thymidylate synthase, and dihydropyrimidine dehydrogenase, are within the acceptable range as defined in the preceding paragraph, amplification of c-myc mRNA in the upper 15%, against a background of wild-type p53 [as defined below] predicts a beneficial response to 5FU (see D. Arango *et al.*, *Cancer Res.* 61:4910-4915 (2001)). In the presence of normal levels of thymidylate synthase and dihydropyrimidine dehydrogenase, levels of NFkB and cIAP2 in the upper 10% indicate resistance of breast tumors to the chemotherapeutic drug 5FU.

Patient resistance to anthracyclines is indicated if the normalized mRNA level of topoisomerase II α is below the 10^{th} percentile, or if the topoisomerase II β normalized mRNA level is below the 10^{th} percentile or if the combined normalized topoisomerase II α and β signals are below the 10^{th} percentile.

Patient sensitivity to methotrexate is compromised if DHFR levels are more than tenfold higher than the average reference set level for this mRNA species, or if reduced folate carrier levels are below 10th percentile.

Patients whose tumors express CYP1B1 in the upper 10%, have reduced likelihood of responding to docetaxol.

The sum of signals for aldehyde dehydrogenase 1A1 and 1A3, when more than tenfold higher than the reference set average, indicates reduced likelihood of response to cyclophosphamide.

5 .

10

15

20

25

30

Currently, estrogen and progesterone receptor expression as measured by immunohistochemistry is used to select patients for anti-estrogen therapy. We have demonstrated RT-PCR assays for estrogen and progesterone receptor mRNA levels that predict levels of these proteins as determined by a standard clinical diagnostic tests, with high degree of concordance (Figures 6 and 7).

Patients whose tumors express ER α or PR mRNA in the upper 70%, are likely to respond to tamoxifen or other anti-estrogens (thus, operationally, lower levels of ER α than this are to defined ER α -negative). However, when the signal for microsomal epoxide hydrolase is in the upper 10% or when mRNAs for pS2/trefoil factor, GATA3 or human chorionic gonadotropin are at or below average levels found in ER α -negative tumors, anti-estrogen therapy will not be beneficial.

Absence of XIST signal compromises the likelihood of response to taxanes, as does elevation of the GST- π or prolyl endopeptidase [PREP] signal in the upper 10%. Elevation of PLAG1 in the upper 10% decreases sensitivity to taxanes.

Expression of ERCC1 mRNA in the upper 10% indicate significant risk of resistance to cisplatin or analogs.

An RT-PCR assay of Her2 mRNA expression predicts Her2 overexpression as measured by a standard diagnostic test, with high degree of concordance (data not shown). Patients whose tumors express Her2 (normalized to cyp.1) in the upper 10% have increased likelihood of beneficial response to treatment with Herceptin or other ErbB2 antagonists. Measurement of expression of Grb7 mRNA serves as a test for HER2 gene amplification, because the Grb7 gene is closely linked to Her2. When Her2 is expression is high as defined above in this paragraph, similarly elevated Grb7 indicates Her2 gene amplification. Overexpression of IGF1R and or IGF1 or IGF2 decreases likelihood of beneficial response to Herceptin and also to EGFR antagonists.

Patients whose tumors express mutant Ha-Ras, and also express farnesyl pyrophosphate synthetase or geranyl pyrophosphonate synthetase mRNAs at levels above the tenth percentile comprise a group that is especially likely to exhibit a beneficial response to bis-phosphonate drugs.

Cox2 is a key control enzyme in the synthesis of prostaglandins. It is frequently expressed at elevated levels in subsets of various types of carcinomas including carcinoma of the breast. Expression of this gene is controlled at the transcriptional level, so RT-PCR serves a valid indicator of the cellular enzyme activity. Nonclinical research has shown that cox2 promotes tumor angiogenesis, suggesting that this enzyme is a promising drug target in solid tumors. Several Cox2 antagonists are marketed products for use in anti-inflammatory conditions. Treatment of familial adenomatous polyposis patients with the cox2 inhibitor Celebrex significantly decreased the number and size of neoplastic polyps. No cox2 inhibitor has yet been approved for treatment of breast cancer, but generally this class of drugs is safe and could be prescribed off-label in breast cancers in which cox2 is over-expressed. Tumors expressing COX2 at levels in the upper ten percentile have increased chance of beneficial response to Celebrex or other cyclooxygenase 2 inhibitors.

5

10

15

20

25

30

The tyrosine kinases ErbB1 [EGFR], ErbB3 [Her3] and ErbB4 [Her4]; also the ligands TGFalpha, amphiregulin, heparin-binding EGF-like growth factor, and epiregulin; also BRK, a non-receptor kinase. Several drugs in clinical development block the EGF receptor. ErbB2-4, the indicated ligands, and BRK also increase the activity of the EGFR pathway. Breast cancer patients whose tumors express high levels of EGFR or EGFR and abnormally high levels of the other indicated activators of the EGFR pathway are potential candidates for treatment with an EGFR antagonist.

Patients whose tumors express less than 10% of the average level of EGFR mRNA observed in the reference panel are relatively less likely to respond to EGFR antagonists [such as Iressa, or ImClone 225]. In cases in which the EGFR is above this low range, the additional presence of epiregulin, TGFα, amphiregulin, or ErbB3, or BRK, CD9, MMP9, or Lot1 at levels above the 90th percentile predisposes to response to EGFR antagonists. Epiregulin gene expression, in particular, is a good surrogate marker for EGFR activation, and can be used to not only to predict response to EGFR antagonists, but also to monitor response to EGFR antagonists [taking fine needle biopsies to provide tumor tissue during treatment]. Levels of CD82 above the 90th percentile suggest poorer efficacy from EGFR antagonists.

The tyrosine kinases abl, c-kit, PDGFRalpha, PDGFbeta, and ARG; also, the signal transmitting ligands c-kit ligand, PDGFA, B, C and D. The listed tyrosine kinases are all targets of the drug Gleevec[™] (imatinib mesylate, Novartis), and the listed ligands stimulate one or more of the listed tyrosine kinases. In the two indications for which Gleevec[™] is approved, tyrosine kinase targets (bcr-abl and ckit) are overexpressed and also contain activating mutations. A finding that one of the Gleevec[™] target tyrosine kinase targets is expressed in breast cancer tissue

will prompt a second stage of analysis wherein the gene will be sequenced to determine whether it is mutated. That a mutation found is an activating mutation can be proved by methods known in the art, such as, for example, by measuring kinase enzyme activity or by measuring phosphorylation status of the particular kinase, relative to the corresponding wild-type kinase. Breast cancer patients whose tumors express high levels of mRNAs encoding GleevecTM target tyrosine kinases, specifically, in the upper ten percentile, or mRNAs for GleevecTM target tyrosine kinases in the average range and mRNAs for their cognate growth stimulating ligands in the upper ten percentile, are particularly good candidates for treatment with GleevecTM.

VEGF is a potent and pathologically important angiogenic factor. (See below under Prognostic Indicators.) When VEGF mRNA levels are in the upper ten percentile, aggressive treatment is warranted. Such levels particularly suggest the value of treatment with anti-angiogenic drugs, including VEGF antagonists, such as anti-VEGF antibodies. Additionally, KDR or CD31 mRNA level in the upper 20 percentile further increases likelihood of benefit from VEGF antagonists.

Farnesyl pyrophosphatase synthetase and geranyl geranyl pyrophosphatase synthetase. These enzymes are targets of commercialized bisphosphonate drugs, which were developed originally for treatment of osteoporosis but recently have begun to prescribe them off-label in breast cancer. Elevated levels of mRNAs encoding these enzymes in breast cancer tissue, above the 90th percentile, suggest use of bisphosphonates as a treatment option.

2. <u>Multidrug Resistance Factors</u>

5

10

15

20

25

30

These factors include 10 Genes: gamma glutamyl cysteine synthetase [GCS]; GST-α; GST-π; MDR-1; MRP1-4; breast cancer resistance protein [BCRP]; lung resistance protein [MVP]; SXR; YB-1.

GCS and both GST- α and GST- π regulate glutathione levels, which decrease cellular sensitivity to chemotherapeutic drugs and other toxins by reductive derivatization. Glutathione is a necessary cofactor for multi-drug resistant pumps, MDR-1 and the MRPs. MDR1 and MRPs function to actively transport out of cells several important chemotherapeutic drugs used in breast cancer.

GSTs, MDR-1, and MRP-1 have all been studied extensively to determine possible have prognostic or predictive significance in human cancer. However, a great deal of disagreement exists in the literature with respect to these questions. Recently, new members of the MRP family have been identified: MRP-2, MRP-3, MRP-4, BCRP, and lung resistance protein [major vault protein]. These have substrate specificities that overlap with those of MDR-1 and MRP-1. The incorporation of all of these relevant ABC family members as well as glutathione synthetic

enzymes into the present invention captures the contribution of this family to drug resistance, in a way that single or double analyte assays cannot.

MRP-1, the gene coding for the multidrug resistance protein.

5

10

15

20

25

30

P-glycoprotein, is not regulated primarily at the transcriptional level. However, p-glycoprotein stimulates the transcription of PTP1b. An embodiment of the present invention is the use of the level of the mRNA for the phosphatase PTP1b as a surrogate measure of MRP-1/p-glycoprotein activity.

The gene SXR is also an activator of multidrug resistance, as it stimulates transcription of certain multidrug resistance factors.

The impact of multidrug resistance factors with respect to chemotherapeutic agents used in breast cancer is as follows. Beneficial response to doxorubicin is compromised when the mRNA levels of either MDR1, GST α , GST π , SXR, BCRP YB-1, or LRP/MVP are in the upper four percentile. Beneficial response to methotrexate is inhibited if mRNA levels of any of MRP1, MRP2, MRP3, or MRP4 or gamma-glutamyl cysteine synthetase are in the upper four percentile.

3. <u>Eukaryotic Translation Initiation Factor 4E [EIF4E]</u>

EIF4E mRNA levels provides evidence of protein expression and so expands the capability of RT-PCR to indicate variation in gene expression. Thus, one claim of the present invention is the use of EIF4E as an added indicator of gene expression of certain genes [e.g., cyclinD1, mdm2, VEGF, and others]. For example, in two tissue specimens containing the same amount of normalized VEGF mRNA, it is likely that the tissue containing the higher normalized level of EIF4E exhibits the greater level of VEGF gene expression.

The background is as follows. A key point in the regulation of mRNA translation is selection of mRNAs by the EIF4G complex to bind to the 43S ribosomal subunit. The protein EIF4E [the m7G CAP-binding protein] is often limiting because more mRNAs than EIF4E copies exist in cells. Highly structured 5'UTRs or highly GC-rich ones are inefficiently translated, and these often code for genes that carry out functions relevant to cancer [e.g., cyclinD1, mdm2, and VEGF]. EIF4E is itself regulated at the transcriptional/ mRNA level. Thus, expression of EIF4E provides added indication of increased activity of a number of proteins.

It is also noteworthy that overexpression of EIF4E transforms cultured cells, and hence is an oncogene. Overexpression of EIF4E occurs in several different types of carcinomas but is particularly significant in breast cancer. EIF4E is typically expressed at very low levels in normal breast tissue.

D. <u>Prognostic Indicators</u>

1. <u>DNA Repair Enzymes</u>

Loss of BRCA1 or BRCA2 activity via mutation represents the critical oncogenic step in the most common type[s] of familial breast cancer. The levels of mRNAs of these important enzymes are abnormal in subsets of sporadic breast cancer as well. Loss of signals from either [to within the lower ten percentile] heightens risk of short survival.

2. <u>Cell Cycle Regulators</u>

5

10

15

20

25

30

Cell cycle regulators include 14 genes: c-MYC; c-Src; Cyclin D1; Ha-Ras; mdm2; p14ARF; p21WAF1/CIP; p16INK4a/p14; p23; p27; p53; PI3K; PKC-epsilon; PKC-delta.

The gene for p53 [TP53] is mutated in a large fraction of breast cancers. Frequently p53 levels are elevated when loss of function mutation occurs. When the mutation is dominant-negative, it creates survival value for the cancer cell because growth is promoted and apoptosis is inhibited. Thousands of different p53 mutations have been found in human cancer, and the functional consequences of many of them are not clear. A large body of academic literature addresses the prognostic and predictive significance of mutated p53 and the results are highly conflicting. The present invention provides a functional genomic measure of p53 activity, as follows. The activated wild type p53 molecule triggers transcription of the cell cycle inhibitor p21. Thus, the ratio of p53 to p21 should be low when p53 is wild-type and activated. When p53 is detectable and the ratio of p53 to p21 is elevated in tumors relative to normal breast, it signifies nonfunctional or dominant negative p53. The cancer literature provides evidence for this as born out by poor prognosis.

Mdm2 is an important p53 regulator. Activated wildtype p53 stimulates transcription of mdm2. The mdm2 protein binds p53 and promotes its proteolytic destruction. Thus, abnormally low levels of mdm2 in the presence of normal or higher levels of p53 indicate that p53 is mutated and inactivated.

One aspect of the present invention is the use of ratios of mRNAs levels p53:p21 and p53:mdm2 to provide a picture of p53 status. Evidence for dominant negative mutation of p53 (as indicated by high p53:p21 and/or high p53:mdm2 mRNA ratios—specifically in the upper ten percentile) presages higher risk of recurrence in breast cancer and therefore weights toward a decision to use chemotherapy in node negative post surgery breast cancer.

Another important cell cycle regulator is p27, which in the activated form blocks cell cycle progression at the level of cdk4. The protein is regulated primarily via phosphorylation/dephosphorylation, rather than at the transcriptional level. However, levels of

p27 mRNAs do vary. Therefore a level of p27 mRNA in the upper ten percentile indicates reduced risk of recurrence of breast cancer post surgery.

Cyclin D1 is a principle positive regulator of entry into S phase of the cell cycle. The gene for cyclin D1 is amplified in about 20% of breast cancer patients, and therefore promotes tumor promotes tumor growth in those cases. One aspect of the present invention is use of cyclin D1 mRNA levels for diagnostic purposes in breast cancer. A level of cyclin D1 mRNA in the upper ten percentile suggests high risk of recurrence in breast cancer following surgery and suggests particular benefit of adjuvant chemotherapy.

3. Other tumor suppressors and related proteins

These include APC and E-cadherin. It has long been known that the tumor suppressor APC is lost in about 50% of colon cancers, with concomitant transcriptional upregulation of E-cadherin, an important cell adhesion molecule and growth suppressor. Recently, it has been found that the APC gene silenced in 15-40 % of breast cancers. Likewise, the E-cadherin gene is silenced [via CpG island methylation] in about 30% of breast cancers. An abnormally low level of APC and/or E-cadherin mRNA in the lower 5 percentile suggests high risk of recurrence in breast cancer following surgery and heightened risk of shortened survival.

4. Regulators of Apoptosis

5

10

15

20

25

30

These include BCl/BAX family members BCl2, Bcl-xl, Bak, Bax and related factors, NFκ-B and related factors, and also p53BP1/ASPP1 and p53BP2/ASPP2.

Bax and Bak are pro-apoptotic and BCl2 and Bcl-xl are anti-apoptotic. Therefore, the ratios of these factors influence the resistance or sensitivity of a cell to toxic (pro-apoptotic) drugs. In breast cancer, unlike other cancers, elevated level of BCl2 (in the upper ten percentile) correlates with good outcome. This reflects the fact that BCl2 has growth inhibitory activity as well as anti-apoptotic activity, and in breast cancer the significance of the former activity outweighs the significance of the latter. The impact of BCl2 is in turn dependent on the status of the growth stimulating transcription factor c-MYC. The gene for c-MYC is amplified in about 20% of breast cancers. When c-MYC message levels are abnormally elevated relative to BCl2 (such that this ratio is in the upper ten percentile), then elevated level of BCl2 mRNA is no longer a positive indicator.

NF κ -B is another important anti-apoptotic factor. Originally, recognized as a proinflammatory transcription factor, it is now clear that it prevents programmed cell death in response to several extracellular toxic factors [such as tumor necrosis factor]. The activity of this transcription factor is regulated principally via phosphorylation/dephosphorylation events. However, levels of NF κ -B nevertheless do vary from cell to cell, and elevated levels should

correlate with increased resistance to apoptosis. Importantly for present purposes, NFκ-B, exerts its anti-apoptotic activity largely through its stimulation of transcription of mRNAs encoding certain members of the IAP [inhibitor of apoptosis] family of proteins, specifically cIAP1, cIAP2, XIAP, and Survivin. Thus, abnormally elevated levels of mRNAs for these IAPs and for NFκ-B any in the upper 5 percentile] signify activation of the NFκ-B anti-apoptotic pathway. This suggests high risk of recurrence in breast cancer following chemotherapy and therefore poor prognosis. One embodiment of the present invention is the inclusion in the gene set of the above apoptotic regulators, and the above-outlined use of combinations and ratios of the levels of their mRNAs for prognosis in breast cancer.

The proteins p53BP1 and 2 bind to p53 and promote transcriptional activation of proapoptotic genes. The levels of p53BP1 and 2 are suppressed in a significant fraction of breast cancers, correlating with poor prognosis. When either is expressed in the lower tenth percentile poor prognosis is indicated.

5. Factors that control cell invasion and angiogenesis

5

10

15

20

25

30

These include uPA, PAI1, cathepsinsB, G and L, scatter factor [HGF], c-met, KDR, VEGF, and CD31. The plasminogen activator uPA and its serpin regulator PAI1 promote breakdown of extracellular matrices and tumor cell invasion. Abnormally elevated levels of both mRNAs in malignant breast tumors (in the upper twenty percentile) signify an increased risk of shortened survival, increased recurrence in breast cancer patients post surgery, and increased importance of receiving adjuvant chemotherapy. On the other hand, node negative patients whose tumors do not express elevated levels of these mRNA species are less likely to have recurrence of this cancer and could more seriously consider whether the benefits of standard chemotherapy justifies the associated toxicity.

Cathepsins B or L, when expressed in the upper ten percentile, predict poor disease-free and overall survival. In particular, cathepsin L predicts short survival in node positive patients.

Scatter factor and its cognate receptor c-met promote cell motility and invasion, cell growth, and angiogenesis. In breast cancer elevated levels of mRNAs encoding these factors should prompt aggressive treatment with chemotherapeutic drugs, when expression of either, or the combination, is above the 90th percentile.

VEGF is a central positive regulator of angiogenesis, and elevated levels in solid tumors predict short survival [note many references showing that elevated level of VEGF predicts short survival]. Inhibitors of VEGF therefore slow the growth of solid tumors in animals and humans. VEGF activity is controlled at the level of transcription. VEGF mRNA levels in the upper ten percentile indicate significantly worse than average prognosis. Other markers of vascularization,

CD31 [PECAM], and KDR indicate high vessel density in tumors and that the tumor will be particularly malignant and aggressive, and hence that an aggressive therapeutic strategy is warranted.

6. Markers for Immune and Inflammatory Cells and Processes

These markers include the genes for Immunoglobulin light chain λ , CD18, CD3, CD68, Fas [CD95], and Fas Ligand.

Several lines of evidence suggest that the mechanisms of action of certain drugs used in breast cancer entail activation of the host immune/inflammatory response (For example, Herceptin®). One aspect of the present invention is the inclusion in the gene set of markers for inflammatory and immune cells, and markers that predict tumor resistance to immune surveillance. Immunoglobulin light chain lambda is a marker for immunoglobulin producing cells. CD18 is a marker for all white cells. CD3 is a marker for T-cells. CD68 is a marker for macrophages.

CD95 and Fas ligand are a receptor: ligand pair that mediate one of two major pathways by which cytotoxic T cells and NK cells kill targeted cells. Decreased expression of CD95 and increased expression of Fas Ligand indicates poor prognosis in breast cancer. Both CD95 and Fas Ligand are transmembrane proteins, and need to be membrane anchored to trigger cell death. Certain tumor cells produce a truncated soluble variant of CD95, created as a result of alternative splicing of the CD95 mRNA. This blocks NK cell and cytotoxic T cell Fas Ligand-mediated killing of the tumors cells. Presence of soluble CD95 correlates with poor survival in breast cancer. The gene set includes both soluble and full-length variants of CD95.

7. Cell proliferation markers

5

10

15

20

25

30

The gene set includes the cell proliferation markers Ki67/MiB1, PCNA, Pin1, and thymidine kinase. High levels of expression of proliferation markers associate with high histologic grade, and short survival. High levels of thymidine kinase in the upper ten percentile suggest in creased risk of short survival. Pin1 is a prolyl isomerase that stimulates cell growth, in part through the transcriptional activation of the cyclin D1 gene, and levels in the upper ten percentile contribute to a negative prognostic profile.

8. Other growth factors and receptors

This gene set includes IGF1, IGF2, IGFBP3, IGF1R, FGF2, FGFR1, CSF-1R/fms, CSF-1, IL6 and IL8. All of these proteins are expressed in breast cancer. Most stimulate tumor growth. However, expression of the growth factor FGF2 correlates with good outcome. Some have anti-apoptotic activity, prominently IGF1. Activation of the IGF1 axis via elevated IGF1, IGF1R, or

IGFBP3 (as indicated by the sum of these signals in the upper ten percentile) inhibits tumor cell death and strongly contributes to a poor prognostic profile.

9. Gene expression markers that define subclasses of breast cancer

These include: GRO1 oncogene alpha, Grb7, cytokeratins 5 and 17, retinal binding protein 4, hepatocyte nuclear factor 3, integrin alpha 7, and lipoprotein lipase. These markers subset breast cancer into different cell types that are phenotypically different at the level of gene expression. Tumors expressing signals for Bcl2, hepatocyte nuclear factor 3, LIV1 and ER above the mean have the best prognosis for disease free and overall survival following surgical removal of the cancer. Another category of breast cancer tumor type, characterized by elevated expression of lipoprotein lipase, retinol binding protein 4, and integrin α 7, carry intermediate prognosis. Tumors expressing either elevated levels of cytokeratins 5, and 17, GRO oncogene at levels four-fold or greater above the mean, or ErbB2 and Grb7 at levels ten-fold or more above the mean, have worst prognosis.

Although throughout the present description, including the Examples below, various aspects of the invention are explained with reference to gene expression studies, the invention can be performed in a similar manner, and similar results can be reached by applying proteomics techniques that are well known in the art. The proteome is the totality of the proteins present in a sample (e.g. tissue, organism, or cell culture) at a certain point of time. Proteomics includes, among other things, study of the global changes of protein expression in a sample (also referred to as "expression proteomics"). Proteomics typically includes the following steps: (1) separation of individual proteins in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identification of the individual proteins recovered from the gel, e.g. my mass spectrometry and/or N-terminal sequencing, and (3) analysis of the data using bioinformatics. Proteomics methods are valuable supplements to other methods of gene expression profiling, and can be used, alone or in combination with other methods of the present invention, to detect the products of the gene markers of the present invention.

Further details of the invention will be described in the following non-limiting Examples.

Example 1

5

10

15

20

25

30

Isolation of RNA from formalin-fixed, paraffin-embedded (FPET) tissue specimens

A. Protocols

I. EPICENTRE® Xylene Protocol

RNA Isolation

(1) Cut 1-6 sections (each 10 μm thick) of paraffin-embedded tissue per sample using a clean microtome blade and place into a 1.5 ml eppendorf tube.

(2) To extract paraffin, add 1 ml of xylene and invert the tubes for 10 minutes by rocking on a nutator.

- (3) Pellet the sections by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (4) Remove the xylene, leaving some in the bottom to avoid dislodging the pellet.
 - (5) Repeat steps 2-4.

5

10

- (6) Add 1 ml of 100% ethanol and invert for 3 minutes by rocking on the nutator.
- (7) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (8) Remove the ethanol, leaving some at the bottom to avoid the pellet.
 - (9) Repeat steps 6-8 twice.
 - (10) Remove all of the remaining ethanol.
- (11) For each sample, add 2 μ l of 50 μ g/ μ l Proteinase K to 300 μ l of Tissue and Cell Lysis Solution.
- 15 (12) Add 300 µl of Tissue and Cell Lysis Solution containing the Proteinase K to each sample and mix thoroughly.
 - (13) Incubate at 65 °C for 90 minutes (vortex mixing every 5 minutes). Visually monitor the remaining tissue fragment. If still visible after 30 minutes, add an additional 2 μ l of 50 μ g/ μ l Proteinase K and continue incubating at 65 °C until fragment dissolves.
- 20 (14) Place the samples on ice for 3-5 minutes and proceed with protein removal and total nucleic acid precipitation.

Protein Removal and Precipitation of Total Nucleic Acid

- (1) Add 150 μ l of MPC Protein Precipitation Reagent to each lysed sample and vortex vigorously for 10 seconds.
- 25 (2) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (3) Transfer the supernatant into clean eppendorf tubes and discard the pellet.
 - (4) Add 500 μ l of isopropanol to the recovered supernatant and thoroughly mix by rocking on the nutator for 3 minutes.
- 30 (5) Pellet the RNA/DNA by centrifugation at 4 °C for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (6) Remove all of the isopropanol with a pipet, being careful not to dislodge the pellet.

Removal of Contaminating DNA from RNA Preparations

- (1) Prepare 200 μl of DNase I solution for each sample by adding 5 μl of RNase-Free DNase I (1 U/μl) to 195 μl of 1X DNase Buffer.
- (2) Completely resuspend the pelleted RNA in 200 μ l of DNase I solution by vortexing.
 - (3) Incubate the samples at 37 °C for 60 minutes.
 - (4) Add 200 μ l of 2X T and C Lysis Solution to each sample and vortex for 5 seconds.
- (5) Add 200 μl of MPC Protein Precipitation Reagent, mix by vortexing for 10 seconds and place on ice for 3-5 minutes.
 - (6) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (7) Transfer the supernatant containing the RNA to clean eppendorf tubes and discard the pellet. (Be careful to avoid transferring the pellet.)
 - (8) Add 500 μl of isopropanol to each supernatant and rock samples on the nutator for 3 minutes.
 - (9) Pellet the RNA by centrifugation at 4 °C for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
- (10) Remove the isopropanol, leaving some at the bottom to avoid dislodging the 20 pellet.
 - (11) Rinse twice with 1 ml of 75% ethanol. Centrifuge briefly if the RNA pellet is dislodged.
 - (12) Remove ethanol carefully.
 - (13) Set under fume hood for about 3 minutes to remove residual ethanol.
 - (14) Resuspend the RNA in 30 μ l of TE Buffer and store at -30 °C.
 - II. Hot Wax/Urea Protocol of the Invention

RNA Isolation

15

- (1) Cut 3 sections (each 10 µm thick) of paraffin-embedded tissue using a clean microtome blade and place into a 1.5 ml eppendorf tube.
- 30 (2) Add 300 μl of lysis buffer (10 mM Tris 7.5, 0.5% sodium lauroyl sarcosine, 0.1 mM EDTA pH 7.5, 4M Urea) containing 330 μg/ml Proteinase K (added freshly from a 50 μg/μl stock solution) and vortex briefly.

(3) Incubate at 65 °C for 90 minutes (vortex mixing every 5 minutes). Visually monitor the tissue fragment. If still visible after 30 minutes, add an additional 2 μ l of 50 μ g/ μ l Proteinase K and continue incubating at 65 °C until fragment dissolves.

- (4) Centrifuge for 5 minutes at 14,000 x g and transfer upper aqueous phase to new tube, being careful not to disrupt the paraffin seal.
- (5) Place the samples on ice for 3-5 minutes and proceed with protein removal and total nucleic acid precipitation.

Protein Removal and Precipitation of Total Nucleic Acid

- (1) Add 150 μl of 7.5M NH₄OAc to each lysed sample and vortex vigorously for 10
 10 seconds.
 - (2) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (3) Transfer the supernatant into clean eppendorf tubes and discard the pellet.
 - (4) Add 500 μ l of isopropanol to the recovered supernatant and thoroughly mix by rocking on the nutator for 3 minutes.
 - (5) Pellet the RNA/DNA by centrifugation at 4 °C for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (6) Remove all of the isopropanol with a pipet, being careful not to dislodge the pellet.

Removal of Contaminating DNA from RNA Preparations

- (1) Add 45 μl of 1X DNase I buffer (10 mM Tris-Cl, pH 7,5, 2.5 mM MgCl₂, 0.1 mM CaCl₂) and 5 μl of RNase-Free DNase I (2U/μl, Ambion) to each sample.
 - (2) Incubate the samples at 37 °C for 60 minutes.

Inactivate the DNaseI by heating at 70 °C for 5 minutes.

B. Results

. 5

15

20

30

Experimental evidence demonstrates that the hot RNA extraction protocol of the invention does not compromise RNA yield. Using 19 FPE breast cancer specimens, extracting RNA from three adjacent sections in the same specimens, RNA yields were measured via capillary electrophoresis with fluorescence detection (Agilent Bioanalyzer). Average RNA yields in nanograms and standard deviations with the invented and commercial methods, respectively, were: 139+/-21 versus 141+/-34.

Also, it was found that the urea-containing lysis buffer of the present invention can be substituted for the EPICENTRE® T&C lysis buffer, and the 7.5 M NH₄OAc reagent used for protein precipitation in accordance with the present invention can be substituted for the

EPICENTRE® MPC protein precipitation solution with neither significant compromise of RNA yield nor TaqMan® efficiency.

Example 2

5

10

15

20

25

30

Amplification of mRNA Species Prior to RT-PCR

The method described in section 10 above was used with RNA isolated from fixed, paraffin-embedded breast cancer tissue. TaqMan® analyses were performed with first strand cDNA generated with the T7-GSP primer (unamplified (T7-GSPr)), T7 amplified RNA (amplified (T7-GSPr)). RNA was amplified according to step 2 of Figure 4. As a control, TaqMan® was also performed with cDNA generated with an unmodified GSPr (amplified (GSPr)). An equivalent amount of initial template (1 ng/well) was used in each TaqMan® reaction.

The results are shown in Figure 8. *In vitro* transcription increased RT-PCR signal intensity by more than 10 fold, and for certain genes by more than 100 fold relative to controls in which the RT-PCR primers were the same primers used in method 2 for the generation of double-stranded DNA for *in vitro* transcription (GSP-T7_r and GSP_f). Also shown in Figure 8 are RT-PCR data generated when standard optimized RT-PCR primers (i.e., lacking T7 tails) were used. As shown, compared to this control, the new method yielded substantial increases in RT-PCR signal (from 4 to 64 fold in this experiment).

The new method requires that each T7-GSP sequence be optimized so that the increase in the RT-PCR signal is the same for each gene, relative to the standard optimized RT-PCR (with non-T7 tailed primers).

Example 3

A Study of Gene Expression in Premalignant and Malignant Breast Tumors

A gene expression study was designed and conducted with the primary goal to molecularly characterize gene expression in paraffin-embedded, fixed tissue samples of invasive breast ductal carcinoma, and to explore the correlation between such molecular profiles and disease-free survival. A further objective of the study was to compare the molecular profiles in tissue samples of invasive breast cancer with the molecular profiles obtained in ductal carcinoma in situ. The study was further designed to obtain data on the molecular profiles in lobular carcinoma in situ and in paraffin-embedded, fixed tissue samples of invasive lobular carcinoma.

Molecular assays were performed on paraffin-embedded, formalin-fixed primary breast tumor tissues obtained from 202 individual patients diagnosed with breast cancer. All patients underwent surgery with diagnosis of invasive ductal carcinoma of the breast, pure ductal carcinoma in situ (DCIS), lobular carcinoma of the breast, or pure lobular carcinoma in situ

(LCIS). Patients were included in the study only if histopathologic assessment, performed as described in the Materials and Methods section, indicated adequate amounts of tumor tissue and homogeneous pathology.

The individuals participating in the study were divided into the following groups:

Group 1: Pure ductal carcinoma in situ (DCIS); n=18

Group 2: Invasive ductal carcinoma n=130

Group 3: Pure lobular carcinoma in situ (LCIS); n=7

Group 4: Invasive lobular carcinoma n=16

Materials and Methods

5

10

15

20

25

30

Each representative tumor block was characterized by standard histopathology for diagnosis, semi-quantitative assessment of amount of tumor, and tumor grade. A total of 6 sections (10 microns in thickness each) were prepared and placed in two Costar Brand Microcentrifuge Tubes (Polypropylene, 1.7 mL tubes, clear; 3 sections in each tube). If the tumor constituted less than 30% of the total specimen area, the sample may have been crudely dissected by the pathologist, using gross microdissection, putting the tumor tissue directly into the Costar tube.

If more than one tumor block was obtained as part of the surgical procedure, all tumor blocks were subjected to the same characterization, as described above, and the block most representative of the pathology was used for analysis.

Gene Expression Analysis

mRNA was extracted and purified from fixed, paraffin-embedded tissue samples, and prepared for gene expression analysis as described in chapters 7-11 above.

Molecular assays of quantitative gene expression were performed by RT-PCR, using the ABI PRISM 7900TM Sequence Detection SystemTM (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA). ABI PRISM 7900TM consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 384-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 384 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

Analysis and Results

Tumor tissue was analyzed for 185 cancer-related genes and 7 reference genes. The threshold cycle (CT) values for each patient were normalized based on the median of all genes

for that particular patient. Clinical outcome data were available for all patients from a review of registry data and selected patient charts.

Outcomes were classified as:

5

10

15

- died due to breast cancer or to unknown cause or alive with breast cancer recurrence;
 - 1 alive without breast cancer recurrence or died due to a cause other than breast cancer

Analysis was performed by:

- 1. Analysis of the relationship between normalized gene expression and the binary outcomes of 0 or 1.
 - 2. Analysis of the relationship between normalized gene expression and the time to outcome (0 or 1 as defined above) where patients who were alive without breast cancer recurrence or who died due to a cause other than breast cancer were censored. This approach was used to evaluate the prognostic impact of individual genes and also sets of multiple genes.

Analysis of 147 patients with invasive breast carcinoma by binary approach

In the first (binary) approach, analysis was performed on all 146 patients with invasive breast carcinoma. At test was performed on the group of patients classified as 0 or 1 and the p-values for the differences between the groups for each gene were calculated.

The following Table 4 lists the 45 genes for which the p-value for the differences between the groups was <0.05.

Table 4

Gene/ SEQ ID NO:	Mean CT Alive	Mean CT Deceased	t-value	Degrees of freedom	p
FOXM1	33.66	32.52	3.92	144	0.0001
PRAME	35.45	33.84	3.71	144	0.0003
Bcl2	28.52	29.32	-3.53	144	0.0006
STK15	30.82	30.10	3.49	144	0.0006
CEGP1	29.12	30.86	-3.39	144	0.0009
Ki-67	30.57	29.62	3.34	144	0.0011
GSTM1	30.62	31.63	-3.27	144	0.0014
CA9	34.96	33.54	3.18	144	0.0018
PR	29.56	31.22	-3.16	144	0.0019
BBC3	31.54	32.10	-3.10	144	0.0023
NME1	27.31	26.68	3.04	144	0.0028
SURV	31.64	30.68	2.92	144	0.0041
GATA3	26.06	26.99	-2.91	144	0.0042
TFRC	28.96	28.48	2.87	144	0.0047
YB-1	26.72	26.41	2.79	144	0.0060
DPYD	28.51	28.84	-2.67	144	0.0084
GSTM3	28.21	29.03	-2.63	144	0.0095
RPS6KB1	31.18	30.61	2.61	144	0.0099
Src	27.97	27.69	2.59	144	0.0105
Chk1	32.63	31.99	2.57	144	0.0113
ID1	28.73	29.13	-2.48	144	0.0141
EstR1	24.22	25.40	-2.44	144	0.0160
p27	27.15	27.51	-2.41	144	0.0174
CCNB1	31.63	30.87	2.40	144	0.0176
XIAP	30.27	30.51	-2.40	144	0.0178
Chk2	31.48	31.11	2.39	144	0.0179
CDC25B	29.75	29.39	2.37	144	0.0193
IGF1R	28.85	29.44	-2.34	144	0.0209

ÁK055699	33.23	34.11	-2.28	144	0.0242
PI3KC2A	31.07	31.42	-2.25	144	0.0257
TGFB3	28.42	28.85	-2.25	144	0.0258
BAGI1	28.40	28.75	-2.24	144	0.0269
CYP3A4	35.70	35.32	2.17	144	0.0317
EpCAM	28.73	28.34	2.16	144	0.0321
VEGFC	32.28	31.82	2.16	144	0.0326
pS2	28.96	30.60	-2.14	144	0.0341
hENT1	27.19	26.91	2.12	144	0.0357
WISP1	31.20	31.64	-2.10	144	0.0377
HNF3A	27.89	28.64	-2.09	144	0.0384
NFKBp65	33.22	33.80	-2.08	144	0.0396
BRCA2	33.06	32.62	2.08	144	0.0397
EGFR	30.68	30.13	2.06	144	0.0414
TK1	32.27	31.72	2.02	144	0.0453
VDR	30.08	29.73	1.99	144	0.0488

In the foregoing Table 4, lower (negative) t-values indicate higher expression (or lower CTs), associated with better outcomes, and, inversely, higher (positive) t-values indicate higher expression (lower CTs) associated with worse outcomes. Thus, for example, elevated expression of the FOXM1 gene (t-value = 3.92, CT mean alive> CT mean deceased) indicates a reduced likelihood of disease free survival. Similarly, elevated expression of the CEGP1 gene (t-value = -3.39; CT mean alive< CT mean deceased) indicates an increased likelihood of disease free survival.

5

10

Based on the data set forth in Table 4, the overexpression of any of the following genes in breast cancer indicates a reduced likelihood of survival without cancer recurrence following surgery: FOXM1; PRAME; SKT15, Ki-67; CA9; NME1; SURV; TFRC; YB-1; RPS6KB1; Src; Chk1; CCNB1; Chk2; CDC25B; CYP3A4; EpCAM; VEGFC; hENT1; BRCA2; EGFR; TK1; VDR.

Based on the data set forth in Table 4, the overexpression of any of the following genes in breast cancer indicates a better prognosis for survival without cancer recurrence following surgery: Blc12; CEGP1; GSTM1; PR; BBC3; GATA3; DPYD; GSTM3; ID1; EstR1; p27; XIAP; IGF1R; AK055699; P13KC2A; TGFB3; BAGI1; pS2; WISP1; HNF3A; NFKBp65.

Analysis of 108 ER positive patient by binary approach

108 patients with normalized CT for estrogen receptor (ER) < 25.2 (i.e., ER positive patients) were subjected to separate analysis. At test was performed on the groups of patients classified as 0 or 1 and the p-values for the differences between the groups for each gene were calculated. The following Table 5 lists the 12 genes where the p-value for the differences between the groups was <0.05.

Table 5

Gene/	Mean CT	Mean CT	t-value	Degrees of	p
SEQ ID NO:	Alive	Deceased		freedom	
PRAME	35.54	33.88	3.03	106	0.0031
Bcl2	28.24	28.87	-2.70	106	0.0082
FOXM1	33.82	32.85	2.66	106	0.089
DIABLO	30.33	30.71	-2.47	106	0.0153
EPHX1	28.62	28.03	2.44	106	0.0163
HIF1A	29.37	28.88	2.40	106	0.0180
VEGFC	32.39	31.69	2.39	106	0.0187
Ki-67	30.73	29.82	2.38	106	0.0191
IGF1R	28.60	29.18	-2.37	106	0.0194
VDR	30.14	29.60	2.17	106	0.0322
NME1	27.34	26.80	2.03	106	0.0452
GSTM3	28.08	28.92	-2.00	106	0.0485

For each gene, a classification algorithm was utilized to identify the best threshold value (CT) for using each gene alone in predicting clinical outcome.

Based on the data set forth in Table 5, overexpression of the following genes in ER-positive cancer is indicative of a reduced likelihood of survival without cancer recurrence following surgery: PRAME; FOXM1; EPHX1; HIF1A; VEGFC; Ki-67; VDR; NME1. Some of these genes (PRAME; FOXM1; VEGFC; Ki-67; VDR; and NME1) were also identified as indicators of poor prognosis in the previous analysis, not limited to ER-positive breast cancer. The overexpression of the remaining genes (EPHX1 and HIF1A) appears to be negative indicator of disease free survival in ER-positive breast cancer only. Based on the data set forth in Table 5, overexpression of the following genes in ER-positive cancer is indicative of a better

15

20

prognosis for survival without cancer recurrence following surgery: Bcl-2; DIABLO; IGF1R; GSTM3. Of the latter genes, Bcl-2; IGFR1; and GSTM3 have also been identified as indicators of good prognosis in the previous analysis, not limited to ER-positive breast cancer. The overexpression of DIABLO appears to be positive indicator of disease free survival in ER-positive breast cancer only.

Analysis of multiple genes and indicators of outcome

Two approaches were taken in order to determine whether using multiple genes would provide better discrimination between outcomes.

First, a discrimination analysis was performed using a forward stepwise approach. Models were generated that classified outcome with greater discrimination than was obtained with any single gene alone.

According to a second approach (time-to-event approach), for each gene a Cox Proportional Hazards model (see, e.g. Cox, D. R., and Oakes, D. (1984), *Analysis of Survival Data*, Chapman and Hall, London, New York) was defined with time to recurrence or death as the dependent variable, and the expression level of the gene as the independent variable. The genes that have a p-value < 0.05 in the Cox model were identified. For each gene, the Cox model provides the relative risk (RR) of recurrence or death for a unit change in the expression of the gene. One can choose to partition the patients into subgroups at any threshold value of the measured expression (on the CT scale), where all patients with expression values above the threshold have higher risk, and all patients with expression values below the threshold have lower risk, or vice versa, depending on whether the gene is an indicator of good (RR>1.01) or poor (RR<1.01) prognosis. Thus, any threshold value will define subgroups of patients with respectively increased or decreased risk. The results are summarized in the following Tables 6 and 7.

25

5

10

15

<u>Table 6</u>

<u>Cox Model Results for 146 Patients with Invasive Breast Cancer</u>

Gene	Relative Risk (RR)	SE Relative Risk	p value
FOXM1	0.58	0.15	0.0002
STK15	0.51	0.20	0.0006
PRAME	0.78	0.07	0.0007
Bcl2	1.66	0.15	0.0009
CEGP1	1.25	0.07	0.0014
GSTM1	1.40	0.11	0.0014
Ki67	0.62	0.15	0.0016
PR	1.23	0.07	0.0017
Contig51037	0.81	0.07	0.0022
NME1	0.64	0.15	0.0023
YB-1	0.39	0.32	0.0033
TFRC	0.53	0.21	0.0035
BBC3	1.72	0.19	0.0036
GATA3	1.32	0.10	0.0039
CA9	0.81	0.07	0.0049
SURV	0.69	0.13	0.0049
DPYD	2.58	0.34	0.0052
RPS6KB1	0.60	0.18	0.0055
GSTM3	1.36	0.12	0.0078
Src.2	0.39	0.36	0.0094
TGFB3	1.61	0.19	0.0109
CDC25B	0.54	0.25	0.0122
XIAP	3.20	0.47	0.0126
CCNB1	0.68	0.16	0.0151
IGF1R	1.42	0.15	0.0153
Chk1	0.68	0.16	0.0155
ID1	1.80	0.25	0.0164
p27	1.69	0.22	0.0168
Chk2	0.52	0.27	0.0175

EstR1	1.17	0.07	0.0196
HNF3A	1.21	0.08	0.206
pS2	1.12	0.05	0.0230
BAGI1	1.88	0.29	0.0266
AK055699	1.24	0.10	0.0276
pENT1	0.51	0.31	0.0293
EpCAM	0.62	0.22	0.0310
WISP1	1.39	0.16	0.0338
VEGFC	0.62	0.23	0.0364
TK1	0.73	0.15	0.0382
NFKBp65	1.32	0.14	0.0384
BRCA2	0.66	0.20	0.0404
CYP3A4	0.60	0.25	0.0417
EGFR	0.72	0.16	0.0436

<u>Table 7</u>

<u>Cox Model Results for 108 Patients wih ER+ Invasive Breast Cancer</u>

Gene	Relative Risk (RR)	SE Relative Risk	p-value
PRAME	0.75	0.10	0.0045
Contig51037	0.75	0.11	0.0060
Blc2	2.11	0.28	0.0075
HIF1A	0.42	0.34	0.0117
IGF1R	1.92	0.26	0.0117
FOXM1	0.54	0.24	0.0119
EPHX1	0.43	0.33	0.0120
Ki67	0.60	0.21	0.0160
CDC25B	0.41	0.38	0.0200
VEGFC	0.45	0.37	0.0288
CTSB .	0.32	0.53	0.0328
DIABLO	2.91	0.50	0.0328
p27	1.83	0.28	0.0341
CDH1	0.57	0.27	0.0352
IGFBP3	0.45	0.40	0.0499

The binary and time-to-event analyses, with few exceptions, identified the same genes as prognostic markers. For example, comparison of Tables 4 and 6 shows that, with the exception of a single gene, the two analyses generated the same list of top 15 markers (as defined by the smallest p values). Furthermore, when both analyses identified the same gene, they were concordant with respect to the direction (positive or negative sign) of the correlation with survival/recurrence. Overall, these results strengthen the conclusion that the identified markers have significant prognostic value.

For Cox models comprising more than two genes (multivariate models), stepwise entry of each individual gene into the model is performed, where the first gene entered is pre-selected from among those genes having significant univariate p-values, and the gene selected for entry into the model at each subsequent step is the gene that best improves the fit of the model to the data. This analysis can be performed with any total number of genes. In the analysis the results of which are shown below, stepwise entry was performed for up to 10 genes.

Multivariate analysis is performed using the following equation:

5

10

15

20

25

30

 $RR = \exp[\operatorname{coef}(\operatorname{geneA}) \times \operatorname{Ct}(\operatorname{geneB}) \times \operatorname{Ct}(\operatorname{genB}) \times \operatorname$

In this equation, coefficiencts for genes that are predictors of beneficial outcome are positive numbers and coefficients for genes that are predictors of unfavorable outcome are negative numbers. The "Ct" values in the equation are ΔCts, i.e. reflect the difference between the average normalized Ct value for a population and the normalized Ct measured for the patient in question. The convention used in the present analysis has been that ΔCts below and above the population average have positive signs and negative signs, respectively (reflecting greater or lesser mRNA abundance). The relative risk (RR) calculated by solving this equation will indicate if the patient has an enhanced or reduced chance of long-term survival without cancer recurrence.

Multivariate gene analysis of 147 patients with invasive breast carcinoma

(a) A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for all 147 patients with invasive breast carcinoma. Genes CEGP1, FOXM1, STK15 and PRAME were excluded from this analysis. The following ten-gene sets have been identified by this analysis as having particularly strong predictive value of patient survival without cancer recurrence following surgical removal of primary tumor.

1. Bel2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;

- 2. Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
- 3. GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65,
- 5 ErbB3;

10

- 4. PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
- 5. CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
- 6. TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65.
- (b) A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for all 147 patients with invasive breast carcinoma, using an interrogation set including a reduced number of genes. The following tengene sets have been identified by this analysis as having particularly strong predictive value of patient survival without cancer recurrence following surgical removal of primary tumor.
 - 1. Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
 - 2. FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- 20 3. PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
 - 4. Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
 - 5. STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
 - 6. GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1,
- 25 PLAUR;
 - 7. PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - 8. CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
- 9. TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC;
 - 10. CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS.

Multivariate analysis of patients with ER positive invasive breast carcinoma

A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for patients with ER positive invasive breast carcinoma. The following ten-gene sets have been identified by this analysis as having particularly strong predictive value of patient survival without cancer recurrence following surgical removal of primary tumor.

1. PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;

5

10

20

25

- 2. Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- 3. Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
- 4. HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 5. IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
 - 6. FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
 - 7. EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - 8. Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - 9. CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
 - 10. VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - 11. CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
 - 12. DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
 - 13. p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - 14. CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
 - 15. IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
 - 16. GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
 - 17. hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - 18. STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;

19. NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;

- 20. VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
- 21. EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
- 22. CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
- 23. ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
- 24. FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
- 25. GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, FBXO5, CA9, CYP, KRT18;
- 10 26. Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF.

It is noteworthy that many of the foregoing gene sets include genes that alone did not have sufficient predictive value to qualify as prognostic markers under the standards discussed above, but in combination with other genes, their presence provides valuable information about the likelihood of long-term patient survival without cancer recurrence

All references cited throughout the disclosure are hereby expressly incorporated by reference.

While the present invention has been described with reference to what are considered to be the specific embodiments, it is to be understood that the invention is not limited to such embodiments. To the contrary, the invention is intended to cover various modifications and equivalents included within the spirit and scope of the appended claims. For example, while the disclosure focuses on the identification of various breast cancer associated genes and gene sets, and on the diagnosis and treatment of breast cancer, similar genes, gene sets and methods concerning other types of cancer are specifically within the scope herein.

15

20

W O 2003/078002		1 C1/032003/00//13
156. Pin1 157. PKC-e 158. Pkc-δ 159. PLAGI (pleiomorphic adenoma 1½ 160. PREP prohl endopeptidase*PEP 161. Progesterone recepior 162. p22/refoil factor 1 163. PTEN 166. RAR-alpha 165. RAR-alpha	167. RCP 168. Reduced Folate Carrier 169. Retinot binding protein 4^ 170. STK15/BTAK 171. Survivin 172. SXR 173. SyR 174. TGD (thymine-DNA glycosylase)* 175. TGFalpha 176. Thymidine Kinase 177. Thymidine Enosphorylase 178. Thomidine Enosphorylase 178. Topoisomerase II-\textit{\textit{\textit{B}}} 181. TRAMP 182. UPA 183. VEGF 184. Vimentin 185. WTH3	186, XAF1 187, XIAP 188, XIST 189, XPA 190, YB-1 *NCI 60 drug Sens/Resist Marker *In Cluster Defining turnor subclasses 1/19/02
	126. microtubule-associated protein 4 127. MCJ 128. mdm2 129. MDR-1 130. microsomal epoxide hydrolase 131. MMPP 132. MRP1 133. MRP2 134. MRP2 135. MRP4 136. MSN (Moesin)* 137. mTOR 138. Muc1/CA 15-3 139. NF-kB 140. P14ARF 141. P16fNK4a/p14 142. p21wAF1/CIP1 143. p23	144, p27 145, p311* 146, p53 147, P411 148, PCNA 149, PDGF-A 150, PDGF-D 151, PDGF-C 153, PDGFR-C 154, PDGFR-C 155, PT3K
		102. Id-2 103. Id-3 104. IGF-1 105. IGF2 106. IGF1R 107. IGFBF3 109. IL.6 110. IL.8 111. IRF-2* 112. IRF9 Protein 113. Kallicrein 5 114. Kallicrein 6
	54. DIABLO 55. Dihydropyrimidine dehydrogenase 56. EGF 57. ECadherin/CDH1^ 58. ELF 3* 59. Endothelin 60. Epiregulin 61. ER-alpha^ 62. ErbB-1 63. ErbB-2 64. ErbB-4 65. ErbB-4 66. ER-Beta 67. Eukaryotic Translation Initiation Factor 48*(EIF4B) 68. EIF4E	pyrolophosphate Synthetase 70. FAS (CD95) 71. FasL 72. FGF R 1* 73. FGF2 [bFGF] 74. 53BP1 75. 53BP2 76. GALC (galactosylceramida -se)*
1. ADD3 (adducin 3 gamma)* 2. AKT1/Protein Kinase B 3. AKT 2 4. AKT 3 5. Aldehyde denydrogenase 1A1 denydrogenase 1A2 6. Aldehyde denydrogenase 1A3 7. amphiregulin 8. APC		29. CD62K4L1 30. Cdc25A 31. Cdc25B 32. CGA 33. COX2 34. CSF-1 35. CSF-1R/fms 36. claP1 37. claP2 38. c-abl 40. c-ltt L 41. c-met

PARTE 2

	•	TABLE	2	
Gene	Accession No.	Forward Primer SEQ ID NO.	Reverse Primer SEQ ID NO.	Amplicon SEQ ID NO.
ABCB1	NM_000927	1	2 5	3
ABCC1	NM_004996	4	5	6 ·
ABCC2	NM_000392	, 7	8	9
ABCC3	NM_003786	10	11	12`
ABCC4	NM_005845	13	14	15
ABL1	NM_005157	16	. 17	18
ABL2 ACTB	NM_005158 NM_001101	19 22	20 23	21 24
AKT1	NM_005163	22 . 25	26	24 27
AKT3	NM_005465	28	29	30
ALDH1	NM 000689	31 .	32	33
ALDH1A3	NM_000693	34	35	36
APC	NM_000038	37	38	39 ⁻
AREG	NM_001657	40	41	42
B2M	NM_004048	43 .	44	45
BAK1	NM_001188	46	47	48
BAX	NM_004324	49	50	51
BCL2	NM_000633	52	53 ·	54
BCL2L1 BIRC3	NM_001191 NM_001165	55 58	56 · 59	57 60
BIRC4	NM_001167	61	62	63
BIRC5	NM 001168	64	65	66
BRCA1	NM_007295	. 67	68	· 69
BRCA2	NM_000059	70	71	72
CCND1	NM_001758	73	74	75
CD3Z	NM_000734	76	77	78
CD68	NM_001251	79	80	81
CDC25A	NM_001789	82	83	84
CDH1	NM_004360	85.	86	87
CDKN1A CDKN1B	NM_000389 NM_004064	88 91	89 92	90 93
CDKN2A	NM_000077	94	92 95	96
CYP1B1	NM_000104	97	98 98	99
DHFR	NM 000791	100	101	102
DPYD	NM 000110	103	104	105
ECGF1	NM_001953	106	107	108
EGFR	NM_005228	109	110	111
EIF4E	NM_001968	112	113	114
ERBB2	NM_004448	115	116	117
ERBB3	NM_001982	118	119	120
ESR1 ESR2	NM_000125 NM_001437	121 124	122 125	123 126
GAPD	NM 002046	127	128	129
GATA3	NM 002051	130	131	132
GRB7	NM 005310	133	134	135
GRO1	NM_001511	136	137	138
GSTP1	NM_000852	139	140	141
GUSB	NM_000181	142	143	144
hHGF	M29145	145	146	147
HNF3A	NM_004496	148	149	150
ID2 IGF1	NM_002166 NM_000618	151	152 155	153 156
IGI I	141M_000010	154	155	156

				.'
IGFBP3	NM 000598	157	158	159
ITGA7	NM 002206	160	161	162
ITGB2	NM 000211	163	164	165
· KDR	NM 002253	166	167	168
KIT	NM 000222	169	170	.171
KITLG	NM 000899	172	173	174
KRT17	NM 000422	175	176	177
KRT5	NM 000424	178	179	180
LPL	NM 000237	181	182	183
MET	NM 000245	184	185	186
MK167	NM 002417	187	. 188	189
MVP	NM 017458	190	191	192
MYC	NM 002467	193	194	195
PDGFA	NM 002607	196	197	198
PDGFB	NM 002608	199	200	201
PDGFC	NM 016205	202	203	204
PDGFRA	NM 006206	205	206	207
PDGFRB	NM 002609	208	209	210
PGK1	NM 000291	211	212	213
PGR	NM_000926	214	215	216
PIN1	NM_006221	217	218	219
.PLAU	NM 002658	220	221	222
PPIH	NM 006347	223	224	225
PTEN	NM 000314	226	227	228
PTGS2	NM 000963	229	230	231
RBP4	NM 006744	232	233	234
RELA	NM 021975	235	236	237
RPL19	NM 000981	238	239	240
RPLP0	NM 001002	241	242	243
SCDGF-B	NM 025208	244	245	246
SERPINE1	NM_000602	4 247	248	249
SLC19A1	NM_003056	250	251	252
TBP	NM 003194	253	254	255
TFF1	NM 003225	256	257	258
TFRC	NM 003234	259	260	261
TK1	NM 003258	262	263	264
TNFRSF6	NM_000043	265	· 266	267
TNFSF6	NM_000639	268	-269	270
TOP2A	NM_001067	271	272	273
TOP2B	NM_001068	274	275	276
TP53	NM_000546	277	278	279
TYMS	NM_001071	280	281	282
VEGF	NM_003376	283	284	285

TABLE 3

GENE	ACCESSION NO.	SEQ ID NO:
AK055699	AK055699	286
BAG1	NM 004323	287
BBC3	NM 014417	288
Bcl2	NM 000633	289
BRCA2	NM 000059	290
CA9	NM 001216	291
CCNB1	NM 031966	292
CDC25B	NM 021874	293
CEGP1	NM 020974	294
Chk1	NM 001274	295
Chk2	NM 007194	296
CYP3A4	NM 017460	297
DIABLO	NM 019887	298
DPYD	NM 000110	299
EGFR	NM 005228	300
EpCAM	NM 002354	301
EPHX1	NM 000120	302
EstR1	NM 000125	303
FOXM1	NM 021953	304
GATA3	NM 002051	305
GSTM1	NM 000561	306
GSTM3	NM 000849	307
hENT1	NM 004955	308
HIF1A	NM 004535	309
HNF3A	NM 004496	310
ID1	NM 002165	311
IGF1R	NM 000875	312
Ki-67	NM 002417	313
NFKBp65	NM 021975	314
NME1	NM 000269	315
p27	NM 004064	316
PI3KC2A	NM 002645	317
PR	NM 000926	318
PRAME	NM 006115	319
pS2	NM 003225	320
RPS6KB1	NM 003223	321
Src	NM 004383	322
STK15	NM 003600	323
SURV	NM 001168	
TFRC	NM 003234	324
TGFB3	NM 003239	326
TK1	NM 003258	
VDR	NM 000376	327
VEGFC		328
WISP1	NM_005429	329
XIAP	NM_003882 NM_001167	330
		331
YB-1 ITGA7	NM_004559	332
	NM_002206	333
PDGFB	NM_002608	334
Upa	NM 002658	335
TBP	NM_003194	336

TABLE 3 (Continued)

PDGFRa	NM 006206	337
Pin1	NM 006221	338
CYP	NM 006347	339
RBP4	NM 006744	340
BRCA1	NM 007295	341
APC	NM 000038	342
GUS	NM 000181	343
CD18	NM 000211	344
PTEN	NM 000314	345
P53	NM 000546	346
ALDH1A3	NM 000693	347
GSTp	NM 000852	348
TOP2B	NM 001068	349
TS	NM 001000	350
	NM 001071	351
Bclx AREG	NM 001191	352
	NM 001953	353
TP		354
EIF4E	NM_001968 NM_001982	355
ErbB3		356
EREG	NM_001432	357
GCLC	NM 001498	
CD9	NM_001769	358
HB-EGF	NM_001945	359
IGFBP2	NM_000597	360
CTSL	NM_001912	361
PREP	NM_002726	362
CYP3A4	NM_017460	363
ILT-2	NM_006669	364
MCM3	NM_002388	365
KRT19	NM_002276	366
KRT18	NM_000224	367
TIMP2	NM_003255	368
BAD	NM_004322	369
CYP2C8	NM_030878	370
DCR3	NM_016434	371
PLAUR	NM_002659	372
PI3KC2A	NM_002645	373
FGF2	NM_002006	374
HLA-G	NM_002127	375
AlB1	NM_006534	376
MCP1	NM_002982	377
Contig46653	Contig46653	378
RhoC	NM_005167	379
DR5	NM_003842	380
RAD51C	NM_058216	381
BIN1	NM_004305	382
VDR	NM_000376	383
TERC	U86046	384

WHAT IS CLAIMED IS:

5

10

20

25

30

1. A method for predicting clinical outcome for a patient diagnosed with cancer, comprising

determining the expression level of one or more genes, or their expression products, selected from the group consisting of p53BP2, cathepsin B, cathepsin L, Ki67/MiB1, and thymidine kinase in a cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set,

wherein a poor outcome is predicted if:

- (a) the expression level of p53BP2 is in the lower 10th percentile; or
- (b) the expression level of either cathepsin B or cathepsin L is in the upper 10th percentile; or
 - (c) the expression level of any either Ki67/MiB1 or thymidine kinase is in the upper 10th percentile.
- 15 2. The method of claim 1 wherein poor clinical outcome is measured in terms of shortened survival or increased risk of cancer recurrence.
 - 3. The method of claim 2 wherein poor clinical outcome is measured in terms of shortened survival or increased risk of cancer recurrence following surgical removal of the cancer.
 - 4. The method of claim 1 wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
 - 5. The method of claim 4 wherein the cancer is breast cancer.
 - 6. The method of claim 5 wherein the expression level of p53BP2 is determined.
 - 7. The method of claim 5 wherein the expression levels of cathepsin B and cathepsin L are determined.
 - 8. The method of claim 5 wherein the expression level of cathepsin L is determined.

9. The method of claim 5 wherein the expression levels of Ki67/MiB1 and thymidine kinase are determined.

10. The method of claim 5 wherein the expression level of Ki67/MiB1 is determined.

5

15

- 11. The method of claim 5 wherein the expression level of thymidine kinase is determined.
- 10 12. The method of claim 1 wherein the expression level of more than one gene, or gene product, is determined.
 - 13. The method of claim 1 wherein the expression level of more than two genes is determined.
 - 14. The method of claim 13 further comprising the step of subjecting the expression data to multivariate analysis using the Cox Proportional Hazards model.
- 15. The method of claim 1 wherein the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample.
 - 16. The method of claim 1 wherein the expression level is determined by reverse phase polymerase chain reaction (RT-PCR).
- 25 17. The method of claim 16 wherein said RNA is fragmented.
 - 18. A method of predicting the likelihood of the recurrence of cancer following treatment in a cancer patient, comprising determining the expression level of p27, or its expression product, in a cancer tissue obtained from said patient, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set, wherein an expression level in the upper 10th percentile indicates decreased risk of recurrence following treatment.
- 19. The method of claim 18 wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer,

pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.

20. The method of claim 19 wherein the cancer is breast cancer.

5

20

25

- 21. The method of claim 20 wherein the expression level is determined following surgical removal of cancer.
- 22. The method of claim 20 wherein the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample.
 - 23. The method of claim 22 wherein said RNA is fragmented.
- 24. The method of claim 22 wherein the expression level is determined by reverse phase polymerase chain reaction (RT-PCR).
 - 25. A method for classifying cancer comprising, determining the expression level of two or more genes selected from the group consisting of Bcl2, hepatocyte nuclear factor 3, ER, ErbB2 and Grb7, or their expression products, in a cancer tissue, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set, wherein (i) tumors expressing at least one of Bcl2, hepatocyte nuclear factor 3, and ER, or their expression products, above the mean expression level in the reference tissue set are classified as having a good prognosis for disease free and overall patient survival following treatment; and (ii) tumors expressing elevated levels of ErbB2 and Grb7, or their expression products, at levels ten-fold or more above the mean expression level in the reference tissue set are classified as having poor prognosis of disease free and overall patient survival following treatment.
 - 26. The method of claim 26 wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
 - 27. The method of claim 26 wherein the cancer is breast cancer.

28. The method of claim 26 wherein the expression level is determined following surgical removal of cancer.

- 29. The method of claim 26 wherein the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample.
 - 30. The method of claim 29 wherein said RNA is fragmented.

15

20

25

- 31. The method of claim 29 wherein the expression level is determined by reverse phase polymerase chain reaction (RT-PCR).
 - 32. A method of predicting the likelihood of long-term survival of a breast cancer patient without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising determining the expression level of one or more prognostic RNA transcripts or their product in a breast cancer tissue sample obtained from said patient, normalized against the expression level of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products, wherein the prognostic transcript is the transcript of one or more genes selected from the group consisting of: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, DIABLO, CDH1, HIF1α, IGFBP3, CTSB, and Her2, wherein overexpression of one or more of FOXM1, PRAME, STK15, Ki-67, CA9, NME1, SURV, TFRC, YB-1, RPS6KB1, Src, Chk1, CCNB1, Chk2, CDC25B, CYP3A4, EpCAM, VEGFC, hENT1, BRCA2, EGFR, TK1, VDR, EPHX1, IF1A, Contig51037, CDH1, HIF1a, IGFBP3, CTSB, Her2, and pENT1 indicates a decreased likelihood of long-term survival without breast cancer recurrence, and the overexpression of one or more of Bcl2, CEGP1, GSTM1, PR, BBC3, GATA3, DPYD, GSTM3, ID1, EstR1, p27, XIAP, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, pS2, WISP1, HNF3A, NFKBp65, and DIABLO indicates an increased likelihood of long-term survival without breast cancer recurrence.
 - 33. The method of claim 32 comprising determining the expression level of at least two of said prognostic transcipts or their expression products.

34. The method of claim 32 wherein the breast cancer is invasive breast carcinoma, comprising determination of the expression levels of the transcripts of the following genes, or their expression products: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2.

5

- 35. The method of claim 32 wherein said breast cancer is characterized by overexpression of the estrogen receptor (ER).
- The method of claim 35 comprising determination of the expression levels of the transcripts of at least two of the following genes, or their expression products: PRAME, Bcl2, FOXM1, DIABLO, EPHX1, HIF1A, VEGFC, Ki-67, IGF1R, VDR, NME1, GSTM3, Contig51037, CDC25B, CTSB, p27, CDH1, and IGFBP3.
- The method of claim 32 wherein the expression level of one or more prognostic RNA transcripts is determined.
 - 38. The method of claim 37 wherein said RNA is isolated from a fixed, waxembedded breast cancer tissue specimen of said patient.
 - 39. An array comprising polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2, immobilized on a solid surface.
- 40. The array of claim 39 comprising polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, CDH1, HIF1α, IGFBP3, CTSB, Her2 and DIABLO, immobilized on a solid surface.

41. A method of predicting the likelihood of long-term survival of a patient diagnosed with invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:

- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
 - (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
 - (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
 - (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
- 10 (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;

15

20

- (e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
- (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
- (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
- (h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
- (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
- (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
- (1) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
- 25 (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
 - (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC; and
 - (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS

in a breast cancer tissue sample obtained from said patient, normalized against the expression levels of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products;

- (2) subjecting the data obtained in step (a) to statistical analysis; and
- (3) determining whether the likelihood of said long-term survival has increased or decreased.

5

10

15

20

25

- 42. A method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-positive invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:
- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
 - (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
 - (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
 - (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - (i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
 - (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
 - (l) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
 - (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO:

(n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;

- (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
- (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
- (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
- (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
- (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bc12, CYP3A4, HLAG;
- (t) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
- 10 (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;

5

20

- (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
- (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
- (x). FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
- 15 (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, EBXO5, CA9, CYP, KRT18; and
 - (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF;
 - (2) subjecting the data obtained in step (1) to statistical analysis; and
 - (3) determining whether the likelihood of said long-term survival has increased or decreased.
 - 43. The method of claim 41 or claim 42 wherein said statistical analysis is performed by using the Cox Proportional Hazards model.
 - 44. An array comprising polynucleotides hybridizing to a gene set selected from the group consisting of
 - (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
 - (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
- 30 (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
 - (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;

(e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;

- (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
- (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
- (h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
- 10 (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
 - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
 - (l) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
 - (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
 - (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC; and
- 20 (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS,

immobilized on a solid surface.

5

- 45. An array comprising polynucleotides hybridizing to a gene set selected from the group consisting of
 - (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- 30 (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;

(e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;

- (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
- (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - (i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
 - (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
 - (l) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
 - (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
 - (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
 - (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
 - (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
 - (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;
 - (t) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
 - (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
 - (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
 - (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
 - (x) FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
 - (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, FBXO5, CA9, CYP, KRT18; and
- 30 (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF,

immobilized on a solid surface.

5

10

15

20

Overall FPET/RT-PCR Flow Chart






FIGURE 1






Scheme for Preparing Fragmented mRNA for Expression Profiling Analysis




SUBSTITUTE SHEET (RULE 26)




RT-PCR (one-step or two-step)

FIGURE 4




Estrogen Receptor Comparison



- Impath Prognostic Grouping: Unfavorable Impath Prognostic Grouping: Favorable

FIGURE 6

Progesterone Receptor Comparison




- Impath Prognostic Grouping: Unfavorable Impath Prognostic Grouping: Favorable

FIGURE 7


Gene Specific Amplication of RNA for Taqman Expression Profiling Test of Concept

WO 2003/078662



Figure

Ct Distribution by Gene



39740-0001PCT.txt

SEQUENCE LISTING

<110>	GENOMIC HEALTH Baker, Joffre B. Cronin, Maureen T. Kiefer, Michael C. Shak, Steve Walker, Michael Graham	
<120>	GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES	
<130>	39740-0001PCT	
<140> <141>	to be assigned 2003-03-12	
<150> <151>	US 60/412,049 2002-09-18	
<150> <151>	US 60/364,890 2002-03-13	
<160>	384	
<170>	FastSEQ for Windows Version 4.0	
<210> <211> <212> <213>	18	
<400> gtccca	1 aggag cccatcct	18
<210> <211> <212> <213>	19	
<400> cccggo	2 ctgtt gtctccata	19
<210> <211> <212> <213>	68	
<400> gtccca cagccg	aggag cccatcctgt ttgactgcag cattgctgag aacattgcct atggagacaa	60 68
<210> <211> <212> <213>	18	
<400> tcatgo	4 ptgcc cgtcaatg	18
<210> <211> <212> <213>	23	
<400> cgattg	5 ptctt tgctcttcat gtg Page 1	23

39740-0001PCT.txt

<210> <211> <212> <213>	79 DNA	sapiens					r
<400> tcatgo tgaaga	tgcc	cgtcaatgct agacaatcg	gtgatggcga	tgaagaccaa	gacgtatcag	gtggcccaca	60 79
<210> <211> <212> <213>	20 DNA	sapiens					
<400> agggga		ttggacacat					20
<210> <211> <212> <213>	20 DNA	sapiens					
<400> aaaact		ggctttgtca				· .	20
<210> <211> <212> <213>	65 DNA	sapiens					a
<400> agggga gtttt		ttggacacat	ctgccattcg	acatgactgc	aattttgaca	aagccatgca	60 65
<210> <211> <212> <213>	22 DNA	sapiens					,
<400> tcatco		gatctacttc	ct				22
<210> <211> <212> <213>	20 DNA	sapiens					
<400> ccgttg		gaatcagcaa	2-3				20
<210> <211> <212> <213>	91 DNA	sapiens					
<400> tcatco ctttca	tggc	gatctacttc cttgctgatt	ctctggcaga ccactcaacg	acctaggtcc g	ctctgtcctg	gctggagtcg	60 91
<210> <211> <212> <213>	20 DNA	sapiens					
<400> agcgcc		atctacaact					20

39740-0001PCT.txt <210> 14 <211> 20 <212> DNA <213> Homo sapiens <400> 14 agagccctg gagagaagat 20 <210> 15 <211> 66 <212> DNA <213> Homo sapiens <400> 15 agcgcctgga atctacaact cggagtccag tgttttccca cttgtcatct tctctccagg 60 ggctct <210> 16 <211> 24 <212> DNA <213> Homo sapiens <400> 16 gcccagagaa ggtctatgaa ctca 24 <210> 17 <211> 22 <212> DNA <213> Homo sapiens <400> 17 gtttcaaagg cttggtggat tt 22 <210> 18 <211> 94 <212> DNA <213> Homo sapiens gcccagagaa ggtctatgaa ctcatgcgag catgttggca gtggaatccc tctgaccggc 60 cctcctttgc tgaaatccac caagcctttg aaac 94 <210> 19 <211> 21 <212> DNA <213> Homo sapiens cgcagtgcag ctgagtatct g 21 <210> 20 <211> 21 <212> DNA <213> Homo sapiens <400> 20 tgcccagggc tactctcact t 21 <210> 21 <211> 80 <212> DNA <213> Homo sapiens <400> 21 cgcagtgcag ctgagtatct gctcagcagt ctaatcaatg gcagcttcct ggtgcgagaa 60 agtgagagta gccctgggca 80 <210> 22

	•		3	9740-0001PC	T.txt		
<211> <212> <213>	DNA	sapiens	•				
<400> cagcag		ggatcagcaa	g	-			21
<210> <211> <212> <213>	18 DNA	sapiens					
<400> gcattt		tggacgat		•	-		18
<210> <211> <212> <213>	66 DNA	sapiens					
<400> cagcag aaatgo	gatgt	ggatcagcaa	gcaggagtat	gacgagtccg	gcccctccat	cgtccaccgc	60 66
<210> <211> <212> <213>	20 DNA	sapiens			5.		•
<400> cgcttc		gcgctgagat		*			20
<210> <211> <212> <213>	20 DNA	sapiens					
<400> tcccgg		ccacgttctt					20
<210> <211> <212> <213>	71 DNA	sapiens					•
<400> cgcttc gtgtac	tatg		tgtgtcagcc	ctggactacc	tgcactcgga	gaagaacgtg	60 71
<210> <211> <212> <213>	25 DNA	sapiens			· .		
<400> ttgtct		cttggactat	ctaca				25
<210> <211> <212> <213>	24 DNA	sapiens					. *
<400> ccagca		attctccaac	ttga				24
<210> <211> <212>	75						

39740-0001PCT.txt

<213> Homo	sapiens	•	33740 000±1 (CI • CXC	*	-
<400> 30 ttgtctctgc agaatctaat		ctacattccg	gaaagattgt	gtaccgtgat	ctcaagttgg	60 75
<210> 31 <211> 25 <212> DNA <213> Homo	sapiens		• .			
<400> 31 gaaggagata	aggaggatgt	tgaca				25
<210> 32 <211> 18 <212> DNA <213> Homo	sapiens	; ·				•
<400> 32 cgccacggag	atccaatc		•			18
<210> 33 <211> 74 <212> DNA <213> Homo	sapiens					
<400> 33 gaaggagata ggatctccgt		tgacaaggca	gtgaaggccg	caagacaggc	ttttcagatt	60 74
<210> 34 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 34 tggtgaacat	tgtgccagga	t				21
<210> 35 <211> 22 <212> DNA <213> Homo	sapiens					
<400> 35 gaaggcgatc	ttgttgatct	ga			•	22
<210> 36 <211> 80 <212> DNA <213> Homo	sapiens					
<400> 36 tggtgaacat agatcaacaa	tgtgccagga gatcgccttc	ttcgggccca	cagtgggagc	agcaatttct	tctcaccctc	60 80
<210> 37 <211> 20 <212> DNA <213> Homo	sapiens					
<400> 37 ggacagcagg	aatgtgtttc					20
<210> 38 <211> 20 <212> DNA <213> Homo	sapiens		Page 5			
		1	raye			

39740-0001PCT.txt

<400> 38 acccactcga	tttgtttctg		-	· .	•	20
<210> 39 <211> 69 <212> DNA <213> Homo	sapiens	• .				٠
<400> 39 ggacagcagg cgagtgggt	aatgtgtttc	tccatacagg	tcacggggag	ccaatggttc	agaaacaaat	60 69
<210> 40 <211> 27 <212> DNA <213> Homo	sapiens	· · · · ·				,
<400> 40 tgtgagtgaa	atgccttcta	gtagtga		2 20 - 1		27
<210> 41 <211> 27 <212> DNA <213> Homo	sapiens	· · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·			
<400> 41 ttgtggttcg	ttatcatact	cttctga		•		27
<210> 42 <211> 82 <212> DNA <213> Homo	sapiens					
	atgccttcta aacgaaccac	gtagtgaacc aa	gtcctcggga	gccgactatg	actactcaga	60 82
<210> 43 <211> 19 <212> DNA <213> Homo	sapiens		•			
<400> 43 gtctcgctcc	gtggcctta					19
<210> 44 <211> 24 <212> DNA <213> Homo	sapiens	5 × †*				
<400> 44 cgtgagtaaa	cctgaatctt	tgga				24
<210> 45 <211> 93 <212> DNA <213> Homo	sapiens					
<400> 45 gtctcgctcc ccagcgtact	gtggccttag ccaaagattc	ctgtgctcgc aggtttactc	gctactctct acg	ctttctggcc	tggaggctat	60 93
<210> 46 <211> 20 <212> DNA <213> Homo	sapiens					

		39740-0001PCT.txt	
<400> 46 ccattcccac	cattctacct	337 10 00017 07 1000	20
<210> 47 <211> 20 <212> DNA <213> Homo	sapiens		
<400> 47 gggaacatag	acccaccaat		20
<210> 48 <211> 66 <212> DNA <213> Homo	sapiens		*
<400> 48 ccattcccac gttccc	cattctacct	gaggccagga cgtctggggt gtggggattg gtgggtctat	60 60
<210> 49 <211> 18 <212> DNA <213> Homo	sapiens		
<400> 49 ccgccgtgga	cacagact		18
<210> 50 <211> 21 <212> DNA <213> Homo	sapiens		
<400> 50 ttgccgtcag	aaaacatgtc	a	2:
<210> 51 <211> 70 <212> DNA <213> Homo	sapiens		
<400> 51 ccgccgtgga ctgacggcaa		ccccgagagg tctttttccg agtggcagct gacatgtttt	60 70
<210> 52 <211> 25 <212> DNA <213> Homo	sapiens		
<400> 52 cagatggacc	tagtacccac	tgaga	2
<210> 53 <211> 24 <212> DNA <213> Homo	sapiens		
<400> 53 cctatgattt	aagggcattt	ttcc	. 24
<210> 54 <211> 73 <212> DNA <213> Homo	sapiens		
<400> 54 cagatggacc	tagtacccac	tgagatttcc acgccgaagg acagcgatgg gaaaaatgcc	60

		39740-0001PC1.TXT	
cttaaatcat	agg	337 TO GOODING FEAC	73
<210> 55 <211> 24 <212> DNA <213> Homo	sapiens		•
<400> 55 cttttgtgga	actctatggg	aaca	24
<210> 56 <211> 19 <212> DNA <213> Homo	sapiens		
<400> 56 cagcggttga	agcgttcct		19
<210> 57 <211> 70 <212> DNA <213> Homo	sapiens		
<400> 57 cttttgtgga tcaaccgctg	actctatggg	aacaatgcag cagccgagag ccgaaagggc caggaacgct	60 70
<210> 58 <211> 24 <212> DNA <213> Homo	sapiens		
<400> 58 ggatatttcc	gtggctctta	ttca	24
<210> 59 <211> 25 <212> DNA <213> Homo	sapiens		
<400> 59 cttctcatca	aggcagaaaa	atctt	25
<210> 60 <211> 86 <212> DNA <213> Homo	sapiens		,
<400> 60 ggatatttcc caagattttt	gtggctctta ctgccttgat	ttcaaactct ccatcaaatc ctgtaaactc cagagcaaat gagaag	60 86
<210> 61 <211> 23 <212> DNA <213> Homo	sapiens		-
<400> 61 gcagttggaa	gacacaggaa	agt	23
<210> 62 <211> 21 <212> DNA <213> Homo	sapiens		
<400> 62 tgcgtggcac	tattttcaag	a	21

39740-0001PCT.txt

<210> <211> <212> <213>	77 DNA	sapiens					
	ggaa	gacacaggaa ccacgca	agtatcccca	aattgcagat	ttatcaacgg	cttttatctt	60 77
<210> <211> <212> <213>	20 DNA	sapiens					
<400> tgtttt	_	cccgggctta			,		20
<210> <211> <212> <213>	24 DNA	sapiens					
<400> caaago		agctctagca	aaag		:		24
<210> <211> <212> <213>	80 DNA	sapiens					
	gatt	cccgggctta gacagctttg	ccaggtgaga	agtgagggag	gaagaaggca	gtgtcccttt	60 80
<210> <211> <212> <213>	20 DNA	sapiens					
<400> tcaggg		agaaatctgt			•		20
<210> <211> <212> <213>	20 DNA	sapiens					
<400> ccattc		tgatctgtgg		. 1		•	20
<210> <211> <212> <213>	65 DNA	sapiens					
<400> tcaggg aatgg		agaaatctgt	tgctatgggc	ccttcaccaa	catgcccaca	gatcaactgg	60 65
<210> <211> <212> <213>	20 DNA	sapiens					
<400> agttcg		ttgcaagatg					20
<210>	71		•	• . •			

				39/40-0001P	CT.txt		
<211> <212> <213>	DNA	sapiens			•		
<400> aaggta		gggtctgctg					20
<210> <211> <212> <213>	70 DNA	sapiens				· · · · · · · · · · · · · · · · · · ·	. *
<400> agttcg agctta	gtgct	ttgcaagatg	gtgcagagct	ttatgaagca	gtgaagaatg	cagcagaccc	60 70
<210> <211> <212> <213>	21 DNA	sapiens					,
<400> gcatgt		ggcctctaag	a				21
<210> <211> <212> <213>	22 DNA	sapiens					
<400> cggtgt		gcacagcttc	tc .				22
<210> <211> <212> <213>	69 DNA	sapiens					
<400> gcatgt tctaca	tcgt.	ggcctctaag	atgaaggaga	ccatccccct	gacggccgag	aagctgtgca	60 69
<210><211><211><212><213>	20 DNA	sapiens					
<400>	76	gaaggcgctt					20
<210> <211> <212> <213>	21 DNA	sapiens					
<400> tgccto		atcggcaact	g				21
<210> <211> <212> <213>	65 DNA	sapiens			\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.\.		
<400> agatga aggca		gaaggcgctt	ttcaccgcgg	ccatcctgca	ggcacagttg	ccgattacag	60 65
<210> <211>							

•		39740-0001PCT.txt	
<212> DNA <213> Homo	sapiens	33740 GOOTECTICKE	
<400> 79 tggttcccag	ccctgtgt		18
<210> 80 <211> 19 <212> DNA <213> Homo	sapiens		
<400> .80 ctcctccacc	ctgggttgt		19
<210> 81 <211> 74 <212> DNA <213> Homo	sapiens		
<400> 81 tggttcccag ccagggtgga		c ccagattcag attcgagtca tgtacacaac	60 74
<210> 82 <211> 20 <212> DNA <213> Homo	sapiens		
<400> 82 tcttgctggc	tacgcctctt		20
<210> 83 <211> 21 <212> DNA <213> Homo	sapiens		,
<400> 83 ctgcattgtg	gcacagttct g		21
<210> 84 <211> 71 <212> DNA <213> Homo	sapiens		<i>3</i>
<400> 84 tcttgctggc ccacaatgca		t tagacgtcct ccgtccatat cagaactgtg	60 71
<210> 85 <211> 21 <212> DNA <213> Homo	sapiens		,
<400> 85 tgagtgtccc	ccggtatctt c		21
<210> 86 <211> 21 <212> DNA <213> Homo	sapiens		
<400> 86 cagccgcttt	cagattttca t		21
<210> 87 <211> 81 <212> DNA <213> Homo	sapiens	Page 11	
		Page 11	, ,

39740-0001pcT.txt

	ccggtatctt gaaagcggct		ccaatcccga	tgaaattgga	aattttattg	60 81
<210> 88 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 88 tggagactct	cagggtcgaa	a				21
<210> 89 <211> 22 <212> DNA <213> Homo	sapiens	7	· · · · · · · · · · · · · · · · · · ·			
<400> 89 ggcgtttgga	gtggtagaaa	tc			•	22
<210> 90 <211> 65 <212> DNA <213> Homo	sapiens					
<400> 90 tggagactct acgcc	cagggtcgaa	aacggcggca	gaccagcatg	acagatttct	accactccaa	60 65
<210> 91 <211> 21 <212> DNA <213> Homo	sapiens	in te				
<400> 91 cggtggacca	cgaagagtta	a				21
<210> 92 <211> 19 <212> DNA <213> Homo	sapiens		•			
<400> 92 ggctcgcctc	ttccatgtc				•	19
<210> 93 <211> 66 <212> DNA <213> Homo	sapiens					
<400> 93 cggtggacca cgagcc	cgaagagtta	acccgggact	tggagaagca	ctgcagagac	atggaagagg	60 66
<210> 94 <211> 19 <212> DNA <213> Homo	sapiens					
<400> 94 gcggaaggtc	cctcagaca				. · · · · · · · · · · · · · · · · · · ·	19
<210> 95 <211> 23 <212> DNA <213> Homo	sapiens					

39740-0001PCT.txt

<400> tctaag		ccgaggtttc	tca	•	*		2 3
<210> <211> <212> <213>	70 DNA	sapiens		· · · · · · · · · · · · · · · · · · ·			2
<400> gcggaa gaaact	aggtc	cctcagacat	ccccgattga	aagaaccaga	gaggctctga	gaaacctcgg	60 70
<210> <211> <212> <213>	22 DNA	sapiens	**************************************				
<400> ccagct		gcctgtcact	at				22
<210> <211> <212> <213>	20 DNA	sapiens					
<400> gggaat		tagcccaaga		•			20
<210> <211> <212> <213>	71 DNA	sapiens					
<400> ccagct accaca	ttgt		attcctcatg	ccaccactgc	caacacctct	gtcttgggct	60 71
<210> <211> <212> <213>	27 DNA	sapiens					
<400> ttgcta		taagtgcttc	tccaaga				27
<210> <211> <212> <213>	22 DNA	sapiens					
<400> gtggaa		agctcactgt	ag.				22
<210> <211> <212> <213>	73 DNA	sapiens					
<400> ttgcta gctgco	ataac	taagtgcttc cac	tccaagaccc	caactgagtc	cccagcacct	gctacagtga	60 73
<210> <211> <212> <213>	19 DNA	sapiens					
<400>	103						

			39/40-000TF	CLITXT		- "
aggacgcaag	gagggtttg					19
<210> 104 <211> 21 <212> DNA <213> Homo	sapiens					
<400> 104 gatgtccgcc	gagtccttac	t				21
<210> 105 <211> 87 <212> DNA <213> Homo	sapiens					
	gagggtttgt aggactcggc		ı ctcgagact <u>c</u>	g taggcactg	c catggcccct	60 87
<210> 106 <211> 24 <212> DNA <213> Homo	sapiens					
<400> 106 ctatatgcag	ccagagatgt	gaca				24
<210> 107 <211> 24 <212> DNA <213> Homo	sapiens					· ·
<400> 107 ccacgagttt	cttactgaga	atgg	-			24
<210> 108 <211> 82 <212> DNA <213> Homo	sapiens					ŀ
	ccagagatgt agaaactcgt		gtggacagco	tgccactca	t cacagcctcc	60 82
<210> 109 <211> 20 <212> DNA <213> Homo	sapiens					
<400> 109 tgtcgatgga	cttccagaac			•		20
<210> 110 <211> 19 <212> DNA <213> Homo	sapiens					
<400> 110 attgggacag	cttggatca					19
<210> 111 <211> 62 <212> DNA <213> Homo	sapiens					
<400> 111 tgtcgatgga at	cttccagaac	cacctgggca	gctgccaaaa	ı gtgtgatcc	a agctgtccca	60 62

39740-0001PCT.txt

<210> <211> <212> <213>	23 DNA	sapiens	· · · · · · · · · · · · · · · · · · ·				
<400> gatcta		ggcgactgtc	gaa				23
<210> <211> <212> <213>	25 DNA	sapiens		·			
<400> ttagat		ttttctcctc	ttctg				25
<210> <211> <212> <213>	82 DNA	sapiens					
	agat	ggcgactgtc aacggaatct		ccacccctac	tcctaatccc	ccgactacag	60 82
<210> <211> <212> <213>	20 DNA	sapiens					
<400> cggtgt		agtgcagcaa					20
<210> <211> <212> <213>	19 DNA	sapiens		. '			
<400> cctctc		gtgctccat					19
<210> <211> <212> <213>	70 DNA	sapiens					
<400> cggtgt ttgcga	gaga	agtgcagcaa	gccctgtgcc	cgagtgtgct	atggtctggg	catggagcac	60 70
<210> <211> <212> <213>	23 DNA	sapiens					
<400> cggtta		atgccagata	cac				23
<210> <211> <212> <213>	24 DNA	sapiens					4
<400> gaactg		ccactgaaga	aagg			*	24
<210>	120	* * * * * * * * * * * * * * * * * * *			_		

<211> <212> <213>	DNA	sapiens.	•				
	itgtc	atgccagata ggtctcagtt		aggtactccc	tcctcccggg	aaggcaccct	60 81
<210> <211> <212> <213>	19 DNA	sapiens					
<400> cgtggt		ctctatgac			· .		19
<210> <211> <212> <213>	19 DNA	sapiens					
<400> ggctag		cgcatgtag					19
<210> <211> <212> <213>	68 DNA	sapiens					
<400> cgtggt cactag	gccc	ctctatgacc	tgctgctgga	gatgctggac	gcccaccgcc	tacatgcgcc	60 68
<210> <211> <212> <213>	20 DNA	sapiens					
<400> tggtco		ccagttatca			•		20
<210> <211> <212> <213>	23 DNA	sapiens					٠
<400> tgttct		atcttgcttc	aca		•		23
<210> <211> <212> <213>	76 DNA	sapiens					-
	atcg	ccagttatca agaaca	catctgtatg	cggaacctca	aaagagtccc	tggtgtgaag	60 76
<210> <211> <212> <213>	24 DNA	sapiens					
<400> catcca		aactttggta	tcgt				24
<210> <211>	128 21			•			,

<212> <213>		sapiens	•		•	•	
<400> cagtct		ggtggcagtg	a	• • • • • • • • • • • • • • • • • • •			21
<210> <211> <212> <213>	74 DNA	sapiens					
<400> catcca caccca	ıtgac		tcgtggaagg	actcatgacc	acagtccatg	ccatcactgc	60 74
<210> <211> <212> <213>	23 DNA	sapiens					
<400> caaagg		cactgtggtg	tct				23
<210> <211> <212> <213>	26 DNA	sapiens					
<400> gagtca		ggcttattca	cagatg				26
<210> <211> <212> <213>	75 DNA	sapiens					
<400> caaagg aagcca	agct		tctgtgttcc	aaccactgaa	tctggacccc	atctgtgaat	60 75
<210> <211> <212> <213>	20 DNA	sapiens					
<400> ccatct		ccatcttgtt			•	-	20
<210> <211> <212> <213>	20 DNA	sapiens					. *
<400> ggccac		gtattatctg					20
<210> <211> <212> <213>	67 DNA	sapiens					
<400> ccatct ggtggc	gcat	ccatcttgtt	tgggctcccc	acccttgaga	agtgcctcag	ataataccct	60 67
<210> <211> <212>	23						

				39740-0001P	CT.txt		
<213>	Homo	sapiens		,	CITCXC		-
<400> cgaaaa		ctgaacagtg	aca				23
<210> <211> <212> <213>	20 DNA	sapiens					
<400>	137	ccaccagtga					20
<210> <211> <212> <213>	73 DNA	sapiens					
<400> cgaaaa tggctg	agatg	ctgaacagtg tga	acaaatccaa	ctgaccagaa	gggaggagga	agctcactgg	60 73
<210> <211> <212> <213>	20 DNA	sapiens		· .			
<400> gagaco		tgtcccagaa	•		•		20
<210> <211> <212> <213>	23 DNA	sapiens	· · · · · · · · · · · · · · · · · · ·				-
<400> ggttgt		agcgaaggag	atc				23
<210> <211> <212> <213>	76 DNA	sapiens					
	ctgc	tgtcccagaa acaacc	ccagggaggc	aagaccttca	ttgtgggaga	ccagatctcc	60 76
<210> . <211> <212> <213>	20 DNA	sapiens					.*
<400> cccact		agccaagtca					20
<210> <211> <212> <213>	20 DNA	sapiens					
<400> cacgca		gtatcagtct					20
<210> <211> <212> <213>	73 DNA	sapiens					

400 : 444			39740-0001p	CT.txt		
<400> 144 cccactcagt taccacctgc	agccaagtca gtg	caatgtttgg	aaaacagccc	gtttacttga	gcaagactga	60 73
<210> 145 <211> 24 <212> DNA <213> Homo	sapiens					-
<400> 145 catcaaatgt	cagccctgga	gttc				24
<210> 146 <211> 26 <212> DNA <213> Homo	sapiens			· ·		•
<400> 146 ttcctgtagg	tctttacccc	gatagc		•		26
<210> 147 <211> 85 <212> DNA <213> Homo	sapiens					. •
	cagccctgga aaagacctac	gttccatgat aggaa	accacacgaa	cacagctttt	tgccttcgag	60 85
<210> 148 <211> 24 <212> DNA <213> Homo	sapiens					
<400> 148 tccaggatgt	taggaactgt	gaag				24
<210> 149 <211> 22 <212> DNA <213> Homo	sapiens					
<400> 149 gcgtgtctgc	gtagtagctg	tt		,		22
<210> 150 <211> 73 <212> DNA <213> Homo	sapiens					
<400> 150 tccaggatgt tacgcagaca		gaagatggaa	gggcatgaaa	ccagcgactg	gaacagctac	60 73
<210> 151 <211> 23 <212> DNA <213> Homo	sapiens					
<400> 151 aacgactgct	actccaagct	caa				23
<210> 152 <211> 22 <212> DNA <213> Homo	sapiens					
400- 153						

	•	39740-0001PCT.txt	
ggatttccat	cttgctcacc	tt	22
<210> 153 <211> 76 <212> DNA <213> Homo	sapiens		
<400> 153 aacgactgct agcaagatgg	actccaagct aaatcc	caaggagctg gtgcccagca tcccccagaa caagaaggtg	60 76
<210> 154 <211> 21 <212> DNA <213> Homo	sapiens		
<400> 154 tccggagctg	tgatctaagg	a	21
<210> 155 <211> 20 <212> DNA <213> Homo	sapiens		
<400> 155 cggacagagc	gagctgactt		20
<210> 156 <211> 76 <212> DNA <213> Homo	sapiens		
<400> 156 tccggagctg cagctcgctc	tgatctaagg tgtccg	aggctggaga tgtattgcgc acccctcaag cctgccaagt	60 76
<210> 157 <211> 17 <212> DNA <213> Homo	sapiens		
<400> 157 acgcaccggg	tgtctga		17
<210> 158 <211> 24 <212> DNA <213> Homo	sapiens		
<400> 158 tgccctttct	tgatgatgat	tatc	24
<210> 159 <211> 68 <212> DNA <213> Homo	sapiens		
<400> 159 acgcaccggg aaagggca	tgtctgatcc	caagttccac cccctccatt caaagataat catcatcaag	60 68
<210> 160 <211> 22 <212> DNA <213> Homo	sapiens		
<400> 160 ccattcaccc	tgtgtaacag	ga	22

<210> <211> <212> <213>	21 DNA	sapiens					
<400> ccgacc		aggttaaggc	a			;	21
<210> <211> <212> <213>	68 Dna	sapiens					* * * * * * * * * * * * * * * * * * *
<400> ccattc agggtc	accc	tgtgtaacag	gaccccaagg	acctgcctcc	ccggaagtgc	cttaacctag	60 68
<210> <211> <212> <213>	20 DNA	sapiens					
<400> cgtcag		caccatgtct					20
<210> <211> <212> <213>	24 DNA	sapiens					
<400> ggttaa		tgacatcctc	aaga				24
<210> <211> <212> <213>	81 DNA	sapiens					
	gacc	caccatgtct accaattaac		gcggccgaga	catggcttgg	ccacagctct	60 81
<210> <211> <212> <213>	23 DNA	sapiens					· .
<400> caaacg		catgtacggt	cta				23
<210> <211> <212> <213>	18 DNA	sapiens					
<400> gctcgt		gcactctt	· . ·				18
<210> <211> <212> <213>	88 DNA	sapiens					
	ctga	catgtacggt aagagtgcgc		cctccccgc	atcacatcca	ctggtattgg	60 88

<210> <211> <212> <213>	25 DNA	sapiens	•				
<400> gaggca		cttatggctt	aatta				25
<210> <211> <212> <213>	18 DNA	sapiens					
<400> ggcact		ttgagcat					18
<210> <211> <212> <213>	75 DNA	sapiens					
<400> gaggca ctcaag	actg		aattaagtca	gatgcggcca	tgactgtcgc	tgtaaagatg	60 75
<210> <211> <212> <213>	18 DNA	sapiens					
<400> gtcccc		tggatgtt					18
<210> <211> <212> <213>	25 DNA	sapiens					
<400> gatcag		gctgtctgac	aattg				25
<210> <211> <212> <213>	79 DNA	sapiens					
	ggga	tggatgtttt tgactgatc	gccaagtcat	tgttggataa	gcgagatggt	agtacaattg	60 79
<210> <211> <212> <213>	21 DNA	sapiens					
<400> cgagga		ttcttcagca	a				21
<210> <211> <212> <213>	22 DNA	sapiens					
<400> actctg		agctcactgt	tg				22
<210> <211>				Page 3	•		·

<212> <213>		sapiens			•	·	
<400> cgagga gctggt	ittgg		agacagagga	actgaaccgc	gaggtggcca	ccaacagtga	60 73
<210> <211> <212> <213>	20 DNA	sapiens		· · · · · · · · · · · · · · · · · · ·			
<400> tcagto		aggagttgga		`.			20
<210> <211> <212> <213>	20 DNA	sapiens				•	* * *
<400> tgccat		agaggaaaca					20
<210> <211> <212> <213>	69 DNA	sapiens			- 1- · · · · · · · · · · · · · · · · · ·		
<400> tcagtg gatatg	gaga	aggagttgga	ccagtcaaca	tctctgttgt	cacaagcagt	gtttcctctg	60 69
<210> <211> <212> <213>	26 DNA	sapiens				•	,
<400> gtacaa		gaaccagact	ccaatg				26
<210> <211> <212> <213>	18 DNA	sapiens					
<400> gtgtag		cggacact	· · · ·	· · · · · · · · · · · · · · · · · · ·			18
<210> <211> <212> <213>	87 DNA	sapiens					
	igaga.	gaaccagact gtgtccgcgg	ccaatgtcat gctacac	tgtggtggac	tggctgtcac	gggctcagga	60 87
<210> <211> <212> <213>	22 DNA	sapiens					
<400> gacatt	_	gtcctgcagt	ca				22
<210> <211> <212>	20						•

<213> Homo	sapiens	•	337 10 00021	C1. CX C		-
<400> 185 ctccgatcgc	acacatttgt					20
<210> 186 <211> 86 <212> DNA <213> Homo	sapiens					
	gtcctgcagt atgtgtgcga		ctgccccacc	ctttgttcag	tgtggctggt	60 86
<210> 187 <211> 24 <212> DNA <213> Homo	sapiens					
<400> 187 gttttggagg	aaatgtgttc	ttca				24
<210> 188 <211> 26 <212> DNA <213> Homo	sapiens					•
<400> 188 ttctctaata	cactgccgtc	ttaagg		•		26
<210> 189 <211> 101 <212> DNA <213> Homo	sapiens			·		
<400> 189 gttttggagg gctctgcaag	aaatgtgttc ccctccctta	ttcagtgcac agacggcagt	agaatgcagc gtattagaga	aaaacagcca a	tctgataaat	60 101
<210> 190 <211> 22 <212> DNA <213> Homo	sapiens					
<400> 190 acgagaacga	gggcatctat	gt				22
<210> 191 <211> 22 <212> DNA <213> Homo	sapiens					
<400> 191 gcatgtaggt	gcttccaatc	ac				22
<210> 192 <211> 75 <212> DNA <213> Homo	sapiens					
<400> 192 acgagaacga gaagcaccta	gggcatctat catgc	gtgcaggatg	tcaagaccgg	aaaggtgcgc	gctgtgattg	60 75
<210> 193 <211> 21 <212> DNA <213> Homo	sapiens		Page 24			

<400> 19 tccctcca	3 ct cggaaggact	a				21
<210> 19 <211> 22 <212> DN <213> Ho						, .
<400> 19 cggttgtt	4 gc tgatctgtct	ca				22
<210> 19 <211> 84 <212> DN <213> Ho	•					-
	5 ct cggaaggact ag atcagcaaca		caagagggtc	aagttggaca	gtgtcagagt	60 84
<210> 19 <211> 19 <212> DN <213> Ho						
<400> 19 ttgttggt	6 gt gccctggtg	•				19
<210> 19 <211> 21 <212> DN <213> Ho						
<400> 19 tgggttct	7 gt ccaaacactg	<u>.</u> g				21
<210> 19 <211> 67 <212> DN <213> HO						
<400> 19 ttgttggt gaaccca	8 gt gccctggtgc	cgtggtggcg	gtcactccct	ctgctgccag	tgtttggaca	60 67
<210> 19 <211> 20 <212> DN <213> Ho	-					
<400> 19 actgaagg	9 ag acccttggag					20
<210> 20 <211> 20 <212> DN <213> Ho						
<400> 20 taaataac	0 cc tgcccacaca					20
<210> 20 <211> 62 <212> DN <213> Ho				t v si		
<400> 20	1		page 3	F.		

				39740-0001P	CT.txt	*	
actgaa ta	ggag	acccttggag	cctaggggca	tcggcaggag	agtgtgtggg	cagggttatt	60° 62
<210> <211> <212> <213>	28 Dna	sapiens					
<400> agttac		aaataccacg	aggtcctt	· ·			28
<210> <211> <212> <213>	21 DNA	sapiens					
<400> gtcggt		gatttgtgca	a '		-		21
<210> <211> <212> <213>	79 DNA	sapiens					- 40
	taaa	aaataccacg ctcaccgac	aggtccttca	gttgagacca	aagaccggtg	tcaggggatt	60 79
<210> <211> <212> <213>	20 DNA	sapiens					* *.
<400> gggagt		aagagatgga					20
<210> <211> <212> <213>	20 DNA	sapiens			d .		
<400> cttcaa		cttcccaaac					20
<210> <211> <212> <213>	72 DNA	sapiens					
<400> gggagt aggtgg	ttcc		ctagtgcttg	gtcgggtctt	ggggtctgga	gcgtttggga	60 72
<210> <211> <212> <213>	23 DNA	sapiens					
<400> aggtgt		catcaacgtc	tct			A . T	23
<210> <211> <212> <213>	20 Dna	sapiens					
<400> tcccga		aatgcacatg					20

<210> 210 <211> 90 <212> DNA <213> Homo	sapiens	:			. · ·	,
	catcaacgtc catgtgcatt		cagtgcagac	tgtggtccgc	cagggtgaga	60 90
<210> 211 <211> 24 <212> DNA <213> Homo	sapiens					
<400> 211 agagccagtt	gctgtagaac	tcaa				24
<210> 212 <211> 21 <212> DNA <213> Homo	sapiens					:
<400> 212 ctgggcctac	acagtccttc	a		•		21
<210> 213 <211> 74 <212> DNA <213> Homo	sapiens					
<400> 213 agagccagtt ctgtgtaggc	gctgtagaac ccag	tcaaatctct	gctgggcaag	gatgttctgt	tcttgaagga	60 74
<210> 214 <211> 26 <212> DNA <213> Homo	sapiens			ing second secon	. • •	,
<400> 214 gaaatgactg	catcgttgat	aaaatc				26
<210> 215 <211> 19 <212> DNA <213> Homo	sapiens			2		
<400> 215 tgccagcctg	acagcactt					19
<210> 216 <211> 78 <212> DNA <213> Homo	sapiens					
<400> 216 gaaatgactg agtgctgtca	catcgttgat ggctggca	aaaatccgca	gaaaaaactg	cccagcatgt	cgccttagaa	60 78
<210> 217 <211> 20 <212> DNA <213> Homo	sapiens					
<400> 217 gatcaacggc	tacatccaga					20

39740-0001PCT.txt <210> 218 <211> 20 <212> DNA <213> Homo sapiens <400> 218 tgaactgtga ggccagagac 20 <210> 219 <211> 68 <212> DNA <213> Homo sapiens <400> 219 gatcaacggc tacatccaga agatcaagtc gggagaggag gactttgagt ctctggcctc 60 acagttca <210> 220 <211> 19 <212> DNA <213> Homo sapiens <400> 220 19 gtggatgtgc cctgaagga <210> 221 <211> 20 <212> DNA <213> Homo sapiens <400> 221 ctgcggatcc agggtaagaa 20 <210> 222 <211> 70 <212> DNA <213> Homo sapiens <400> 222 gtggatgtgc cctgaaggac aagccaggcg tctacacgag agtctcacac ttcttaccct 60 ggatccgcag <210> 223 <211> 27 <212> DNA <213> Homo sapiens tggacttcta gtgatgagaa agattga 27 <210> 224 <211> 22 <212> DNA <213> Homo sapiens <400> 224 cactgcgaga tcaccacagg ta 22 <210> 225 <211> 84 <212> DNA <213> Homo sapiens <400> 225 tggacttcta gtgatgagaa agattgagaa tgttcccaca ggccccaaca ataagcccaa 60 gctacctgtg gtgatctcgc agtg <210> 226

				39740-0001	PCT txt	* * * * * * * * * * * * * * * * * * * *	
<211> <212> <213>	DNA	sapiens		327.10 0002	. CITEXC		
<400> tggcta		aagatgacaa	tcatg			,	25
<210><211><211><212><213>	25 DNA	sapiens					
<400>	227	attacaccag	ttcgt		٠.	•	25
<210> <211> <212> <213>	81 DNA	sapiens					
<400> tggcta actggt	agtg	aagatgacaa tgatatgtgc	tcatgttgca a	gcaattcac	t gtaaagctg	g aaagggacga	60 81
<210> <211> <212> <213>	23 DNA	sapiens					
<400> tctgca		tggaagcact	cta	*			23
<210> <211> <212> <213>	21 DNA	sapiens			· · · · · · · · · · · · · · · · · · ·		
<400> gccgag		ttctaccaga	a				21
<210> <211> <212> <213>	79 DNA	sapiens					
<400> tctgca ctggta	gagt	tggaagcact agcctcggc	ctatggtgac	atcgatgct	g tggagctgta	a tcctgccctt	60 79
<210> <211> <212> <213>	24 DNA	sapiens					* * * * * * * * * * * * * * * * * * *
<400> acgaca		tgccgtacag	tact				24
<210> <211> <212> <213>	18 DNA	sapiens					
<400> ccggga		acgaagga					18
<210> <211> <212>	86			Page 2	29		•

<213>	Homo.	sapiens				•	
<400> acgaca acagct	ıcgta	tgccgtacag cttcgtgttt	tactcctgcc tcccgg	gcctcctgaa	cctcgatggc	acctgtgctg	60 86
<210> <211> <212> <213>	19 DNA	sapiens					
<400> ctgccg		ggcttctat			•		19
<210> <211> <212> <213>	22 DNA	sapiens					
<400> ccaggt		gaaactgtgg	at				· 22
<210> <211> <212> <213>	68 DNA	sapiens					
<400> ctgccg gaacct	ggat	ggcttctatg	aggctgagct	ctgcccggac	cgctgcatcc	acagtttcca	60 68
<210> <211> <212> <213>	20 DNA	sapiens					
<400> ccacaa		aaggcagaca					20
<210> <211> <212> <213>	21 DNA	sapiens					
<400> gcgtgc		ttggtcttag	a		e ·		21
<210> <211> <212> <213>	85 DNA	sapiens					
<400> ccacaa caggto	gctg	aaggcagaca accaaggaag	aggcccgcaa cacgc	gaagctcctg	gctgaccagg	ctgaggcccg	60 85
<210> <211> <212> <213>	24 DNA	sapiens					
<400> ccattc		atcaacgggt	acaa				24
<210> <211> <212> <213>	23 DNA	sapiens		Page 2/			; ,

<400> 242 tcagcaagtg	ggaaggtgta	atc	23
<210> 243 <211> 75 <212> DNA <213> Homo	sapiens		,
<400> 243 ccattctatc cttcccactt		acaaacgagt cctggccttg tctgtggaga cggattacac	60 75
<210> 244 <211> 20 <212> DNA <213> Homo	sapiens		-
<400> 244 tatcgaggca	ggtcatacca		20
<210> 245 <211> 20 <212> DNA <213> Homo	sapiens		
<400> 245 taacgcttgg	catcatcatt		20
<210> 246 <211> 74 <212> DNA <213> Homo	sapiens		-
<400> 246 tatcgaggca gatgccaagc		tgaccggaag tcaaaagttg acctggatag gctcaatgat	60 74
tatcgaggca	gtta	tgaccggaag tcaaaagttg acctggatag gctcaatgat	60 74
tatcgaggca gatgccaagc <210> 247 <211> 19 <212> DNA	gtta sapiens	tgaccggaag tcaaaagttg acctggatag gctcaatgat	60 74
tatcgaggca gatgccaagc <210> 247 <211> 19 <212> DNA <213> Homo <400> 247	gtta sapiens gttttctca	tgaccggaag tcaaaagttg acctggatag gctcaatgat	74
tatcgaggca gatgccaagc <210> 247 <211> 19 <212> DNA <213> Homo <400> 247 ccgcaacgtg <210> 248 <211> 21 <212> DNA <213> Homo <400> 248	gtta sapiens gttttctca		74
tatcgaggca gatgccaagc <210> 247 <211> 19 <212> DNA <213> Homo <400> 247 ccgcaacgtg <210> 248 <211> 21 <212> DNA <213> Homo <400> 248	sapiens gtttctca sapiens ctcctcctgt		19
tatcgaggca gatgccaagc <210> 247 <211> 19 <212> DNA <213> Homo <400> 247 ccgcaacgtg <210> 248 <211> 21 <212> DNA <213> Homo <400> 248 tgctgggttt <210> 249 <211> 81 <212> DNA <213> Homo <400> 249 <211> 81 <212> DNA <213> Homo	sapiens gtttctca sapiens ctcctcctgt sapiens	t cctatggggt ggcctcggtg ttggccatgc tccagctgac	741921

				39740-0001pc	CT.txt		
<400> tcaaga		catcactttc	attgt	4			25
<210> <211> <212> <213>	27 DNA	sapiens					
<400> ggatca		gtacacggag	tataact	· .*.		*	27
<210> <211> <212> <213>	96 DNA	sapiens			·		
	ccat		attgtctcgg gtgtacttcc	acgtgcgggg tgatcc	cctgggcctc	ccggtccgca	60 96
<210> <211> <212> <213>	19 DNA	sapiens					
<400> gcccga		ccgaatata					19
<210> <211> <212> <213>	23 DNA	sapiens					
<400> cgtggd		ttatcctcat	gat				23
<210> <211> <212> <213>	65 DNA	sapiens					
<400> gcccga ccacg		ccgaatataa	tcccaagcgg	tttgctgcgg	taatcatgag	gataagagag	60 65
<210> <211> <212> <213>	19 DNA	sapiens					, -
<400> gcccto		tgtgcaaat					19
<210> <211> <212> <213>	25 DNA	sapiens		\$			
<400> cgtcga		attaggatag	aagca				25
<210> <211> <212> <213>	86 DNA	sapiens					
<400> gcccto		tgtgcaaata	agggctgctg	tttcgacgac	accgttcgtg	gggtcccctg	60

		39740~0001PC1	T. txt	~
gtgcttctat	cctaatacca			36
<210> 259 <211> 27 <212> DNA <213> Homo	sapiens			
<400> 259 caagctagat	cagcattctc	aacttg	. 2	27
<210> 260 <211> 25 <212> DNA <213> Homo	sapiens			-
<400> 260 cacatgactg	ttatcgccat	tact	2	25
<210> 261 <211> 99 <212> DNA <213> Homo	sapiens			-
<400> 261 caagctagat agcctggctc	cagcattctc ggcaagtaga	aacttgttt ggtggagaac c ggcgataac agtcatgtg		50 99
<210> 262 <211> 22 <212> DNA <213> Homo	sapiens			
<400> 262 cacaggaaca	acagcatctt	: c		22
<210> 263 <211> 20 <212> DNA <213> Homo	sapiens			
<400> 263 agataagccc	ctgggatcca		2	20
<210> 264 <211> 75 <212> DNA <213> Homo	sapiens			-
<400> 264 cacaggaaca cccaggggct	acagcatctt tatct	caccaagat gggtggcacc a	accttgctg ggacttggat 6 7	50 75
<210> 265 <211> 21 <212> DNA <213> Homo	sapiens			• .
<400> 265 ggattgctca	acaaccatgc			21
<210> 266 <211> 24 <212> DNA <213> Homo	sapiens			
<400> 266 ggcattaaca	cttttggacg	taa	2	24

<210> <211> <212> <213>	91 DNA	sapiens					•
<400> ggattg tgctag	ctca	acaaccatgc tcgtccaaaa	tgggcatctg gtgttaatgc	gaccctccta c	cctctggttc	ttacgtctgt	60 91
<210> <211> <212> <213>	24 DNA	sapiens					
<400> gcactt		attctttcca	ttat				24
<210> <211> <212> <213>	24 DNA	sapiens		• .			4. • 5
<400> gcatgt		agaccctcac	tgaa	, · ·			24
<210> <211> <212> <213>	80 DNA	sapiens					4
<400> gcactt gtgagg	tggg	attctttcca tcttacatgc	ttatgattct	ttgttacagg	caccgagaat	gttgtattca	60 80
<210> <211> <212> <213>	20 DNA	sapiens					
<400> aatcca		ggagagtgat					20
<210> <211> <212> <213>	20 DNA	sapiens					
<400> gtacag		tgcccgagga					20
<210> <211> <212> <213>	72 DNA	sapiens					
<400> aatcca caaaat	aggg		gacttccata	tggactttga	ctcagctgtg	gctcctcggg	60 72
<210> <211> <212> <213>	21 DNA	sapiens		· · · · · · · · · · · · · · · · · · ·			
<400> tgtgga		ttcccctcag	a .				21
<210>	275			- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1-	• • • • • • • • • • • • • • • • • • • •	1	

•		30740 0001pcT +v+	
<211> 18 <212> DNA <213> Homo	sapiens	39740-0001PCT.txt	٠
<400> 275 ctagcccgac	cggttcgt		18
<210> 276 <211> 66 <212> DNA <213> Homo	sapiens		•
<400> 276 tgtggacatc ggctag	ttcccctcag	acttccctac tgagccacct tctctgccac gaaccggtcg	60 66
<210> 277 <211> 20 <212> DNA <213> Homo	sapiens		
<400> 277 ctttgaaccc	ttgcttgcaa		20
<210> 278 <211> 18 <212> DNA <213> Homo	sapiens		
<400> 278 cccgggacaa	agcaaatg		18
<210> 279 <211> 68 <212> DNA <213> Homo	sapiens		,
<400> 279 ctttgaaccc gtcccggg	ttgcttgcaa	taggtgtgcg tcagaagcac ccaggacttc catttgcttt	60 68
<210> 280 <211> 18 <212> DNA <213> Homo	sapiens		
<400> 280 gcctcggtgt	gcctttca		18
<210> 281 <211> 19 <212> DNA <213> Homo	sapiens		•
<400> 281 cgtgatgtgc	gcaatcatg		19
<210> 282 <211> 65 <212> DNA <213> Homo	sapiens		
<400> 282 gcctcggtgt tcacg	gcctttcaac	atcgccagct acgccctgct cacgtacatg attgcgcaca	60 65

<210> 283 <211> 20

39740-0001PCT.txt <212> DNA <213> Homo sapiens <400> 283 ctgctgtctt gggtgcattg 20 <210> 284 <211> 18 <212> DNA <213> Homo sapiens <400> 284 gcagcctggg accacttg 18 <210> 285 <211> 71 <212> DNA <213> Homo sapiens <400> 285 ctgctgtctt gggtgcattg gagccttgcc ttgctgctct acctccacca tgccaagtgg 60 tcccaggctg c <210> 286 <211> 1947 <212> DNA <213> Homo sapiens <400> 286 ttttccccag atatggggtt ctattcagcc atagataatc tagacagagg atttcagaat 60 gaaaggaaaa atgtgtggag attagtccta gttcattctg agggccgact aagtggctca 120 gccagcttct tactccatct gcagttcata ctgccaaaga gctccactt ccaaatcccc 180 agtgacttta tggagaagat tctgcattaa attgtctttc gaatgatggg gaagcaaggc 240 ataatatgcg atgatgagga gaaagtagac cagtgaggtg attgcaagac taacaaggag 300 actcaatggg aagttttct ttctttaga tattgctttt gaagtagatg gtaaaatttt 360 tgtcatcctt cttgtaattt ttgtacccca agttacaatt ttcttcttc cttgtaaaat 420 atttaaacag tatttattt tgtaaggcat aactagaaac taaaatatat tctaaaaaat 480 tcattattct gaacaaagtg atcaaattag aatacatatt tttcaacagt ggtagagctt 540 ttaatatatg tttattgaaa gttatctata atacttgcac cagtgttgaa aaaagttaac 600 atgtaggaa gagcaatatg tttgtctcaa ggatttttc catggttgaa tattcaggtg gtgaccatca ctggtctaag tttgtgtgca gggtttcag 720 acgtgttttt gtgaaacttg gtagaaccat aggtaataaa gaggacagtg ttgtcaggat 780 acgtgttttt gtgaaacttg gtagaaccat ggctaataaa gaggacagtg ttgtcagggt 780 ccatctgccc tccatagaaa aatgtctctg gctcataaaa tgagactccc tcagggacta 840 aatatgaact gacagcagta actctgatac agaataatct aaattgcatc aaatggcctt 900 aattcagagt ttgttaggct tatcagtatg ttgcttttaa ttggggtggg aaagtagagg 960 gagagaaagc aagacattta ttaagcacct cgtatgtgcc aggcactatg ctaagcactt 1020 tacataagtt aggattaatc cctgcaagaa tcctataaag aatgttacta gcatttacac 1080 ttcccaaatg aaggtaccaa agctcaaacg caatgttgtg aagctgttc cttcagattt 1140 aggttatgtg ggattgaaga ggaaagaaag gtgggattat ccccctagga 1200 agactttcag gcctgacttc ataggaattc atccatctta tcatgtggag tttatctcac 1260 cctgctgttg caggatgcta tttgcatgtg tccccaggtg atgtttttc tttggggagt 1320 aggggtttgg cttcctcatt catccctctt gctaaagag gagatagttg atgttgcatc 1380 taaagactgct ataagacaat gaaagttga tgtgtgtacat acctacaagt accatttttg 1440 tgcatgatta cactccactg acatcttcca agtactgcat gtgattgaat aagaaacaag 1500 aaagtgacca caccaaagcc tccctggctg gtgtacaggg atcaggtcca cagtggtaca 1560 gattcaacca ccaccaggg agtgcttgca gactctgcat agatgttgct gcatgcgtcc 1620 catgtgcctg tcagaatggc agtgttaat tctcttgaaa gaaagttatt tgctcactat 1680 ccccagcctc aaggaggccaa ggaagagtca ttcacatat aggtcctgga taggaggcca 1800 actctgactt ttctaccaca ttaaattctc cattacatct cactattggt aatggcttaa 1800 gtgtaaagag ccatgatgtg tatattaagc tatgtgccac atatttattt ttagactctc 1860 cacagcattc atgtcaatat gggattaatg cctaaacttt gtaaatattg tacagtttgt 1920 aaatcaatga ataaaggttt tgagtgt

<210> 287 <211> 1311 <212> DNA <213> Homo sapiens

		:	39740-0001pc	CT.txt	· · · .	
tagicggcg cgggcctggc ccggcctgcg gtggtccgcc ccaccagggg gctcgacccg cctggagtga gccaggaggt ttacctcca aggtcatagg aaatggaaac ggaaaaagaa ctgtggagaa agggtttct aagccacaat aaaattcaa tagccgagtg gcacctgg gcgcaccag ggcaactgg	tcagcgcggg cgcccttcgg tccctctcgg cgccgccgcc gagcgaggag agagggacc gacccgggac tgggctcacc gcagggcagc ggttccacag accgttgtca cagtccacag gatagctgac gcccaaggat agacagttt agacagtgac tggacacagtg ccttggccgag ctttgccaa	ggggcgcgga ccaggccggg cgtccacctg ggcgctcgca ttgacccgga cagagtgagg gaggagtcga gtgactgtca agtgaaccag tctttcaga gcacttggaaa gcacttggaaa gtgaagattg cagctggaag ttgaaagatct ttgaaagatct ttgaaagatct ttgaaagatct ttgaaagatct ttgaaagatct ttgaagatcga gagcagaaca gagcagaaca ttgaggtgtagg tttcctact	gaccgcgagg agccgcgcca cccggagtac ggcgaggagtt aggcgaccca cccggagcga cccacagcaa ttgtccaaga aactcatatt tacaagatgg aactaaagaa agttgaataa aggttgagagat aaggcttctgt tggaggagat tctgccagga cagaaaaaagg aatttacctg ctcacactgg	cgaccgggag gtcggagccc tgccagcggg gaagaagaaa gaccctgagt gggcgaagag ggaggtgacc ttgagaagcac cctggcccag taagggaaaa ttgccgggtc gttgaaacat agagcttact caaacttgat tgacacactg aaaaaaggtt gactgagcgg ctgtgctgcc atttcttcag ttctcaatga	cggctgggtt ccggcccagc catgaccgac acccggcgcc gaggaagcga atgaatcgaa aggcgaggaaa gaccttcatg gttgttgaag tctctgaagg atgttaattg ttggagaagt ggaatccagc aggagagtaa atcctgccag caggcagtcta ctgcagtcta ggctgctggg aaaatagtgt	120 180 240 300 420 480 540 660 720 780 840 960 1020 1140 1200
<210> 288 <211> 582 <212> DNA <213> Homo	sapiens					
ggcccgcgcc gagcccggcc gcccccaccg ccccgcagcc gagcagcacc caggcggccc ctgcggcgga cagcggcacc	ccttcccgct tggctgccgc ccccacccgc ggccccgagg tggagtcgcc cgggagtccg tggcggacga gcccctcacc	cggccgcctg ccccgccgcc cgtcaccgc cgtgcccagc cggggaggag cctcaacgca ctggagggtc	gtgccctcgg cccaccctgc gccctggggg gacggtcctc gccccggggg gaacagtggg cagtacgagc ctgtacaatc	cagtgtcctg tgcccgctgc gttcccgctg agccctcgct ctctggcggg cccgggagat ggcggagaca tcatcatggg	cggcctctgc ctacctctgc gcctgggggt ctcgctggcg cggtcccacc cggggcccag agaggagcag	120 180 240 300 360 420 480
<210> 289 <211> 6030 <212> DNA <213> Homo	sapiens					
taaccgggag ggatgcggga ctcgcagccc gccgctgcag acctgtggtc cgacttcgcc ttgcacggtg ctttgagttc ggacaacatc ggataacgga tgatttctcc caccctgggt caacagga agctgcaggc cacacaca agggaaata gtcccatcaa tggctccacc gatcaccatc	atagtgatga gatgtgggcg gggcacacgc accccggctg cacctgaccc gagatgtcca gtggaggacg ggtggggtca gcctgtgga tggctgtctc gcctatctgg actaaagcag tgtttaagaa caacaattaat taactcctgtc tggatgtct tggatgtct tggatgtct	agtacatcca ccgcgccccc cccatacagc cccccggcgc tccgccaggc ggcagctgca tcttcaggga tgactgagta cctttgtgga tgaagactct gccacaagtg tagaaataat aaaataacac cagtcttcag tttacattat tttggaaatc gtgcctgtaa acggatggaa	ttataagctg gggggccgcc cgcatcccgg cgccgcgggg cggcgacgac cctgacgccc cggggtgaac gagcgtcaac cctgaaccgg actgtacggc gctcagtttg aagtcaacat atgcattgtc acatataaac gcaaaacata acgacactaa acgacactaa acatagattc aaaggacctg tcattcactt	tcgcagaggg cccgcgccgg gacccggtcg cctgcgctca ttctcccgcc ttcaccgcgc tgggggagatgt cacctgcaca cccagcatgc gcctgccca agtgatgttc atcacacaca gaatcagcta agattattt ttgccaagca gctttccatg atcattgggg gcatttcttt	gctacgagtg gcatcttctc ccaggacctc gcccggtgcc gctaccgccg ggggacgctt ttgtggcctt cctggatcca ggcctctgtt gagcttgcat aacaaatatg catgaaacaa cagacagaca tttactgcca atttaatgcca atttagcca gttgtggctg	120 180 240 360 420 480 540 660 720 780 840 960 1020 1140 1200
	cgggcctggc cccggctgcg gtggtccgcg gtggtccggc gctcgaccgggctgg gctcgaagtggt ttggcaggaagaaa aggtcataagaa aaggtcataaa aaggctaaaa ctggagaaaa ctggagaaaa cggaaaacttgg gcaaactggc caaccacgggcaactggcaaactggcaaactggcaaactggcccggcccgagccccgagcccgagcccgagccccagggcagccccagggcggc	tagtcgggcg cgggcctggc ccgggctgcg cccggctgcg cccggctgcg cccggctgcg ccccgccgcc ccaccagggg cctgaacccg gagcgaggag cctggagtga agaggcgaggac cgcaggaggt cgcaggggag cdggaggag cdggaggag cdggaggag cdggaggag cdggaggag cdggaggag caggcaacag cggaaaaagaa caggtcacaaa caggcaacaaa cagcaacaaa cagcaacaaa cagcaacaaa cagcaacag ccttgtgag caacctggc caacaggg caacctggc caccaaggag caacctggc caccaaggag caacctggc caccaaggag caccacaat aagacagtaga cagcagagg cccaccag cctttgtgatt caccaaggag caccacaat cagcagagg cccgccgag ccccccaccg cccccaccg ccccccaccg cccccaccg cccccaccg cccccaccg cccccaccg ccccccaccg cccccaccg ccccccaccg cccccaccg ccccccaccg ccccccaccg ccccccaccg ccccccaccg ccccccaccg ccccccaccg ccccccaccg cccccacac ccccggagg cccggagg cccggagg cccggagg cccggagg cccggagg cccggagg cccgcaccac ccccggcg ccccccaccg cccccacacaca	<pre><400> 287 tagtcgggcg tggtcggcc tcgggcctggc ccggcctgcg ccggcctgcg cccggctgcg gtggtccgcc tcacctctcgg gtggtccgcc gcccacagggg gccacagggg gccaggaggag cctggaccg gccgcgccg gacgggaggag cctggaggag gccaggaggag gccaggaggag gccaggaggag gccaggaggag gccaggaggag gaggaggag gccaggaggag gccaggaggag gccaggaggag gccaggaggag gccaggaggag gccaggaggag gagagtcga ttggccgag gagagtcaacag gaggtcatag gagtcacag gaggtcacag gaggttttct gagccacaag gagagagac caggggtgttccacag ttggagaga gagagttgt ctggggaga gadaccacaa agagcagttt aagagagttt aagagcagatt aagagcagttt aagagagttt aagagagtt tagaaaagga ttgaaaagga ttgaaaagga ttgaaaagga ttgaaaagga ttgaaaagga ttgaaaagga ttgaaaagga ttctcgcgt tctggatag gggcagaaca caaactttgc cctggccgag gcgcacaag tctgccgca tcttgcgtc tctggatag gggcagacac cattigccaa ttctctact ttgatt tgagtaaag tcctattctg <210> 288 <211> 582 <211> DNA <213> Homo sapiens </pre> <pre><400> 288 atggcccggc ggccccgagag ggcccggcc ggagagcac cccggagc ggcccggag ggcccggc gggagtccc gggaggag ggcagcac cccggcgc gggagagcac ccttccgcc gggagagcac cctgcgcc gggagagcac cctgcgcc gggagagcac cctgcgcc gggagagcac cctggaga ccctgacc cgggagaga ccctggaga gggagaga cccaggag gggagaga ccaaaagga gggagaac cctggaga gggagaga cccaaagag ccctgacc cgggagaga gggagaac cccggaga gggagaga ccctggaga gggagaga cccaaagag cccaaagag cccaaagag cccaaagag cccaaagag cccgcccg</pre>	<pre><400> 287 tagtcgggcg gggttgtgag acgccgcgct cgggcctggc tcagcgcggg ggggcgcgga ccgggctgg cgccttccgg cgagcgcgg gtggtccgcc tccttcgg gtgcacctg ccaccagggg cgccyccgc gycgctcacc gcacagggg agaggaggtgag cctggagtga agaggcgac cagagtgagg cctggagtga agaggcgac cagagtgagg cctggagtga gagggggcgcgcgcgcgcgcggaggagggggggggg</pre>	tagtcgggcg tgggcctggc tcggcgcggg cgggccggg cgggctcggc ccgccttcgg cggcctccgc tcccttcgg cgcccttcgg cgcccttcgg cgccctcaggg caccagggg caccaggaggt gaccagggac caggaggtca caggaggt gaccaggagc caggaggcag caggagagc aggacacag aggagagaga	<pre><400> 287 tagtcgggcg gggttgdag tcagcgcggg gggttcgcct tcagcctggc tcagcctggc tcagccggg gggtcggga tcagcgcggg ggggtcggga tcagcgcggg gggtccgcc tcctctcgg cgcctctcgg tcagccggg gggtccgcc tcctctcgg tcagccggg gggtccgcc tcctctcgg tcagccggg gggtccgcc gcctcaccaggag tcagcgaggag tcagcaggag tcagaggag tattcacag tagagaaaaaa cagtcacaa tagagaaaaaa cagtcacaaa tagagaattt atgaagattt tagaagaat tcggggag tgaaaaag tcagagag tcagaggag tcagaggag tcagaggag tcagaggag tcagaggag tcagagg tgagagaaaa aggtcacaa tcgcaagag tcagagag ttgaaaaag tcgagagag tagaaaaag tcgagagag tagaaaag tcgagagag tgagagagaa cagggagaa aaatagag tagacagaa tcagagag tcagagagag tgagagaga tgagagaga tgagagaga tcagagagag tcagagagag tgagagaga tgagagaga tgagagaga tgagagaga</pre>

39740-0001PCT.txt

aaacaataaa tgtgcagttt taactaacag gatatttaat gacaaccttc tggttggtag 5100 ggacatctgt ttctaaatgt ttattatgta caatacagaa aaaaatttta taaaattaag 5160 caatgtgaaa ctgaattgga gagtgataat acaagtcctt tagtcttacc cagtgaatca 5220 ttctgttcca tgtctttgga caaccatgac cttggacaat catgaaatat gcatctcact 5280 ggatgcaaag aaaatcagat ggagcatgaa tggtactac ccggttcatc tggactgccc 5340 5160 Page 38

39740-0001PCT.txt cagaaaaata acttcaagca aacatcctat caacaacaag gttgttctgc ataccaagct 5400 cagaaaaata acttcaagca aacatcctat caacaacaag gttgttctgc ataccaagct gagcacagaa gatgggaaca ctggtggagg atggaaaggc tcgctcaatc aagaaaattc tgagactatt aataaataag actgtagtgt agatactgag taaatccatg cacctaaacc ttttggaaaa tctgccgtgg gcctccaga tagctcattt cattaagttt ttccctcaa ggtagaattt gcaagagtga cagtggattg catttctttt ggggaagctt tcttttggtg gttttgtta ttataccttc ttaagtttc aaccaaggtt tgcttttgtt ttgagttact ggggttattt ttgtttaaa taaaaataag tgtacaataa gtgtttttgt attgaaagct ttgttataca agatttcat acattacct tccatggctc tttttaagat tgatactttt aagaggtggc tgatattctg caacactgta cacataaaaa atacggtaag gatactttac atggttaggg taaagtaagt ctccagttgg ccaccattag ctataatggc actttgtttg tgtgttgtgga aaaagtcaca ttgccattaa actttccttg tctgtctagt taatattgtg aagaaaaata aagtacagtg tgagatactg 5640 5880 5940 6000 aagaaaata aagtacagtg tgagatactg 6030

<210> 290 <211> 10987 <212> DNA

<213> Homo sapiens

<400> 290 ggtggcgcga gcttctgaaa ctaggcggca gaggcggagc cgctgtggca ctgctgcgcc 60 tctgctgcgc ctcgggtgtc ttttgcggc gtgggtcgcc gccgggagaa gcgtgagggg 120 acagatttgt gaccggcgc gttttgtca gcttactccg gccaaaaaag aactgcacct 180 ctggagcgga cttatttacc aagcattgga ggaatatcgt aggtaaaaat gcctaattgga 240 tccaaaggaa ggccaacatt ttttgaaatt tttaagacac gctgcaacaa agcagattta 300 ggaccaataa gtcttaattg gtttgaagaa ctttctcag aagctccacc ctataattct 360 gaacctgcaa aagaatctga acataaaaac aacaattacg aaccaaacct atttaaaaca 420 ccacaaagga aaccatctta taatcagctg gcttcaactc caataatatt caaagagcaa 480 gggctgactc tgccgctgta ccaatctcct gtaaaagaat tagataaatt caaattagac 540 ttaggaagga atgttcccaa tagtagacat aaaagtcttc gcacagtgaa aactaaaatg 600 gatcaagcag atgatgttc ctgtccactt ctaaattctt gtcttagtga aagtcctgtt 660 gttctacaat gtacacatgt aacaccacaa agagataagt cagtggtatg tgggagtttg 720 tttcatacac caaagtttgt gaagggtcgt cagacaccaa aacatatttc tgaaagtcta 780 ggagctgagg tggatcctga tatgtcttgg tcaagttctt tagctacacc acccaccctt 840 agttctactg tgctcatagt cagaaatgaa gaagcatctg aaacttgtat tcctcatgat 900 actactgcta atgtgaaaag ctattttcc aatcatgatg aaagtctgaa gaaaaatgat 960 agatttatgg cttctgtgac agacagtgaa aacacaaatc aaagagaagc tgcaagtcat 1020 ggatttggaa aaacatcagg gaattcattt aaagtaaata gctgcaaaga ccacattgga 1080 aagtcaatgc caaatgtcct agaagatgaa gtatatgaaa cagttgtaga tacctctgaa 1140 gaagatagtt tttcattatg tttttctaaa tgtagaacaa aaaatctaca aaaagtaaga 1200 actagcaaga ctaggaaaaa aattttccat gaagcaaacg ctgatgaatg tgaaaaatct 1260 aaaaaccaag tgaaagaaaa atactcattt gtatctgaag tggaaccaaa tgatactgat 1320 ccattagatt caaatgtagc acatcagaag ccctttgaga gtggaagtga caaaatctcc 1380 aaggaagttg taccgtcttt ggcctgtgaa tggtctcaac taaccctttc aggtctaaat 1440 gaggcccaga tggagaaaat acccctattg catatttctt catgtgacca aaatatttca 1500 gaaaaagacc tattagacac agagaacaaa agaaagaaag attttcttac ttcagagaat 1560 tctttgccac gtatttctag cctaccaaaa tcagagaagc cattaaatga ggaaacagtg 1620 gtaaataaga gagatgaaga gcagcatctt gaatctcata cagactgcat tcttgcagta 1680 aagcaggcaa tatctggaac ttctccagtg gctttcat ttcagggtat caaaaagtc 1740 atattcagaa taagagaatc acctaaagag actttcaatg caagtttttc aggtcatatg 1800 actgatccaa actttaaaaa agaaactgaa gcctctgaaa gtggactgga aatacatact 1860 gtttgctcac agaaggagga ctccttatgt ccaaatttaa ttgataatgg aagctggcca 1920 gccaccacca cacagaattc tgtagctttg aagaatgcag gtttaatatc cactttgaaa 1980 aagaaaacaa ataagtttat ttatgctata catgagaa cactttataa aggaaaaaaa 2040 ataccgaaag accaaaaatc agaactaatt aactgttcag cccagtttga agcaaatgct 2100 tttgaagcac cacttacatt tgcaaatgct gattcaggtt tattgcattc ttctgtgaaa 2160 agaagctgtt cacagaatga ttctgaagaa ccaactttgt ccttaactag ctcttttggg 2220 acaattctga ggaaatgttc tagaaatgaa acatgttcta ataatacagt aatctctcag 2280 gatcttgatt ataaagaagc aaaatgtaat aaggaaaaac tacagttatt tattacccca 2340 gaagctgatt ctctgtcatg cctgcaggaa ggacagtgtg aaaatgatcc aaaaagcaaa 2400 aaagtttcag atataaaaga agaggtcttg gctgcagcat gtcacccagt acaacattca 2460 aaagtggaat acagtgatac tgactttcaa tcccagaaaa gtcttttata tgatcatgaa 2520 aatgccagca ctcttatttt aactcctact tccaaggatg ttctgtcaaa cctagtcatg 2580 attictagag gcaaagaatc atacaaaatg tcagacaagc tcaaaggtaa caattatgaa 2640 tctgatgttg aattaaccaa aaatattccc atggaaaaga atcaagatgt atgtgcttta 2700 aatgaaaatt ataaaaacgt tgagctgttg ccacctgaaa aatacatgag agtagcatca 2760 ccttcaagaa aggtacaatt caaccaaaac acaaatctaa gagtaatcca aaaaaatcaa 2820

39740-0001PCT.txt gaagaaacta cttcaatttc aaaaataact gtcaatccag actctgaaga acttttctca 2880 gaagaaacta cttcaatttc aaaaataact gtcaatccag actctgaaga acttttctca 2880 gacaatgaga ataattttgt cttccaagta gctaatgaaa ggaataatct tgctttagga 2940 aatactaagg aacttcatga aacagacttg acttgtgtaa acgaacccat tttcaagaac 3000 tctaccatgg ttttatatgg agacacaggt gataaacaag caacccaagt gtcaattaaa 3060 aaagatttgg tttatgttct tgcagaggag aacaaaaata gtgtaaagca gcatataaaa 3120 atgactctag gtcaatgaa caaatgggca atctcttga atatagataa aataccagaa 3180 aaaaataatg attacatgaa caaatgggca ggactcttag gtccaatttc aaatcacagt 3240 tttggaggta gcttcagaac agcttcaaat aaggaaatca agctctctga acataacatt 3300 gttgaaattg taaatacctt ggcattagat aatcaaaaga aactgagcaa gcctcagtca 3420 attaatactg tatctgcaca tttacagagt agtgtagttg tttctgattg taaaaatagt 3480 attaatactg tatctgcaca tttacagagt agtgtagttg tttctgattg taaaaatagt 3480 catataaccc ctcagatgtt attttccaag caggatttta attcaaacca taatttaaca 3540 cctagccaaa aggcagaaat tacagaactt tctactatat tagaagaatc aggaagtcag 3600 tttgaattta ctcagtttag aaaaccaagc tacatattgc agaagagtac atttgaagtg 3660 cctgaaaacc agatgactat cttaaagacc acttctgagg aatgcagaga tgctgatctt catgtcataa tgaatgccc atcgattggt caggtagaca gcagcaagca atttgaaggt acagttgaaa ttaaacggaa gtttgctggc ctgttgaaaa atgactgtaa caaaagtgct tctggttatt taacagatga aaatgaagtg gggtttaggg gctttattc tgctcatggc acaaaactga atgttctac tgaagctctg caaaaagctg tgaaactgtt tagtgataat 3840 3900 acaaaactga atgtttctac tgaagctctg caaaaaagctg tgaaactgtt tagtgatatt 3960 gagaatatta gtgaggaaac ttctgcagag gtacatccaa taagtttatc ttcaagtaaa 4020 tgtcatgatt ctgttgttc aatgtttaag atagaaaatc ataatgataa aactgtaagt 4080 gaaaaaaaata ataaatgcca actgatatta caaaataata ttgaaatgac tactggcact 4140 tttgttgaag aaattactga aaattacaag agaaatactg gaagtgattc gtattcataa agatgaaacg gacttgctat ttactgatca gcacaacata 4200 gatactgttt gtattcataa agatgaaacg gacttgctat ttactgatca gcacaacata 4200 gatactgttt gtattcataa agatgaaacg gacttgctat ttactgatca gcacaacata 4320 tgtcttaaat tatctggcca gtttatgaag gagggaaaca ctcagattaa agaagatttg 4380 tcagatttaa cttttttgga agttgcgaaa gctcaagaag catgtcatgg taatacttca 4440 aaaattgtaa agttacatgc tactaaaacg gagcaaaata taaaagatt tgagacttct 4500 gatacatttt ttagactgc aagtgggaaa aatattagtg tcgccaaaga gtcatttaat 4560 aaaattgtaa atttctttga tcagaacaaa atggacattc taagttatga ggaaacagac 4680 atagttaaac acaaaatact gaaagaaagt gtcccagttg gtactggaaa tcaactagtg 4740 accttccagg gacaacccga acgtgatgaa aagatcaaag aagatcaaag aacctactct gttgggtttt 4800 3960 accttccagg gacaacccga acgtgatgaa aagatcaaag aacctactct gttgggtttt 4800 catacagcta gcgggaaaaa agttaaaatt gcaaaggaat ctttggacaa agtgaaaaac 4860 ctttttgatg aaaaaggca aggtactagt gaaatcacca gttttagcca tcaatgggca 4920 aagaccctaa agtacagaga ggcctgtaaa gaccttgaat tagcatgtga gaccattgag 4980 atcacagctg ccccaaagtg taaagaaatg caattctc tcaataatga taaaaacctt 5040 atcacagctg ccccaaagtg taaagaaatg cagaattctc tcaataatga taaaaacctt 5040 gtttctattg agactgtggt gccacctaag ctcttaagtg ataatttatg tagacaaact 5100 gaaaatctca aaacatcaaa aagtatcttt ttgaaagtta aagtacatga aaatgtagaa 5160 aaagaaacag caaaaagtcc tgcaacttgt tacacaaatc agtcccctta ttcagtcatt 5220 gaaaattcag ccttagcttt ttacacaagt tgtagtagaa aaacttctgt gagtcagact 5280 tcattacttg aagcaaaaaa atggcttaga gaaggaatat ttgatggtca accagaaaga 5340 ataaatactg cagattatgt aggaaattat ttgtatgaaa ataattcaaa cagtactata 5400 gctgaaaatg acaaaaatca tctctccgaa aaacaagata cttattaag taacagtagc 5460 atgtctaaca gctattccta ccattctgat gaggtatata atgatcagg atatctctca 5520 actagtttt ccaaagtaat atccaatgta aaagatgcaa atgttgaaga tcaaaaaaac 5580 actagtttt ccaaagtaat atccaatgta aaagatgcaa atgcataccc acaaactgta 5640 aatgaagata tttgcgtaa gaacttgta actagctct caccctgcaa aaataaaaat 5700 aatgaagata tttgcgttga ggaacttgtg actagctctt caccctgcaa aaataaaaat 5700 gcagccatta aattgtccat atctaatagt aataattttg aggtagggcc acctgcattt 5760 aggatagcca gtggtaaaat cgtttgtgtt tcacatgaaa caattaaaaa agtgaaagac 5820 atattacag acagtttcag taaagtaatt aaggaaaaca acgagaataa atcaaaaatt 5880 tgccaaacga aaattatggc aggttgttac gaggcattgg atgattcaga ggatattctt 5940 cataactctc tagataatga tgaatgtagc acgcattcac ataaggtttt tgctgacatt 6000 cagagtgaag aaattttaca acataaccaa aatatgtctg gattggagaa agtttctaaa 6060 atatcacctt gtgatgttag tttggaaact tcagatatat gtaaatgtag tatagggaaa 6120 cttcataagt cagtctcatc tgcaaatact tgtgggatt ttagcacagc aagtggaaaa 6180 tctgtccagg tatcagatgc ttcattacaa aacgcaagac aagtgtttc tgaaatagaa 6240 gatagtacca agcaagtctt ttccaaagga tgtttaaaa gtaacgaaca ttcagaccag 6300 ctcacaagag aagaaaatac tgctatacgt actccagaac atttaatatc ccaaaaaggc 6360 ttttcatata atgtggtaaa ttcatctgct ttctctggat ttagtacagc aagtggaaaa 6420 ctcacaagag aagaaaatac tgctatacgt actccagaac atttaatatc ccaaaaaggc 6360 ttttcatata atgtggtaaa ttcatctgct ttctctggat ttagtacagc aagtggaaag 6420 caagtttcca ttttagaaag ttccttacac aaagttaagg gagtgttaga ggaatttgat 6480 ttaatcagaa ctgagcatag tcttcactat tcacctacgt ctagacaaaa tgtatcaaaa 6540 atacttcctc gtgttgataa gagaaaccca gagcactgtg taaactcaga aatggaaaaa 6600 acctgcagta aagaatttaa attatcaaat aacttaaatg ttgaaggtgg ttcttcagaa 6660 aataatcact ctattaaagt ttctccatat ctctctaat ttcaacaaga caaacaacag 6780 gcttcaccta aaaacgtaaa aatggaaatt ggtaaaactg aaacttttc tgatgttcct 6840 gtgaaaacaa atatagaagt ttgttctact tactccaaag attcagaaaa ctactttgaa 6900 Page 40

39740-0001PCT.txt

acagaagcag tagaaattgc taaagctttt atggaagatg atgaactgac agattctaaa 6960 ctgccaagtc atgccacaca ttctcttttt acatgtcccg aaaatgagga aatggttttg 7020 tcaaattcaa gaattggaaa aagaagagga gagccctta tcttagtggg agaaccctca 7080 atcaaaagaa acttattaaa tgaatttgac aggataatag aaaatcaaga aaaatcctta 7140 aaggattcaa aaagaactcc agatggcaca ataaagatc gaagattgtt tatgcatcat 7260 gtttctttag agccgattac ctgtgtaccc tttcgcacaa ctaaggaacg tcaagagata 7260 cagaatccaa attttaccgc acctggtcaa gaatttctgt ctaaatctca tttgtatgaa 7320 catctgactt tggaaaaatc ttcaagcaat ttagcagttt caggacatcc attttatcaa 7380 gtttctgcta caagaaatga aaaaatgaga cacttgatta ctacaggcag accaaccaaa 7400 gtctttgttc caccttttaa aactaaatca cattttcaca gagttgaaca gtgtgttagg 7500 attattatt tggaggaaaa cagacaaaag caaaacattg atggacatgg ctctgatgat 7560 agtaaaaata agattaatga caatgagatt catcagttta acaaaaacaa ctccaatcaa 7620 gcagcagctg taactttcac aaagtgtgaa gaagaacctt tagatttaat tacaagtctt 7680 cagaatgcca gagatataca ggatatgcga attaagaaga aacaaaggca acgcgtcttt 7740 ccacagccag gcagtctgta tcttgcaaaa acatccactc tgcctcgaat ctctctgaaa 7800 gcagcagtag gaggccaagt tccctctgcg tgttctcata aacagctgta tacgtatggc 7860 gtttctaaac attgcataaa aattaacagc aaaaatgcag agtcttttca ggttcacact 7920 gaagattatt ttggtaagga aagtttatgg actggaaaag gaatacagtt ggctgatggt 7980 ggataggctca taccctcaa tgatggaaag gctggaaaag gaatacagtt ggctgatggt 7980 gaagattatt ttggtaagga aagtttatgg actggaaaaag gaatacagtt ggctgatggt 7980 ggatggctca taccctccaa tgatggaaag gctggaaaag aagaatttta tagggctctg 8040 tgtgacactc caggtgtgga tccaaagctt atttctagaa tttgggttta taatcactat 8100 agatggatca tatggaaact ggcagctatg gaatgtgcct ttcctaagga atttgctaat 8160 agatgcctaa gcccagaaag ggtgcttctt caactaaaat acagatatga tacggaaatt 8220 gatagaagca gaagatcggc tataaaaaaag ataatggaaa gggatgacac agctgcaaaa 8280 acacttgttc tctgtgttc tgacataaat tcattgagcg caaatatatc tgaaacttct 8340 agcaataaaa ctagtagtgc agatacccaa aaagtggcca ttattgaact tacagatggg 8400 tggtatgctg ttaaggccca gttagatcct cccctcttag ctgtcttaaa gaatggcaga 8460 ctgacagttg gtcagaagat tattcttcat ggagcagaac tggtgggctc tcctgatgcc 8520 tgtacacctc ttgaagcccc agaatctctt atgttaaaga tttctgctaa cagtactcgg 8580 cctgctcgct ggtataccaa acttggattc tttcctgacc ctagaccttt tcctctgccc 8640 ttatcacca tacagtggat ggagaagaca tcatctggat taatacatatt tcgcaatgaa 8760 agagaggaag aaaaggaag agcaaaatat gtggaggccc aacaaaagag actagaagcc 8820 ttattcacta aaattcagga ggagaatttgaa gaacatgaag aaaaccaaca aaaaccatat 8880 ttaccatcac gtgcactaac aagacagcaa gttcgtgctt tgcaagatgg tgcagagg 9000 cagttaagag ccttgaataa tcacaggcaa atggtgaatc ggagaacaaa aggctcagag 9000 cagttaagaa ttaggaaggc cattggaatct gctgaacaaa aggctcaagag 9120 cagttggaaa ttaggaaggc cattggaatct gctgaacaaa aggaacaagg ttaatcaagg 9120 cagttggaaa ttaggaaggc cattggaatct gctgaacaaa aggctcaagag 9120 cagttggaaa ttaggaaggc cattggaatct gctgaacaaa aggaacaaag gttagaacaaa aggctcaagag 9120 cagttggaaa ttaggaaggc cattggaatct gctgaacaaa aggctcaaga 9120 cagttggaaa ttaggaaggc cattggaatct gctgaacaaa aggaacaaag gttagaagaacaaa aggctcaagag 9120 cagttggaaa ttaggaaga cattggaacaaaa aggaacaaaa aggctcaagag 9120 cagttggaaa ttaggaaga cattggaaaaaaa aggaacaaaa aggaacaaaa aggaacaaaa aggaacaaaa aggaacaaaa aggaacaaaa aggaacaaaa aggaacaaaa aggaacaaaa aggaacaaaaa aggaacaaaa aggaacaaaaa aggaacaaaaaa aggaacaaaaaa aggaaca cccatttgta catttgttc tccggctgca cagaaggcat ttcagccacc aaggagttgt 10140 ggcaccaaat acgaaacacc cataaagaaa aaagaactga attctctca gatgactcca 10200 tttaaaaaaat tcaatgaaat ttctctttg gaaagtaatt caatagctga cgaagaactt 10260 gcattgataa atacccaagc tcttttgtct ggttcaacag gagaaaaaca atttatatct 10320 gtcagtgaat ccactaggac tgctcccacc agttcagaag attatctcag actgaaacga 10380 cgttgtacta catctctgat caaagaacag gagagttccc aggccagtac ggaagaatgt 10440 gagaaaaaata agcaggacac aattacaact aaaaaaatata tctaagcatt tgcaaaggcg 10500 acaataaatt attgacgct aacctttcca ggttataaga ctggaatata atttcaaacc 10560 acaattagt acttatgtg cacaatgaga aaagaaatta gttcaaatt tacctcagcg 10620 tttgtgtatc gggcaaaaat cgtattgccc ggattccgtat tggtatactt ttgcttcagt 10680 tgcatatctt aaaactaaat gtatttatat aactaatcaa gaaaaacacc tttggctgag 10740 caggccaggag ttcaagacca gcctgggcaa catagggaga cccccatctt tacgaagaaa 10860 aaaaaaaaagg ggaaaagaaa atcttttaaa tctttggat tggtcactac cattcaatt 10920 ttacaatcaa caaatggtc atccaaaccc aaccttgaga aaattacttg ctttcaaatt 10980 Page 41

39740-0001PCT.txt

```
gacacta
                                        10987
<210> 291
<211> 1552
<212> DNA
<213> Homo sapiens
<400> 291
gcccgtacac accgtgtgct gggacacccc acagtcagcc gcatggctcc cctgtgcccc 60
<210> 292
<211> 1578
<212> DNA
<213> Homo sapiens
<400> 292
```

aagatgctgc agctggttgg tgtcactgcc atgtttattg caagcaaata tgaagaaatg 960 taccctccag aaattggtga ctttgctttt gtgactgaca acacttatac taagcaccaa 1020 atcagacaga tggaaatgaa gattctaaga gctttaaact ttggtctggg tcggcctcta 1080 cctttgcact tccttcggag agcatctaag attggagagg ttgatgtcga gcaacatact 1140 ttggccaaat acctgatgga actaactatg ttggactatg acatggtgca ctttcctcct 1200 tctcaaattg cagcaggagc tttttgctta gcactgaaaa ttctggataa tggtgaatgg 1260 acaccaactc tacaacatta cctgtcatat actgaagaat ctcttctcc agttatgcag 1320 cacctggcta agaatgtagt catggtaaat caaggactta caaagcacat gactgtcaag 1380 aacaagtatg ccacatcgaa gcatgctaag atcagcactc taccacagct gaattctgca 1440 ctagttcaag atttagccaa ggctgtggca aaggtgtaac ttgtaaactt gagttggagt 1500 Page 42

39740-0001PCT.txt aaaaaaaaa aaaaaaaa <210> 293 <211> 3195 <212> DNA <213> Homo sapiens <400> 293 cccaccctg gaagagccca gtctgttgag ttagttaagt tgggttaata ccagcttaaa 2280 ggcagtattt tgtgtcctcc aggagcttct tgtttccttg ttagggttaa cccttcatct 2340 tcctgtgtcc tgaaacgctc ctttgtgtgt gtgtcagctg aggctgggga gagccgtggt 2400 ccctgaggat gggtcagagc taaactcctt cctggcctga gagtcagctc tctgccctgt 2460 gtacttcccg ggccagggct gcccctaatc tctgtaggaa ccgtggtatg tctgccatgt 2520 tgccctttc tctttcccc tttcctgtcc caccatacga gcacctccag cctgaacaga 2580 agctcttact ctttcctatt tcagtgttac ctgtgtgtt ggtctgtttg actttacgcc 2640 agctcttact cactactact agagtatac ctgtgtgtct ggtctgtttg actttacgcc 2640 agctcttacaga cactactacta gascatttaag gtccctta cacatacaga ttacccacta 2700 gcgttttgtt gagcatgaca cctgcagcag gaatatatgt gtgcctattt gtgtggacaa aaatatttac acttagggtt tggagctatt caagaggaaa tgtcacagaa gcagctaaac caaggactga gcacctctg gattctgaat ctcaagatgg gggcagggct gtgcttgaag gccctgctga gtcatctgtt agggccttgg ttcaataaag cactgagcaa gttgagaaaa 3120 3180 aaaaaaaaa aaaaa 3195 <210> 294

<210> 294 <211> 3737 <212> DNA <213> Homo sapiens

39740-0001PCT.txt

<400> 294 ggcgtccgcg cacacctcc cgcgccgccg ccgccaccgc ccgcactccg ccgcctctgc 60 ccgcaaccgc tgagccatcc atgggggtcg cgggccgcaa ccgtcccggg gcggcctggg 120 cggtgctgct gctgctgctg ctgctgccgc cactgctgct gctggcggg gcgtcccgc 180 cgggtcgggg ccgtcccgc gggccgcagg aggatgtaga tgagtgtgc caagggctag 240 atgactgcca tgccgacgcc ctgtgtcaga acacaccac ctcctacaag tgctcctgca 300 agcctggcta ccaaggggaa ggcagtcag gtgaggacat cgatgatgt ggaaatgag 360 tcaatggagg ctgtgtccat gactgttga atattccagg caattatcgt tgcacttgt 420 agaacaatgg cggctgccag catacctgtg tcaacggtc ataattgtct tgatgtggac gagtgcctg 480 agaacaatgg cggctgcag catacctgtg tcaacggtcat gaggagctat gagtgctgc 540 agttctaagc agtgctcgtg aaaaaaaaaa gcagaaagaa ttagaaataa ataaaaacta 3720 ağcacttcig gagacat

39740-0001PCT.txt

<212> DNA <213> Homo sapiens <400> 295 ggggccagtc gttcgccgga aagcatttgt ctcccacctc atcataacaa caattaattt 60 tcatttttat caaaacattt tgtttaattc aaaaagtaca tatttcttcc atgttgattt 1980 2042 <210> 296 <211> 2547 <212> DNA <213> Homo sapiens <400> 296 gaacctttgt aaatacagag cttgtaggga aaggaaaacg ccgtcctttg aataacaatt 1320 Page 45

39740-0001PCT.txt ctgaaattgc actgtcacta agcagaaata aagtttttgt cttttttgat ctgactgtag 1380 atgatcagtc agtttatcct aaggcattaa gagatgaata catcatgtca aaaactcttg atgatcagtc agtttatcct aaggcattaa gagatgaata catcatgtca aaaactcttg 1440 gaagtggtgc ctgtggagag gtaaagctgg ctttcgagag gaaaacatgt aagaaagtag 1500 ccataaagat catcagcaaa aggaagtttg ctattggttc agcaagagag gcagacccag 1560 ctctcaatgt tgaaacagaa atagaaattt tgaaaaagct aaatcatcct tgcatcatca 1620 agattaaaaa ctttttgat gcagaagatt attatattgt tttggaattg atggaagggg 1680 gagagctgtt tgacaaagtg gtggggaata aacgcctgaa agaagctacc tgcaagctct 1740 attttacca gatgctcttg gctgtgcagt accttcatga aaacggtatt atacaccgtg 1800 acttaaagcc agagaatgtt ttactgtcat ctcaagaaga ggactgtctt ataaagatta 1860 ctgatttgg gcactccaag attttgggag agacctctct catgagaacc ttatgtggaa 1920 ccccaccta cttggcgcct gaagttcttg tttctgttgg gactgctggg tataaccgtg 1980 ctgtggactg ctggagttat ggagttattc tttttatctg ccttagtggg tatcaccctt 2040 tcctgagca taggacccaa gtgtcactga aggatcagat caccagtgga aaatacaact 2100 tcattcctga agtctgggca gaagtctcag agaagctct ggacctttgtc aagaagttgt 2160 tctctgagca taggactcaa gtgtcactga aggatcagat caccagtgga aaatacaact 2100 tcattcctga agtctggca gaagtctcag agaagctct ggaccttgtc aagaagttgt 2160 tggtagtgga tccaaaggca cgttttacga cagaagaagc cttaagacac ccgtggcttc 2220 aggatgaaga catgaagaga aagtttcaag atcttctgtc tgaggaaaat gaatccacag 2280 ctctacccca ggttctagcc cagccttcta ctagtcgaaa gcggccccgt gaaggggaag 2340 ccgagggtgc cgagaccaca aagcgcccag ctgtgtgtgc tgctgtgttg tgaactccgt 2400 ggtttgaaca cgaaagaaat gtaccttctt tcactctgtc atctttcttt tctttgagtc 2460 tgtttttta tagtttgtat tttaattatg ggaataattg cttttcaca gtcactgatg 2520 tacaattaaa aacctgatg aacctgg <210> 297 <211> 2768 <212> DNA <213> Homo sapiens <400> 297 cactgctgtg cagggcagga aagctccatg cacatagccc agcaaagagc aacacagagc 60 tgaaaggaag actcagagga gagagataag taaggaaagt agtgatggct ctcatcccag 120 acttggccat ggaaacctgg cttctcctgg ctgtcagcct ggtgctcctc tatctatatg 180 gaaaccattc acttgacct tttaagaagc tggaaacct agggcccata cactgacct 240 ttttgggaaa tattttgtcc taccataagg gcttttgtat gtttgacatg gaatgtcata 300 aaaagtatgg aaaagtgtgg ggcttttatg atggtcaaca gcctgtgctg gctatcacag 360 atcctgacat gatcaaaaca gtgctagtga aagaatgtta ttctgtcttc acaaaccgga 420 ggccttttgg tccagtggga tttatgaaaa gtgccatctc tatagctgag gatgaagaat 480 ggaagagatt acgatcattg ctgtctcaa ccttcaccag tggaaaactc aaggagatgg 540 tccctatcat tgcccagtat ggagatgtgt tggtgagaaa tctgaggcgg gaagcagaga 600 caggcaagcc tgtcaccttg aaagacgtct ttggggcaa cagcatggat gtgatcacta 660 acaccacat tggagtgaac atcgactct tcaacaacc acaagaccc tttggggaaa 720 acaccaagaa gcttttaaga tttgatttt tggatcatt ctttctca ataacagtct 780 acaccaagaa gcttttaaga tttgattttt tggatccatt ctttctctca ataacagtct 780 ttccattcct catcccaatt cttgaagtat taaatatctg tgtgtttcca agagaagtta 840 caaatttttt aagaaaatct gtaaaaagga tgaaagaaag tcgcctcgaa gatacacaaa 900 agcaccgagt ggattcctt cagctgatga ttgactctca gaattcaaaa gaaactgagt 960 cccacaaagc tctgtccgat ctggagctcg tggcccaatc aattatctt attttgctg 1020 gctatgaaac cacgagcagt gttctctcct tcattatgta tgaactggcc actcaccctg 1080 atgtccagca gaaactgcag gaggaaattg atgcagtttt acccaataag gcaccaccca 1140 cctatgatac tgtgctacag atggagtatc ttgacatggt ggtgaatgaa acgctcagat 1200 tattcccaat tgctatgaga cttgagaggg tctgcaaaaa agatgttgag atcaatggga 1260 tgttcattcc caaaggggtg gtggtgatga ttccaagcta tgctcttcac cgtgacccaa 1320 agtactggac agagcctgag aagttcctc ctgaaagatt cagcaagaag aacaaggaca 1380 acatagatcc ttacatatac acacctttg gaagtggacc cagaaactgc attggcatga 1440 ggtttgctct cagaacaatg atcacctga aacttgctc taatcagagt ccttcagaac ttctccacca 1560 aaccttgtaa agaaacacag atccccctga aattaagctt aggaggactt cttcaaccag 1560 aaacctgtaa agaaacacag atcccctga aattaagctt aggaggactt cttcaaccag 1560 aaaaacccgt tgttctaaag gttgagtcaa gggatggcac cgtaagtgga gcctgaattt 1620 tcctaaggac ttctgctttg ctcttcaaga aatctgtgcc tgagaacacc agagacctca 1680 aattactttg tgaatagaac tctgaaatga agatgggctt catccaatgg actgcataaa 1740 taaccgggga ttctgtacat gcattgagct ctctcattgt ctgtgtagag tgttatactt 1800 gggaatataa aggaggtgac caaatcagtg tgaggaggta gatttggctc ctctgcttct 1860 cacgggacta tttccacac ccccagttag caccattaac tcctcctgag ctctgataag 1920 agaatcaaca tttccaata atttcctca caaattatta atgaaaataa gaattattt 1980 gattggctcta acaatgacat ttataccaca tgttttcctc ggagtattct ataagtttta 2040 gattggctca ataagacca ctttaccaaa gattattcct ggagtattct ataagtttta 2040 tgttaaatca ataaagacca ctttacaaaa gtattatcag atgctttcct gcacattaag 2100 gagaaatcta tagaactgaa tgagaaccaa caagtaaata tttttggtca ttgtaatcac 2160 tgttggcgtg gggcctttgt cagaactaga atttgattat taacataggt gaaagttaat 2220 ccactgtgac tttgcccatt gtttagaaag aatattcata gtttaattat gccttttttg 2280 atcaggcaca gtggctcacg cctgtaatcc tagcagtttg ggaggctgag ccgggtggat 2340 cgcctgaggt caggagttca agacaagcct ggcctacatg gttgaaaccc catctctact 2400

```
39740-0001PCT.txt
 aaaaatacac aaattagcta ggcatggtgg actcgcctgt aatctcacta cacaggaggc 2460
tgaggcagga gaatcacttg aacctgggag gcggatgttg aagtgagctg agattgcacc 2520 actgcactcc agtctgggtg agagtgagac tcagtcttaa aaaaatatgc ctttttgaag 2580 cacgtacatt ttgtaacaaa gaactgaagc tcttattata ttattagttt tgatttaatg 2640 ttttcagccc atctcctttc atatttctgg gagacagaaa acatgtttcc ctacacctct 2700 tgcattccat cctcaacacc caactgtctc gatgcaatga acacttaata aaaaacagtc 2760
 gattggtc
 <210> 298
 <211> 1358
  <212> DNA
 <213> Homo sapiens
 <400> 298
ggcgtccgcg cgctgcacaa tggcggctct gaagagttgg ctgtcgcgca gcgtaacttc 60 attcttcagg tacagacagt gtttgtgtgt tcctgttgtg gctaacttta agaagcggtg 120 tttctcagaa ttgataagac catggcacaa aactgtgacg attggctttg gagtaaccct 180 gtgtgcggtt cctattgcac agaaatcaga gcctcattcc cttagtagtg aagcattgat 240 gaggagagca gtgtctttgg taacagatag cacctctacc tttctctct agaccacata 300 tgcgttgatt gaagctattac ttgaaataac taaggctgtt tataaccttaa cttctcttta 360
ccgacaatat acaagtttac ttgggaaaat gaattcagag gaggaagatg aagtgtggca 420 ggtgatcata ggagccagag ctgagatgac ttcaaaacac caagagtact tgaagctgga 480 aaccacttgg atgactgcag ttggtctttc agagatggca gcagaagctg catatcaaac 540
tggcgcagat caggcctcta taaccgccag gaatcacatt cagctggtga aactgcaggt 600 ggaagaggtg caccagctct cccggaaagc agaaaccaag ctggcagaag cacagataga 660 agagctccgt cagaaaacac aggaggaagg ggaggagcgg gctgagtcgg agcaggaggc 720 ctacctgcgt gaggattgag ggcctagagca cactgcctg tctccccact cagtggggaa 780 agcaggggag gatgccaccc tgcccagggt tggcatgact gtctgtgac cgagaaggag 840
agcagggca gatgccaccc tgcccagggt tggcatgact gtctgtgcac cgagaagagg cggcaggtcc tgccctggcc aatcaggcga gacgcctttg tgagctgtga gtgcctcctg tggtctcagg cttgcgctgg acctggttct tagcccttgg gcactgcacc ctgtttaaca tttcaccca ctctgtacag ctgctcttac ccatttttt tacctcacac ccaaagcatt ttgcctacct gggtcagaga gaggagtcct ttttgtcatg cccttaagtt cagcaactgt ttaacctgtt ttcagtctta tttacgtcgt caaaaatgat ttagtacttg ttccctctgt tgggatgca gttgtggcag ggggaggga acctgccag tttgtacgat ttctttgtat gtattctga tgtgttctct gatctgccc cactgtcctg tgaggacagc tgaggccaag gagtgaaaaa cctattacta ctaagagaag gggtgcagag tgtttacctg gtgctctcaa caggacttaa catcaacagg acctaacaca gaaaaaaa
                                                                                                                                                                                                                                                900
                                                                                                                                                                                                                                                960
                                                                                                                                                                                                                                                1020
                                                                                                                                                                                                                                                1080
                                                                                                                                                                                                                                                1200
                                                                                                                                                                                                                                                 1260
                                                                                                                                                                                                                                                1320
<210> 299
<211> 4407
 <212> DNA
<213> Homo sapiens
 <400> 299
tttcgactcg cgctccggct gctgtcactt ggctctctgg ctggagcttg aggacgcaag 60
gagggtttgt cactggcaga ctcgagactg taggcactgc catggcccct gtgctcagta 120 aggactcgc ggacatcgag agtatcctgg ctttaaatcc tcgaacacaa actcatgcaa 180 ctctgtgttc cacttcggcc aagaaattag acaagaaaca ttggaaaaga aatcctgata 240 agaactgctt taattgtgag aagctggaga ataattttga tgacatcaag cacacgactc 300 ttggtgagcg aggagctctc cgagaagcaa tgagatgcct gaaatgtgca gatgccccgt 360 gtcagaagag ctgtccaact aatcttgata ttaaatcatt catcacaagt attgcaaaca 420 agaactatta tggagctgct aagatgatat tttctgacaa cccacttggt ctgacttgtg 480 gaatggtatg tccaacctct gatctatgtg taggtggatg caatttatat gccactgaag 540 agggacccat taatattggt ggattgcagc aatttgctac tgaggtattc aaagcaatga 600 gtaccaaagat tgcfcttttt ggtgctggc ctgcaagtat aagttggct tcctttttgg 720
ctcttagcac tttgaaagaa aaaggctaca aagctgcttt cattggaata ggtttgccag 960 aacccaataa agatgccatc ttccaaggcc tgacgcagga ccaggggttt tatacatcca 1020 aagacttttt gccacttgta gccaaaggca gtaaagcagg aatgtgcgcc tgtcactctc 1080 cattgccatc gatacggga gtcgtgattg tacttggagc tggagacact gccttcgact 1140 gtgcaacatc tgctctacgt tgtggagctc gccgagtgtt catcgtcttc agaaaaggct 1200
ttgttaatat aagagctgtc cctgaggaga tggagcttgc taaggaagaa aagtgtgaat
ttctgccatt cctgtccca cggaaggtta tagtaaaagg tgggagaatt gttgctatgc 1320 agtttgttcg gacagagcaa gatgaaactg gaaaatggaa tgaagatgaa gatcagatgg 1380 tccatctgaa agccgatgtg gtcatcagtg cctttggttc agttctgagt gatcctaaag 1440
                                                                                                                                        Page 47
```

```
39740-0001PCT.txt
  taaaagaagc cttgagccct ataaaattta acagatgggg tctcccagaa gtagatccag 1500 aaactatgca aactagtgaa gcatgggtat ttgcaggtgg tgatgtcgtt ggtttggcta 1560 acactacagt ggaatcggtg aatgatggaa agcaagcttc ttggtacatt cacaaatacg 1620 tacagtcaca atatggagct tcggttctg ccaagcctga actacccctc ttttacactc 1680
aatatgtaat ttcaaaatac atttgtaagt gtaaaaaatg tctcatgtca atgaccattc aattagtggc ataaaataga ataattcttt tctgaggata gtagttaaat aactgtgtgg cagttaattg gatgttcact gccagttgtc ttatgtgaaa aattaacttt ttgtgtggca attagtgga cagtttcaa attgccctat gctgtgctcc atattgatt tctaattgta agtggaaatta agcattttga aacaaagtac tctttaacat gctgtgaaa gaaatgaaag
                                                                                                                                                                                                                                                   3420
 aacatttta tcaataaaaa ttacctttaa ttttaatgct gtttctaaga aaatgtagtt agctccataa agtacaaatg aagaaagtca aaaattattt gctatggcag gataagaaag cctaaaattg agtttgtgga ctttattaag taaaatcccc ttcgctgaaa ttgcttattt ttggtgttgg atagaggata gggagaatat ttactaacta aataccattc actactcatg cgtgagatgg gtgtacaaac tcatcctctt ttaatggcat ttctctttaa actatgttcc
                                                                                                                                                                                                                                                   3840
                                                                                                                                                                                                                                                   3900
 taaccaaatg agatgatagg atagatcctg gttaccactc tittactgtg cacatatggg 3960 ccccggaatt ctttaatagt caccttcatg attatagcaa ctaatgtttg aacaaagctc 4020 aaagtatgca atgcttcatt attcaagaat gaaaaatata atgttgataa tatatattaa 4080 gtgtgccaaa tcagtttgac tactctctgt tttagtgttt atgtttaaaa gaaatatatt 4140
 ttttgttatt attagataat atttttgtat ttctctattt tcataatcag taaatagtgt 4200 catataaact catttatctc ctcttcatgg catcttcaat atgaatctat aagtagtaaa 4260 tcagaaagta acaatctatg gcttatttct atgacaaatt caagagctag aaaaataaaa 4320 tgttcatta tgcactttta gaaatgcata tttgccacaa aacctgtatt actgaataat 4380
  atcaaataaa atatcataaa gcatttt
  <210> 300
  <211> 5532
   <212> DNA
  <213> Homo sapiens
  <400> 300
<400> 300
gccgcgctgc gccggagtcc cgagctagcc ccggcgccgc cgccgcccag accggacgac 60
aggccacctc gtcggcgtcc gcccgagtcc ccgcctcgcc gccaacgcca caaccaccgc 120
gcacggcccc ctgactccgt ccagtattga tcgggagagc cggagcgagc tcttcgggga 180
gcagcgatgc gaccctccgg gacggccggg gcagcgctcc tggcgctgct ggctgcgctc 240
tgcccggcga gtcgggctct ggaggaaaag aaagtttgcc aaggcacgag taacaagctc 300
acgcagttgg gcacttttga agatcattt ctcagcctcc agaggatgt caataactgt 360
gaggtggtcc ttgggaattt ggaaattacc tatgtgcaga ggaattatga tctttccttc 420
ttaaagacca tccaggaggt ggctggttat gtcctcattg ccccaacac agtggagcga 480
attcctttgg aaaacctgca gatcatcaga ggaaatatgt actacgaaaa ttcctatgcc 540
ttagcagtct tatctaacta tgatgcaaat aaaaccggac tgaaggagct gcccatgaga 600
aatttacagg aaatcctgca tggcgccgtg cggttcagca acaaccctgc cctgtgcaac 660
  aatītacagg aaatcctgca togcgccgtg cggttcagca acaaccctgc cctgtgcaac 660
                                                                                                                                         Page 48
```

39740-0001PCT.txt

gtggagagca tccagtggcg ggacatagtc agcagtgact ttctcagcaa catgtcgatg 720 gačttocága accacctogg cágotgocaa aágtotgato caagototoc caatoggago 780 tgctggggtg caggagaga gaactgccaa aagtgtgatc caagctgtcc caatgggagc 780 tgctggggtg caggagaga gaactgccag aaactgacca aaatcatctg tgcccagcag 840 tgctccgggc gctgccgtgg caagtcccc agtgactgct gccacaacca gtgtgctgca 900 ggctgcacag gcccccggga gagcgactgc ctggtctgcc gcaaattccg agacgaagcc 960 acgtgcaagg acacctgcc cccactcatg ctctacaacc ccaccacgta ccagatggat 1020 gtgaaccccg agggcaaata cagctttggt gccacctgcg tgaagaagtg tccccgtaat 1080 tatgtggtga cagatcacgg ctcgtgcgtc cgagcctgtg gggccgacag ctatgagatg 1140 gaggaagagg gcgtccgcaa gtgtaagaag tgcgaagggc cttgccgcaa agtgtgtaac 1200 ggaataggta ttggtgaatt taaagactca ctctccataa atgctacgaa tattaagaggt 1320 cagaaaggca gccacaaat tagcctggac aaccctgact accagcagga cttctttccc 3720 aaggaagcca agccaaatgg catctttaag ggctcacaag ctgaaaatgc agaataccta 3780 agggtcgcgc cacaaagcag tgaatttatt ggagcatgac cacggaggat agtatgagcc 3840 ctaaaaatcc agactctttc gatacccagg accaagccac agcaggtcct ccatccaac 3900 agccatgccc gcattagctc ttagacccac agactggtt tgcaacgttt acaccgacta 3960 gccaggaagt acttccacct cgggcacatt ttgggaagtt gcattccttt gtcttcaaac 4020 tgtgaagcat ttacagaaac gcatccagca agaatattgt ccctttgagc agaaatttat 4080 ctttcaaaga ggtatatttg aaaaaaaaaa aaaaagtata tgtgaggatt tttattgatt 4140 ggggatcttg gagtttttca ttgtcgctat tgatttttac ttcaatggc tcttccaaca 4200 aggaagaagc ttgctggtag cacttgctac cctgagttca tccaggcca actgtgagca 4260 ggggatcttg gagttttca ttgtcgctat tgattttac ttcaatgggc tcttccaaca 4200 aggaagaagc ttgctggtag cacttgctac cctgagttca tccaggccca actgtgagca 4260 aggagcacaa gccacaagtc ttccagagga tgcttgattc cagtggttct gcttcaaggc 4320 ttccactgca aaacactaaa gatccaagaa ggccttcatg gccccagcag gccggatcgg 4380 tactgtatca agtcatggca ggtacagtag gataagccac tctgtccctt cctgggcaaa 4440 gaagaaacgg aggggatgaa ttcttcctta gacttacttt tgtaaaaatg tccccacggt 4500 acttactcc cactgatgga ccagtggttt ccagtcatga gcggtagact gacttgtttg 4560 tcttccattc cattgttttg aaactcagta tgccgccct gtcttgctgt catgaaatca 4620 gcaagaagag atgacacatc aaataataac tcggattca gcccacattg gattcatcag 4680 catttggacc aatagcccac agctgagaat gtggaatacc taaggataac accgcttttg 4740 Page 49

```
39740-0001PCT.txt
     ttctcgcaaa aacgtatctc ctaatttgag gctcagatga aatgcatcag gtcctttggg 4800
     gcatagatca gaagactaca aaaatgaagc tgctctgaaa tctcctttag ccatcacccc 4860
    gcatagatca gaagactaca aaaatgaagc tgctctgaaa tctcctttag ccatcacccc 4860 aacccccaa aattagtttg tgttacttat ggaagatagt tttctccttt tacttcactt 4920 caaaagcttt ttactcaaag agtatatgtt ccctccaggt cagctgccc caaaccccct 4980 ccttacgctt tgtcacacaa aaagtgtctc tgccttgagt catctattca agcacttaca 5040 gctctggcca caacagggca ttttacaggt gcgaatgaca gtagcattat gagtagtgtg 5100 aattcaggta gtaaatatga aactagggtt tgaaattgat aatgctttca caacatttgc 5160 agatgttta gaaggaaaaa agttccttcc taaaataatt tctctacaat tggaagattg 5220 gaagattcag ctagttagga gcccatttt tcctaaactg tgtgtgccct gtaacctgac 5280 tggttaacag cagtcctttg taaacatggt tttaaactct cctagtcaat atccacccca 5340 tccaatttat caaggaagaa atggttcaga aaatatttc agcctacagt targttcaga 5400
    tccaatttat caaggaagaa atggttcaga aaatattttc agcctacagt tatgttcagt cacacacaca tacaaaatgt tccttttgct tttaaagtaa tttttgactc ccagatcagt cagagcccct acagcattgt taagaaagta tttgatttt gtctcaatga aaataaaact
                                                                                                                                                                                                                                                                                                                                    5400
                                                                                                                                                                                                                                                                                                                                     5460
                                                                                                                                                                                                                                                                                                                                    5520
     atăticattt cc
    <210> 301
<211> 1528
     <212> DNA
     <213> Homo sapiens
    <400> 301
  cggcgagcga gcaccttcga cgcggtccgg ggaccccctc gtcgctgtcc tcccgacgcg 60 gacccgcgtg ccccaggcct cgcgctgccc ggccggctcc tcgtgtccca ctcccggcgc 120 acgccctccc gcggctccc ggcccctcct tctcggcgcg cgcgcagcat 180 ggcgcccccg caggtcctcg cgttcgggct tctgcttgcc gcggcgacgg cgacttttgc 240 cgcagctcag gaagaatgtg tctgtgaaaa ctacaagctg gccgtaaact gctttgtgaa 300 taataatcgt caatgccagt gtacttcagt tggtgcacaa aatactgtca tttgctcaaa 360 gcggctgccc aaatgtttgg tgatgaaggc agaaatgaat ggctcaaaac ttgggagaag 420 agaagaacct gaaggggccc tccagaacaa tgatgggctt tatgatcctg actgcgatga 480 gagcgggctc tttaaggcca agaagaacaa acaaggacac tgaaataacc tgctctgagc gagtgagaac 540 tgctgaggtc agaagaacaa acaaggacac tgaaataacc tgctctgagc gagtgagaac 600
gagcgggctc tttaaggcca agcagtgcaa cggcacctcc acgtgctggt gtgtgaacac 540 tgctggggtc agaagaacag acaaggacac tgaaataacc tgctctgagc gagtgagaac 600 ctactggatc atcattgaac taaaacacaa agcaagagaa aaaccttatg atagtaaaag 660 tttgcggact gcacttcaga aggagatcac aacgcgttat caactggatc caacatttat 720 cacgagtatt ttgtatgaga ataatgttat cactattgat ctggttcaaa attcttctca 780 aaaaaactcag aatgatgtgg acatagctga tgtggcttat tattttgaaa aagatgttaa 840 aggtgaaccc ttgtttcatt ctaagaaaat ggacctgaca gtaaatgggg aacaacctgga 900 tctggatcct ggtcaaacctt taatttatta tgttgatgaa aaagcacctg aatgctggt ttattgctgt tattgtggtt ggtggtgatag cagttgttgc 1020 tggaattgtt gtgctggtta tttccagaaa gaagagaatg gcaaagtatg gggaagaga aggggagaa acccaatgca taactatata atttgaaga atgggtgaga tgcataggga acccaatgca taactatata atttgaaga 1140 tatagaagaa tataaagcagc ttgaaactgg ctttaccaat cagaacttgg acccacaagt 1320 gtcttatata tgcagatcta attcaaatg gtgcattaaa tatgcttcca cagtaaaacc tgaaaaacc tgaaaacct 1260 gtcttatata tgcagatcta atgtaaaatc cagaacttgg acccacacgt taaaaatca 1380 tatgtgtaac attcaaatg gtgcattaaa tatgcttcca cagtaaaacc tgaaaaacc tgaaaacct 1260
  tatgtgtaac attcaaatgt gtgcattaaa tatgcttcca cagtaaaatc tgaaaaactg 1440 atttgtgatt gaaagctgcc tttctattta cttgagtctt gtacatacat actttttat 1500 gagctatgaa ataaaacatt ttaaactg 1528
  <210> 302
<211> 1856
  <212> DNA
  <213> Homo sapiens
  <400> 302
ctgacttggc aggactgtgc aattgtcaga aggccgtggg gagtgggggc cagtgcctgc 60 agcctgcctt gcctctcta caggcctta gagcatcgcc aggtgcagag ctccacagct 120 ctcttcca aggagtaatc agagggtgag aacgtggagc ctggtggaca ggtgaaagca 180 ctgggatctt tctgcccaga aaggggaaag ttgcacattt atatcctaga gggaagcgac 240 agcagtgctt ctccctgtgc tgaggtacag gagccatgtg gctagaaatc ctcctcactt 300 cagtgctggg ctttgccatc tactggtca tctcccggga caaagaggaa actttgccac 360 gccctttcaa ggtggaaacg tcagatgagg ggtggaaacg ctagatgag gacagcatcc 420 agctcttcaa ggtggaaacg tcagatgagg agatccacga cttacaccag aggatcgata 480 agctccgttt cacccacct ttgaagaaca gctgcttca ctatggttc aactccaact 540
  agttccgttt caccccacct ttggaggaca gctgcttcca ctatggcttc aactccaact 540
 acctgaagaa agtcatctcc tactggcgga atgaatttga ctggaagaag caggtggaga 600 ttctcaacag ataccctcac ttcaagacta agattgaagg gctggacatc cacttcatcc 660 acgtgaagcc ccccagctg cccgcaggcc ataccccgaa gcccttgctg atggtgcacg 720
```

39740-0001PCT.txt gctggcccgg ctctttctac gagttttata agatcatccc actcctgact gaccccaaga 780 accatggctt gagcgatgag cacgtttttg aagtcatctg cccttccatc cctggctatg 840 gcttctcaga ggcatcctcc aagaaggggt tcaactcggt ggccaccgcc aggatcttt 900 acaagctgat gctgcggctg ggcttccagg aattctacat tcaaggaggg gactgggggt 960 ccctgatctg cactaatatg gcccagctgg tgcccagcca cgtgaaaggc ctgcacttga 1020 acatggcttt gggtttaagc aacttctcta ccctgaccct cctcctggga cagcgtttcg 1080 ggaggtttct tggcctcact gagagggagt tggaggctgt gtaccccgtc aaggaggagg 1140 tatctacag cctgatgagg gactctcttg tgggtctgct gtaccccgt aaggaggagg 11260 ttccacctg gaccaatacg gaattccgat acctggagga tggaggcctg gaaaggaagg 1320 tctccctgga cgacctgctg accaacgtca tgctctactg gacaacaggc accatcatct 1380 cctcccagcg cttctacaag gagaacctgg gacagggctg gatgacccag aagcatgagc 1440 ggatgaaggt ctatgtgcc actggcttc ctgccttccc ttttgagcta ttgcacacgc 1500 ctgaaaaagtg ggtgaggtc aggagccgg agctcactc ctattcctaa atggtccgt 1560 ggggccactt tgcggccttt tggggaggtc aggaccccacc cccccaca aggctttct tggggaagat accccccacc cccccaca 1680 agcccccacc cctgtgggta agcaacatgg ctttgatgat aacccccaa ccccccaacc 1800 acccccaact ccgtgtgta agcaacatgg cttttgatgat aaccccca accccca accccca 1800 acccccaact ccgtgtggta agcaacatgg cttttgatgat aaccccta accccca acccccaacc gctggcccgg ctctttctac gagttttata agatcatccc actcctgact gaccccaaga 780 acccccaact ccgtgtggta agcaacatgg ctttgatgat aaacgacttt actcta 1856 <210> 303 <211> 6450 <212> DNA <213> Homo sapiens <400> 303 gagttgtgcc tggagtgatg tttaagccaa tgtcagggca aggcaacagt ccctggccgt 60 cctccagcac ctttgtaatg catatgagct cgggagacca gtacttaaag ttggaggccc 120 gggagcccag gagctggcgg agggcgttcg tcctgggagc tgcacttgct ccgtcgggtc 180 gggagcccag gagctgggg agggcgttcg tcctgggagc tgcacttgct ccgtcgggtc 180 gccggcttca ccggaccgca ggctcccggg gcagggccgg ggccagagct cgcgtgtcg 240 cgggacatgc gctgcgtcg ctctaacctc gggctgtgct ctttttccag gtggcccgc 300 ggtttctgag ccttctgcc tgcggggaca cggtctgcac cctgcccgcg gccacggacc 360 atgaccatga ccctccacac caaagcatct gggatggccc tactgcatca gatccaaggg 420 aacgagctgg agcccctgaa ccgtccgcag ctcaagatcc ccctggagcg gcccctgggc 480 gaggtgtacc tggacagcag caagcccgc gtgtacaact accccgaggg cgccgcctac 540 gagttcaacg ccgcggccgc cgccaacgcg caggtctacg gtcagaccgg cctcccctac 600 ggccccgggt ctgaggctgc ggcgttcggc tccaacggc tggggggttt ccccccactc 660 aacagcgtgt ctccaacgc gctgatca ctgcaccgc cgccaagct gtcgcctttc 720 ggccccgggt ctgaggctgc ggcgttcggc tccaacggcc tggggggttt cccccactc 660 aacagcgtgt ctccgagccc gctgatgcta ctgcacccgc cgccgcagct gtcgcctttc 720 ctgcagccc acggccagca ggtgccctac tacctggaga acgagccag cggctacacg 780 gtgcgcgagg ccggcccgcc ggcattctac aggccaaatt cagataatcg acgccagggt 840 ggcagagaaa gattggccag taccaatgac aagggaagta tggctatgga atctgccaag 900 gagactcgct actgtgcagt gtgcaatgac tatgcttcag gctaccatta tggagtctgg 960 tcctgtgagg gctgcaaggc cttcttcaag agaagtattc aaggacataa cgactatatg 1020 tgtccagca ccaaccagtg caccattgat aaaaacagga ggaagagctg ccaggcctgc 1080 cggctccgca aatgctacga agtgggaatg atgaagagtg ggagagggaga tgttgaaaca caagcgccag agagatgatg gggagggcag gggtgaagtg 1200 gggtctgctg gagacatgag agctgccaac ctttggccaa gcccgctcat gatcaaacgc 1260 tctaagaaga acagcctggc cttgtccctg acggccgacc agatggtcag tgccttgttg 1320 gatgctgac cccccatact ctattccgag tatgatccta ccagaccctt cagtgaagct 1380 tcgatgatgg gcttactgac caacctggca gacagggagc tggttcacat gatcaactgg 1440 tcgatgatgg ccccatact ctattccgag tatgatccta ccagaccett cagtgaaget 1580 tcgatgatgg gcttactgac caacctggca gacagggagc tggttcacat gatcaactgg 1440 gcgaagaggg tgccaggctt tgtggatttg accctccatg atcaggtcca ccttctagaa 1500 tgtgcctggc tagagatcct gatgattggt ctcgtctggc gctccatgga gcacccagtg 1560 aagctactgt ttgctcctaa cttgctcttg gacaggaacc agggaaaatg tgtagagggc 1620 atggtggaga tcttcgacat gctgctggct acatcatctc ggttccgcat gatgaatctg 1680 caggagaga tettegacat getgetgget acateatete ggtteegeat gatgaatetg 1680 caggagagag agtttgtgtg ceteaaatet attattttge ttaattetgg agtgtacaca 1740 tttetgteea geaceetgaa gtetetggaa gagaaggace atateeaceg agteetggae 1800 aagateacag acaetttgat ecacetgatg gecaaggeag geetgaeeet geageageag 1860 caceagegge tggeeeaget ecteetate eteteeaca teaggeacat gagtaacaaa 1920 ggeatggage atetgtacag eatgaagtge aagaaegtgg tgeeeeteta tgaeetgetg 1980 etggagatge tggaeeeca eegeetaat gegeeeacat geeggagag ggeateegtg 2040 gaggagaegg accaaageea ettggeeact gegggeteta etteategea tteettgeaa 2100 aagtattaca teaeggggga ggeagaggggt tteeetgea eagtetgaga geteeetgge 2160 teeeacaegg tteagataat eeetgeegeatg eateeacae caategeett etagatgagt 2280 aattetgtet eetgeataea eteeggeatg eateeacae eaatggettt etagatgagt 2280 aattetgtet cetgeataaa eteeggeatg catecaacac caatggett etagatgagt 2280 ggccatteat ttgettgete agttettagt ggcacatett etgetetet ttgggaacag 2340 ccaaagggat tecaaggeta aatetttgta acagetetet ttececettg etatgttaet 2400 aagegtgagg attecegtag etetteacag etgaacteag tetatgggtt ggggeteaga 2460 taactetgtg catttaaget acttgtagag acceagget ggagagtaga cattttgeet 2520

39740-0001PCT.txt

ctgataagca ctttttaaat ggctctaaga ataagccaca gcaaagaatt taaagtggct 2580 cctttaattg gtgacttgga gaaagctagg tcaagggttt attatagcac cctcttgtat 2640 tcctatggca atgcatcctt ttatgaaagt ggtacacctt aaagctttta tatgactgta 2700 gcagagtatc tggtgattgt caattcactt ccccctatag gaatacaagg ggccacacag 2760 ggaaggcaga tcccctagtt ggccaagact tattttaact tgatacactg cagattcaga 2820 gtgtcctgaa gctctgcctc tggctttccg gtcatgggtt ccagttaatt catgcctcc 2880 atggacctat tgttttatt tttgtgtac aaaagaaagc cctccctct tgaacttgca 3000 gtaaggtcag cttcaggacc tgttccagtg ggcactgtac ttggatcttc ccggcgtgtg 3060 tgtgccttac acaggggtga actgttcact gtggtgatgc atgatgggg taaatggtag 3120 ttgaaaggag cagggccct ggtgttgcat ttagccctgg ggcatggagc tgaacagtac 3180 ttgtgcagga ttgttgggc tactagagaa caagagggaa agtagggcag aaactggata 3240 cagtctgag cagaccccgc attgcctagg tgggagccct ggggatccct ggggtgccct ggggttccttatc atttccagc gtggccctgg ttggaagaag caggctgcag ctacctagga 3300 gctcttattc attccagc gtggccctgg ttggaagaag cagctgcag ctacctagga 3300 gctcttattc attcccagc gtggccctgg ttggaagaag caggctgcag ctacctagga 3300 gctcttattc attcccagc gtggccctgg ttggaagaag caggctgcag gggatccctg ggggatccctg ggggatccct atcacatcga 3420 gctgttcc tacaattggc ccagcacct ggggcacgga agaagggtgg ggaccgttgc 3480 tgtcactact caggctgact gggtttggga agaaaatcct cccccttcct ccccccccc 3600 gttccctacc gccccacc ctgccagct atttcctta atttccttag acctataggc 3660 taaaaaaaaa aggcccatcc ctgccagcc atttcctta atttccttag acctataggc 3780 ctgataagca ctttttaaat ggctctaaga ataagccaca gcaaagaatt taaagtggct 2580 ttgaatgtag taattetgtt etggatttaa tttgaetggg ttaacatgca aaaaccaagg 4200 aaaaatattt agttttttt ttttttttg tatactttte aagetacett gteatgtata 4260 cagteattta tgeetaaage etggtgatta tteatttaa tgaagateae attteatate 4320 aaettttgta tecacagtag acaaaatage actaatecag atgeetattg ttggatattg 4380 aatgaeagae aatettatgt ageaaagatt atgeetgaaa aggaaaatta tteagggeag 4440 etaattttge tttaaccaaa atateagag taatatttt ggaeagtage taatgggtea 4500 gtgggttett tttaatgatt atacetagat ttteetttaa aaaaaattaaa ataaaacaaa 4560 aaaaatteet aggaetaga atgtgaatge tatteatgag 4680 tgggeagaga acateagag atggataga atggaatga atggaaaga 4680 tgggcagaga acatcagatg attgaaatgt tcgcccaggg gtctccagca actttggaaa 4740 tctctttgta tttttacttg aagtgccact aatggacagc agatattttc tggctgatgt 4800 tggtattggg tgtaggaaca tgatttaaaa aaaaactct tgcctctgct ttccccact 4860 ctgaggcaag ttaaaatgta aaagatgtga tttatctggg gggctcaggt atggtgggga 4920 agtggattca ggaatctggg gaatggcaaa tatattaaga agagtattga aagtatttgg 4980 aggaaaatgg ttaattctgg gtgtgcacca aggttcagta ggatccactt ctgccttgga 5040 gaccacaaat caactagctc catttacagc catttctaaa atggcagctt cagttctaga 5100 cgccattgcc tagcttgccg taatgattct ataatgccat catgcagcaa ttatgagagg 5220 ctaggtcatc caacaagagaag accctatcaa tgtaggttgc aaaaatctaac ccctaaggaa 5280 cgccattgcc tagcttgccg taatgatct atgatagcat catgcagcaa ttatgagagg 5220 ctaggtcatc caaagagaag accctatcaa tgtaggttgc aaaatctaac ccctaaggaa 5280 gtgcagtctt tgatttgatt tccctagtaa ccttgcagat atgtttaacc aagccatagc 5340 ccatgccttt tgagggctga acaaataagg gacttactga taatttactt ttgatcacat 5400 taaggtgttc tcaccttgaa atcttataca ctgaaatggc cattgatta ggccactggc 5460 ttagagtact ccttccctg catgacactg attacaaata ctttcctatt catactttcc 5520 aattatgaga tggactgtgg gtactgggag tgatcactaa caccatagta atgtctaata 5580 attacaagga gacttacttg gggaagctag ttatgtgaaa ggcaaataaa gtcatacagt 5640 aggtcaaaag gcaaccataa ttctctttgg tgcaagtctt ggggaggtga tctagattac 5700 actgcaccat tcccaagta atccctttggg tgcaagtctt ggggaggtga tctagattac 5700 actgcaccat tcccaagta atcccctgaa aacttactct caactggagc aaatgaactt 5760 tggtcccaaa tatccatctt ttcagtagcg ttaattatgc tctgtttcca actgcattcc 5820 ctttccaatt gaattaaagt gtggcctcgt ttttagtcat ttaaaaattgt tttctaagta 5880 attgctgcct ctattatggc acttcaattt tgcactgtct tttgagatcc aagaaaaaatt 5940 tctattcatt tttttgcatc caattgtgcc tgaactttta aaaatagtaa atgctgccat 6000 gtcccaagac cacgtccag gtgtgtgtt agagctggc accctagaaa cacatactt 6060 gtcccatgag caggtgcctg agacacagac ccctttgcat tcacagagag gtcattggt 6120 atagagactt ttggcactac ataccttca gtgtagagct cttgtttat ggggaaaaggc 6240 tcaaatgcca aattgtgtc gatggattaa tatgcccttt tgccgatgca tactattact 6300 gatgtggactc ggttttgtg cagctttgt ttgttaatg aaacacactt gtaacctct 6360 gatgtgactc ggttttgtcg cagctttgct ttgtttaatg aaacacactt gtaaacctct 6360 tttgcacttt gaaaaagaat ccagcgggat gctcgagcac ctgtaaacaa ttttctcaac 6420 ctatttgatg ttcaaataaa gaattaaact 6450

39740-0001PCT.txt

<210> 304 <211> 3336 <212> DNA <213> Homo sapiens <220> <221> unsure <222> (0)...(0) <223> n = A, T, C or G cggcggcgac tgcagtctgg agggtccaca cttgtgattc tcaatggaga gtgaaaacgc 60 agattcataa tgaaagctag ccccgtcgg ccactgattc tcaaaagacg gaggctgccc 120 cttcctgttc aaaatgcccc aagtgaaaca tcagaggagg aacctaagag atcccctgcc 180 caacaggagt ctaatcaagc agaggcctcc aaggaagtgg cggagtccaa ctcttgcaag 240 atccccaca atgctaatat tcacagcat atcacagca tgactgccaa gggaaaagag 360 aggagaata gtgagaccaa caaattcatc ctcatcagct gtgaggagc cccaactcag 420 tagtataaat tctccaaatt atcctctaat tataaatgta agcttatttc cttagatcat 2760 tatccagaga ctgccagaag gtgggtagga tgacctgggg tttcaattga cttctgttcc 2820 ttgcttttag ttttgataga agggaagacc tgcagtgcac ggtttcttcc aggctgaggt 2880 acctggatct tgggttcttc actgcaggga cccagacaag tggatctgct tgccagagtc 2940 ctttttgccc ctccctgcca cctccccgtg tttccaagtc agctttcctg caagaagaaa 3000 tcctggttaa aaaagtcttt tgtattgggt caggagttga atttggggtg ggaggatgga 3060 tgcaactgaa gcagagtgg ggtgcccaga tgtgcgctat tagatgttc tctgataatg 3120 tccccaatca taccagggag actggcattg acgagaactc aggtggaggc ttgagaaggc 3180 cgaaagggc cctgacctgc ctggcttcct tagcttgcc ctcagctttg caaagagcca 3240 ccctaggccc cagctgaccg catgggtgtg agccagcttg agaacactaa ctactcaata 3300 aaagcgaagg tggaccnaaa aaaaaaaaa aaaaaaa Page 53

39740-0001PCT.txt

```
<210> 305
<211> 2365
   <212> DNA
   <213> Homo sapiens
   <400> 305
tcccagcctt cccatcccc caccgaaagc aaatcattca acgacccccg accctccgac 60 ggcaggagcc ccccgacctc ccaggcggac cgccttccc tccccgcgcg ggttccgggc 120
  cattcagttg gcaaaaaaaa aaaaa
  <210> 306
  <211> 1117
  <212> DNA
  <213> Homo sapiens
  <400> 306
 <400> 306
gcaccaacca gcaccatgcc catgatactg gggtactggg acatccgcgg gctggcccac 60
gccatccgcc tgctcctgga atacacagac tcaagctatg aggaaaagaa gtacacgatg 120
ggggacgctc ctgattatga cagaagccag tggctgaatg aaaaattcaa gctgggcctg 180
gactttccca atctgcccta cttgattgat ggggctcaca agatcaccca gagcaacgcc 240
atcttgtgct acattgccg caagcacaac ctgtggggg agacagaaga ggagaagatt 300
cgtgtggaca ttttggagaa ccagaccatg gacaaccata tgcagctggg catgatctgc 360
tacaatccag aatttgagaa actgaagcca aagtacttgg aggaactccc tgaaaagcta 420
aagctctact cagagttct ggggaagcgg ccatggttg caggaacaaa gatcactttt 480
gtagatttc tcgtctatga tgtccttgac ctccaccgta tatttgagcc caactgcttg 540
qacqccttcc caaatctgaa ggacttcatc tcccgctttg agggcttgga gaagatctct 600
 gacgccttcc caaatctgaa ggacttcatc tcccgctttg agggcttgga gaagatctct 600 gcctacatga agtccagccg cttcctcca agacctgtgt tctcaaagat ggctgtctgg 660 ggcaacaagt agggccttga aggcaggagg tgggagtgag gagcccatac tcagcctgct 720 gcccaggctg tgcagcgcag ctggactctg catcccagca cctgcctcct cgttcctttc 780 tcctgtttat tcccatcttt actcccaaga cttcattgtc cctcttcact ccccctaaac 840
                                                                                                                       Page 54
```

```
39740-0001PCT.txt
  ccctgtccca tgcaggccct ttgaagcctc agctacccac tatccttcgt gaacatcccc 900
 tcccatcatt acccttccct gcactaaagc cagcctgacc ttccttcctg ttagtggttg 960 tgtctgcttt aaagcctgcc tggcccctcg cctgtggagc tcagccccga gctgtccccg 1020 tgttgcatga aggagcagca ttgactggtt tacaggccct gctcctgcag catggtccct 1080 gcctaggcct acctgatgga agtaaagcct caaccac
                                                                                                                                                   1020
 <210> 307
<211> 1266
  <212> DNA
  <213> Homo sapiens
 <400> 307
 ctcggaagcc cgtcaccatg tcgtgcgagt cgtctatggt tctcgggtac tgggatattc 60 gtgggctggc gcacgccatc cgcctgctcc tggagttcac ggatacctct tatgaggaga 120
 aacggtacac gtgcggggaa gctcctgact atgatcgaag ccaatggctg gatgtgaaat 180
tggagaaaat cgctgcctac ttacagtctg atcagttctg caagatgccc atcaacaaca 660 agatggccca gtggggcaac aagcctgtat gctgagcagg aggcagactt gcagagcttg 720 ttttgtttca tcctgtccgt aaggggtcag cgctcttgct ttgctctttt caatgaatag 780 cacttatgtt actggtgtc agctgagttt ctcttgggta taaaggctaa aagggaaaaa 840 ggatatgtgg agaatcatca agatatgaat tgaatcgctg cgatactgtg gcatttccct 900 actccccaac tgagttcaag ggctgtaggt tcatgcccaa gccctgagag tgggtactag 960 aaaaaaacgag attgcacagt tggagagagc aggtgtgta aatggactga agtccctgtg 1020 aagactgggt gaggataaca caagtaaaac tgtggtactg atggacttaa ccggagttcg 1080 gaaaccgtcc tgtgtacaca tgggagtta tgaaactcat taaaaataat agagcccac 1200 attgacactat tcactaaaat taatctggaa tttaaggccc aacattaaac acaaagctgt 1260 attgat
 attgat
                                                                                                                                                   1266
 <210> 308
 <211> 2162
 <212> DNA
 <213> Homo sapiens
<400> 308
                                                                                   Page 55
```

```
39740-0001PCT.txt
    atcctgagtg gtctggcggt tttttcttct aactgacttc tgctttccac ggcgtgtgct 1680
  atcctgagtg gtctggcggt tttttcttct aactgacttc tgcttccac ggcgtgtgct 1680 gggcccggat ctccaggccc tggggaggga gcctctggac ggacagtggg gacattgtgg 1740 gtttggggct cagagtcgag ggacggggtg tagcctcggc atttgcttga gtttctccac 1800 tcttggctct gactgatccc tgcttgtgca ggccagtgga ggctcttggg cttggagaac 1860 acgtgtgtct ctgtgtatgt gtctgtgt ctgcgtccgt gtctgtcaga ctgtctgcct 1920 gtcctgggt ggctaggagc tgggtctgac cgttgtatgg tttgacctga tatactccat 1980 tctcccctgc gcctcctct ctgtgtttt tccatgtcc cctccaact ccccatgccc 2040 agttttacc catcatgcac cctgtacagt tgccacgtta ctgccttttt taaaaatata 2100 tttgacagaa accaggtgcc ttcagaggct ctctgattta aataaacctt tcttgtttt 2160 tt
   <210> 309
<211> 3933
    <212> DNA
   <213> Homo sapiens
   <400> 309
   cacgaggcag cactctcttc gtcgcttcgg ccagtgtgtc gggctgggcc ctgacaagcc 60
 acctgaggag aggeteggag ecgggeegg acceeggga ttgeegeegg etteteta 120 gteteacgag gggtteegg ectegace ceacetetgg acttgeett cetteteta 120 gteteacgag gggtteegg ectegace ceacetetgg acttgeett cettetett 180 teegegtgtg gagggagea gegettagge eggagegge etgggggeeg ecegeeggg 240 agacategeg gggacegat eaccatggag ggegeeggeg gegegaaega eaagaaaaag 300 ataagttetg aacgtegaaa agaaaagtet egagatgeag ecagateteg gegagtaaa 360 gaatetgaag tititatga gettgeteat eagttgeeae ticeacataa tgigagtieg 420 eatettgata aggeetetgt gatgaggett accateaget attigegtgt gaggaaaett 480 etggatgetg gigattigga tattgaagat gacatgaaag eacagatgaa tigetittat 540 tigaaageet tggatggit tgitatggit eteacagatg atggigaeat gattaeatt 600 tetgataatg tgaacaaata eatgggata acteagtitg aactaactgg acacagtgig 660
ttgatagctt tggatggttt tgttatggtt ctcacagatg atggtgacat gatttacatt 600 tctgataatg tgaacaaata catgggatta actcagtttg aactaactgg acacagtgtg 660 tttgattta ctcatccatg tgaccatgag gaaatgagag aaatgcttac acacagaaat 720 ggccttgtga aaaagggtaa agaacaaaac acacagcgaa gctttttct cagaatgaag 780 tgtaccctaa ctagccgagg aagaactatg aacaacagta accaacctca gtgtgggtat 900 aagaaaccac ctatgacctg cttggtgctg atttgtgaac ccattcctaa cccatcaaat 960 attgaaattc ctttagtgac caagactttc ctcagtcgac acagcctgga attgaaatt 1020 tcttattgtg atgaaaagaat taccgaattg atgggatatg atccgacagagaa actttaggc 1080 cgctcaattt atgaatatta tcatgctttg gactctgatc atctgaccaa aactcacat 1140 ggatatgtta ctaaaggaca agtcaccaca ggacagtaca ggatgcttgc caaaagaggt 1200 ggatatgtct gggttgaaac tcaagcaact gtcatatata acaccaagaa ttccaacca 1260 cagtgcattg tatggtgaa tcaagaagat acaagtagc ctttagaca acttaagaag 1440 gaacctgatg ctttaacttt gctggcccca gccgctggag acacaatcat atctttagat 1500
 gaacctgatg ctttaacttt gctggcccca gccgctggag acacaatcat atctttagat 1500 tttggcagca acgacacaga aactgatgac cagcaacttg aggaagtacc attatataat 1560 gatgtaatgc tcccctcacc caacgaaaaa ttacagaata taaatttggc aatgtctcca 1620 ttacccaccg ctgaaacgcc aaagccactt gagaagtacctgc actgaacaca 1640
gaagttgcat taaaattaga accaaatcca gagtcactgg aactttcttt taccatgccc 1740 cagattcagg atcagacacc tagtccttcc gatggaagca ctagacaaag ttcacctggg 1800 cctaatagtc ccagtgaata ttgttttat gtggatagtg atatggtcaa tgaattcaag 1860 ttggaattgg tagaaaaact ttttgctgaa gacacagaag caaagaaccc attttctact 1920 caggacacag atttagactt ggagatgtta gctccctata tcccaatgga tgatgacttc 1980 cagttacgtt ccttcgatca gttgtcacca ttagaaagca gttccgcaag ccctgaaagc 2040 gcaagtcctc aaagcacagt tacagtattc cagcagactc aaatacaaga acctactgct 2100 gaagacatta aaatattgat tgcatctcca tctcctaccc accatacataa agaacctact 2220 agtgccacat catcaccata tagagatact caaagtcgga cagcctcacc aaacagagca 2280
gaagacatta aaatattgat tgcatctcca tctcctaccc acatacataa agaaactact 2220 agtgccacat catcaccata tagagatact caaagtcgga cagcctcacc aaacagagca 2280 ggaaaaggag tcatagaaca gacagaaaaa tctcatccaa gaagccctaa cgtgttatct 2340 gtcgctttga gtcaaagaac tacagttcct gaggaagaac taaatccaaa gatactagct 2400 ttgcagaatg ctcagagaaa gcgaaaaatg gaacatgatg gttcactttt tcaagcagta 2460 ggaattggaa cattattaca gcagccagac gatcatgcag ctactacatc acttcttgg 2520 gttaatggaa aaggatgcaa atctagtgaa cagaatggaa tggagcaaaa gacaattatt 2580 ttaataccct ctgattagc atgagacaa ccagaatggaat caatagatga 2640
ttaataccct ctgatttagc atgtagactg ctggggcaat caatggatga aagtggatta 2640 ccacagctga ccagttatga ttgtgaagtt aatgctccta tacaaggcag cagaaaccta 2700 ctgcagggtg aagaattact cagagctttg gatcaagtta actgagcttt ttcttaattt 2760 cattcctttt tttggacact ggtggctcac tacctaaagc agtctattta tattttctac 2820
atctaatttt agaagcctgg ctacaatact gcacaaactt ggttagttca atttttgatc 2880 ccctttctac ttaatttaca ttaatgctct tttttagtat gttctttaat gctggatcac 2940 agacagctca ttttctcagt tttttggtat ttaaaccatt gcattgcagt agcatcattt 3000 taaaaaaatgc acctttttat ttatttattt ttggctagg
                                                                                                                                                                                                                         Page 56
```

```
39740-0001PCT.txt
 tatttttaag aagatgccaa tataattttt gtaagaaggc agtaaccttt catcatgatc 3120 ataggcagtt gaaaaatttt tacacctttt ttttcacatt ttacataaat aataatgctt 3180
 gcctagtatg ttaatttgct caaaatacaa tgtttgattt tatgcacttt gtcgctatta 3720 acatcctttt tttcatgtag atttcaataa ttgagtaatt ttagaagcat tattttagga 3780 atatataggt gtcacagtaa atatcttgtt ttttctatgt acattgtaca aatttttcat 3840 tccttttgct ctttgtggtt ggatctaaca 2322
 acatcttctg tggaaaaaaa aaaaaaaaaa aaa
 <210> 310
<211> 2872
<212> DNA
 <213> Homo sapiens
<400> 310
 tccaggaatc gatagtgcat tcgtgcgcgc ggccgcccgt cgcttcgcac agggctggat 60
 ttacatgttg ggaggaggag ataagttata gggagctgga tttcaaacgg tggtccaaga 2520 ttcaaaaatc ctattgatag tggccatttt aatcattgcc atcgtgtgct tgtttcatcc 2580 agtgttatgc actttccaca gttggtgtta gtatagccag agggtttcat tattatttct 2640 ctttgctttc tcaatgttaa tttattgcat ggtttattct ttttctttac agctgaaatt 2700 gctttaaatg atggttaaaa ttacaaatta aattgggaa
```

Page 57

```
39740-0001PCT.txt
 ttaaaaatat tttgatttaa ataacaaaaa taataccaga ttttaagccg cggaaaatgt 2820
 tcttgatcat ttgcagttaa ggactttaaa taaatcaaat gttaacaaaa aa
 <210> 311
 <211> 926
 <212> DNA
  <213> Homo sapiens
<400> 311
 aataatttag atggtgaaaa aaaaaa
                                                                                                                                                                                                                926
 <210> 312
 <211> 4989
 <212> DNA
 <213> Homo sapiens
 <400> 312
ttttttttt ttttgagaaa gggaatttca tcccaaataa aaggaatgaa gtctggctcc 60 ggaggagggt ccccgacctc gctgtggggg ctcctgttc tctccgccgc gctctcgctc 120 tggccgacga gtggagaaat ctgcgggcca ggcatcgaca tccgcaacga ctatcagcag 180 ctgaaggcc tggagaactg cacggtgatc gagggctacc tccaatcct gctatcttc 240
aaggccgagg actaccgcag ctaccgcttc cccaagctca cggtcattac cgagtacttg 300 ctgctgttcc gagtggctgg cctcgagagc ctcggagacc tcttcccaa cctcacggtc 360 atccgcggct ggaaactctt ctacaactac gccctggtca tcttcgagat gaccaatctc 420 aaggatattg ggctttacaa cctgaggaac attactcggg gggccatcag gattgagaaa 480 aatgctgacc tctgttacct ctccactgtg gactggtccc tgatcctgga tgcggtgtcc 540 aataactaca ttgtgggaa taagccccaa aaggaatgtg gggacctgtg tccagggacc 600 atggagagaa accgctgca gaaaatgtc ccaagcacca atgaggacaa accgctgca gaaaatgtc ccaagcacca ggggaccacaa accgctgca gaaaatgtc ccaagcacca gtgggaagacg ggcgtgcacc 720 gagaacaatg agtgctgcaa accgctgca cccaagaacca ctgagaacaaca 780
gagaacaatg agtgctgcca ccccgagtgc ctgggcagct gcagcgcgc tgacaacgac 780 acggcctgtg tagcttgccg ccactactac tatgccggtg tctgtgtgcc tgcctgccg 840 cccaacacct acaggttga gggctggcgc tgtgtggacc gtgacttctg cgccaacatc 900 ctcagcgccg agagcagcga ctccgagggg tttgtgatcc acgacggcga gtgcatgcag 960 gagtgcccct cgggcttcat ccgcaacggc agccagagca tgtactgcat cccttattact 1020
ggtccttgcc cgaaggtctg tgaggaagaa aagaaaacaa agaccattga ttctgttact 1080 tctgctcaga tgctccaagg atgcaccatc ttcaagggca atttgctcat taacatccga 1140 cgggggaata acattgcttc agagctggag aacttcatgg ggctcatcga ggtggtgacg 1200 ggctacgtga agatccgcca ttctcatgcc ttggtctcct tgtccttcct aaaaaacctt 1260
 cgcctcatcc taggagagga gcagctagaa gggaattact ccttctacgt cctcgacaac 1320
cagaacttgc agcaactgtg ggactgggac caccgcaacc tgaccatcaa agcagggaaa 1380 atgtactttg ctttcaatcc caaattatgt gtttccgaaa tttaccgcat ggaggaagtg 1440 acggggacta aagggcgcca aagcaaaggg gacataaaca ccaggaacaa cggggagaga 1500 gcctcctgtg aaagtgacgt cctgcatttc acctccacca ccacgtcgaa gaatcgcatc 1560
atcataacct ggcaccggta ccggcccct gactacaggg atctcatcag cttcaccgtt 1620 tactacaagg aagcaccctt taagaatgtc acagagtatg atgggcagga tgcctgcggc 1680 tccaacagct ggaacatggt ggacgtggac ctcccgcca acaaggacgt ggagcccggc 1740 atcttactac atgggctgaa gccctggact cagtacgccg tttacgtcaa ggctgtgacc 1800
ctcaccatgg tggagaacga ccatatccgt ggggccaaga gtgagatctt gtacattcgc 1800 accaatgctt cagttccttc cattcccttg gacgttcttt cagcatcgaa ctcctcttct 1920 cagttaatcg tgaagtggaa ccctccctct ctgcccaacg gcaacctgag ttactacatt 1980 gtgcgctggc agcggcagcc tcaggacggc tacctttacc ggcacaatta ctgctccaaa 2040 gacaaaatcc ccatcaggaa gtatgccgac ggcaccatcg acattgagga ggtcacagag 2100 aaccccaaga ctgaggtgtg tggtggggag aaagggcctt gctgcgcctg ccccaaaact 2160
                                                                                                                    Page 58
```

39740-0001PCT.txt gaagccgaga agcaggccga gaaggaggag gctgaatacc gcaaagtctt tgagaatttc 2220 ctgcacaact ccatcttcgt gcccagacct gaaaggaagc ggagagatgt catgcaagtg 2280 gccaacacca ccatgtccag ccgaagcagg aacaccacgg ccgcagacac ctacaacatc 2340 accgacccgg aagagctgga gacagagtac cctttctttg agagcagagt ggataacaag 2400 gagagagaactg tcattctaa ccttcggcct ttcacattgt accgcatcga tatccacagc 2460 gagagaactty tcattctctaa ccttcggcct tcacattgt accgcatcga tatccacag 2460 tgcaaccacg aggctgagaa gctgggctgc aggccccca acttcgtctt tgcaaggact 2520 atgcccgcag aaggagcaga tgacattcct gggccagtga cctgggagcc aaggcctgaa 2580 aactccatct ttttaaagtg gccggaacct gagaatccca atggattgat tctaatgtat 2640 aggaagatatg gaggggccaa aggtgaggat caagcaggaat gtgtgtccag acaggaatac 2700 aggaagtatg gaggggccaa gctaaaccgg ctaaacccgg ggaactacac aggccggatt 2760 caggccacat ctctctcgg gaatgggtcg tggacagat cttcatccat ctgatcggga atggagtggt gattatgctg gagggttggt gattatgctg tacgtcttcc atagaaagag aaataacag 2940 aggctgggga atggagtggt gattatgctg tacgtcttcc atagaaagag aaataacag 2940 aggctgggga atggagtgc gtatgcctct gtgaacccgg aggaattccag cgctggtgat 3000 gtgtacgttc ctgatgagtg ggtctatgaa gaggttgcca aaggagtggt gggaaggaga tcaccatgag cgggaactt 3060 gggcaggggt cgtttgggat gattatgcag gaggttgca aaggagtggc caggaagaac acaggagggc caggaggat ggttctcaaacag ggtttctaa acgaaggcc ccagacaac ctggtcatca tggaacctgg ggaaggttggt gattatcaga gagttcaatt gtgaacctgg gagggttggt gaggtttctaa acgaaggcg caggcagac ctgggaaaga tcaccatgag ggaggaaga 3120 cctgaaacca gagtggccat taaaacagtg gagttcaatt gtgaacctgg ggaggggt ggtctcagaa aggagttggc aaggaggat ggtccaataa aggaggggg caggagaac ctgggaaaa 3200 gatttcaaaa gttatcccg gtctctgagg ccagaaaatgg agattacaa ggaggggg ggtgggc gattatcaaa ggaggggg caggaagaa ttgcaacagg ggtggggg gagggggca aagaaaacaa ctgggaaaa 320 cctcaaagcc tgagcaagat gattcagag gccggaagaa ttgcaacagg ggtggggg agattcaaaa ggaataacc agaaagaga agaataacc agaagaaca 3420 ctcaacgca ataagttcgt ccacaggaac cttgctgcc ggaaaatgca tggaagaaca 3420 ctcaacgca ataagttcgt ccacaggac cttgcccgaga atactcaag ggccgcaaa 3480 gatttcacag ccagacagc ctaccaagac cttgcctcc ggggcgcct tggacgaaa 3780 cgcatggaggcg gccttctgga caagccagac aagcctcct tccacagaa agaacaaa caagaagaa aacaagaaga acaagaaaa 3780 cgcatggaggcg gccttctgga aagagagac aagagacct tcctacaaaaa agaacaaaa acaagagaa aacaagagaa aacaagagaa agaacaaaa 3780 tgaaccggc <210> 313 <211> 12515 <212> DNA <213> Homo sapiens <400> 313 ctaccgggcg gaggtgagcg cggcgccggc tcctcctgcg gcggactttg ggtgcgactt 60 gacgagcggt ggttcgacaa gtggccttgc gggccggatc gtcccagtgg aagagttgta 120 aatttgcttc tggccttccc ctacggatta tacctggctt tcccctacgg attatactca 180 acttactgtt tagaaaatgt ggcccacgag acgcctggtt actatcaaaa ggagcggggt 240 cgacggtccc cactttccc tgagcctcag cacctgcttg tttggaaggg gtattgaatg 300 tgacatccgt atccagcttc ctgttgtgc aaaacaacat tgcaaaattg aaatccatga 360 gcaggaggca atattacata atttcagttc cacaaatcca acacaagtaa atgggtctgt 420 caggtatgaa aatgaaagtc taaaacatgg agatgtaata actattattg atcgttcctt 480 caggtatgaa aatgaaagtc ttcagaatgg aaggaagtca actgaatttc caagaaaaaat 540 acgtgaacag gagccagcac gtcgtgtctc aagatcagc ttctctctctg accctgatga 600 gaaagctcaa gattccaagg cctattcaaa aatcactgaa ggaaaagtt caaggaaatcc 660 tcaggtacat atcaagaatg tcaaagaaga cagtaccgca gatgactcaa aagacagtgt 720 tgctcaggga acaactaatg ttcattcctc agaacatgct ggacgtaatg gcagaaatgc 780 Page 59 <400> 313

Page 59

39740-0001PCT.txt

agctgatccc atttctgggg attttaaaga aatttccagc gttaaattag tgagccgtta 840 tggagaattg aagtctgttc ccactacaca atgtcttgac aatagcaaaa aaaatgaatc 900 tcccttttgg aagctttatg agtcagtgaa gaaagagttg gatgtaaaat cacaaaaaga 960 aaatgtccta cagtattgta gaaaatctgg attacaaact gattacgcaa cagagaaaga 1020 aagtgctgat ggtttacagg gggagaccca actgttggtc tcgcgtaagt caagaccaaa 1080 atctggtggg agcggcacg ctgtggcaga gcctgcttca cctgaacaag agcttgacca 1140 gaacaagggg aagggaagag acgtggagtc tgttcagact cccagcaagg ctgtgggcgc 1200 cagctttcct ctctatgagc cggctaaaat gaagacccct gtacaatatt cacagcaaca 1260 aaattctcca caaaaacata agaacaaaga cctgtataaa actgtagaa gagaatctgt 1320 gaatctgggt aaaagtgaag gcttcaaggc tggtgataaa actcttactc ccaggaagct 1380 tcaactaga aatcgaacac cagctaaagt tgaagatgca gctgactctg ccactaagcc 1440 agaaaatctc tcttccaaaa ccagaggaag tattcctaca gatgtggaag ttctgcctac 1500 ggaaactgaa attcacaatg agccatttt aactctgtgg ctcactcaag ttgagaggaa 1560 gatccaaaag gattccctca gcaagcctga gaaattgggc actacagctg gacagatgtg 1620 ctctgggtta cctggtctta gtcagtgga tattacatt ggtgaga 21260 tattagagga 21260 tatta gagtgaggga atacctttga aaagaaggcg tgtgtccttt ggtgggcacc taagacctga 1740 actatttgat gaaaacttgc ctcctaatac gcctctcaaa aggggagaag ccccaaccaa 1800 aagaaagtct ctggtaatgc acactccacc tgtcctgaag aaaatcatca aggaacagcc 1860 tcaaccatca ggaaaacaag agtcaggttc agaaatccat gtggaagtga aggcacaaag 1920 cttggttata agccctccag ctcctagtcc taggaaaact ccagttgcca gtgatcaacg 1980 ccgtaggtcc tgcaaaacag ccctgcttc cagcagcaaa tctcagacag aggttcctaa 2040 gagaggagga gaaagagtgg caacctgctt tcaaaagaga gtgtctatca gccgaagtca 2100 acatgatatt ttacagatga tatgttccaa aagaagaagt ggtgcttcgg aagcaaactc 2160 gattgttgca aaatcatggg cagatgtagt aaaacttggt gcaaaacaaa cacaaactaa 2220 agtcataaaa catggtcctc aaaggtcaat gaacaaaagg caaagaagac ctgctactcc 2280 aaagaagcct gtgggcgaag ttcacagtca atttagtaca ggccacgcaa actctccttg 2340 taccataata atagggaaag ctcatactga aaaagtacat gtgcctgctc gaccctacag 2460 agtgctcaac aacttcattt ccaaccaaaa aatggacttt aaggaagatc tttcaggaat 2460 aacaaataca gaaattgttg agtgcatcct aaaaagaggt cagaaggcaa cactactaca 2940 acaaaggaga gaaggagaga tgaaggaaat agaaagacct tttgagacat ataaggaaaa 3000 acaaaggaga gaaggagaga tgaaggaaat agaaagacct tttgagacat ataaggaaaa 3000 tattgaatta aaagaaaacg atgaaaagat gaaagcaatg aagagatcaa gaacttgggg 3060 gcagaaatgt gcaccaatgt ctgacctgac agacctcaag agcttgcctg atacagaact 3120 catgaaagac acggcacgtg gccagaatct cctccaaacc caagatcatg ccaaggcacc 3180 aaagaggtgag aaaggcaaa tcactaaaat gccctgccag tcattacaac cagaaccaat 3240 aaacaccca acacacaaa aacaacagtt gaaggcatcc ctggggaaag taggtggaa 3300 agaaggagca ctagcagtgg gcaaggtcac acggacgtca ggggagacca cgcacacgca 3360 cagaaggagca gcaggagacg caaggagatg caagaacgtt aaaggagtcc ctaggaaga ggaagacat cagaacgtt ttccagacac caagacaga 3420 cctggaacca gcagccgtg taactggaat gaagaagtgg ccaagaacgc ctaaggaaga 3480 ggcccagtca atgaccgatg agaaaactac caaaatagcc ttccagacac cagaaggaga 3600 atcagtggac actccaacaa gcaccaagaa atggcctaag agaagtctca ggaaagcaga 3600 atcagtggaa gaattcttag gaacacacaa actaacacca tcagcaggga aagccatgct 3720 tacgcccaaa ccagcaggag gtgatgagaa agacattaaa gcatttatgg gaactccagt 3780 tgtagaggaa gaattcttag cactcaggaa actaacacca tcagcaggga aagccatgct 3720 tacgcccaaa ccagcaggag gtgatgagaa agacattaaa gcatttatgg gaactccagt 3780 gcagaaactg gacctggcag gaactttacc tggcagcaaa agacagctac agactcctaa 3840 ggaaaaggcc caggctctag aagacctggc tggctttaaa gagctcttcc agactcctgg 3900 tcacaccgag gaattagtgg ctgctggtaa aaccactaaa ataccctgcg actctccaca 3960 gtcagacca gtggacaccc caacaagcac aaagcaacga cccaagagaa gtatcaggaa 4020 agcagatgta gagggagaac tcttagcgtg caggaatcta atgccatcag caggcaaagc 4080 catgcacacg cctaaaccat cagtaggtga agagaaagac atcatcatat ttgtgggaac 4140 tccagtgcag aaactggac cagtggtga cctggaagaa cttaacaggc agcaagagac ggccacaaac 4200 tcctaaggaa gaggcccagg cagtggctgc tggcaaaact actaaaatgc cctgcgaatc 4320 ttctccacca gaatcagcag acaccccaac aagcacaaga aggcagccaa agacaccttt 4380 ggaaaaccaca cacacagata aggagctctc agccctggaggat aaaagcacca aggaggcacc 4560 aaaaactaag gaaaaggccc aacccctaga agaccctggc ggctggaaag agctctcca 4620 aaaaactaag gaaaaggccc aacccctaga agacctggct ggctggaaag agctcttcca 4620 gacaccagta tgcactgaca agcccacgac tcacgagaaa actaccaaaa tagcctgcag 4680 atcacaacca gacccagtgg acacaccaac aagctccaag ccacagtcca agagaagtct 4740 caggaaagtg gacgtagaag aagaattctt cgcactcagg aaacgaacac catcagcagg 4800 caaagccatg cacacacca aaccagcagt aagtggtagaagaacatct acgcatttat 4860 Page 60

39740-0001PCT.txt gggaactcca gtgcagaaac tggacctgac agagaactta actggcagca agagacggct 4920 gggaactcca gtgcagaaac tggacctgac agagaactta actggcagca agagacggct 4920 acaaactcct aaggaaaagg cccaggctct agaagacctg gctggcttta aagagctctt 4980 ccagacacga ggtcacactg aggaatcaat gactaacgat aaaactgcca aagtagcctg 5040 caaatcttca caaccagacc tagacaaaaa cccagcaagc tccaagcgac ggctcaagac 5100 atcctgggg aaagtgggcg tgaaagaaga gctcctagca gttggcaagc tcacacagac 5160 atcaggagg actacacaca cacacacaga gccaacagga gatggtaaga gcatgaaagc 5220 attatggag tctccaaagc agatcttaga ctcagcagca agtcctaactg gcagcaagag 5280 gcagctgaga actcctaagg gaaagtctga agtccctgaa gacctggccg gcttcatcga 5340 gctctccag acaccaagtc acactaagga atcaatgact aatgaaaaaa ctaccaaagt 5400 atcctacaga gcttcacagc cagacctagt ggacacccca acaagctcca agccacagcc 5460 caagagaagt ctcaggaaag cagacactga agaagaattt ttagcattta qqaaacaaac 5520 atcctacaga gcttcacagc cagacctagt ggacacccca acaagctcca agccacagcc 5460 caagagaagt ctcaggaaag cagacactga agaagaattt ttagcattta ggaaacaaac 5520 gccatcagca ggcaaagcca tgcacacac caaaccagca gtaggtgaag agaaagacat 5580 caacacgttt ttgggaactc cagtgcagaa actggaccag ccaggaaatt tacctggcag 5640 caatagacgg ctacaaactc gtaaggaaaa ggcccaggct ctagaagaac tgactggctt 5700 cagagagctt ttccagacac catgcactga taaccccaca gctgatgaga aaactaccaa 5760 aaaaatactc tgcaaatctc cgcaatcaga cccagggaa accccaacaa acacaaagca 5820 acggccaag agaagcctca agaaagcaga cgtagaggaa gaattttag cattcaggaa 5840 actacacca tcagcaggca aagccatgca cacgcctaaa gcagcagtag gtgaagagaa 5940 agacatcaac acatttgtgg ggactccagt ggagaaactg gacctgctag gaaatttacc 6000 tggcagcaag agacggccac aaactcctaa agaaaaggcc aaggctctag aagatcttgc 6060 tggcttcaaa ggactcttcc agacaccagg tcacactgag gaatcaatga ccgatgacaa 6120 tggcttcaaa gagctcttcc agacaccagg tcacactgag gaatcaatga ccgatgacaa 6120 aatcacagaa gtatcctgca aatctccaca accagaccca gtcaaaaccc caacaagctc 6180 caagcaacga ctcaagatat ccttggggaa agtaggtgtg aaagaagagg tcctaccagt 6240 cggcaagctc acacagacgt cagggaagac cacacagaca cacagagaga cagcaggaga 6300 tggaaagagc atcaaagcgt ttaaggaatc tgcaaagcag atgctggacc cagcaaacta 6360 tggaactggg atggagaggt ggccaagaac acctaaggaa gaggcccaat cactagaaga 6420 cctggccggc ttcaaagagc tcttccagac accagaccac actgaggaat caacaactga 6480 tgacaaaact accaaaatag cctgcaaatc tccacacaa gaatataatgg acactccaac 6540 agcacaaact accaaaatag cctgcaaatc tccaccacca gaatcaatgg acactccaac 6540 aagcacaagg aggcggccca aaacaccttt ggggaaaagg gatatagtgg aagagctctc 6600 aggcctgaag cagctcacac agaccacac cacagacaaa gtaccaggag atgagggataa 6660 aggcatcaac gtgttcaggg aaactgcaaa acagaaactg gacccagcag caagtgtaac 6720 tggtagcaag aggcagccaa gaactcctaa gggaaaagcc caacccctag aagacttggc 6780 tggcttgaaa gagctttcc agacaccagt atgcactgac aagcccacga ctcacgagaa 6840 aactaccaaa atagcctgca gatctccaca accagaccca gtgggtaccc caacaatctt 6900 caagcaacag tccaaggaaa gtctcaggaa agcagcgta gaggaagaat ccttagcact 6960 caggaaacga acaccatcag tagggaaagc tatgggacaca cccaaaccag caggaggtga 7020 tgagaaagac atgaaagcat ttatgggaac tccaaggaa aaattggacc tgccaggaaa 7080 tttacctggc agcaaaagat ggccacaaac tcctaaggaa aaggcccagg ctctagaaga 7140 tgagaaagac atgaaagcat ttatgggaac tccagtgcag aaattggacc tgccaggaaa 7080 tttacctggc agcaaaagat ggccacaaac tcctaaggaa aaggcccagg ctctagaaga 7140 cctggctggc ttcaaagagc tcttccagac accaggcact gacaagccca cgactgatga 7200 gaaaactacc aaaatagcct gcaaatctcc acaaccagac ccagtggaca ccccagcaag 7260 cacaaagcaa cggcccaaga gaaacctcag gaaagcagac gtagaggaag aattttagc 7320 actcaggaaa aatatcaaca catttgtgga aactccagtg cagaaactgg acctgatga 7380 tgatgagaaa aatatcaaca catttgtgga aactccagtg cagaaactgg acctgctagg 7440 aaatttacct ggcagcaaga gacagccaca gactcctaag gaaaaggctg aggctctaga 7500 ggacctggtt ggcttcaaag aactcttcca gacaccaggt cacactggagca aatcaatgac 7560 tgatgacaaa atcacagaag tatcctgtaa atcccacag ccagagtcat tcaaaacctc 7620 aagaaggctc aagaagctc aagaagacc aaggagaac aggaggaact accagagaca accaggagc 7740 aacaggagat agtaagagca tcaaaggct taaaggagtc ccaggagaac aggaggagac agcaggagac aggaggagac ccaggagaac ccagggcaca ccagggcaac ccagggcaacac aggagagac agcaggagac 7680 agcagcaagt gtaactggta gcaggaggca gctgagaact cgtaaggaaa aggcccgtgc 7860 tctagaagac ctggttgact tcaaagagct ctctcaagaacc ccaggtcaca ccaggtcaca ccaggacaca ccaggacaca aggcccgtgc 7860 tctagaagac ctggttgact tcaaagagct ctctcagca ccaggtcaca ccaggtcaca ccagagacc 7920 tctagaagac ctggttgact tcaaagagct cttctcagca ccaggtcaca ctgaagagtc aatgactatt gacaaaaaca caaaaattcc ctgcaaatct ccccaacag aactaacaga cactgccacg agcacaaaga gatgccccaa gacacgtccc aggaaagaag taaaagagga gctctcagca gttgagaggc tcacgcaaac atcagggcaa agcacacaca cacacaaaga 8040 8100 accagcaagc ggtgatgagg gcatcaaagt attgaagcaa cgtgcaaaga agaaaccaaa 8160 accagcaagc ggtgatgagg gcatcaaagt attgaagcaa cgtgcaaaga agaaaccaaa 8160 cccagtagaa gaggaaccca gcaggagaag gccaagagca cctaaggaaa aggcccaacc 8220 cctggaagac ctggccggct tcacagagct ctctgaaaca tcaggtcaca ctcaggaatc 8280 actgactgct ggcaaagcca ctaaaatacc ctgcgaatct cccccactag aagtggtaga 8340 caccacagca agcaccaaga ggcatctcag gacacgtgtg cagaaggtac aagtaaaaga 8400 agagccttca gcagtcaagt tcacacaaac atcaggggaa accacggatg cagacaaaga 8460 accagcaggt gaagataaag gcatcaaaga attgaaggaa tctgcaaaac agacacacggc 8520 tccagcagca agtgtaactg gcagcaggag accggccaaga gcacccaggg aaagtgccca 8580 agccatagaa gacctagctg gagcagaga cccagcagca ggtcacactg aagaatcaat 8640 gactgatgac aaaaccacta aaataccctg caaatcatca ccagaactag aagaaccac 8700 aacaagctca aagaacgc ccaggacacg tgcccagaaa gtagaagtga aggaggagct 8760 aacaagctca aagagacggc ccaggacacg tgcccagaaa gtagaagtga aggaggagct 8760 gttagcagtt ggcaagctca cacaaacctc aggggagacc acgcacaccg acaaagagcc 8820 ggtaggtgag ggcaaaggca cgaaagcatt taagcaacct gcaaagcgga acgtggacgc 8880 agaagatgta attggcagca ggagacagcc aagagcacct aaggaaaagg cccaacccct 8940

Page 61

39740-0001PCT.txt

ggaagacctg gccagcttcc aagagctctc tcaaacacca ggccacactg aggaactggc 9000 aaatggtgct gctgatagct ttacaagcgc tccaaagcaa acacctgaca gtggaaaacc 9060 tctaaaaata tccagaagag ttcttcgggc ccctaaagta gaacccgtgg gagacgtggt 9120 aagcaccaga gaccctgtaa aatcacaaag caaaagcaac acttccctgc ccccactgcc 9180 cttcaagagg ggaggtggca aagaatggaag cgtcacgga accaagaggc tgcgctgcat 9240 gccagcacca gaggaaatta tgagaggagct gccagccagc aagaagcaga ggcttgctcc 9300 cagggcaaga attgaacctg cggaagagct ggcaaatcat tgaggactt cggaacacaaa attgaacctg cggaagagct gacaagcaac gacatgaaaa ccaacaaaga 9420 ggaacacaaa ttacaagact cggtccctga aaataaggga atatccctgc gctccagacg 9480 ccaagataaq actgaggcag aacagcaaat aactgaggtc tttgtattag cagaaagaat 9540 ccaagataag actgaggcag aacagcaaat aactgaggtc tttgtattag cagaaagaat 9540 agaaataaa actgaggcag aacagcaaat aactgaggtc tttgtattag cagaaagaat 9540 agaaataaac agaaatgaaa agaagcccat gaagacctcc ccagagatgg acattcagaa 9600 tccagatgat ggagcccgga aacccatacc tagagacaaa gtcactgaga acaaaaggtg 9660 cttgaggtct gctagacaga atgagagctc ccagcctaag gtggcagagg agagcggagg 9720 gcagaaggt gcgaaggtc tcatgcagaa tcagaaaggg aaaggagaag caggaaattc 9780 agactccatg tgcctgagat caagaaagac aaaaagccag cctgcagcaa gcactttgga 9840 gagcaaatct gtgcagagag taacgcggag tgtcaagaag tgtgcagaaa atccaaagaa 9900 ggctgaggac aatgtgtgg tcaagaaaat aacaaccaga agtcataagg acagtgaaga 9960 tatttgacag aaaaatcgaa ctgggaaaaa ttaaataaag ttagttttgt gataagttct 10020 aggcagttt ttgtcataaa ttacaagtga taaggctgtc aggctgtc aggctgtta 10080 gctccctta ggcaggcacc tccaaccacc acacactccc tgctgtttc cctgcctgga 12180 actttccac cagcccacc aagatcattt catccagtcc tgagctcagc ttaagggagg 12240 cttcttgcct gtgggttccc tcaccccat gcctgtcctc caggctgggg caggttctta 12300 gtttgcctgg aattgttctg tacctctttg tagcacgtag tgttgtgaaa ctaagccact 12360 aattgagttt ctggctccc tcctggggtt gtaagttttg ttcattcatg agggccgact 12420 gtatttcctg gttactgtat cccagtgacc agccacagga gatgtccaat aaagtatgtg 12480 atgaaatggt cttaaaaaaa aaaaaaaaa aaaaaa

<210> 314 <211> 2444 <212> DNA

<213> Homo sapiens

39740-0001PCT.txt

```
<400> 314
  ggcacgaggc ggggccgggt cgcagctggg cccgcggcat ggacgaactg ttcccctca 60 tcttcccggc agagcagccc aagcagcggg gcatgcgctt ccgctacaag tgcgaggggc 120 gctccgcggg cagcatcca ggcgagagga gcacagatac caccaagacc caccccacca 180 tcaagatcaa tggctacaca ggaccaggga cagtgcgcat ctccctggtc accaaggacc 240
aactaataaa gctgttgcca agctggacgg cacgagctcg tgcc
                                                                                                                                                                              2444
 <210> 315
  <211> 732
  <212> DNA
  <213> Homo sapiens
 <400> 315
 tgctgcgaac cacgtgggtc ccgggcgcgt ttcgggtgct ggcggctgca gccggagttc 60 aaacctaagc agctggaagg aaccatggcc aactgtgagc gtaccttcat tgcgatcaaa 120 ccagatgggg tccagcgggg tcttgtggga gagattatca agcgttttga gcagaaagga 180 ttccgccttg ttggtctgaa attcatgcaa gcttccgaag atctctcaa ggaacactac 240
 gttgacctga aggaccgtcc attctttgcc ggcctggtga aatacatgca ctcagggccg 300 gtagttgcca tggtctggga ggggctgaat gtggtgaaga cgggccgagt catgctcggg 360 gagaccaacc ctgcagactc caagcctggg accatccgtg gagacttctg catacaagtt 420 ggcaggaaca ttatacatgg cagtgattct gtggagagtg cagagaagga gatcggcttg 480 tggttcacc ctgaggaact ggtagattac acgagctgg ctcagaactg gatctatgaa 540 tggacaggagg gcagaccaca ttgcttttca catcacttc ccctcctcc catgggcaga 660
 ggaccaggct gtaggaaatc tagttattta caggaacttc atcataattt ggagggaagc 660 tcttggagct gtgagttctc cctgtacagt gttaccatcc ccgaccatct gattaaaatg 720 cttcctcca gc
 <210> 316
 <211> 2422
```

<212> DNA

<213> Homo sapiens

39740-0001PCT.txt

```
<400> 316
 gtcagcctcc cttccaccgc catattgggc cactaaaaaa agggggctcg tcttttcggg 60
  tagtittac cittagta gcacataaac titggggaag ggagggcagg giggggctga 1380 ggaactgacg tggagcgggg tatgaagagc tigcitigat tiacagcaag tagataaata 1440 titgacitgc atgaagagaa gcaatiitgg ggaagggtit gaatigtiit cittaaagat 1500 gtaatgiccc titcagagac agcigataci tcatitaaaa aaatcacaaa aatitgaaca 1560
   ctggctaaag ataattgcta titattttta caagaagttt attctcattt gggagatctg 1620
  gtgatctccc aagctatcta aagtttgtta gatagctgca tgtggctttt ttaaaaaagc 1680 aacagaaacc tatcctcact gccctccca gtctctctta aagttggaat ttaccagtta 1740 attactcagc agaatggtga tcactccagg tagtttgggg caaaaatccg aggtgcttgg 1800 gagttttgaa tgttaagaat tgaccaactg cttttataa atttgtgac aaaatttct 1860
  cattttcttt tcacttcggg ctgtgtaaac acagtcaaaa taattctaaa tccctcgata 1920 tttttaaaga tctgtaagta acttcacatt aaaaaatgaa atattttta atttaaagct 1980 tactctgtcc attatcac aggaaagtgt tattttaaa ggaaggttca tgtagagaaa 2040 agcacacttg taggataagt gaaatggata tattatctt taatgacta 2160
 tgtatggaaa aaccatttga agtgtacctg tgtacataac tctgtaaaaa cactgaaaaa 2160 ttatactaac ttatttatgt taaaagattt tttttaatct agacaatata caagccaaag 2220 tggcatgttt tgtgcatttg taaatgctgt gttgggtaga ataggttttc ccctcttttg 2280 ttaaataata tggctatgct taaaaggttg catactgagc caagtataat tttttgtaat 2340 gtgtgaaaaa gatgccaatt attgttacac attaagtaat caataaagaa aacttccata 2400
  gctaaaaaaa aaaaaaaaaa aa
  <210> 317
  <211> 5061
  <212> DNA
  <213> Homo sapiens
  <400> 317
  atggctcaga tatttagcaa cagcggattt aaagaatgtc cattttcaca tccggaacca 60
 acaagagcaa aagatgtgga caaagaagaa gcattacaga tggaagcaga ggctttagca 120 aaactgcaaa aggatagaca agtgactgac aatcagagag gctttgagtt gtcaagcagc 180 accagaaaaa aagcacaggt ttataacaag caggattatg atctcatggt gtttcctgaa 240 tcagattccc aaaaaagagc attagatat gatgtagaaa agctcaccca agctgaactt 300
tcagattccc aaaaaagagc attagatatt gatgtagaaa agctcaccca agctgaactt 300 gagaaactat tgctggatga cagtttcgag actaaaaaaa cacctgtatt accagttact 360 cctattctga gcccttcctt tcagcacag ctctatttta gacctactat tcagagagga 420 cagtggccac ctggattacc tgggccttcc acttatgctt taccttctat ttatccttct 480 acttacagaa ctatatattt aagtcttccg ggacaatctc caagaatgcc cacttttca 540 tctacagaac cacctttca tccacaaga agcttaccta tctatcgtc agtagtcagt 660 actgacatgg caaaactatt tgacaaaata gctagtacat gcaattttt aagtcttgag atatcagaa atttgacagga ttaacagat cagaattttt aaaaaaatggg 720 aaagcaagga ctgatttgga gataacagat tcaaaagtca gcaatctacca ggtatccca 780 atgtgataatg tggaggtatt agaccatgag gaagagaaaa atgtttcaag ttagcctaag 840 gtggataatg tggaggtatt agaccatgag gaagagaaaa atgtttcaag ttagcctaag 900 aaggatcctt gggatgctgt tcttcttgaa gagaggatcga cagcaaattg tcatcttgaa 960 agaaaggtga atggaaaatc cctttctgtg gcaactgtta caagaagcca gtctttaaat 1020 atcgaacaa ctcagcttgc aaaagcccag ggccatatat ctcaagaag cccaaatggg 1080 accagtagtt tgccaactgg aagttctct cttcaagaag ttgaagtaca gaatgaggag 1140 Page 64
```

Page 64

39740-0001PCT.txt

atggcagctt tttgtcgatc cattacaaaa ttgaagacca aatttccata taccaatcac 1200 cgcacaaacc caggctattt gttaagtcca gtcacagcgc aaagaaacat atgcggagaa 1260 aatgctagtg tgaaggtctc cattgacatt gaaggatttc agctaccagt tacttttacg 1320 tgtgatgtga gttctactgt agaaatcatt ataatgcaag ccctttgctg ggtacatgat 1380 gacttgaatc atgatgagt tggaagtcat gttctaaaag tttgtggtca agaggaagtg 1440 gacttgaatc aagtagatgt tggcagctat gttctaaaag tttgtggtca agaggaagtg 1440 ctgcagaata atcattgcct tggaagtcat gagcatattc aaaactgtcg aaaatgggac 1500 acagaagtat gactacaact cttgaccttc agtgcaatgt gtcaaaatct ggcccgaaca 1560 gcagaagatg atgaaacacc cgtggattta aacaaacacc tgtatcaaat agaaaaaacct 1620 tgcaaagaag ccatgacgag acaccctgtt gaagaactct tagattctta tcacaaccaa 1680 gtagaactgg ctcttcaaat tgaaaaccaa caccgaggag tagatcaagt aattaaagct 1740 gtagaagaaaa tctgtagtgc tatatcttca agagagacact ttgccattac agaatcagta 1800 tttggaggag aagacactag caggagttca actaggggct cacttaatcc tgaaaatcct 1920 gttcaagtaa gcataaacca attaactgca gcaatttatg atcttctcag actccatgca 1980 aattctggta ggagtcctac agactgtqcc caaagtaqca agagtgtcaa ggaagcactag 2040 aattctggta ggagtcctac agactgtgcc caaagtagca agagtgtcaa ggaagcatgg 2040 actacaacag agcagctcca gtttactatt tttgctgctc atggaatttc aagtaattgg 2100 gtatcaaatt atgaaaaata ctacttgata tgttcactgt ctcacaatgg aaaggatctt 2160 tttaaaccta ttcaatcaaa gaaggttggc acttacaaga attcttcta tcttattaat 2220 tgggatgaac taatcatttt tcctatcaag atatcacaaa tgccattaga atcagttctt 2280 caccttactc tttttggaat tttaaatcag atatcacaat tgccattaga atcagttctt 2280 caccttactc tttttggaat tttaaatcag agcagtggaa gttcccctga ttctaataag 2340 cagagaaagg gaccagaagc tttgggcaaa gtttctttac ctctttgtga ctttagacgg 2400 tttttaacat gtggaactaa acttctatat ctttggactt catcacatac aaattctgtt 2460 cctggaacag ttaccaaaaa aggatatgtc atggaaagaa tagtgctaca ggttgatttt 2520 ccttctcctg catttgatat tatttataca actcctcaag ttgacagaag cattatacag 2580 caacataaact tagaaacact agagaatgat ataaaaggga aacttcttga tattctcat 2640 aaagactcat cacttggact ttctaaagaa gataaaagctt ttttatggga gaaacgttat 2700 tattgctca aacacccaaa ttgcttcct caaaatattag caagcgcccc aaactggaaa 2760 tggggtaatc ttgccaaaac ttactcattg cttcaccagt ggcctgcatt gtacccacta 2820 tattgcttca aacacccaaa ttgtcttcct aaaatattag caagcgcccc aaactggaaa 2760 tggggtaatc ttgccaaaac ttactcattg cttcaccagt ggcctgcatt gtacccacta 2820 attgcattgg aacttcttga ttcaaaattt gctgatcagg aagtaagatc cctagctgtg 2880 acctggattg aggccattag tgatgatgag ctaacagatc ttcttccaca gtttgtacaa 2940 gctttgaaat atgaaattta cttgaatagt tcattagtgc aattcctttt gtccagggca 3000 ttgggaaata tccagatagc acacaattta tattggcttc tcaaagatgc cctgcatgat 3060 gtacagttta gtacccgata cgaacatgtt ttgggtgctc tcctgtcagt aggaggaaaa 3120 cgacttagag aagaacttct aaaacagacg aaacttgtac agcttttagg aggagtagca 3180 gaaaaagtaa ggcaggctag tggatcagc agacaggttg ttctccaaag aagtatggaa 3240 cgagtacagt ccttttttca gaaaaataaa tgccgtctcc ctctcaagcc aagtctagtg 3300 gcaaaagaat taaatattaa gtcgtgtcc ttcttcagtt ctaatgctgt ccccctaaaa 3360 gcaaaagaat taaatattaa gtcgtgttcc ttcttcagtt ctcatagct ccccctaaaa 3360 gtcacaatgg tgaatgctga ccctctggga gaagaaatta atgtcatgtt taaggttggt 3420 gaagatcttc ggcaagatat gttagcttta cagatgataa agattatgga taagatctgg 3480 cttaaagaag gactagatct gaggatggta attttcaaat gtctctcaac tggcagagat 3540 cgaggcatgg tggagctggt tcctgctcc gataccctca ggaaaatcca agtggaatat 3600 ggtgtgacag gatcctttaa agataaacca cttgcagagt ggctaaggaa atacaatccc 3660 tctgaagaag aatatgaaaa ggcttcagag aactttatct attcctgtgc tggatgctgt 3720 gtagccacct atgttttagg catctgtgat cgacacaatg acaatataat gcttcgaagc 3780 acgggacaca tgtttcacat tgactttgga aagtttttgg gacatgcaca gatgtttggc 3840 aggctcaaaa gggatcgggc tccttttgg ctgacctctg atatggcata tgtcataat 3900 gagggtgaaa agccaccat tcgttttcag ttggatgctgt ttggatgctgt ttggatgctga accttgataa gaagcagac aaaccttttt ttgaaaatacg ttagaagatg tccttcaacc 4020 gagttaccag acgcagaagc tactaatttc ttgaaaatacg ttagagatgc acttcaaccc 4080 caaactacaag acgcagaagc tacaattttc cacaaccttg ctcagcttcg tttttctggt 4200 cttccttcta atgatgacga catccttca ttttcaccta agaaacaaca 4260 gatggtcgaa tcaaggaagt ctcttttca atgatgacaa atttgacaa 4260 gatggtcgaa atgatgccg aattttggg aattttttgg gaaggacaga ttgaaccatc atttgtctc 4380 cattatattt atgatgtccg aatttttgg gaaggacaga ttgaaccatc atttgtctc 4380 gcaaaagaat taaatattaa gtcgtgttcc ttcttcagtt ctaatgctgt ccccctaaaa 3360 cattatattt atgtagtccg aattttgtgg gaaggacaga ttgaaccatc atttgtcttc 4380 cgaacatttg tcgaatttca ggaacttcac aataagctca gtattatttt tccactttgg 4440 aagttaccag gctttcctaa taggatggtt ctaggaagaa cacacataaa agatgtagca 4500 gccaaaagga aaattgagtt aaacagttac ttacagagtt tgatgaatgc ttcaacggat 4560 gtagcagagt gtgatcttgt ttgtactttc ttccaccctt tacttcgtga tgagaaagct 4620 gaagggatag ctaggtctgc agatgcaggt tccttcagtc ctactccagg ccaaatagga 4680 ggagctgtga aattatccat ctcttaccga aatggtactc ttttcatcat ggtgatgcat 4740 atcaaagatc ttgttactga agatggagct gacccaaatc catatgtcaa aacataccía 4800 cttccagata accacaaaac atccaaacgt aaaaccaaaa tttcacgaaa aacgaggaat 4860 ccgacattca atgaaatgct tgtatacagt ggatatagca aagaaaccct aagacagcga 4920 gaacttcaac taagtgtact cagtgcagaa tctctgcggg agaattttt cttgggtgga 4980 gtaaccctgc ctttgaaaga tttcaacttg agcaaagaga cggttaaatg gtatcagctg 5040 actgcggcaa catacttgta a 5061

39740-0001PCT.txt

```
<210> 318
  <211> 3014
<212> DNA
  <213> Homo sapiens
<400> 318
  ctgaccagcg ccgccctccc ccgcccccga cccaggaggt ggagatccct ccggtccagc 60 cacattcaac acccacttc tcctccctct gcccctatat tcccgaaacc ccctcctct 120
 <210> 319
<211> 2148
 <212> DNA
 <213> Homo sapiens
 <400> 319
 gcttcagggt acagctccc cgcagccaga agccgggcct gcagcgcctc agcaccgctc 60 cgggacaccc cacccgcttc ccaggcgtga cctgtcaaca gcaacttcgc ggtgtggtga 120 actctctgag gaaaaaccat tttgattatt actctcagac gtgcgtggca acaagtgact 180
                                                         Page 66
```

```
39740-0001PCT.txt
 gagacctaga aatccaagcg ttggaggtcc tgaggccagc ctaagtcgct tcaaaatgga 240 acgaaggcgt ttgtggggt ccattcagag ccgatacatc agcatgagtg tgtggacaag 300 cccacggaga cttgtggagc tggcaggca gagcctgctg aaggatgagg ccctggccat 360 tgccgcctg gagttgctgc ccagggagct cttcccgcca ctcttcatgg cagcctttga 420 cgggagacac agccagaccc tgaaaggcaat ggtgcaggcc tggcccttca cctgcctcc 480 tctgggagtg ctgatgaagg gacaacatct tcacctggag accttcaaag ctgtgcttga 540 tcggacttgat gtgctccttg cccaggaggt tcgccccagg aggtggaaac ttcaagtgct 600 ggatttacgg aagaactctc atcaggactt ctggactgta tggtctggaa acagggccag 660 tctgtactca tttccagagc cagaagcagc tcagcccatg acaaagaagc gaaaagtaga 720 tggtttgagc acagagcag agcagcctt cattccagta gaggtgctcg tagacctgtt 780 cctcaaggaa ggtgcctgtg atgaattgtt ctcctacctc attgaqaaag tgaagcgaaa 840
tgttgaaaat aaagagaagc aatgtgaagc aaaaaaaaa aaaaaaaa
                                                                                                                                                                                              2148
 <210> 320
 <211> 540
 <212> DNA
 <213> Homo sapiens
 <400> 320
<210> 321
<211> 2346
 <212> DNA
 <213> Homo sapiens
 <400> 321
 gcacgaggct gcggcgggtc cgggcccatg aggcgacgaa ggaggcggga cggcttttac 60
ccagccccgg acttccgaga cagggaagct gaggacatgg caggagtgtt tgacatagac 120 ctggaccagc cagaggacgc gggctctgag gatgagctgg aggagggggg tcagttaaat 180 gaaagcatgg accatggggg agttggacca tatgaacttg gcatggaaca ttgtgagaaa 240 tttgaaatct cagaaactag tgtgaacaga gggccagaaa aaatcagacc agaatgtttt 300 gagctacttc gggtacttgg taaagggggc tatggaagg ttttcaagt acgaaaagta 360 acaggagcaa atactgggaa aatatttgcc atgaaggtgc ttaaaaaggc aatgatagta 480
agaaatgcta aagatacagc tcatacaaaa gcagaacgga atattctgga ggaagtaaag 480 catcccttca tcgtggattt aatttatgcc tttcagactg gtggaaaact ctacctcatc 540 cttgagtatc tcagtggagg agaactattt atgcagttag aaagagaggg aatatttatg 600 gaagacactg cctgctttta cttggcagaa atctccatgg ctttggggca tttacatcaa 660
                                                                                                           Page 67
```

39740-0001PCT.txt aaggggatca tctacagaga cctgaagccg gagaatatca tgcttaatca ccaaggtcat 720 gtgaaactaa cagactitgg actatgcaaa gaatctattc aigatggaac agtcacacac 780 acattttgtg gaacaataga atacatggcc cctgaaatct tgatgagaag tggccacaat 840 cgtgctgtgg attggtggag tttgggagca ttaatgtatg acatgctgac tggagcaccc 900 ccattcactg gggagaatag aaagaaaaca attgacaaaa tcctcaaatg taaactcaat 960 ttgcctccct acctcacaca agaagccaga gatctgctta aaaagctgct gaaaagaaat 1020 gctgcttctc gtctgggagc tggtcctggg gacgctggag aagttcaagc tcatccattc 1080 tttagacaca ttaactggga agaacttctg gctcgaaagg tggagccccc ctttaaacct 1140 ctgttgcaat ctgaagagga tgtaagtcag tttgattcca agtttacacg tcagacacct 1200 gtcgacagcc cagatgactc aactctcagt gaaagtgcca atcaggtctt tctgggtttt 1260 acatatgtgg ctccatctgt acttgaaagt gtgaaagaaa agttttcctt tgaaccaaaa 1320 atccgatcac ctcgaagatt tattggcagc ccacgaacac ctgtcagccc agtcaaattt 1380 tctcctgggg atttctgggg aagaggtgct tcggccagca cagcaaatcc tcagacacct 1440 gtggaatacc caatggaaac aagtggcata gagcagatgg atgtgacaat gagtggggaa 1500 gcatcggcac cacttccaat acgacagccg aactctgggc catacaaaaa acaagctttt 1560 cccatgatct ccaaacggcc agagcacctg cgtatgaatc tatgacagag caatgctttt 1620 aatgaattta aggcaaaaag gtggagaggg agatgtgga gcatcctgca aggtgaaaca 1680 agactcaaaa tgacagtttc agaagagtcaa tgtcataca tagacagact tagacagag 1800 aaaaataaac giggaittta aaaaaicaat caatggtgca aaaaaaaact taaagcaaaa 1800 tagtattgct gaactcttag gcacatcaat taattgattc ctcgcgacat ctttctcaac 1860 cttatcaagg attttcatgt tgatgactcg aaactgacag tattaagggt aggatgttgc 1920 tctgaatcac tgtgagtctg atgtgtgaag aagggtatcc tttcattagg caagtacaaa 1980 ttgcctataa tacttgcaac taaggacaaa ttagcatgca agcttggtca aacttttccc 2040 aggcaaaatg ggaaggcaaa gacaaaagaa acttaccaat tgatgtttta cgtgcaaaca 2100 acctgaatct tittittata taaatatata tttttcaaat agatitttga ticagctcat 2160 tatgaaaaac atcccaaact ttaaaatgcg aaattattgg ttggtgtgaa gaaagccaga caacttctgt ttcttctctt ggtgaaataa taaaatgcaa atgaatcatt gttaacacag 2280 ctgtggctcg tttgagggat tggggtggac ctggggttta ttttcagtaa cccagctgcg 2340 2346 gagcct 2710 222

<7 T U >	344	
<211>	2420	
<212>	DNA	
<213>	Homo	sapien

<400> 322							
tccggggcgg	cccccggcag	ccagcgcgac	gttccaaaat	cgaacctcag	tggcggcgct	60	
cggaagcgga	actctgccgg	ggccgcgccg	gctacattgt	ttcctccccc	cgactccctc	120	
ccgccccctt	cccccgcctt	tcttccctcc	gcgacccggg	ccgtgcgtcc	gtccccctgc	180	
				acctctttgt			
ctggggaccc	ctgcgcccct	cccctccccc	ctgaccgcat	ggaccgtccc	gcaggccgct	300	
				aagagagctc		360	
aagtgacagg	ttggctttac	tgtgactcgg	ggacgccaga	gctcctgaga	agatgtcagc	420	
aatacaggcc	gcctggccat	ccggtacaga	atgtattgcc	aagtacaact	tccacggcac	480	
	gacctgccct			accattgtgg	ccgtcaccaa	540	
ggaccccaac	tggtacaaag	ccaaaaacaa	ggtgggccgt	gagggcatca	tcccagccaa	600	
ctacgtccag	aagcgggagg	gcgtgaaggc	gggtaccaaa	ctcagcctca	tgccttggtt	660	
				tacccgccgg		720	
				acgctgtgcg		780	
				aagctcagca		840	
				acctcagacg		900	
				gtggcggccc		960	
				ctgctgcaga		1020	
				aacaaagtcg		1080	
	gacgccactg	cccaggcctt	cctggctgaa	gcctcagtca		1140	
	aacctggtgc	agctcctggg	cgtgatcgtg	gaggagaagg	gcgggctcta	1200	
catcgtcact				tacctgcggt		1260	
gtcagtgctg				gatgtctgcg	aggccatgga	1320	
atacctggag	- -			gcccgcaatg	5 55 5	1380	
tgaggacaac				aaggaggcgt	~	1440	
ggacacgggc				gccctgagag		1500	
					actcctttgg	1560	
			ggacgtcgtc		agaagggcta	1620	
caagatggat				gaagtcatga		1680	
				cgagagcagc		1740	
				tgggtcatgg		1800	
				tgggcccgag		1860	
gccccagcgg	geeggegge	cittttcctg		tgcacccctc	cygccccgtc	1920	
Page 68							

```
39740-0001PCT.txt
 tctcttggac ccacctgtgg ggcctgggga gcccactgag gggccaggga ggaaggaggc 1980 cacggagcgg gcggcagcgc cccaccacgt cgggcttccc tggcctcccg ccactcgcct 2040 tcttagagtt ttattccttt cctttttga gattttttt ccgtgtgttt atttttatt 2100 attttcaag ataaggaga agaaagtacc cagcaaatgg gcattttaca agaagtacga 2160 atcttatttt tcctgtcctg cccgtgaggt gggggggacc gggcccctct ctagggaccc 2220 ctcgcccag cctcattccc cattctgtgt cccatgtccc gtgtctcctc ggtcgcccg 2280 tgtttgcgct tgaccatgtt gcactgtttg catgcgccg aggcagacgt ctgtcagggg 2340 cttggattc gaggaaaaaa gaggaaaaaa 2400 accacgccat gaggaaaaaa 2400 accacgccat gaggaaaaaa
  <210> 323
<211> 2253
<212> DNA
  <213> Homo sapiens
<400> 323
<210> 324
<211> 1619
 <212> DNA
 <213> Homo sapiens
 <400> 324
ccgccagatt tgaatcgcgg gacccgttgg cagaggtggc ggcggcggca tgggtgcccc 60 gacgttgcc cctgcctggc agccctttct caaggaccac cgcatctcta cattcaagaa 120 ctggcccttc ttggagggct gcgcctgcac cccggagcgg atggccgagg ctggcttcat 180 ccactgcccc actgagaacg agccagactt ggcccagtgt ttcttctgct tcaaggagct 240 ggaaggctgg gagccagatg acgaccccat agaggaacat aaaaagcatt cgtccggttg 300 cgctttcctt tctgtcaaga agcagttga agaattaacc cttggtgaat ttttgaaact 360 ggacagagaa agagccaaga acaaaattgc aaaggaaacc aacaataaga agaaagaatt 420
                                                                                                                Page 69
```

```
39740-0001PCT.txt
   tgaggaaact gcgaagaaag tgcgccgtgc catcgagcag ctggctgcca tggattgagg 480
cčtčťggccg gagctgcctg gtcccagagt ggctgcacca cttccagggt ttattccctg 540
  <210> 325
<211> 5010
   <212> DNA
   <213> Homo sapiens
   <400> 325
  ggcggctcgg gacggaggac gcgctagtgt gagtgcgggc ttctagaact acaccgaccc 60 tcgtgtcctc ccttcatcct gcggggctgg ctggagcggc cgctccggtg ctgtccagca 120
tcgtgtcctc ccttcatcct gcggggctgg ctggagcggc cgctccggtg ctgtccagca 120 gccataggga gccgcacggg gagcgggaaa gcggtcgcgg ccccaggcgg ggcggccggg 180 atggagcggg gccgcagcc tgtggggaag gggctgtggc ggcgcctcga gcggctgcag 240 gttcttctgt gtggcagttc agaatgatgg atcaagctag atcaagcattc tctaacttgt 300 ttggtggaga accattgtca tatacccggt tcagcctggc tcggcaagta gatggcgata 360 acagtcatgt ggagatgaaa cttgctgtag atgaagaaga aaatgctgac aataacacaa 420 agaccaatgt ttctttgat ggagtttatga ttggctactt gggctattgt aaaaggggtag 480 gagaggactt ttctttgatt ggatttatga ttggctactt gggctattgt aaaggggtag 540 aacaaaaac tgagtgtgag agactggcag gaaccgagtc tccagtgagg gaggagccag 600 gagaggactt ccctgcagca cgtcgcttat attgggatga cctgaagga aagttgtcgg 660 agaaactgga taaactcag acaaaagatg taaactcagc ggtgatcatag ttggtagat taaactcagc aaagtctggc gtgatcataa ttttgtgaatt taaactcagc acaaaactgg gtgatcataag ttggataaaca tttgggagaatc tcgaggggtca tttgggggttat ggtggcgtat gtggagaacc ggtgatcatag ttggagaatct tttggggatat ttgggggtat ttggagaatct tttggggagatca ttttgggagaatcc tcaaaaagatg ttggagagaccag aaagtctggc ggtaaaactag ggtgaaactcg ggtgatcatag ttggaggatct ggtgataatag ttggaggatt attacggtca aaaaaaagatt ttgggggtta aaaaggctgc aacagttact ggtaaactgg 960 tccaatgctaa ttttggtact aaaaaaagatt ttgaggatt atacactcct gtgaatggat 1020 ctatagtgat gatcataca ttggagcagac taaattccc attgttaacg 1140 cagaactttc attcttgga catgctcatc tggggacagg tgacccttaa acaccttggat 1200 caagaacttc attcttgga catgctcatc tggggacagg tgacccttaa acaccttgat 1200
cagaactttc attettega catgetcate tggggacagg tgaccettae acacetggat 1200 tecettectt caatcacact cagtttecae cateteggte atcaggattg cetaatatae 1260 etgtecagae aatetecaga getgetgeag aaaagetgtt tgggaatatg gaaggagaet 1320 getectetga etgggaaaaca gactetacat gtaggatggt aaceteagaa ageaagaatg 1380 tgaageteae tgtgageaat gtgetgaaag agataaaaat tettaacate tttggagtta 1440 ttaaaggett tgtagaacca gateactatg ttgtagttgg ggeecagaga gatgeatggg 1500 geectggage tgeaaaatee ggtgtaggea cageteteet attgaaactt geecagatgt 1560 teteagatat ggtettaaaa gatgggtte ageecageag aageattate tttgeeagtt 1620 ggagtgetgg agactttgga teggttggtg ceaetgaatg getagaggga tacetttegt 1680 eeetgeatt aaaggettte acetatatta atetggataa ageggttett ggtaecagea 1740
  ccctgcattt aaaggctttc acttatatta atctggataa agcggttctt ggtaccagca 1740 acttcaaggt ttctgccagc ccactgttgt atacgcttat tgagaaaaca atgcaaaatg 1800 tgaagcatcc ggttactggg caatttctat atcaggacag caactgggcc agcaaagttg 1860 agaaactcac tttagacaat gctgctttcc ctttccttgc atattctgga atcccagcag 1920
 agaaactcac tttagacaat gctgctttcc ctttccttgc atattctgga atcccagcag 1920 tttctttctg tttttgcgag gacacagatt atccttattt gggtaccacc atggacacct 1980 ataaggaact gattgagagg attcctgagt tgaacaaagt ggcacgagca gctgcagagg 2040 tcgctggtca gttcgtgatt aaactaaccc atgatgttga attgaacctg gactatgaga 2100 ggtacaacag ccaactgctt tcatttgtga gggatctgaa ccaatacaga gcagacataa 2160 aggaaatggg cctgagttta cagtggctgt attctgctcg tggagacttc ttccgtgcta 2220 cttccagact acaacagat ttcgggaatg ctgagaaaac agacagattt gtcatgaaga 2280 aactcaatga tcgtgtcatg agagtggagt atcacttcct ctctccctac gtatctccaa 2340 aagagtctcc tttccgacat gtcttctggg gctccggctc tcacacgctg ccagctttac 2400 tggagaactt gaaactgcgt aaacaaaata acggtgcttt taatgaaacg ctgttcagaa 2460
                                                                                                                                                                                                               Page 70
```

accagitiggs titagcatact tggactatit agggagsctgs aaatgcctc tctggtgacg 2520 titigggacat tgacaatgag tititaaatg gataccata gcttscatga gaacagagg 2580 gtagtctggt tictagactt gtgctgatgt tgctaaattt tcagtaagggc tacaaaacct 2640 gatgttaaaa ttccatccat tcatcttggt actactagat gtctitaggc agcagcttt 2700 aatacaggg agataacctg tacttcaggt tacatagagg tgctitagg aatgactgct 2760 tgatggaata ttcccctat tctagaattt taagtgat aaccacttaag accacttaa 2760 tgatggaata ttccctatt tctagaattt taagtgatt gatgatgggaa acgctctt 2820 cctgtigtig tratagaaga tggtagaac aggttagtg aatgatggga actacagcta 2880 agggctggtc tctgctgaag gitgtaagg gitgtatgtg aatgatgtct ctdgaatctc 2880 agggctggtc tctgctgaag gitgtaagg gitgctcat tttagagtgat cctcaactt 2940 cattiggg taataaggag ataccaggt gaaagacct tccaaatggag actaagagc 3000 ttccataagg atttctccat tcctgaaggac actagaggct 3000 ttccataagg atttcttcca ggaataaagc cttaatagt taacctcag tttcagaag 3120 aggttgggctc tttggttga ggaataaggc cttaatagt taacctcag tttcagaaga 3120 aggttcaact gttgattga ggaataaggc cttaatagt taacctcagt gaaagaagagg actagagggg acagaagcc aaagactag tatattttct tttcctctgt cccttcccc 3240 ataagctcca atttagtct tttgttattt ttgttatttt ttttcttctctgt cccttcccc 3240 aaattatgga ggattaagg gagacttagg aggactttct gtccttttgg cacttagaga 3360 aaatttagga gagactgggac tcaaaattat ggaaggtat accttagggg aggactttct gtccttttgg cacttacata 3480 aattatgga gagactgggac tctcaaatta agaccaaca gaatgtgaat ttaagaaga 3420 aattataggg tttagaaac agccgcaca aggacaca gagactagg tttagaaac agcagaca cacgataag 3720 aatgctggt ttcctaaatg cacgtgaact gaaattaatt taataaggg ttgctcaaca gaataaatt taataaggg ttgctaagaa gcagaccac aaattaata gaccagtaca cacgataag 3720 aatgctggt gaaattaact taatagagg ttgccaacaga accagataag 3720 aatgctggt gtactcctga accagataga accagataga accagataga 3720 aatgctggta gtactcctga cacagataga accagataga accagataga accagataga accagataga 3720 aatgctggta gtactcctga accagataga accagataga accagataga accagataga 3720 aatgctggta gtactcctga accagataga accagat 39740-0001PCT.txt accagttggc tctagctact tggactattc agggagctgc aaatgccctc tctggtgacg 2520 atctcctctt ttatcttgga ctgacattta gcgtagctaa gtgaaaaggt catagctgag 4740 attcctggt cgggtgttac gcacacgtac ttaaatgaaa gcatgtggca tgttcatcgt 4800 ataacacaat atgaatacag ggcatgcatt ttgcagcagt gagtctcttc agaaaaccct 4860 tttctacagt tagggttgag ttacttccta tcaagccagt acgtgctaac aggctcaata 4920 tcctggaatg aaatatacagg taagtgaata ggagtagggc cttttggagg taaaggtata

```
<210> 326
<211> 2574
<212> DNA
<213> Homo sapiens

<400> 326
cctgtttaga cacatggaca accaatcccag cgctacaagg cacacagtcc cgcagggtt gccagcgctt cctggaagtc ctgaagctct cgcagtgcag tgagttcatg 120
cacttcttg ccaagcctca gtctttgga tctgggagg cgcctggt ttcctcctc tccaggcctt accatgaaga tgcacttgcag aagggctct ggggaggcca cacatgaaga tgcacttgca aagggctct gtggtccccc tggcctctct 240
tcccagctca cacatgaaga tgcacttgca aagggctct gtggtcctgg ccctgctgaa 300
ctttgccacg gtcagcctct ctctgtccac ttgcaccac ttggactctg gccacatcaa 360
gaagaagaagg gtggaagcca ttaggggaca gatcttgagc aagctcaggc tcaccagccc 420
ccctgagcca acggtgatga cccacgtccc ctatcaggtc ctggaccttt acacaaggac cgggaggaga tactatgcca aagaaatcca taaattcgac aggatggaga ggctggcgga 600
gccaaacgaa ctggctgtct ggaatgagca attccagga gaggatgag ctcttccag ggaatgagca attgccaaccac aggaatgagca gaggatgag ctcttccaga tcttctcggcc 780
agatgagcac attgccaaca aggcctatat cggtggcg gagtggctgt tgagaagaga 900
gccaactta ggtctagaaa tcagcattca ctgtccatgt cacaccttt agcccaatgg 960
Page 71
```

```
39740-0001PCT.txt
 agatatcctg gaaaacattc acgaggtgat ggaaatcaaa ttcaaaggcg tggacaatga 1020 ggatgaccat ggccgtggag atctgggcg cctcaagaag cagaaggatc accacaaccc 1080 tcatctaatc ctcatgatga ttccccaca ccggctcgac aacccgggcc agggggggtca 1140 gaggaagaag cgggctttgg acaccaatta ctgcttccgc aacttggagg agaactgctg 1200 tgtgcgccc ctctacattg acttccgaca ggatctgggc tggaagtggg tccatgaacc 1260 taagggctac tatgccaact tctgctcagg cccttgccca tacctccgca gtgcagacac 1320 aacccaacg acggtgctgg gactgtacaa cactctgaac cctgaagcat ctgctgcgc 1380 ttgctgcgtg ccccaggacc tggagccct gacacctgt tactatgttg ggaggacccc 1440 caaagtggag cagctctcca acatggtggt gaagtcttgt aaaatgtagct ggagccccaca 1500 gtgcgacaa gagggggag agagaaccac acctgcctga ctgcccgct ctcgggaaac 1500 ggcgaaagaa gaggttcct ttggaagacc ttcttcttctg ctggctctga gaatcacggt 1680 ggtaaagaaa gtgtgggttt ggttagagga aggaaaggga tggtaagttg agatgttgtg 1800 tggcaatggg atttgggatag atttgggcta ccctaaaggg agaagaagg gcagagaatg gctgggtcag 1860
   agatatcctg gaaaacattc acgaggtgat ggaaatcaaa ttcaaaggcg tggacaatga 1020
 tggcaatggg atttgggcta ccctaaaggg agaaggaatg gcagagaatg gctgggtcag 1860 ggccagactg gaagacactt cagatctgag gttggatttg ctcattgctg taccacatct 1920 gctctaggga atctggatta tgttatacaa ggcaagcatt tttttttta aagacaggtt 1980 acgaagacaa agtcccagaa ttgtatctca tactgtctgg gattaagggc aaatctatta 2040 cttttgcaaa ctgtcctcta catcaattaa tagaggctt tagagagaga agaagacaa 2160
ggtcatgcag ttcctggcc atcaactga ttgggccttt tggatatgct gaacgcagaa 2160 gaaagggtgg aaatcaaccc tctcctgtct gccctctggg tccctcctct cacctctcc 2220 tcgatcatat ttccccttgg acacttggtt agacgccttc caggtcagga tgcacatttc 2280 tggattgtgg ttccatgcag ccttggggca ttatgggtct tccccactt cccctccaag 2340 accctgtgtt catttggtgt tcctggaagc aggtgctaca acatgtgagg cattcgggga 2400 agctgcacat gtgccacaca gtgacttggt cccagacgca tagactgagg tataaagaca 2460 agtatgaata ttactctcaa aatctttgta taaataaata tttttggggc atcctggatg 2520 atttcatctt ctggaatatt gtttctagaa cagtaaaagc cttattctaa ggtg
 <210> 327
<211> 1421
  <212> DNA
  <213> Homo sapiens
  <400> 327
 acttactgcg ggacggcctt ggagagtact cgggttcgtg aacttcccgg aggcgcaatg 60 agctgcatta acctgcccac tgtgctgccc ggctcccca gcaagacccg ggggcagatc 120
  caggigatte tegggeegat giteteagga aaaageacag agttgatgag acgegteegt 180
 cgcttccaga ttgctcagta caagtgcctg gtgatcaagt atgccaaaga cactcgctac 240 agcagcagct tctgcacaca tgaccggaac accatggagg cgctgcccgc ctgcctgctc 300 cgagacgtgg cccaggaggc cctgggggg gctgtcatag gcatcgacga ggggcagttt 360 ttccctgaca tcatggagtt ctgcgaggcc atggccaacg ccgggaagac cgtaattgtg 420
 gctgcactgg atgggacctt ccagaggaag ccatttgggg ccatcctgaa cctggtgccg 480 ctggccgaga gcgtggtgaa gctgacggcg gtgtgcatgg agtgcttccg ggaagccgcc 540 tataccaaga ggctcggcac agagaaggag gtcgaggtga ttgggggagc agacaagtac 600 cactccgtgt gtcggctctg ctacttcaag aaggcctcag gccagcctgc cgggccggac 660
cactccgtgt gtcggctctg ctacttcaag aaggcctcag gccagcctgc cgggccggac 660 aacaaagaga actgcccagt gccaggaaag ccaggggaag ccgtggctgc caggaagctc 720 tttgccccac agcagattct gcaatgcagc cctgccaact gagggacctg caaggggcgc 780 ccgctcctt cctgccactg ccgcctactg gacgctgccc tgcatgctgc caaggggcgc 780 caggaggaag tcgggaggcg tggagggtga ccacaccttg gccttctggg aactctcctt 900 tgtgtggctg ccccacctgc cgcatgctcc ctcctctct acccactggt ctgctaaag 960 cttcctctc agctgctgg acgatcgcc aggggagag aggatcggac cactcctct ccttggggtg agggacagag ccccacgctg ttgacatcag 1020 ggatctggaa cactcctct ccttggggtg agggacagag ccccacgctg ttgacatcag 1080 cctgcttctt ccctctgcg gccttaactg ctgagttct ttgagccttg gcccacactg aggcttaagc ctctctgct ggaaggcctgt 1140 gccagcacct ttgagccttg gcccacactg aggcttaagc ctctctgct gggatgggct 1200 ccctcctcc cctggtgat ggcttgaaca ggaacaaca catcttcac caagatggt 1320 ggcaccaacc ttgctggac ttggatcca gggaccaaca gggcttatc tcttcaagtg tggagagggc 1380 agggtccacg cctctgtgt agcttatgaa attaactaat t
  <210> 328
  <211> 4604
  <212> DNA
  <213> Homo sapiens
  <400> 328
 ggaacagctt gtccaccgc cggccggacc agaagccttt gggtctgaag tgtctgtgag 60 acctcacaga agagcaccc tgggctccac ttacctgccc cctgctcctt cagggatgga 120 ggcaatggcg gccagcactt ccctgcctga ccctggagac tttgaccgga acgtgccccg 180
                                                                                                                                                                                    Page 72
```

39740-0001PCT.txt

gatctgtggg gtgtgtggag accgagccac tggctttcac ttcaatgcta tgacctgtga 240 gccttggata atgctgttgc ctcatctata acatgcatt gtctttgtaa tgtcaccacc 4020 ttcccagctc tccctctggc cctgcttctt cggggaactc ctgaaatatc agttactcag 4080 ccctgggccc caccacctag gccactcctc caaaggaagt ctaggagctg ggaggaaaag 4140 aaaagagggg aaaatgagtt tttatggggc tgaacgggga gaaaaggtca tcatcgattc 4200 tactttagaa tgagagtgtg aaatagacat ttgtaaatgt aaaactttta aggtatatca 4260 Page 73

```
39740-0001PCT.txt
   ttataactga aggagaaggt gccccaaaat gcaagatttt ccacaagatt cccagagaca 4320
   ggaaaatcct ctggctggct aactggaagc atgtaggaga atccaagcga ggtcaacaga 4380
gaaggcagga atgtgtggca gatttagtga aagctagaga tatggcagcg aaaggatgta 4440 aacagtgcct gctgaatgat ttccaaagag aaaaaaagtt tgccagaagt ttgtcaagtc 4500 aaccaatgta gaaagctttg cttatggtaa taaaaatggc tcatacttat atagcactta 4560
   ctttgtttgc aagtactgct gtaaataaat gctttatgca aacc
                                                                                                                                                                                                                                                                                                                      4604
  <210> 329
<211> 2076
   <212> DNA
   <213> Homo sapiens
<400> 329
cggggaaggg gagggaggag ggggacgagg gctctggcgg gtttggaggg gctgaacatc 60
gcggggtgtt ctggtgtcc ccgcccgcc tctccaaaaa gctacaccga cgcggaccgc 120
ggcggcgtcc tccctcgccc tcgcttcacc tcgcgggctc cgaatgcggg gagctcggat 180
gtccggtttc ctgtgaggct tttacctgac acccggcgcc tttccccggc actggctggg 240
agggcgccct gcaaagttgg gaacgcggag ccccggaccc gctcccgccg cctccggct 300
gccaggggg ggtcgccgg aggagcccgg gggagaggga ccaggagggg cccgcggcct 360
cgcagggggg cccgccc cacccctgcc cccctgcc cccccgcc tttccccgg acccccggcct 360
cgcagggggg cccggccc cacccctgcc ccccgcagcg gaccggtcc ccaccccgg 420
tccttccacc atgcacttgc tgggcttctt ctctgggcg tgttctctcg
gctgctcccg ggtcctcgcg aggcgcccg cgccgccgcc gccttcgagt ccggactcga 540
cctctcggac gggagcccg acgcgggcga aggcgccgc ggccacggct tatgcaagca aagatctgga 600
ggagcagtta cggtctgtgt ccagtgtaga tgaactcatg actgtactct acccagaata 660
ttggaaaatg tacaagtgc agctaaggaa aggaggctgg caacataaca gagaacaggc 720
caacctcaac tcaaggacag aagagactat aaaatttgct gcagcacatt ataatacaga 780
gatcttgaaa agtattgata atgagtggag aaagacccaa tgcatgccac gggaggtgtg 840
tatagatgtg gggaaggagt ttggagtcgc gacaaacacc ttctttaaac ctccatgtgt 900
gtccgtctac agatgtgggg gttgctgaa tagtgagggg ctgcagtgca tgaacaccag 960
   <400> 329
gtccgtctac agatgtgggg gttgctgcaa tagtgagggg ctgcagtgca tgaacaccag 960 cacgagctac ctcagcaaga cgttatttga aattacagtg cctctctct aaggccccaa 1020 accagtaaca atcagttttg ccaatcacac ttcctgccga tgcatgtcta aactggatgt 1080 ttacagaacaa gttcattcca ttattagacg ttccctgcca gcaacactac cacagtgtca 1140 ggcagcgaac aagacctgcc ccaccaatta catgtggaat aatcacatct gcagatgcct 1200 ggctcaggaa gatttatgt tttcctcgga tgctggagat gactcaacag atggattcca 1260 tgaacatctgt ggaccaaaca aggagctgga tgaagagacc tgtcagtgtg tctgcagagc 1320 ggggcttcgg cctgccagct gtgaaccca caaagaacta gacagaaact catgccagtg 1380 tgtctgtaaa aacaaactct tccccagcca atgtggggc aaccgagaat ttgatgaaaa 1440 cacatgccag tgtgtatgta aaagaacctg ccccaqaaat caacccctaa atcctqqaaa 1500
tgtctgtaaa aacaaactct tccccagcca atgtggggcc aaccgagaat ttgatgaaaa 1440 cacatgccag tgtgtatgta aaagaacctg ccccagaaat caacccctaa atcctggaaa 1500 atgtgcctgt gaatgtacag aaagtccaca gaaatgcttg ttaaaaggaa agaagttcca 1560 ccaccaaaca tgcagctgtt acagacggcc atgtacgaac cgccagaagg cttgtgagcc 1620 aggatttca tatagtgaag aagtgtgcg ttgtgtccct tcatattgga aaagaccaca 1680 aatgagctaa gattgtactg ttttccagtt catcgattt ctattatgga aaactgtgtt 1740 gccacagtag aactgtctgt gaacagagag acccttgtgg gtccatgcta acaaagacaa 1800 aagtctgct ttcctgaacc atgtggataa ctttacagaa atggactgga gctcatctgc 1860 aaaaggcctc ttgtaaagac tggttttctg ccaatgacca aacagccaag atttcctct 1920 tgtgatttct ttaaaagaat gactatataa tttattcca ctaaaaatat tgtttctgca 1980 ttcatttta tagcaacaac aattggtaaa actcactgtg atcaatatt ttatatcata 2040
  ticattttta tagcaacaac aattggtaaa actcactgtg atcaatattt tiatatcatg 2040
  caaaatatgt ttäaaataaa atgaāaattg tattat
                                                                                                                                                                                                                                                                                                                     2076
 <210> 330
<211> 2819
  <212> DNA
  <213> Homo sapiens
  <400> 330
 ctgggcccag ctccccgag aggtggtcgg atcctctggg ctgctcggtc gatgcctgtg 60 ccactgacgt ccaggcatga ggtggttcct gccctggacg ctggcagcag tgacagcagc 120 agccgccagc accgtcctgg ccacggccct ctctccagcc cctacgacca tggactttac 180 cccagctcca ctggaggaca cctcctacag ccccaattc tgcaagtgg catggagga 240
cccgccatcc ccacccgct gccgctggg ggtcagcctc atcacagatg gctgtgagtg 300 ctgtaagatg tgcgctcagc agcttgggga caactgcacg gaggctgcca tctgtgaccc 360 ccaccggggc ctctactgtg actacagcgg ggaccgcccg aggtacgcaa taggagtgtg 420 tgcacaggtg gtcggtgtg gctgctct ggatggggtg cgctacaaca acggccagtc 480 cttccagcct aactgcaagt acaactgcac gtgcatcgac ggcgcggtgg gctgcacacc 540 acctgtgcctc cgagtgcgcc ccccgcgtct ctggtgcccc cacccgcggc gcgtgagcac 660 acctggccac tactgtgagc aactgcac aactgcacg agggagcgac 660
 acctggccac tgctgtgagc agtgggtatg tgaggacgac gccaagaggc cacgcaagac 660 cgcacccgt gacacaggag ccttcgatgc tgtgggtgag gtggaggcat ggcacaggaa 720 ctgcatagcc tacacaagcc cctggagccc ttgctccacc agctgcggcc tgggggtctc 780
                                                                                                                                                                              Page 74
```

39740-0001PCT.txt cacteggate tecaatgtta acgeecagtg etggeetgag caagagagee geetetgeaa 840 cttgcggcca tgcgatgtgg acatccatac actcattaag gcagggaaga agtgtctggc 900 tgtgtaccag ccagaggcat ccatgaactt cacacttgcg ggctgcatca gcacacgctc 960 ctatcaaccc aagtactgtg gagtttgcat ggacaatagg tgctgcatcc cctacaagtc 1020 taagactatc gacgtgtcct tccagtgtcc tgatgggat cccaatgaca tctttgctga 1140 cttggaatcc taccctgact tctcagaaat tgccaactag gcaggcacaa actcttgggt 1200 ttggggacta acccaatgcc tgtgaagaag tcagccctta tggccaataa cttttcacca 1260 atgagcctta gttaccctga tctggaaccct tggcctccat ttctgtct aaccattcaa 1320 atgagcctta atggtgctgc tcaggccct tggcctccat ttctcttga tatcattcag 1380 catctactct aaagaaaaat gcctgctct agctgttctg gactacaccc aagcctgatc 1440 cagcctttcc aagtcactag aagtcctgct ggatcttgc taaatcccaa gacaatggaat 1500 gccattcag atgaatagat ggaattttgga acaatagaat aactattata ttggaggctg 1620 ccaagaggta actgaaggt tatctcata accaacaa gtcatctagg taattctgac gtcaggcac caaaaccacaa gcctgttctaatt 1740 ttgatttta atggaaagt gtatccatta acctgggcat tgtgaaggt tagttctaat 1740 ttgatttta atggaaagt gtatccatta acctgggcat tgtgaagg gaaaggtcag 1620 cccgtttcaa actggaagg gtacagatta acctcaaggg gtacagaat aacaattaca caaacattc ctgattccaa 1680 aacactccaa actggaagg gtacagatta ggtttgtccc aggacagg gaaaggtcag 1920 cccgtttcag aaggaccaat tgactcaa acctgaaccaa ccagagacagg gaaaggtcag 1920 cccgtttcag aaggaccaat tgactcaa acctgaaccaa cctgaagccag ctgcaggcctt 1980 cttgcggcca tgcgatgtgg acatccatac actcattaag gcagggaaga agtgtctggc 900 cccgtttcag aaggaccaat tgactctcac actgaatcag ctgctgactg gcagggcttt 1980 gggcagttgg ccaggctctt ccttgaatct tctcccttgt cctgcttggg gttcatagga 2040 attggtaagg cctctggact ggcctgtctg gcccctgaga gtggtgccct ggaacactcc 2100 tctactctta cagagccttg agagacccag ctgcagacca tgccagaccc actgaaatga 2160 ccaagacagg ttcaggtagg ggtgtgggtc aaaccaagaa gtgggtgccc ttggtagcag 2220 cctggggtga cctctagagc tggaggctgt gggactccag gggcccccgt gttcaggaca 2280 catctattgc agagactcat ttcaccctt ttcgtctgc ggcccccgt gttcaggaca 2240 tggtaggaag atggaggttt accggttgtt tagaacaga aatagactta ataaaggttt 2400 tagagctgaag aggttgaagc taaaaggaaa aggttgttgt taatgaatat caggctatta 2460 tttattgtat taggaaaata taatattac tgttagaatt cttttattta gggccttttc 2520 tttattgtat taggaaaata taatatttac tgttagaatt cttttattta gggccttttc 2520 tgtgccagac attgctctca gtgctttgca tgtattagct cactgaatct tcacgacaat 2580 gttgagaagt tcccattatt atttctgttc ttacaaatgt gaaacggaag ctcatagagg 2640 tgagaaaact caaccagagt cacccagttg gtgactggga aagttaggat tcagatcgaa 2700 attggactgt ctttataacc catatttcc ccctgtttt agagcttcca aatgtgtcag 2760 aataggaaaa cattgcaata aatggcttga ttttttaaaa aaaaaaaaa aaaaaaaaa <210> 331 <211> 2540 <212> DNA <213> Homo sapiens <400> 331 qaaaaggtgg acaagtccta ttttcaagag aagatgactt ttaacagttt tgaaggatct 60 aaaacttgtg tacctgcaga catcaataag gaagaagaat ttgtagaaga gtttaataga 120 ttaaaaactt ttgctaattt tccaagtggt agtcctgttt cagcatcaac actggcacga 180 gcagggtttc tttatactgg tgaaggagat accgtgcggt gctttagttg tcatgcagct 240 gtagatagat ggcaatatgg agactcagca gttggaagac acaggaaggt atcccaaat 300 tgcagatta tcaacggctt ttatctgaa aatagtgca cgcagtctac aaattctggt 360 atccagaatg gtcagtacaa agttgaaaac tatctgggaa gcagagatca ttttgcctta 420 gacaggccat ctgagacaca tgcagactat cttttgagaa ctgggcaggt tgtagatata 480 tcagacacca tatacccgag gaaccctgcc atgtattgtg aagaagctag attaaagtcc 540 tttcagaact ggccagacta tgctcaccta accccaagag agttagcaag tgctggactc 600 tttcagaact ggccagacta tgctcaccta accccaagag agttagcaag tgctggactc 600 tactacacag gtattggtga ccaagtgcag tgcttttgtt gtggtggaaa actgaaaaat 660 tgggaacctt gtgatcgtgc ctggtcagaa cacaggcgac actttcctaa ttgcttcttt 720 gttttgggc ggaatcttaa tattcgaagt gaatctgatg ctgtgagttc tgataggaat 780 ttcccaaaatt caacaaatct tccaaggaat ccatccatgg cagattatga agcacggatt 840 tttacttttg ggacatggat atactcagtt aacaaggagc agcttgcaag agctggattt 900 tatgctttag gtgaaggtga taaagtaaag tgctttcact gtggaggagg gctaactgat 960 tggaagccca gtgaagaccc ttgggaacaa catgctaaat ggtatccagg gtgcaaatat 1020 ctgttagaac agaagggaca agaatatata aacaatattc atttaactca ttcacttgag 1080 1020 1080 gagtgtctgg taagaactac tgagaaaaca ccatcactaa ctagaagaat tgatgatacc 1140 atcttccaaa atcctatggt acaagaagct atacgaatgg ggttcagttt caaggacatt 1200 aagaaaataa tggaggaaaa aattcagata tctgggagca actataaatc acttgaggtt 1260 ctggttgcag atctagtgaa tgctcagaaa gacagtatgc aagatgagtc aagtcagact 1320 tcattacaga aagagattag tactgaagag cagctaaggc gcctgcaaga ggagaagctt 1380 tgcaaaatct gtatggatag aaatattgct atcgttttg ttccttgtgg acatctagtc 1440 acttgtaaac aatgtgctga agcagttgac aagtgtccca tgtgctacac agtcattact 1500 tcaagcaaa aaatttttat gtcttaatct acctcatag taggcatgtt atgttgttct 1560 page 75

```
tagcatttgc taccaagtag gaaaaaaaat gtacatggca gtgttttagt tggcaatata 1680 atctttgaat ttcttgattt ttcagggtat tagctgtatt atccatttt tttactgtta 1740 tttaattgaa accatagact aagaataaga agcatcatac tataactgaa cacaatgtgt 1800 atcttcaagt tagcttaac aaatggagct ttctgtatat aaatgtggag attagagtta 1920 atctcccaa tcacataatt tgttttgtgt gaaaaaggaa taaattgttc catgctggtg 1980 gaaagataga gattgtttt agaggttggt tgttgtgtt taggattctg tccattttct 2040 tgtaaaggga taaacacgga cgtgtgcgaa atatgttgt aaagtgattt gccattgttg 2100 aaagcgtatt taatgataga agagatatgt taatgataga atactatcga gccaacatgt actgacatgg aaagtatgt aagtgtaaaa tgcatacga gggacactat gtgtgttaata tgcatagaac ggggacactat gtgtagaactat tgcatagaac gagagatttg gaaagatata caccaaactg 2280 taaaatggggc tttctcttcg gggagggggg gattggggga ggggccccaa aggggtttta tgggaactaa catcagtaac ctaaccccc tagggggttta tggggacctat ttttgttctg ttcggattt ttataaagtat 2400 gtagaccccg aagggttta tgggaactaa caccaacac ccttccctct gaacaaatgc 2520 ctgagtgctg gggcactttg
                                                                                                                                                                                                39740-0001PCT.txt
    ctgagtgctg gggcactttg
    <210> 332
<211> 1474
    <212> DNA
    <213> Homo sapiens
<400> 332
    <210> 333
<211> 4079
    <212> DNA
<213> Homo sapiens
 <400> 333
ggagcggcgg gcgggcggga gggctggcgg ggcgaacgtc tgggagacgt ctgaaagacc 60
aacgagactt tggagaccag agacgcgct ggggggacct gggggcttggg gcgtgcgaga 120
tttcccttgc attcgctggg agctcgcga gggatcgtc catggccggg gctcggagc 180
gcgacccttg gggggcctcc gggatttgct acctttttgg ctccctgctc gtcgaactgc 240
tcttctcacg ggctgtcgcc ttcaatctgg acgtgatggg tgccttgcg aaggagggcg 300
agccaggcag cctcttcggc ttctctgtg ccctgcaccg gcagttgcag ccccgaccc 360
agagctggct gctggtggt gcccccagg ccctggaga acctggaga cctcttcgct tgcccatgg gcctggaga gactgactgc tacagagtgg 480
gcactggagg cctcttcgct tgccaaaagg aaagcaagga gaaccagtgg ttgggagtca 540
gtgttcggag cgagctgat atgcaaaagg tggtacctg ttggagacc 540
gtgttcggag ggaccagat ctggagacg gggatatgat tggtcgctgc tttgtggagca 600
ggcagcgagt ggaccagatc ctggagacg gggatatgat tggtcgctgc tttgtgaggac 720
gcccccaagg ccatgaaca tttgggttct gccagcaggg cacagctgcc gccttctccc 780
Page 76
   <400> 333
```

Page 76

```
39740-0001PCT.txt
<210> 334
<211> 3373
<212> DNA
<213> Homo sapiens
<400> 334
```

```
39740-0001PCT.txt
 agtctgctcc accaaggggc tcttgaaccc cttattaagg ccccagatga ccccagtcac 2640 tcctctctag ggcagaagac tagaggccag ggcagcaagg gacctgctca tcatattcca 2700 acccagccac gactgccatg taaggttgtg cagggtgtg actgcacaag gacattgtat 2760 gcagggagca ctgttcacat catagataaa gctgattgt atatttatta tgacaatttc 2820 tggcagaatgt aggtaaagag gaaaaggatc cttttcctaa ttcacacaaa gactccttgt 2880 ggactggctg tgcccctgat gcagcctgtg gctggagtgg ccaaatagga gggagactgt 2940 ggtaggggca gggaggcaac actgctgtcc acatgacctc catttcccaa agtcctctgc 3000 tccagcaact gcccttccag gtgggtgtg gacacctggg agaaggtctc caagggaggg 3060 tgcagccctc ttgcccgcac ccctccctgc ttgcacact cccatcttt gatccttctg 3120 agctcacct ctggtgccct ctcctaggaa accacctcgt gggctggaa tgggggaag 3180
 agctccacct ctggtggctc ctcctaggaa accagctcgt gggctgggaa tgggggagag
                                                                                                                                                                                    3180
 aagggaaaag atccccaaga ccccctgggg tgggatctga gctcccacct cccttcccac ctactgcact ttccccttc ccgccttcca aaacctgctt ccttcagttt gtaaagtcgg tgattatatt tttgggggct ttcctttat tttttaaatg taaaatttat ttatattccg
                                                                                                                                                                                    3240
                                                                                                                                                                                     3300
                                                                                                                                                                                    3360
 tatttaaagt tgt
 <210> 335
<211> 2304
  <212> DNA
 <213> Homo sapiens
 <400> 335
 gtccccgcag cgccgtcgcg ccctcctgcc gcaggccacc gaggccgccg ccgtctagcg 60
 ccccgacctc gccaccatga gagccctgct ggcgcgcctg cttctctgcg tcctggtcgt 120 gagcgactcc aaaggcagca atgaacttca tcaagttcca tcgaactgtg actgtctaaa 180 tggaggaaca tgtgtgtcca acaagtactt ctccaacatt cactggtgca actgcccaaa 240 gaaattcgga gggcagcact gtgaaataga taagtcaaaa acctgctatg aggggaatgg 300
 tcacttttac cgaggaaagg ccagcactga caccatgggc cggccttgcc tgccctggaa 360 ctctgccact gtccttcagc aaacgtacca tgcccacaga tctgatgctc ttcagctggg 420 cctggggaaa cataattact gcaggaaccc agacaaccgg aggcgaccct ggtgctatgt 480 gcaggtgggc ctaaagccgc ttgtccaaga gtgcatggtg catgactgcg cagatggaaa 540 aaagccctcc tctcctccag aagaattaaa atttcagtgt ggccaaaaga ctctgaggcc 600
                                                                                                      Page 78
```

39740-0001PCT.txt ccgctttaag attattgggg gagaattcac caccatcgag aaccagccct ggtttgcggc 660 catctacagg aggcaccggg ggggctctgt cacctacgtg tgtggaggca gcctcatcag 720 cccttgctgg gtgatcagcg ccacacactg cttcattgat tacccaaaga aggaggacta 780 catcgtctac ctgggtcgct caaggcttaa ctccaacacg caaggggaga tgaagtttga 840 ggtggaaaac ctcatcctac acaaggacta cagcgctgac acgcttgctc accacaacga 900 atcaataaaa tgtgattttt ctga 2304 <210> 336 <211> 1876 <212> DNA <213> Homo sapiens <400> 336 cgcggccgcg gttcgctgtg gcgggcgcct gggccgccgg ctgtttaact tcgcttccgc 60 tggcccatag tgatctttgc agtgacccag cagcatcact gtttcttggc gtgtgaagat 120 aacccaagga attgatgaag ttgctgagaa gagtgtgctg gagatgctct aggaaaaaat 180 tgaatagtga gacgagttcc agcgcaaggg tttctggtt gccaagaaga aagtgaacaa 240 catggatcag aacaacagcc tgccacctta cgctcagggc ttggcctcc ctcaggggtg 300 catgactccc ggaatcccta tctttagtcc aatgatgcct tatggcactg gactgacccc 360 acagcctatt cagaacacca atagtctgtc tattttggaa gagcaacaaa ggcagcagca 420 gcaacaacaa cagcagcagc agcagcagca gcagcagcaa cagcaacaac agcagcagca 480 gcagcagcag cagcagcag agcagcagca gcagcagca gcagcagcag cagcagcag tggcagctgc 540 agccgttcag cagtaacgt cccagcaggc aacaacagga aacaccagga agcagcagca 600 agccgttcag cagtcaacgt cccagcaggc aacacaggga acctcaggcc aggcaccaca 600 gctcttccac tcacagactc tcacaactgc acccttgccg ggcaccactc cactgtatcc 660 ctccccatg actcccatga cccccatcac tcctgccacg ccagcttcgg agagttctgg 720 gattgtaccg cagctgcaaa atattgtatc cacagtgaat cttggttgta aacttgacct 780 gattgtaccg cagctgcaaa atattgtatc cacagtgaat cttggttgta aacttgacct 780 aaagaccatt gcacttcgtg cccgaaacgc cgaatataat cccaagcggt ttgctgcggt 840 aatcatgagg ataagagagc cacgaaccac ggcactgatt ttcagttctg ggaaaatggt 900 gtgcacagga gccaagagtg aagaacagtc cagactggca gcaagaaaat atgctagagt 960 tgtacagaag ttgggtttc cagctaagtt cttggacttc aagattcaga acatggtggg 1020 gagctgtgat gtgaagttc ctataaggtt agaaggcctt gtgctcaccc accaacaatt 1080 tagtagttat gagccagagt tatttcctgg tttaatctac agaatgatca aacccagaat 1140 tgttctcctt attttgttt ctggaaaagt tgtattaaca ggtgctaaag tcagagcagta 1260 atggctctca tgtacccttg cctcccccac cccttcttt ttttttttt aaacaaatca 1320 gtttgttttg gtacctttaa atggtggtgt gtttgttttg gtacctttaa atggtggtgt tgtgagaaga tggatgttga gttgcagggt 1380 gtggcaccag gtgatgccct tctgtaagtg cccaccgcgg gatgccggga aggggcatta 1440 tttgtgcact gagaacaccg cgcagcgtga ctgtgagttg ctcataccgt gctgctatct 1500 gggcagcgt gcccatttat ttatatgtag attttaaaca ctgctgttga caagttggtt 1560 aatgttttt aatgttttc cccatgaacc acagtttta tatttctacc agaaaagtaa aaatcttttt 1680 taaaagtgtt gtttttctaa tttataactc ctaggggtta tttctgtgcc agacacattc 1740 cacctctcca gtattgcagg acggaatata tgtgttaatg aaaatgaatg gctgtacata 1800 ttttttctt tcttcagagt actctgtaca ataaatgcag tttataaaag tgttaaaaaa 1860

aaaaaaaaa aaaaaa

1876

39740-0001PCT.txt

<210> 337 <211> 6633 <212> DNA <213> Homo sapiens <400> 337 ttctccccgc ccccagttg ttgtcgaagt ctgggggttg ggactggacc ccctgattgc 60 gtaagagcaa aaagcgaagg cgcaatctgg acactgggag attcggagcg cagggagttt 120 ccctggagaa gtgaaaggca aaggcatcac aatgctggaa gaaatcaaagg gagattacga 1200 atgtgctgcc cgccaggcta ccagggaggt caaagaaatg aagacagtg gagattaccga 1220 ccatgagaaa ggtttcattg aaatcaaacc caccttcagc cagttggaag ctgtcaacct 1380 gcatgaagtc aatctgactc tgattgaaaa tctcactga atcaccactg ggttcaacct 1380 gcattcaggaa ataaggtact tgattgaaaa tctcactga atcaccactg atgtggaaaa 1500 gattcaggaa ataaggtact gaagcaaatt aaagctgatc cgtgctaaagg atcaccactg atgtggaaaa 1500 gttaactcaa gttccttcat ccattctgga cttggtgat gatcaccatg atgtggaaaa 1500 gttaactcaa gttccttcat ccattctgga cttggtgat gatcaccatg gctcaactgg 1680 gggacagacg gtgaggtgca cagctgaagg cacgccgctt cctgatattg agtggatgat 1740 atgcaaagat attaagaaat gtaataatga aacttcctgg actattttgg ccaacaatgt 1800 ctcaaacatc atcacggaga tccactcccg agacaggagt accgtggagg gccgtgtgac 1860 tttcgccaaa gtggaggaga ccatcgccgt gcgatgcctg gctaagaact tccttggagc 1920 tgagaaccga gagctgatg aaattcgcg gaggtgatt acccttcgg accactccgg ttggaggac 1920 tgagaaccga gtgctgttgg tgattgtgat catctcactt attgtcctgg tggtggtcg 1980 gaaacagaaa ccgaggtatg aaattcgcg gaggtcatt attatgtgg acccgatgca gctgcttat gaaccaatca gggagtttcc 2160 aagagatgga ctagtgctg gtgaaaaaca agccgatca gctgaacaaca acctgaataa accacacg gccagatca gtgaaaaaca agccgatcaa gccgatcca gctgaacaca aaggagatga 2220 aggaacagcc tatggattaa gccggtccca accttcactg tctgaactca agaataatga 2240

Page 80

39740-0001PCT.txt

```
gtaactggcg gattcgaggg gttccttcca cttctgggc cacctctgga tcccgttcag 3720 aaaaccactt tattgcaatg cggaggttga gaggaggact tggttgatgt ttaaagagaa 3780 gttcccagcc aagggcctcg gggagcgttc taaatatgaa tgaatgggat attttgaaat 3840 gaactttgtc agtgttgcct ctcgcaatgc ctcagtagca tctcagtggt gtgtgaagtt 3900 tggagataga tggataaggg aataataggc cacaaaggt gaactttgtg cttcaaggac 3960 attggtgaga gtccaacaga cacaatttat actgcgacag aacttcagca ttgtaattat 4020 gtaaataact ctaaccaagg ctgtgttag attgtattaa ctatcttctt tggacttctg 4080 aagagaccac tcaatccatc catgtacttc cctcttgaaa cctgatgtca gctgctgttg 4140 aacttttaa agaagtgcat gaaaaaccat ttttgaacct taaaaggtac tggtactata 4200 gcattttgct atcttttta gtgttaagag ataaagaata ataattaacc aaccttgttt 4260 aatagatttg ggtcatttag aagcctgaca actcattttc ataattgtaat ctatgttat 4320
   aatagatttg ggtcatttag aagcctgaca actcattttc atattgtaat ctatgttat 4320 aatactacta ctgttatcag taatgctaaa tgtgtaataa tgtaacatga tttccctcca 4380 gagaaagcac aatttaaaac aatccttact aagtaggtga tgagtttgac agtttttgac 4440 atttatatta aataacatgt ttctctataa agtatggtaa tagctttagt gaatttaaatt 4500
actgccttcg tttatatttt tttaactgtg ataatcccca caggcacatt aactgttgca 6420 cttttgaatg tccaaaattt atattttaga aataataaaa agaaagatac ttacatgttc 6480 ccaaaacaat ggtgtggtga atgtgtgaga aaaactaact tgatagggtc taccaataca 6540 aaatgtatta cgaatgcccc tgttcatgtt tttgttttaa aacgtgtaaa tgaagatctt 6600
   tatatttcaa taaatgatat ataatttaaa gtt
```

```
<211> 994
<212> DNA
 <213> Homo sapiens
<400> 338
tgctggccag cacctcgagg gaagatggcg gacgaggaga agctgccgcc cggctgggag 60 aagcgcatga gccgcagctc aggccgagtg tactacttca accacatcac taacgccagc 120 cagtgggagc ggcccagcgg caacagcagc agtggtggca aaaacgggca gggggagcct 180 gccagggcagg agaagatcac cctgctggtg aagcacagcc agtcacggcg gccctcgtcc 240 tggcggcagg agaagatcac ccggaccaag gaggaggcc tggagctgat caacggctac 300 atccagaaga tcaagtcgag agaggaggac tttgagtctc tggcctcaca gttcagcgac 360
Page 81
```

<210> 338

```
39740-0001PCT.txt
cggggcaggg cagggcgct aggccggcca gctcccctt gcccgccagc cagtggccga 600 acccccact ccctgccacc gtcacacgt atttattgtt cccacaatgg ctgggaggg 660 gcccttccag attggggcc ctggggtcc cactcctgt ccatcccag ttggggctg 720 gaccgccaga ttctccctta aggaattgac ttcagcaggg gtgggaggct cccagaccca 780 gggcagtgtg gtgggaggg tgttccaaag agaaggcctg gtcagcagag ccgccccgtg 840 tcccccagg tgctggaggc agactcgagg gccgaattgt ttctagttag gccacgctcc 900 tctgttcagt cgcaaaggtg aacactcatg cggcagcat gggccctctg agcaactgtg 960 cagacccttt caccccaat taaacccaga acca
 <210> 339
<211> 772
<212> DNA
 <213> Homo sapiens
 <400> 339
 agctcgtgcc gaattcggca cgagccgggt cggagccatg gcggtggcaa attcaagtcc 60 tgttaacccc gtggtgttct ttgatgtcag tattggcggt caggaagttg gccgcatgaa 120 gatcgagctc tttgcagacg ttgtgcctaa gacggccgag aactttaggc agttctgcac 180
gatcgagctc tttgcagacg ttgtgcctaa gacggccgag aactttaggc agttctgcac 180 cggagaattc aggaaagatg gggttccaat aggatacaaa ggaagcacct tccacagggt 240 cataaaggat ttcatgattc agggtggaga ttttgttaat ggagatggta ctggagtcgc 300 cagtatttac cgggggccat ttgcagatga aaattttaaa cttagacact cagctccagg 360 cctgctttcc atggcgaaca gtggtccaag tacaaatggc tgtcagttct ttatcacctg 420 ctctaagtgc gattggctgg atgggaagca tgtgggtgtt ggaaaaatca tcgatggact 480 tctagtgatg agaaagattg agaatgttcc cacaggcccc aacaataagc ccaagctacc 540 tgtggtgatc tcgcagtgg gggagatgta gtccagacaa agactgaatc aggccttccc 600 ttcttcttgg tggtgttctt gagtaagata atctggactg gccccgtct ttgcttccct 660 gcctgctgct gccccatttg atcaagagac catggaagtg tcagagattc agaatccaag 720 attgtcttta agttttcaac tgtaaataaa gttttttgt atgcgtaaaa aa 772
 <211> 919
 <212> DNA
 <213> Homo sapiens
 <400> 340
cgctcgcctc cctcgctcca cgcgcgccg gacgcggcgg ccaggcttgc gcgtggttcc 60 cctcccggtg ggcggattcc tgggcaagat gaagtgggtg tgggcgctct tgctgttggc 120 ggcgtgggca gcggccgagc gcgactgccg agtgagcagc ttccgagtca aggagaactt 180 cgacaaggct cgcttctctg ggacctggta cgccatggcc aagaaggacc ccgagggcct 240 cttctgcag gacaacatcg tcgcggagt ctcggtgac gagaccggcc agatgagcgc 300 cacagccaag ggccgagtcc gtctttgaa taactgggac gtgtgcgcag acatggtgg 360 caccttcaca gacaccaga accctgcaa gttcaagatg aagtactggg gcgtagcctc 420
caccttcaca gacaccgagg accctgccaa gttcaagatg aagtactggg gcgtagcctc 420 ctttctgcag aaaggaaatg atgaccactg gatcgtcgac acagactacg acacgtatgc 480 cgtacagtac tcctgccgc tcctgaacct cgatggcacc tgtgctgaca gctactcctt 540 cgtgttttcc cgggacccca acggcctgcc cccagaagcg cagaagattg taaggcagcg 600
gcaggaggag ctgtgcctgg ccaggcagta caggctgatc gtccacaacg gttactgcga 660 tggcagatca gaaagaaacc ttttgtagca atatcaagaa tctagtttca tctgagaact 720 tctgattagc tctcagtctt cagctctatt tatcttagga gttaatttg cccttctct 780 cccatcttcc ctcagttcc ataaaacctt cattacacat aaagatacac gtgggggtca 840
 gtgaatctgc ttgcctttcc tgaaagtttc tggggcttaa gattccagac tctgattcat 900
 taaactatag tcacccgtg
                                                                                                                                                                                                                                                         919
 <210> 341
 <211> 7365
 <212> DNA
 <213> Homo sapiens
 <400> 341
Page 82
```

39740-0001PCT.txt

aaccaaaagg agcctacaag aaagtacgag atttagtcaa cttgttgaag agctattgaa 660 aatcatttgt gcttttcagc ttgacacagg tttggagtat gcaaacagct ataattttgc 720 aaaaaaaggaa aataactctc ctgaacatct aaaagatgaa gtttctatca tccaaagtat 780 gggctacaga aaccgtgcca aaagacttct acagagtgaa cccgaaaatc cttccttgca 840 ggaaaccagt ctcagtgtcc aactctctaa ccttggaact gtgagaactc tgaggacaaa 900 gcagcggata caacctcaaa agacgtctgt ctacattgaa ttgggatctg attcttctga 960 agataccgtt aataaggcaa cttattgcag tgtgggagat caagaattgt tacaaatcac 1020 ccctcaagga accagggatg aaatcagttt ggattctgca aaaaaggctg cttgtgaatt 1080 ttctgagacg gatgtaacaa atactgaaca tcatcaaccc agtaataatg atttgaacac 1140 cactgagaag cgtgcagctg agaggcatcc agaaaagtat cagggtagtt ctgtttcaaa 1200 cactgagaag cgtgcagctg agaggcatcc agaaaagtat cagggtagtt ctgtttcaaa 1200 cttgcatgtg gagccatgtg gcacaaatac tcatgccagc tcattacagc atgagaacag 1260 cagtttatta ctcactaaag acagaatgaa tgtagaaaag gctgaattct gtaataaaag 1320 caaacagcct ggcttagcaa ggagccaaca taacagatgg gctggaagta aggaaacatg 1380 taatgatagg cggactccca gcacagaaaa aaaggtagat ctgaatgctg atcccctgtg 1440 tgagagaaaaa gaatggaata agcagaaact gccatgctca gagaatccta gagatactga 1500 agatgttcct tggataacac taaatagcag cattcagaaa gttaatgagt ggttttccag 1560 aagtagctgaa ctgttaggtt ctgatgactc acatgatgag gagtctgaat caaatgccaa 1620 agtagctgat gtattggacg ttctaaatga ggtagatgaa tattctggtt cttcagagaa 1680 aatagactta ctggccagtg atcctcatga ggctttaata tgtaaaagtg aaagagttca 1740 atttgttaaa actaaatgta agaaaaatct gctagaggaa aactttgagg aacattcaat gtcacctgaa agagaaatgg gaaatgagaa cattccaagt acagtgagca caattagccg taataacatt agagaaaatg tttttaaaga agccagctca agcaatatta atgaagtagg 3420 taataacatt agagaaaatg tttttaaaga agccagctca agcaatatta atgaagtagg 3540 ttccagtact aatgaagtgg gctccagtat taatgaaata ggttccagtg atgaaaacat 3600 tcaagcagaa ctaggtagaa acaagagggc aaaattgaat gctatgctta gattaggggt 3660 tttgcaacct gaggtctata aacaaagtct tcctggaagt aattgtaagc atcctgaaat 3720 aaaaaagcaa gaatatgaag aagtagttca gactgttaat acagatttct ctccatatct 3780 gatttcagat gacctgttag atgatggtga aataaaggaa gatactagtt ttgctgaaaa 3900 tgacattaag gaaagttctg ctgttttag caaaagcgtc cagaaaggag agcttagcag 3960 gagtcctagc cctttcaccc ataacaattt ggctcagggt taccgaagag gggccaagaa 4020 ataagatct tcagaagtaa acaatatacc ttctcagtct actaggcata gcaccgttgc 4140 taccgaggtgt aaccaggaa accaggaga ggcatctaga accagaggag gaatttatta tcattgaaga acaccaggta tattggaga gaacatcacc ttagtgaga 4260 aacaaaatgt tctgctagct tgttttctc acagtgcagt gaacatcacc ttagtgaga 4260 aacaaaacaa accaggatc ctttcttgat tggttcttcc aaaacaatga ggcatcagtc 4380 tgaaagccag ggagttggtc tgagtgacaa gggaattggtt tcagatgat aagaaaagag 4440 3540 tgaaagccag ggagttggtc tgagtgacaa ggaattggtt tcagatgatg aagaaagagg 4440 aacgggcttg gaagaaaata atcaagaaga gcaaagcatg gattcaaact taggtgaagc 4500 agcatctggg tgtgagagtg aaacaagcgt ctctgaagac tgctcagggc tatcctctca 4560 gagtgacatt ttaaccactc agcagaggga taccatgcaa cataacctga taaagctcca 4620 gcaggaaatg gctgaactag aagctgtgtt agaacagcat gggagccagc cttctaacag 4680 Page 83

```
39740-0001PCT.txt
  ctacccttcc atcataagtg actcttctgc ccttgaggac ctgcgaaatc cagaacaaag 4740
 cacatcagaa aaagcagtat taacttcaca gaaaagtagt gaatacccta taagccagaa 4800 tccagaaggc ctttctgctg acaagtttga ggtgtctgca gatagttcta ccagtaaaaa 4860 taaagaacca ggagtggaaa ggtcatcccc ttctaaatgc ccatcattag atgataggtg 4920 gtacatgcac agttgctctg ggagtcttca gaatagaaac tacccatctc aagaggagct 4980
 cattaaggtt gttgatgtgg aggagcaaca gctggaagag tctgggccac acgatttgac 5040 ggaaacatct tacttgccaa ggcaagatct agagggaacc ccttacctgg aatctggaat 5100 cagcctcttc tctgatgacc ctgaatctga tccttctgaa gacagagccc cagagtcagc 5160 tcgtgttggc aacataccat cttcaacctc tgcattgaaa gttccccaat tgaaagttgc 5220 agaatctgcc cagagtccag ctgctgctca tactactgat actgctgggt ataatgcaat 5280
 ggaagaaagt gtgagcaggg agaagccaga attgacagct tcaacagaaa gggtcaacaa aagaatgtcc atggtggtgt ctggcctgac cccagaagaa tttatgctcg tgtacaagtt tgccagaaaa caccacatca ctttaactaa tctaattact gaagagacta ctcatgttgt tatgaaaaca gatgctgagt ttgtgtgtga acggacactg aaatatttc taggaattgc
                                                                                                                                                                                                                                                                                                                       5400
 gggaggaaaa tgggtagtta gctatttctg ggtgacccag tctattaaag aaagaaaaat gctgaatgag catgattttg aagtcagagg agatgtggtc aatggaagaa accaccaagg tccaaagcga gcaagagaat cccaggacag aaagatcttc agggggctag aaatctgttg ctatgggccc ttcaccaaca tgcccacaga tcaactggaa tggatggtac agctgtgtgg
                                                                                                                                                                                                                                                                                                                       5640
                                                                                                                                                                                                                                                                                                                       5760
tgcttctgtg gtgaaggagc tttcatcatt cacccttggc acaggtgtcc acccaattgt 5820 ggttgtgcag ccagatgcct ggacagagga caatggcttc catgcaattg ggcagatgtg 5880 tgaggcacct gtggtgaccc gagagtgggt gttggacagt gtagcactct accagtgcca 5940 ggagctggac acctacctga taccccagat ccccacagc cactactgac tgcagccagc 6000 cacaggtaca gagccacagg accccaagaa tgagcttaca aagtggcctt tccaggccct 6060 gggagctcct ctcactcttc agtccttcta ctgtcctggc tactaaatat tttatgtaca 6120 tcagcctgaa aaggacttct ggctatgcaa gggtccctta aagattttct gcttgaagtc 6180 tcccttggaa aacccatta aacgccacca attgagcaaga tatggtgatt tttcacctga gaagatttta 6240 attctattca ggctgttgtt ggcttagggc tggaagcaca gagtggcttg gcctcaagag 6360 aatagctggt ttccctaagt ttacttctct aaaaccctgt gttcacaaag gcagagagtc 6420 agacccttca atggaaggag agtgcttggg atcgattatg tgacttaaag tcagaatagt 6480 ccttgggcag ttctcaaatg ttggagtgga acattgggga ggaaattctg aggcaggtat 6540 tagaaatgaa aaggaaactt gaaacctggg catggtggct cacgcctgta atcccagcac 6600 tttgggaggc caaggtggcc agatcactgg aggtcaggag ttcgaaacca gagtcgccaa 6600 tttgggaggc caaggtggcc agatcactgg aggtcaggag ttcgaaacca 6600
  tgcttctgtg gtgaaggagc tttcatcatt cacccttggc acaggtgtcc acccaattgt
 tttgggaggc caaggtgggc agatcactgg aggtcaggag ttcgaaacca gcctggccaa 6660 catggtgaaa ccccatctct actaaaaata cagaaattag ccggtcatgg tggtggacac 6720 ctgtaatccc agctactcag gtggctaagg caggagaatc acttcagccc gggaggtgga 6780 ggttgcagtg agccaagatc ataccacggc actccagcct gggtgacagt gagactgtgg 6840
ctcaaaaaa aaaaaaaa aggaaaatga aactaggaa ggtttcttaa agtctgagat 6900 atatttgcta gatttctaaa gaatgtgttc taaaacagca gaagattttc aagaaccggt 6960 ttccaaagac agtcttctaa ttcctcatta gtaataagta aaatgtttat tgttgtagct 7020 ctggtatata atccattcct cttaaaatat aagacctctg gcatgaatat ttcatatcta 7080 taaaatgaca gatcccacca ggaaggaagc tgttgcttc tttgaggtga ttttttcct 7140 ttgctccctg ttgctgaaac catacagctt cataaataat tttgcttgct gaaggaagaa 7200 aaagtgtttt tcataaaccc attatccagg actgtttata gctgttgaa ggactaggtc 7260 ttccctagcc cccccagtgt gcaagggcag tgaagacttg attgtacaaa atacgttttg 7320 raaatgttgt gctgttaaca ctgcaaataa acttggtagc aaaca 7365
 <210> 342
  <211> 10386
 <212> DNA
  <213> Homo sapiens
 <220>
  <221> unsure
```

```
<222> (0)...(0)
<223> n = a, t, c or g

<400> 342
attgaggact cggaaatgag gtccaagggt agccaaggat ggctgcagct tcatatgatc 60
agttgttaaa gcaagttgag gcactgaaga tggagaactc aaatcttcga caagagctag 120
aagataattc caatcatctt acaaaactgg aaactgaggc atctaatatg aaggaagtac 180
ttaaacaact acaaggaagt attgaagatg aagctatggc ttcttctgga cagattgatt 240
tattagagcg tcttaaagag cttaacttag atagcagtaa tttccctgga gtaaaactgc 300
ggtcaaaaat gtccctccgt tcttatggaa gccgggaagg atctgtatca agccgttctg 360
gagagtgcag tcctgttcct atgggttcat ttccaagaag agggtttgta aatggaagca 420
gagaaagtac tggatatta gaagaacttg agaaagagag gtcattgctt cttgctgatc 480
ttgacaaaga agaaaaggaa aaagactggt attacgctca acttcagaat ctcactaaaa 540
Page 84
```

39740-0001PCT.txt

gaatagatag tetteettta aetgaaaatt ttteettaca aacagatatg aecagaagge 600 aattggaata tgaagcaagg caaatcagag ttgcgatgga agaacaacta ggtacctgcc 660 aggatatgga aaaacgagca cagcgaagaa tagccagaat tcagcaaatc gaaaaggaca 720 caatatgttt ttcaagatgt agttcattat catctttgtc atcagctgaa gatgaaatag 3900 gatgtaatca gacgacacag gaagcagatt ctgctaatac cctgcaaata gatgaaatag 3900 gatgtaatca gacgacacag gaagcagatt ctgctaatac cctgcaaata gcagaaataa 3960 aagaaaagat tggaactagg tcagctgaag atcctgtgag cgaagttcca gcagtgtcac 4020 agcaccctag aaccaaatcc agcagactgc agggttctag tttatcttca gaatcagcca 4080 ggcacaaagc tgttgaattt tcttcaggag cgaaatctcc ctccaaaagt ggtgctcaga 4140 cacccaaaag tccacctgaa cactatgttc aggagacccc actcatgttt agcagatgta 4200 cttctgtcag ttcacttgat agttttgaga gtcgttcgat tgccagctcc gttcagagtg 4260 aaccatgcag tggaatggta agtggcatta taagccccag tgatcttcca gatagccctg 4320 gacaaaccat gccaccaagc agaagtaaaa cctccacc acctcctcaa acagctcaaa 4380 ccaagcgaga agtacctaaa aataaagcac ctactgctga aagaggaga agtggaccta 4440 ccaagcgaga agtacctaaa aataaagcac ctactgctga aaagagagag agtggaccta 4440 agcaagctgc agtaaatgct gcagttcaga gggtccaggt tcttccagat gctgatactt 4500 tattacattt tgccacggaa agtactccag atggattttc ttgttcatcc agcctgagtg 4560 ctctgagcct cgatgagcca tttatacaga aagatgtgga attaagaata atgcctccag 4620 Page 85

39740-0001PCT.txt

ttcaggaaaa tgacaatggg aatgaaacag aatcagagca gcctaaagaa tcaaatgaaa 4680 taaccattcc tacagaaggc agaagtacag atgaggctca aggaggaaaa acctcatctg 5160 taaccatacc tgaattggat gacaataaag cagaggaagg tgatattctt gcagaatgca 5220 ttaattctgc tatgcccaaa gggaaaagtc acaagccttt ccgtgtgaaa aagataatgg 5280 accaggtcca gcaagcatct gcgtcgtctt ctgcacccaa caaaaatcag ttagatggta 5340 agaaaaagaa accaacttca ccagtaaaac ctataccaca aaatactgaa tataggacac 5400 gtgtaaagaaa aaatgcagac tcaaaaaata atttaaatgc tgagagagtt ttctcagaca 5460 acaaagattc aaagaaacag aatttgaaaa ataattccaa ggacttcaat gataagctcc 5520 caaataatga agatagagtc agaggaagtt ttgcttttga ttcacctcat cattacacgc 5580 ctattgaagg aactccttac tgtttttcac gaaatgattc tttgagttct ctagattttg 5640 atgatgatga tgttgacctt tccagggaaa aggctgaatt aagaaaggca aaagaaaata 5700 aggaatcaga ggctaaagtt accagccaca cagaactaac ctccaaccaa caatcagcta 5760 aggaatcaga ggctaaagtt accagccaca cagaactaac ctccaaccaa caatcagcta 5760 adatigat teataticea ggagitegaa atageteete aagtacaagi eetgitteta 6780 aaaaaggee acceettaag actecageet eeaaaagee tagtgaaggi eaaacageea 6840 ceettetee tagaggagee aageeatetg tgaaateaga attaageet gttgeeagge 6900 agacateea aataggtggg teaagtaaag eacettetag ateaggatet agagattega 6960 eeeetteeag acctgeeag eaaceattaa gtagacetat acagteteet ggeegaaaet 7020 eaattateee tggtagaaat ggaataagte etcetaacaa attateteaa etteeaagga 7080 eeeegagage eaacagaace teaacaaaca aacaggtta teeaagaatg 7200 eeagtagtat teeaagaagt gaateteeta gaatgteete aaateagatg aataatggta 7260 atggageeaa taaaaaggta gaactteeta gaatgteete aactaaatea agtggaagtg 7320 aatetgatag ateagaaga eeegagagee aactteeta aacgeeagee 7380 aatctgatag atcagaaaga cctgtattag tacgccagtc aactttcatc aaagaagctc 7380 caagcccaac cttaagaaga aaattggagg aatctgcttc atttgaatct ctttctccat 7440 catctagacc agcttctccc actaggtccc aggcacaaac tccagtttta agtccttccc 7500 ttcctgatat gtctctatcc acacattcgt ctgttcaggc tggtggatgg cgaaaactcc 7500 ttcctgatat gtctctatcc acacattcgt ctgttcaggc tggtggatgg cgaaaactcc 7560 cacctaatct cagtcccact atagagtata atgatggaag accagcaaag cgccatgata 7620 ttgcacggtc tcattctgaa agtccttcta gacttccaat caataggtca ggaacctgga 7680 aacgtgagca cagcaaacat tcatcatccc ttcctcgagt aagcacttgg agaagaactg 7740 gaagttcatc ttcaattctt tctgcttcat cagaatccag tgaaaaagca aaaagtgagg 7800 atgaaaaaca atggagaaa attacaggaa ccaaacaaag taaagaaaac caagtatccg 7860 caaaaggaac atggagaaaa ataaaagaaa atgaatttc tcccacaaat agtacttctc 7920 cagccgttc ctcaggtgct acaaatggtg ctgaatcaaa gactctaatt tatcaaatgg 7980 cacctgctgt ttctaaaaca gaggatgtt ggggagaat tgaggactgt cccattaaca 8040 atcctagatc tggaagatct cccacaggta atactcccc ggtgattgac agtgtttcag 8100 aaaaggcaaa tccaacatt aaagattcaa aagataatca ggcaaaacaa aatgtaggta 8160 atcctagatc tggaagatct cccacaggta atactcccc ggtgattgac agtgtttcag 8100 aaaaggcaaa tccaaacatt aaagattcaa aagataatca ggcaaaacaa aatgtgggta 8160 atggcagtgt tcccatgcgt accgtgggtt tggaaaatcg cctgaactcc tttattcagg 8220 tggatgccc tgaccaaaaa ggaactgaga taaaaccagg acaaaataat cctgtccctg 8280 tatcagagac taatgaaagt tctatagtgg aacgtaccc attcagttct agcagctcaa 8340 gcaaacacag ttcacctagt gggactgttg ctgccagagt gactccttt aattacaacc 8400 caagccctag gaaaagcagc gcagatagca cttcagctcg gccatctcag atcccaactc 8460 cagtgaataa caacacaaag agcggaatt ccaaaactga cagcacagaa tccagtggaa 8520 caatgaaact taaggccat tctgggtctt accttgtgac atctgtttaa aaggaggaa 8580 gaatgaaact aagaaaattc tatgttaatt acaactgcta tatagacatt ttgtttcaaa 8640 tgaaacttta aaagactgaa aaattttgta aataggtttg attcttgtta gagggttttt 8700 tgaaacttta aaagactgaa aaattttgta aataggtttg attcitgtta gagggttttt 8700

<210> 343 <211> 2191 <212> DNA <213> Homo sapiens

Page 87

```
39740-0001PCT.txt
 tcatgactga acagtcaccg acgagagtgc tgggggaataa aaagggggatc ttcactcggc 1860 agagacaacc aaaaagtgca gcgttccttt tgcgagagag atactggaag attgccaatg 1920 aaaccaggta tccccacca gtagccaagt cacaatgttt ggaaaacagc ccgtttactt 1980 gagcaagact gataccacct gcgtgtccct tcctcccga gtcagggcga cttccacagc 2040 agcagaacaa gtgcctcctg gactgttcac ggcagaccag aacgtttctg gcctgggttt 2100 aaataaagag ttggcataa aggcgctact g
  aaataaagag ttggcatgaa agtcgctact g
  <210> 344
<211> 2776
  <212> DNA
  <213> Homo sapiens
  <400> 344
 cagggcagac tggtagcaaa gccccacgc ccagccagga gcaccgccgc ggactccagc 60 acaccgaggg acatgctggg cctgcccc ccactgctcg ccctggtggg gctgctctcc 120 ctcgggtgcg tcctctcta ggagtgcacg aagttcaagg tcagcagctg ccgggaatgc 180 atcgagtcgg ggcccggctg cacctggtgc cagaagctga acttcacagg gccgggggat 240
cctgactcca ticgcigcga cacccggcca cagctgctca tgaggggcig igcggcigac 300
gccacagagt gcatccagga gcagtcgttt gtcatccggg cgctgggctt cacggacata 1380 gtgaccgtgc aggttcttcc ccagtgtgag tgccggtgcc gggaccagag cagagaccgc 1440 agcctctgcc atggcaaggg cttcttggag tgcggcatct gcaggtgtga cactggctac 1500 attgggaaaa actgtgagtg ccagacacag ggccggagca gccaggagct ggaaggaagc 1560 tgccggaagg acaacaactc catcatctgc tcagggctgg gggactgtgt ctgcgggcag 1620 tgcctgtgcc acaccagga cgtcccggc aagctgatat acgggcagta ctgcgggtgt 1680 gacaccatca actgtgagcg ctacaacggc caggtctggg gcggcccggg gagggggctc 1740 tgcttctgcg ggaagtgccg ctacaacggc cggcttgagg gctcagcgtg gagggggctc 1860 aggaccacct aagggctgcct gaacccgcgg cgtgttgagt gtagtggtcg tggccggtg 1800 aggacccctg agggctgcc cacccgg cagttcagctg ctctgtgccaccg ggcttgcccc caccctgtgg caagtacatc tcctgcgccg agtgcctgaa gtcgaaaag 1980 ggcccctttg ggaagaactg cagcaggcg tgtccggcc tgcagctgtc gaacaacccc 2040 gtgaagggca ggacctgcaa ggaggggac ccgctacccc atctatgtg atgagagccg agagtgtgtg 2160 gagcagcagg acgggatgga ccgctacccc atctatgtgg atgagagccg agagtgtgtg 2160
  gccacagagt gcatccagga gcagtcgttt gtcatccggg cgctgggctt cacggacata 1380
gagcagcagg acgggatgga ccgctacctc atctatgtgg atgagagccg agagtgtgtg 2160 gcaggcccca acatcgccgc catcgtcggg ggcaccgtgg caggcatcgt gctgatcggc 2220 attctctgc tggtcatctg gaaggctctg atccacctga gcgacctccg ggagtacagg 2280 cgctttgga aggagaagct caagtcccag tggaacaatg ataatcccct tttcaagagc 2340 gccaccacga cggtcatgaa ccccaagttt gctgagagtt aggagcactt ggtgaagaca 2460
aggccgtcag gacccaccat gtctgcccca tcacgcggcc gagacatggc ttggccacag ctcttgagga tgtcaccaat taaccagaaa tccagttatt ttccgccctc aaaatgacag ccatggccgg ccggtgcttc tggggggctcg tcggggggac agctccactc tgactggcac agtctttgca tggagacttg aggagggctt gaggttggtg aggttaggtg cgtgttcct
                                                                                                                                                                                                                                    2460
                                                                                                                                                                                                                                     2520
                                                                                                                                                                                                                                     2580
gtgcaagtca ggacatcagt ctgattaaag gtggtgccaa tttatttaca tttaaacttg 2700 tcagggtata aaatgacatc ccattaatta tattgttaat caatcacgtg tatagaaaaa 2760 aaaataaaac ttcaat
 <210> 345
 <211> 3160
  <212> DNA
 <213> Homo sapiens
 <400> 345
```

```
39740-0001PCT.txt
  ggcggcggcg gcacatccag ggacccgggc cggttttaaa cctcccgtcc gccgccgccg 720 cacccccgt ggccgggct ccggaggccg ccggcggagg cagccgttcg gaggattatt 780 cgtcttctc ccattccgct gccgccgctg ccaggcctct ggctgctgag gagaagcagg 840 cccagtcgct gcaaccatcc agcagccgcc gcagcagcca ttacccggct gcggtccaga 900
 gccaagcggc ggcagagcga ggggcatcag ctaccgccaa gtccagagcc atttccatcc 960 tgcagaagaa gccccgccac cagcagcttc tgccatctct ctcctcttt ttcttcagcc 1020 acaggctccc agacatgaca gccatcatca aagagatcgt tagcagaaac aaaaggagat 1080 atcaagagga tggattcgac ttagacttga cctatattta tccaaacatt attgctatgg 1140
 gatttcctgc agaaagactt gaaggcgtat acaggaacaa tattgatgat gtagtaaggt 1200
gatttcctgc agaaagactt gaaggcgtat acaggaacaa tattgatgat gtagtaaggt 1200 ttttggattc aaagcataaa aaccattaca agatatacaa tctttgtgct gaaagacatt 1260 atgacaccgc caaatttaat tgcagagttg cacaatatcc ttttgaagac cataacccac 1320 cacagctaga acttatcaaa cccttttgtg aagatcttga ccaatggcta agtgaagatg 1380 acaatcatgt tgcagcaatt cactgtaaag ctggaaaggg acgaactggt gtaatgatat 1440 gtgcatattt attacatcgg ggcaaatttt taaaggcaca agaggcccta gatttctatg 1500 gggaagtaag gaccagagac aaaaagggag taactattcc cagtcagagg cgctatgtgt 1560 acaagatgat gtttgaaact attccaatgt tcagtggcgg aacttgcaat cctcagttt 1620 acaagatgat gtttgaaact attccaatgt tcagtggcgg aacttgcaat cctcagtttg 1680 tggtctgcca gctaaaggtg acgatatatt cctccaattc aggacccaca cgacgggaag 1740 acaagttcat gtactttgag ttccctcagc cgttacctgt qtqtqqtaat atcaaaqtag 1800
acaagttcat gtactttgag ttccctcagc cgttacctgt gtgtggtgat atcaaagtag 1800 agttcttcca caaacagaac aagatgctaa aaaaggacaa aatgtttcac ttttgggtaa 1860 atacattctt cataccagga ccagaggaaa cctcagaaaa agtagaaaat ggaagtctat 1920 gtgatcaaaa aatgataga aattgaataga aattgaataga agtagaaaat 2000
<210> 346
 <211> 2629
 <212> DNA
 <213> Homo sapiens
 <400> 346
acttgtcatg gcgactgtcc agctttgtgc caggagcctc gcaggggttg atgggattgg 60 ggttttcccc tcccatgtgc tcaagactgg cgctaaaagt tttgagcttc tcaaaagtct 120 agagccaccg tccagggagc aggtagctgc tgggctccgg ggacactttg cgttcgggct 180 gggagcggc tttccacgac ggtgacacgc ttccctggat tggcagccag actgccttcc 240
gggtcactgc catggaggag ccgcagtcag atcctagcgt cgagcccct ctgagtcagg 300 aaacattttc agacctatgg aaactacttc ctgaaaacaa cgttctgtcc cccttgccgt 360 cccaagcaat ggatgatttg atgctgtcc cggacgatat tgaacaatgg ttcactgaag 420 acccaggtcc agatgaagct cccagaatgc cagaggctgc tccccgcgtg gcccctgcac 480
                                                                                                      Page 89
```

```
39740-0001PCT.txt
     agcagctcc tacaccggcg gcccctgcac cagccccctc ctggcccctg tcatcttctg 540 tcccttcca gaaaacctac cagggcagct acggtttccg tctgggcttc ttgcattctg 600 ggacagccaa gtctgtgact tgcacgtact cccctgccct caacaagatg ttttgccaac 660 tggccaagac ctgccctgtg cagctgtggg ttgattccac acccccgcc ggcacccgcg 720 tccgcgccat ggccatctac aagcagtcac agcacatgac ggaggttgtg aggcgctgcc 780 cccaccatga gcgctgctca gatagcgatg gtctggccc tcctcagcat cttatccgag 840 tggaaggaaa tttgcgtgtg gagtatttgg atgacagaaa cacttttcga catagtgtgg 900 tggtgcccta tgagccgcct gaggttggct ctgaccgtac caccatcac tacaactaca 960 tggtaacag ttcctgcatg ggcggcatga accggaggc catcctcacc atcatcaca 1020 tggaagactc cagtggtaat ctactgggac ggaacagctt tgaggtgcgt gtttgtgcct 1080 gtcctgggag agaccgccc acagaggaag agaactcccc 1140
   gtcctgggag agaccggcgc acagaggaag agaatctccg caagaaaggg gagcctcacc 1140 acgagctgcc cccagggagc actaagcgag cactgccaa caacaccagc tcctctcccc 1200 agccaaagaa gaaaccactg gatggagaat atttcaccct tcagatccgt gggcgtgagc 1260 gcttcgagat gttccgagag ctgaatgagg ccttggaact caaggatgcc caggctggga 1320 aggagccagg ggggagcagg gctcactcca gccacctgaa gtccaaaaag ggtcagtcta 1380 cctcccgca taaaaaactc atgttcaaga cagaagggcc tgactcagac tgacattctc 1440 cactcttgt tcccactga cagcctcca caccccatct tccctcccct gccattttgg 1500 atttgggtc tttgaaccct tgcttgaaca aggtggcgt cagaagcacc caggacttcc 1560 atttgctttg tcccggggt ccactgaaca aggtggcgt cactggtgt ttgttggggt 1620
   gttttgggtc tttgaaccct tgcttgcaat aggtgtgcgt cagaagcacc caggacttcc 1560 atttgctttg tcccggggct ccactgaaca agttggcctg cactggtgtt ttgttgtggg 1620 gaggaggatg gggagtagga cataccagct tagattttaa ggtttttact gtgagggatg 1680 tttgggagat gtaagaaatg ttcttgcagt taagggttag tttacaatca gccacattct 1740 aggtaggtag gggcccactt caccgtacta accagggaag ctgtccctca tgttgaattt 1800 tctctaactt caaggcccat atctgtgaaa tgctggcatt tgcacctacc tcacagagtg 1860 cattgtgagg gttaatgaaa taatgtacat ctggccttga aaccaccttt tattacatgg 1920 ggtctaaaac ttgaccccct tgaggggtgcc tgttccctct ccctctccct gttggctggt 1980 gggttggtag tttctacagt tgggcagctg gttaggtaga gggagttgtc aagtcttgct 2040 ggcccagcca aaccctgtct gacaacctct tggtcgacct tagtacctaa aaggaaatct 2100 caccccatcc cacaccctgg aggattcat ctcttgtaata tgatgatctg gatccacca 2160
   cacccatcc cacacctgg aggattcat ctcttgtata tgatgatctg gatcaccaa 2160 gattgttt atgctcaggg tcaatttctt ttttcttttt ttttttttt tttcttttt 2220 tttgagactg ggtctcgctt tgttgccag gctggagtgg agtggcgtga tcttggctta 2280 ctgcagcctt tgcctcccg gctcgagcag tcctgcctca gcctccggag tagctgggac 2340 cacaggttca tgccaccatg gccagccaac ttttgcatgt tttgtagaga tgggggtctca 2400 cagtgttgcc caggctggtc tcaaactcct gggctcaggc gatccacctg tctcagcctc 2460 ccagagtgct gggattacaa ttgtgagcca ccacgtggag ctggaagggt caacatcttt 2520 tacattctgc aagcacatct gcattttcac cccacccttc ccctcttct ccctttttat 2580 atcccatttt tatatcgatc tcttatttta caataaaact ttgctgcca 2629
     <210> 347
<211> 3442
     <212> DNA
      <213> Homo sapiens
     <400> 347
  <400> 347
agccggtgcg ccgcagacta gggcgcctcg ggccagggag cgcggaggag ccatggccac 60
cgctaacggg gccgtggaaa acgggcagcc ggacggaag ccgccggccc tgccgcgccc 120
catccgcaac ctggaggtca agttcaccaa gatatttatc aacaatgaat ggcacgaatc 180
caagagtggg aaaaagtttg ctacatgtaa cccttcaact cgggagcaaa tatgtgaagt 240
ggaagaagga gataagcccg acgtggacaa ggctggagg gctgcacagg ttgccttcca 300
gaggggctcg ccatggcgc ggctggatgc cctgagtcgt gggcggctgc tgcaccagct 360
ggctgacctg gtggagaggg accgcgccac cttggccgcc ctggagacga tggatacagg 420
gaagccattt cttcatgctt ttttcatcga cctggagggc tgtattagaa ccctcagata 480
ctttgcaggg tggagagaga acaaccaagag caagaccatc cccacagata acaacgtcgt 540
gaagccattt cttcatgctt ttttcatcga cctggagggc tgtattagaa ccctcagata 480 ctttgcaggg tgggcagaca aaatccaggg caagaccatc cccacagatg acaacgtcgt 540 atgcttcacc aggcatgagc ccattggtgt ctgtggggcc atcactccat ggaacttccc 600 cctgctgatg ctggtgtga agctggcacc cgccctctgc tgtggggaca ccatggtcct 660 gaagcctgcg gagcagacac ctctcaccgc cctttatctc ggctctctga tcaaagaggc 720 cgggttccct ccaggagtgg tgaacattgt gccaggattc ggcccacag tgggagcagc 780 aattcttct caccctcaga tcaacaagat cgccttcacc ggctccacag aggttggaaa 840 actggttaaa gaagctgcgt cccggagcaa tctgaagcgg gtgacgctgg agctgggggg 900 gaagaacccc tgcatcgtgt gtgcggacgc tgacttggac ttggcagtgg agttggcaa 860 tcagggagtg ttcttcaacc aaggccagtg ttgcacagga gcctccaagg gggcccacag gggagagccc ttcgatgtca aaacagaaca ggggcctcag attgccaaga aacggcccgt 1080 gggagacccc ttcgatgtca aaacagaaca ggggcctcag attgatcaaa agcagttcga 1140 caaaatctta gaagctagg aggaggagga gaaggagggg caaccaatac tgaagtcaa 1260 caacatgcgg aagtgataa aaagagcgaa taggcaggt caaccaatac tgaagttcaa 1320 aagtatcgaa gaagtgataa aaagagcgaa taggcaggt caaccaatac tgaagttcaa 1320 aagtatcgaa gaagtgataa aagagcgaa taggcacgac tattggactca cagcagccgt 1380 gttcacaaaa aatctcgaca aagccctgaa gttggctca tttggaggc cccctctatgc gccttcaac cacaggccca tttggaacggt ttaaaaatgtc 1500 Page 90
```

Page 90

```
39740-0001PCT.txt
aggaaatggc agagaactag gtgaatacgc tttggccgaa tacacagaag tgaaaactgt 1560 caccatcaaa cttggcgaca agaacccctg aaggaaaggc ggggctcctt cctcaaacat 1620 cggacggcgg aatgtggcag atgaaatgtg ctggaggaaa aaaatgacat ttctgacctt 1680 cccgggacac attcttctgg aggctttaca tctactggag ttgaatgatt gctgttttcc 1740 tctcactctc ctgtttattc accagactgg ggatgcctat aggttgtctg tgaaatcgca 1800 gtcctgcctg gggaggagc tgttggccat ttctgtgtt ccctttaaac cagatcctgg 1860 agacagtgag atactcaggg cgttgttaac agggagtggt atttgaagtg tccagcagtt 1920 agacagtgag atactcaggg cgttgttaac agggagtggt atttgaagtg tccagcagtt 1920 cttgaaatg ctttgccgaa tctgactcca gtaagaatgt gggaaaaccc cctgtgtgtt 1980 ctgcaagcag ggctcttgca ccagcggtct cctcagggtg gacctgcta cagagcaagc 2040 cacgcctctt tccgaggtga aggtgggacc attccttggg aaaggattca cagtaaggtt 2100 ttttggtttt tgtttttgt tttcttgtt ttaaaaaaaag gatttcacag tgagaaagtt 2160 ttggttagtg cataccgtgg aagggcgcca gggtctttgt ggattgcatg ttgacattga 2220 ccgtgagatt cggcttcaaa ccaatactgc ctttggaata tgacagaatc aatagcccag 2280 agagcttagt caaaagacgat atcacggtct accttaacca aggcacttc ttaagcagaa 2340 gcaaatccta ggataattca cctcctcatt tgacaaatca gagctgtaat tcaacgcaa 2400 gcaaatccta ggataattca cctcctcatt tgacaaatca gagctgtaat tcaccttaacc 2460 aaattacgca tttctatcac gttcactaac agcttatgat aagtctgtg aggacttcctt 2520 ttctccagtt ctgatacca atttagatta gtaaagcgta cacaactgga aagactgctg 2580 taataacacc tggattctat ggaggacctc gggtcttcatc caagtggcct gagtattca 2700
   aggaaatggc agagaactag gtgaatacgc tttggccgaa tacacagaag tgaaaactgt 1560
taataacaca gccttgttat ttttaagtcc tattttgata ttaatttctg attagttagt 2640 aaataacacc tggattctat ggaggacctc ggtcttcatc caagtggcct gagtatttca 2700 ctggcaggtt gtgaattttt cttttcctct ttgggaatcc aaatgatgat gtgcaatttc 2760 atgttttaac ttggggaaact gaaagtgttc ccatatagct tcaaaaacaa aaacaaatgt 2820 gttatccgac ggatactttt atggttacta actagtactt tcctaattgg gaaagtagtg 2880 cttaagtttg caaattaagt tggggaggc aataataaaa tgagggcccg taacagaacc 2940 agtgtgta taacgaaaac catgtataaa atgggcctat cacccttgtc agagatataa 3000 attaccacat ttggcttccc tcatcacgca attttcagta accacttatc acttatacta ccaataactt 3060 gttaaataca gatttggctt catacactga ggttcctatt cttccattgt acgataataa 3120 gtaagtacac ttgatagtga tacgttagag ggttcctatt cttccattgt acgataatgt 3180 gtaagtacac agaggtggta tatttaaact tctgtaatat acttgattct ttttatagtt 3240 gtaagtacac gggaattccg accctagcc cagatcgcat caccacatgc gggaattccg accctagcc cagatcgcat ccccacaatgc gagaatgata 3300 ctataggcct gggaattccg accctagccg cagatcgcat ccccacaatgc gagaatgata 3420 aaataaaaatt gggatatttga ga
   aaataaaatt ggatatttga ga
<210> 348
<211> 737
   <212> DNA
   <213> Homo sapiens
  <400> 348
   ggagtttcgc cgccgcagtc ttcgccacca tgccgcccta caccgtggtc tatttcccag 60
ggagtttcgc cgccgcagtc ttcgccacca tgccgcccta caccgtggtc tatttcccag 60 ttcgaggccg ctgcgggcc ctgcgcatgc tgctggcaga tcagggccag agctggaagg 120 aggaggtggt gaccgtggag acgtggcagg agggctcact caaagcctcc tgcctatacg 180 ggcagctccc caagttccag gacggagacc tcaccctgta ccagtccaat accatcctgc 240 gtcacctggg ccgcaccctt gggctctatg ggaaggacca gcaggaggca gccctggtgg 300 acatggtgaa tgacggcgtg gaggacctcc gctgcaaata catctcctc atctacacca 360 actatgaggc gggcaaggat gactatgtga aggcactgcc cgggcaactg aagccttttg 420 agaccctgct gtcccagaac cagggaggca agaccttcat tgtgggagac cagatctcct 480 tcgctgacta caacctgctg tcagcatatg tgaggcgcc cagggcccgg cccaagctca 600 aggccttcct ggcctcccct gagtacgtga acctccccat caatggcaac gggaaacagt 660 gagggttog gggaacttga ggggaggaa gagtttgcct tcctttctcc aggaccaata 720
   gagggttggg gggactctga gcgggaggca gagtttgcct tcctttctcc aggaccaata 720
  aaatttctaa gagagct
  <210> 349
  <211> 5189
   <212> DNA
   <213> Homo sapiens
  <400> 349
atggccaagt cgggtggctg cggcggga gccggcgtgg gcggcggcaa cggggcactg 60 acctgggtga acaatgctgc aaaaaaagaa gagtcagaaa ctgccaacaa aaatgattct 120 tcaaagaagt tgtctgttga gagagtgtat cagaagaaga cacaacttga acacattctt 180 cttcgtcctg atacatatat tgggtcagtg gagccattga cgcagttcat gtgggtgtat 240 gatgaagatg taggaatgaa ttgcagggag gttacctttg tgccaggttt atacaagatc 300 tttgatgaaa ttttggttaa tgctgctgac aataaacaga gggataagaa catgacttgt 360 attaaagttt ctattgatcc tgaatctaac attatagca tttggaataa tgggaaaggc 420 attccagtag tagaacacaa ggtagagaaa ggttatgttc ctgctttaat ttttggacag 480
                                                                                                                                                                                                                                         Page 91
```

39740-0001PCT.txt

gatttggctg gttcgtgtag aggggtcaag gtcatgttta atggaaagaa attgcctgta 840 aatggatttc gcagttatgt agatctttat gtgaaagaca aattggatga aactggggtg 900 gccctgaaag ttattcatga gcttgcaaat gaaagatggg atgtttgtct cacattgagt 960 gaaaaaaggat tccagcaaat cagctttgta aatagtattg caactacaaa aggtggacgg 1020 1020 cacgtggatt atgtggtaga tcaagttgtt ggtaaactga ttgaagtagt taagaaaaag aacaaagctg gtgtatcagt gaaaccattt caagtaaaaa accatatatg ggttttatt aattgcctta ttgaaaatcc aacttttgat tctcagacta aggaaaacat gactctgcag cccaaaagtt ttgggtctaa atgccagctg tcagaaaaat tttttaaagc agcctctaat 1080 1140 cccaaaagtt ttgggtctaa atgccagctg tcagaaaaat tttttaaagc agcctctaat 1260 tgtggcattg tagaaagtat cctgaactgg gtgaaatta aggctcagac tcagctgaat 1320 aagaagtgtt catcagtaaa atacagtaaa atcaaaggta ttcccaaact ggatgatgct 1380 aatgatgctg gtggtaaaca ttccctggag tgtacactga tattaacaga gggaggactct 1440 gccaaatcac tggctgtgtc tggattaggt gtgattggac gagacagata cggaggttttt 1500 ccactcaggg gcaaaattct taatgtacgg gaagcttctc ataaacagat catggaaaat 1560 gctgaaataa ataatattat taaaatagtt ggtctacaat ataagaaaag ttacgatgat 1620 gcagaatctc tgaaaacctt acgctatgga aagattatga ttatgaccga tcaggatcaa 1680 gatggttctc acataaaagg cctgcttatt aattcatcc atcacaattg gccatcactt 1740 ttgaagcatg gtttcttga agagttcatt actcctattg taaaggcaag caaaaataag 1800 caggaacttt ccttctacag tattcctgaa tttgagcgaat ggaaaaaaca tatagaaaac 1860 cagaaagcct ggaaaataaa gaaaggcat cgcatcttgt ttagatatgc tggtcctgaa 1980 gatgatgctg ccattacctt ggaaaggcat ccggagacag cgtaggctac atggctacc agaaaggcatt ttatggaaga ccggagacag cgtaggctac atggcttacc agaagaatgt 2040 ttaacaaatt ttatggaaga ccggagacag cgtaggctac atggcttacc agaactgatt 2100 ttatatggta cctgcaacaa tgaaagact taaaagaatct ttataaccaa ggaattgatt 2160 ctcttctcaa actcagacaa tgaaagatct ataccatctc ttgttgatgg ctttaaacct 2220 1260 ctcttctcaa actcagacaa tgaaagatct ataacgatt tcatcaacaa ggaattgatt 2160 ctcttctcaa actcagacaa tgaaagatct ataccatctc ttgttgatgg ctttaaacct 2220 ggccagcgga aagttttatt tacctgtttc aagaggaatg ataaacgtga agtaaaagtt 2280 gcccagttgg ctggctctgt tgctgagatg tcggcttatc atcatggaga acaagcattg 2340 atgatgacta ttgtggaattt ggctcagaac tttgtgggaa gtaacaacat taacttgctt 2400 cagcctattg gtcagttgg aactcggctt catggtggca aagatgctgc aagccctcgt 2460 tatatttca caatgttaag cactttagca aggctacttt ttcctgctgt ggatgacaac 2520 ctccttaagt tcctttatga tgataaacaa cggcatagata ctagatggta tattcctataa 2580 tatatttica caatgitaag cacittagca aggitactit ticctgetit ggatgacaac 2520 ctccttaagt tccttataga tgataatcaa cgigtagagc ctgagtggta tattcctata 2580 attccatgg tittaataaa tggitgetaga ggcattggia ctggatgggc tigaaacta 2640 cccaactatg atgctaggga aattgigaac aatgicagac gaatgctaga tggcctggat 2760 cctcatccca tgcttccaag cacacagaca titaaaaggca gaatgctaga tggcctggat 2760 aaccagtatg cagtcaggg tgaaaatatt gagtggaca gaatacaaga acttggtcaa 2760 aaccagtatg cagtcaggg tgaaaatattt gagtggaca gaaacacagt agaaaattaca 2820 gagcttccag ttagaactg gcacacaggta tataaaagaca aggttitaga acctatgcta 2880 aatggaacag ataaaacacc agcattaatt tctgattata aagaatatca tactgacaca 2940 actgtgaaaa tttggagaa aatagacaga gagaaactag cacaagcaga agctgctgag 1940 ctgataaag titttaaact tcaaactact cttacttgta attccatggt acttittgat 3060 catatgggat gttaaacaaca agcccgttic atttagaga agatacaagg agctgctgaa 3000 ctgcataaag titttaaact tcaaactact cttacttgta attccatggt acttittgat 3120 ttacgataa gttaatacgg tttacgtaag gagtggccttg tgggaatgtt gggagacagaa 3180 attagagaata gttaaacaca agcccgttic attttagaga agatacaagg gaaaattaca 3240 gacccagtga aagcctggaa aggccgttca attttagaga gagtacaaagaga attgaatct 3300 gaccagtga aagcctggaa aggaacacaa gaaaaggcag cagaagaggg ttgaaacacaa 3360 aaccagcag atgatgatc ctccgattca ggaaccct caggcccaga ttttaataacag 3480 aggagatgaa aagggcgaga ggtcaatgat tgtgaagaac agttgaagaa aggacacaa aggagagaca aatgaagaaa aggactgccaga aggaaattca agaacagagaa 3600 gatgttctgg ctggaatgt tggaagaacgaa actccttc agaacctcttg agaacgagaa aggaagaacag cagaagaacag aagttggcaa aggaacacaa aggagaacaca agttggagaa aggaacacaa aggagaacaca agttggagaa aggacacaa aggagaacacaa aggtggaga aggaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa agaagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggagaacacaa aggag aagcccaaga gagccccaaa acagaagaaa gtagtagagg ctgtaaactc tgactcggat 4560 Page 92

```
39740-0001PCT.txt
   tcagaatttg gcattccaaa gaagactaca acaccaaaag gtaaaggccg aggggcaaag 4620
  aaaaggaaag catctggctc tgaaaatgaa ggcgattata accctggcag gaaaacatcc 4680 aaaacaacaa gcaagaaacc gaagaagaca tcttttgatc aggattcaga tgtggacatc 4740 ttccctcag acttcctac tgagccacct tctctgccac gaaccggtcg ggctaggaaa 4800 gaagtaaaat attttgcaga gtctgatgaa gaagaagatg atgttgattt tgcaatgttt 4860 aattaagtgc ccaaagagac caaacatttt tcaacaaata tcttgtgttg tccttttgtc 4920
   ttctctgtct cagacttttg tacatctggc ttattttaat gtgatgatgt aattgacggt 4980 tttttattat tgtggtaggc cttttaacat tttgttctta cacatacagt tttatgctct 5040 tttttactca ttgaaatgtc acgtactgtc tgattggctt gtagaattgt tatagactgc 5100 cgtgcatag cacagatttt aattgctatg gttacaaact acagacctgc tttttgaaat 5160
   gaaatttaaa cattaaaaat ggaactgtg
                                                                                                                                                                                                                                                                                                                                                 5189
   <210> 350
<211> 1536
   <212> DNA
   <213> Homo sapiens
   <400> 350
 ggggggggg ggaccacttg gcctgcctcc gtcccgccg gccacttggc ctgcctccgt 60 cccgccgcg cacttcgct gcctccgtc cccgccgcc gcgccatgcc tgtggccggc 120 tcggagctgc cgcgccgcc cttgccccc gccgcacagg agcgggacgc cgagccgcgt 180 ccgccgcacg gggagctgca gtacctgggg cagatccaac acatcctccg ctgcggcgtc 240 aggaaggacg accgcacgg caccggcacc ctgctggtat tcggcatgca ggcgcgctac 300 agcctgaaga atgaattcc tctgctgaca accaaacgtg tgttctggaa gggtgttttg 360 gaggagttgc tgtggtttat caagggatcc acaaacgtg tgtctggaa gggtgttttg 360 gaggagttgc tgtggttcaa tggatcccga gactttttgg acagcctggg attctccacc 480 aggaagaaga gggatctaa gggatcccaa ggctccaat ggatcccga gacttttat gggatccaat tggatccaa 540
   agagaagaag gggacttggg cccagtttat ggcttccagt ggaggcattt tggggcagaa 540
 tacagagata tggaatcaga ttattcagga cagggagttg accaactgca aagagtgatt 600 gacaccatca aaaccaaccc tgacgacaga agaatcatca tgtgcgcttg gaatccaaga 660 gatcttcctc tgatggcgct gcctccatgc catgccctct gccagttcta tgtggtgaac 720 agtgagctgt cctgccagct gtaccagaga tcgggagaca tgggcctcgg tgtgcctttc 780 aacatcgcca gctacgccct gctcacgtac atgattgcgc acatcacggg cctgaagcca 840 ggtgacttta tacacacttt gggagatgca catattacc tgaatcacat cgagccactg 900 aaaattcagc tcagcgaga acccagacct ttcccaaagc tcaggattct tcgaaaagtt 960 gagaaaattg atgacttcaa agctgaagac tgtttagag gaggtacaa tccgcatcca 1020 actattaaaa tggaaatagc tgtttagagg tgtttagagg gagattgta 1080
 actattaaaa tggaaatggc tgtttagggt gctttcaaag gagcttgaag gatattgtca 1020 gtctttaggg gttgggctgg atgccgaggt aaaagttctt tttgctctaa aagaaaaagg 1140 aactaggtca aaaatctgtc cgtgacctat cagttattaa tttttaagga tgttgccact 1200 ggcaaatgta actgtgccag ttctttccat aataaaaggc tttgagttaa ctcactgagg 1260 gtatctgaca atgctgaggt tatgaacaaa gtgaggagaa tgaaatgtat gtgctcttag 1320 caaaaacatg tatgtgcatt tcaatcccac gtacttataa agaaggttgg tgaatttcac 1380 aagctatttt tggaatattt ttagaatatt ttaagaattt cacaagctat tccctcaaat 1440 ctgagggagc tgagtaacac catcgatcat gatgtagagt gtggttatga actttatagt 1500 tgttttatat gttgctataa taaagaagtg ttctgc 1536
  <210> 351
<211> 2386
   <212> DNA
   <213> Homo sapiens
   <400> 351
   ggaggaggaa gcaagcgagg gggctggttc ctgagcttcg caattcctgt gtcgccttct 60 gggctcccag cctgccgggt cgcatgatcc ctccggccgg agctggtttt tttgccagcc 120
gggctccag cctgcggt cgcatgatcc ctccggccgg agctggtttt tttgccagcc 120 accgcgaggc cggctgagtt accggcatcc ccgcagccac ctcctctcc gacctgtgat 180 acaaaagatc ttccggggc tgcacctgcc tgcctttgcc taaggcggat ttgaatctct 240 ttctctccct tcagaatctt atcttggctt tggatcttag aagagaatca ctaaccagag 300 acgagactca gtgagtgagc aggtgttttg gacaatggac tggttgagcc catccctatt 360 ataaaaatgt ctcagagcaa ccgggagctg gtggttgact ttctctccta caagctttcc 420 cagaaaggat acagctggag tcagtttagt gatgtggaag agaacaggac tgaggcccca 480 gaagggactg aatcggagat ggagacccc agtgccatca atggcaaccc atcctggcac 540 ctggcagaca gccccgggt gaatggagc agcagcagta gagcagctg agtgtgacc ccatggcaga ccatggcagac ggagtgatcc ccatggcagc agtaaagcaa gcgctgaggg aggcaggcga cgagtttgaa 660 ctgcggtacc ggcgggcatt cagtgacctg acatcccagc tccacatcac cccagggaca 720 gcatatcaga gctttgaaca ggatactttt gtggaactct atgggaacaa tgcagcagcc 780 gagagccgaa agggccagga acgcttcaac cgctggttcc tgacgggcat gactgtggcc 840 ggcgtggttc tgctgggct actcttcagt cggaaatgac cagacactga ccatccactc 900 Page 93
```

Page 93

```
39740-0001PCT.txt
 taccetecca ecceptete tgetecacca cateeteegt ecageegeea ttgecaccag 960
gagaaccact acatgcagcc catgcccacc tgcccatcac agggttgggc ccagatctgg 1020
 ttcagtaata aactgtgttt actcagtgaa aaaaaaaaa aaaaaa
                                                                                                                                                            2386
 <210> 352
<211> 1270
 <212> DNA
 <213> Homo sapiens
 <400> 352
 agacgttcgc acacctgggt gccagcgccc cagaggtccc gggacagccc gaggcgccgc 60
agacgttcgc acacctgggt gccagcgccc cagaggtccc gggacagccc gaggcgccgc 60 gcccgccgcc ccgagctccc caagccttcg agagcggcg acactcccgg tctccactcg 120 ctcttccaac acccgctcgt tttggcggca gctcgtgtcc cagagaccga gttgccccag 180 agaccgagac gccgccgtg cgaaggacca atgagagcc cgctgctacc gccggcgccg 240 gtggtgctgt cgctcttgat actcggctca ggccattatg ctgctggatt ggacctcaat 300 gacacctact ctgggaagcg tgaaccattt tctggggacc acactgctga tggatttgag 360 gttacctcaa gaagtgagat tgaacacctact tctggcagac tatgactact cagaagagta tgataacgaa 480 cccaaaatac ctggctatat tgtcgatgat tcagtcagag ttgaacaggt tgaacaagga 600 ggcaaaaatg gaaaaaatag aagaagaaaa aagaagaaaa atccatgtaa tgcagaattt 660
ggcaaaaatg gaaaaaatag aagaaacaga aagaagaaaa atccatgtaa tgcagaattt 660 caaaatttct gcattcacgg agaatgcaaa tatatagagc acctggaagc agtaacatgc 720 aaatgtcagc aagaatattt cggtgaacgg tgtggggaaa agtccatgaa aactcacagc 780 atgattgaca gtagtttatc aaaaattgca ttagcagcca tagctgcctt tatgtctgct 840
gtgatcctca cagctgttgc tgttattaca gtccagctta gaagacaata cgtcaggaaa 900 tatgaaggag aagctgagga acgaaagaaa cttcgacaag agaatggaaa tgtacatgct 960 atagcataac tgaagataaa attacaggat atcacattgg agtcactgcc aagtcatagc 1020 cataaatgat gagtcggtcc tctttccagt ggatcataag acaatggacc ctttttgtta 1080 tgatggtttt aaacttttcaa ttgtcacttt ttatgctatt tctgataataa aaggtgcacg 1140
                                                                                                                                                            1080
                                                                                                                                                            1140
 aaggtaaaaa gtattttttc aagttgtaaa taatttattt aatatttaat ggaagtgtat
                                                                                                                                                            1200
 aaaaaaaaa
 <210> 353
<211> 1600
 <212> DNA
 <213> Homo sapiens
 <400> 353
gccccgccgc cggcagtgga ccgctgtgcg cgaaccctga accctacggt cccgacccgc 60 gggcgaggcc gggtacctgg gctgggatcc ggagcaagcg ggcgagggca gcgccctaag 120 caggcccgga gcgatggcag ccttgatgac cccgggaacc ggggccccac ccgcgcctgg 180 tgactctcc ggggaaggga gccagggact tcccgacct tcgccagagc ccaagcagct 240
 cccggagctg atccgcatga agcgagacgg aggccgcctg agcgaagcgg acatcagggg 300 cttcgtggcc gctgtggtga atgggagcgc gcagggcgca cagatcgggg ccatgctgat 360 ggccatccga cttcggggca tggatctgga ggagacctcg gtgctgaccc aggccctggc 420
                                                                                        Page 94
```

```
39740-0001PCT.txt
 tcagtcggga cagcagctgg agtggccaga ggcctggcgc cagcagcttg tggacaagca 480 ttccacaggg ggtgtgggtg acaaggtcag cctggtcctc gcacctgccc tggcggcatg 540
ttccacaggg ggtgtgggtg acaaggtcag cctggtcctc gcacctgccc tggcggcatg 540 tggctgcaag gtgccaatga tcagcggacg tggtctgggg cacacaggag gcaccttgga 600 taagctggag tctattcctg gattcaatgt catccagagc ccagagcaga tgcaagtgct 660 gctggaccag gcgggctgct gtatcgtggg tcagagtgag cagctggtc ctgcggacgg 720 aatcctatat gcagccagag atgtgacagc caccgtggac agcctgccac tcatcacagc 780 ctccattctc agtaagaaac tcgtggaggg gctgtccgct ctggtggtgg acgttaagtt 840 cggaggggc gccgtcttcc ccaaccagga gcagcccgg gagctggcaa agacgctggt 900 tggcgtgga gccagcctag ggcttcggt cgcgcagcg ctgaccgca tggacaagcc 960 cctgggtcgc tgcgtgggcc acgcctgga ggtggaggag gcgctgctct gcatggacgg 1020 cgcaggcccg ccagacttaa gggacctggt caccacgctc gggggcgcc tgctctggct 1080 cagcggacac gcgggactc aggctcagag cgctgcca ggtggacga 1140
<210> 354
<211> 1842
 <212> DNA
 <213> Homo sapiens
 <400> 354
 cgatcagatc gatctaagat ggcgactgtc gaaccggaaa ccacccctac tcctaatccc 60
 ccgactacag aagaggagaa aacggaatct aatcaggagg ttgctaaccc agaacactat 120 attaaacatc ccctacagaa cagatgggca ctctggttt ttaaaaaatga taaaagcaaa 180
ctttatagaa ggaattigta cttcttattig caggcaagtc tctatattat gtcctctttt 1740 gtggtgtctt ccatgtgaac agcataagtt tggagcacta gtttgattat tatgtttatt 1800
 acaatttta ataaattgaa taggtagtat catatatatg ga
 <210> 355
<211> 4975
 <212> DNA
 <213> Homo sapiens
 <400> 355
 ctctcacaca cacacaccc tccctgcca tccctcccg gactccggct ccggctccga 60 ttgcaatttg caacctccgc tgccgtcgcc gcagcagcca ccaattcgcc agcggttcag 120 gtggctcttg cctcgatgtc ctagcctagg ggcccccggg ccggacttgg ctgggctccc 180
                                                                                     Page 95
```

39740-0001PCT.txt

ttcaccctct gcggagtcat gagggcgaac gacgctctgc aggtgctggg cttgcttttc 240 agcctggccc ggggctccga ggtgggcaac tctcaggcag tgtgtcctgg gactctgaat 300 ggcctgagtg tgaccggcga tgctgagaac caataccaga cactgtacaa gctctacgag 360 aggtgtgagg tggtgatggg gaaccttgag attgtgctca cgggacacaa tgccgacctc 420 tccttcctgc agtggattcg agaagtgaca ggctatgtcc tcgtggccat gaatgaattc 480 tccttcctgc agatggattcg agaagtgaca ggctatgtcc tcgtggccat gaatgaattc 480 tctactctac cattgcccaa cctccgcgtg gtgcgaggga cccaggtcta cgatgggaag 540 tttgccatct tcgtcatgtt gaactataac accaactcca gccacgctct gcgccagctc 600 cgcttgactc agctcaccga gattctgtca gggggtgttt atattgagaa gaacgataag 660 ctttgtcaca tggacacaat tgactggagg gacatcgtga gggaccgaga tgctgagata 720 gtggtgaagg acaatggcag aagctgtccc ccctgtcatg aggtttgcaa ggggcgatgc 780 tggggtcctg gatcagaga ctgccagaca ttgaccaaga ccatctgtgc tcctcagtgt 840 aatggtcact gctttgggc caaccccaac cagtgctgc atgatgagtg tgccggggg 900 tgctcaggcc ctcaggacac agactgcttt gcctgccggc acttcaatga cagtggagcc 960 tgtgtacctc gctgtccaca gcctcttgtc tacaacaagc taactttcca gctggaaccc 1020 aatccccaca ccaagtatca gtatggagga gttgtgtgag ccagctgtcc ccataacttt 1080 gtggtggatc aaacatcctg tgtcagggc gccttgtgg ggactatgtc ccaaagactg tgtggaaca 1200 ggctctggga gccgcttcca gactgtggac tcgagcaaca ttgatggaga cccctggcac 1320 aagatccctg ccctggaccc agagaagctc agagagaccc agacgacaca 1380 aagatcctg ccctggaccc agagaagctc aatgtcttcc ggacagtacg ggagatcaca 1380 ggttacctga acatccagtc ctggccgcc cacatgcaca acttcagtgt tttttccaat 1440 ttgacaacca ttggaggcag aagcctctac aaccggggct tctcattgtt gatcatgaag 1500 aacttgaatg tcacatctct gggcttccga tccctgaagg aaattagtgc tgggcgtatc 1560 aacttgaatg tcacatctct gggcttccga tccctgaagg aaattagtgc tgggcgtatc 1560 tatataagtg ccaataggca gctctgctac caccactctt tgaactggac caaggtgctt 1620 cgggggccta cggaagagcg actagacatc aagcataatc ggccgcgcag agactgcgtg 1680 gcagagggca aagtgtgtga cccactgtgc tcctctgggg gatgctgggg cccaggccct 1740 ggtcagtgct tgtcctgtcg aaattatagc cgaggaggtg tctgtgtgac ccactgcaac 1800 tttctgaatg gggagcctcg agaatttgcc catgaggccg aatgcttctc ctgccacccg 1860 gaatgccaac ccatggggg cactgccaca tgcaatggct cgggctctga tacttgtgct 1920 caatgccaac attttcgaga tgggccccac tgtgtgagca gctgcccca tggagtccta 1980 ggtgccaagg gcccaatcta caagtaccca gatgttcaga gctgcccca tggagtccta 1980 ggtgccaagg gcccaatcta caagtaccca gatgttcaag actgtttagg acaaacacctg 2100 gagaactgca gccaagaccca tctgacaatg gcttcaag actgtttagg acaaacacctg 2100 attttcatga tgctgggcgg cacttttctc tactggcgtg ggcgccggat tcagaataaa 2220 agggctatga ggcgatactt ggaacgggt gagagcatag agcctctgga ccccagtgag 2280 aaggctaaca aagtcttgg cagaatcttc aaagagacag agctaaggaa gcttaaagtg 2340 cttggctcgg gtgctctgg gtgctcttag gggtgaatca 2400 atgcccatga accagggtaa tcttgggggg tcttgccagg agtctgcagt ttctgggagc 3420 agtgaacggt gcccccgtcc agtctctcta caccaatgc cacggggatg cctggcatca 3480 gagtcatcag aggggcatgt aacaggctct gaggctgagc tccaggagaa agtgtcaatg 3540 tgtagaagcc ggagcaggag ccggagccca cggccacgcg gagatagcgc ctaccattcc 3600 cagcgccaca gtctgctgac tcctgttacc ccactctcc cacccgggtt agaggaagag 3660 gatgtcaacg gttatgtcat gccagataca cacctcaaag gtactccctc ctccgggaa 3720 ggcacccttt cttcagtggg tctcagttct gtcctgggta ctgaagaaga agatgaagat 3780 gaggagtatg aatacatgaa ccggaggaga aggcacagtc cacctcatcc ccctaggcca 3840 agttcccttg aggagctggg ttatgagtac atggatgtgg ggtcagacct cagtgcctct 3900 ctgggcagca cacagagttg cccactccac cctgtaccca tcatgcccac tgcaggcaca 3960 actccagatg aagactatga atatatgaat cggcaacgag atggaggtgg tcctggggt 4020 actccagatg aagactatga atatatgaat cggcaacgag atggaggtgg tcctgggggt 4020 gattatgcag ccatgggggc ctgcccagca tctgagcaag ggtatgaaga gatgagagct 4080 tttcaggggc ctggacatca ggcccccat gtccattatg cccgcctaaa aactctacgt 4140 agcttagagg ctacagactc tgcctttgat aaccctgatt actggcatag caggcttttc 4200 cccaaggcta atgcccagag aacgtaactc ctgctccag tggcactcag ggagcattta 4260 Page 96

39740-0001PCT.txt atggcagcta gtgcctttag agggtaccgt cttctcccta ttccctctct ctcccaggtc 4320 ccagccctt ttccccagtc ccagacaatt ccattcaatc tttggaggct tttaaacatt 4380 ttgacacaaa attcttatgg tatgtagcca gctgtgcact ttcttctctt tcccaacccc 4440 aggaaaggtt ttccttattt tgtgtgcttt cccagtccca ttcctcagct tcttcacagg 4500 cactcctgga gatatgaagg attactctcc atatcccttc ctctcaggct cttgactact 4560 tggaactagg ctcttatgtg tgcctttgtt tcccatcaga ctgtcaagaa gaggaaaggg 4620 aggaaaccta gcagaggaaa gtgtaatttt ggtttatgac tcttaaccc ctagaaagac 4680 agaagcttaa aatctgtgaa gaaagaggtt aggagtagat attgattact atcataattc 4740 agcacttaac tatgagccag gcatcatact aaacttcacc tacattatct cacttagtcc 4800 tcgggcatgg tgggctgat tctggacat acatattatc tcattttaca caaagggaag 4860 tcgggcatgg tggctcatgg ctgtaatctc agcactttag gaggctgagg cagaaggat 4920 tcgggcatgg tggctcatgc ctgtaatctc agcactttgg gaggctgagg cagaaggatt 4920 acctgaggca aggagtttga gaccagctta gccaacatag taagaccccc atctc 4975 <210> 356 <211> 4627 <212> DNA <213> Homo sapiens <400> 356 <400> 356 tcacttgcct gatatttcca gtgtcagagg gacacagcca acgtggggtc ccttctaggc 60 tgacagccgc tctccagcca ctgccgcgag cccgtctgct cccgccctgc ccgtgcactc 120 tccgcagccg ccctccgca agccccagcg cccgctcca tcgccgatga ccgcggggag 180 gaggatggag atgctctgg ccggcagggt ccctgcgtg ctgctctgcc tgggtttcca 240 tcttctacag gcagtcctca gtacaactgt gattccatca tgtatcccag gagagtccag 300 tgataactgc acagctttag ttcagacaga agacaatcca cgtgggct aagtgtcaat 360 aacaaaggt agctctgaca tgaatggcta ttgtttgcat ggacagtgca tctatctggt 420 ggacatgagt caaaactact gcaggtgtga agtgggttat actggtgtcc gatgtgaaca 480 cttcttttta accgtccacc aacctttaag caaagagtat gtggctttga ccgtgattct 540 tattattttg tttcttatca cagtcgtcgg ttccacatat tatttctgca gatggacag 600 tattatttta accgrccacc aacctrtaag caaagagtat grggcrtrga ccgrgaffct 540 tattattttg tricttatca cagrcgrcgg triccacatat tattrictgca garggtacag 600 aaatcgaaaa agraaagaac caaagaagga atatgagaga gracctcag grggatccaga 660 grtgccgcaa grctgaatgg cgccatcaaa criatgggca grggataacag tgrgcctggt 720 taatattaat atriccattri atraataata triatgrigg grcaagtgrt aggrcaataa 780 cactgraff taatgract gaaaaatgri triatrittig trittatritti gacagactat 840 trigctaatgr ataatgraca gaaaatatri aatatcaaaa gaaaattgat artitataca 900 aagtacttaga agraagcaat tcccaggrca tagcrcaaga atrigtragca aargacagat 1020 agraagaac criatatata agraagaacg atricaaag atrigtragca aargacagat 1080 1020 ttctgtaagc ctatatatat agtcaaatcg atttagtaag tatgttttt atgttcctca 1080 aatcagtgat aattggtttg actgtaccat ggtttgatat gtagttggca ccatggtatc 1140 atatataaa acaataatgc aattagaatt tgggagaagc aaatataggt cctgtgttaa 1200 acactacaca tttgaaacaa gctaaccctg gggagtctat ggtctcttca ctcaggtctc 1260 agctataatt ctgttatatg aggggcagtg gacagttccc tatgccaact cacgactcct 1320 acaggtacta gtcactcatc taccagattc tgcctatgta aaatgaattg aaaacaaatt 1380 ttctgtaatc ttttattaa gtagtgggca tttcatagct tcacaatgtt ccttttttgt 1440 atatacaca atttatgtga ggtaattatt gctcaacaga caattagaaa aaagtccaca 1500 cttgaagcct aaatttgtgc tttttaagaa tatttttaga ctattcttt ttataggggc 1560 tttgctgaat tctaacatta aatcacagcc caaaatttga tggactaatt attatttaa tttgctgaat tctaacatta aatcacagcc caaaatttga tggactaatt attatttaa 1620 aatatatgaa gacaataatt ctacatgttg tcttaagatg gaaatacagt tatttcatct 1680 tttattcaag gaagtttaa ctttaataca gctcagtaaa tggcttcttc tagaatgtaa 1740 agttatgtat ttaaagttgt atcttgacac aggaaatggg aaaaaactta aaaattaata 1800 tggtgtattt ttccaaatga aaaatctcaa ttgaaagctt ttaaaatgta gaaacttaaa 1800 tggtgtattt ttccaaatga aaaatctcaa ttgaaagctt ttaaaatgta gaaacttaaa 1860 cacaccttcc tgtggaggct gagatgaaaa ctagggctca ttttcctgac atttgtttat 1920 tttttggaag agacaaagat ttcttctgca ctctgagccc ataggtctca gagagttaat 1980 aggagtattt ttgggctatt gcataaggag ccactgctgc caccactttt ggatttatg 2040 ggaggctcct tcatcgaatg ctaaaccttt gagtagagtc tccctggatc acataccagg 2100 tcagggagga tctgttctc ctctacgttt atcctggcat gtgctagggt aaacgaaggc 2160 ataataagcc atggctgacc tctggagcac caggtgccag gacttgtctc catgtgtatc 2220 catgcattat ataccctggt gcaatcacac gactgcatca taaagtcctg gccctggccc 2280 ttactatatag gaaaataaac agacaaaaac aagtaaatat atatggtcct atacatattg 2340 qtcatttggt gctctgctaa ccatttatat aaaacttaaa aacaagagaa aagaaaaac 2460 tatatatatt catatacaaa catgtatgta tacatgacct taatggatca tagaattgca 2400 gtcatttggt gctctgctaa ccatttatat aaaacttaaa aacaagagaa aagaaaaatc 2460 aattagatct aaacagttat ttctgttcc tatttaatat agctgaagtc aaaatatgta 2520 agaacacatt ttaatacct tacttacagt tggccctctg tggttagttc cacatctgtg 2580 gattcaacca accaaggacg gaaaatgctt aaaaaataat acaacaacaa caaaaaatac 2640 attataacaa ctatttactt ttttttttt ctttttgaga tggagtctcg ctctgttgcc 2700 caggttggag tgcagtggca cgatctcggc tcactgcaac ctcacctccc gggttcaaga 2760 gatcctcctg cctcagcctc ctgagcagct gggactacag gcgcatgcca ccatgcccag 2820 ctaatttttg tattttagt agaggcgggg tttcaccatg gctgggatta caggcgtgag 2940 Page 97

CCACCGCACG tagcatttac attaggatat accangulatery taaagaatgat taaagaatgat tataggatat accangulatery gaataagatgat tataggatat accangulatery gactulaga gagaggatgi gaataggata tatagcaagca cataggacca catagacca cataggacca cataggacca cataggacca cataggacca catagacca catagacc

<210> 357 <211> 2634 <212> DNA

<213> Homo sapiens

<400> 357ggcacgaggctgagtgtccgtctcgcgccggaagcgggcgaccgccgtcagcccggagg60aggaggaggagggaggaggagggagggggcggccatggggctgctgtcccagggctcgccgc120tgagctgggaggaagaaccaagcgccatgccgaccacgtgcggcggcacgggatctctcagt180tcctgcacatctaccacgccgtcaaggacgggcacaaggacgttctccagtggggcatg240aggtggaatacatgttggtaatctttgaaagaagaggggaaagacagggggaaaggacaagg240ctggggagaaagttctttgaaacttttgaaagaagaggggaaaggacaacaccgaaagccct420acggaggaacaattgccgagttcaatacagttcaatacagcattrttgaaaaggacaacacgacaggccct420acggaggaactatattagaaataaacaaggctcttttgcaaattaacttacagcacttcttgaggaacaaattaacttaagggaggagtt60caagaatatccggcaagagttcaatacagctcattttgaaaaggacaacaaaggacaacacacagtggaagggagaggct480ctcatatggaacacactcatatctattcaaggacatatattaagaacatttttaagaacatttttaagaacatttttaagaacatttttaagaacatttttaagaacatttttaagaacatttttaagaacatttttaagaacatttttaagaacatttttaagaacatttttaagaadatacctttaggaatgggca480ttcaagcattgattgtctttcaattttttgaaggacatttgaagatagattgaagatagaatacctttaagactgattgtg840ttgcaagaattgattgtctttgaagaacattgaagaacattgaagataattgattacttttgaagataattgaagata

```
39740-0001PCT.txt
 atgaattatg tgaatgccca gagttacttg gatcagcatt taggaaagta aaatatagtg 1980 gaagtaaaac tgactcatcc aactagacat tctacagaaa gaaaaatgca ttattgacga 2040 actggctaca gtaccatgcc tctcagcccg tgtgtataat atgaagacca aatgatagaa 2100
<210> 358
<211> 1246
<212> DNA
 <213> Homo sapiens
 <400> 358
 gaccagccta cagccgcctg catctgtatc cagcgccagg tcccgccagt cccagctgcg 60 cgcgccccc agtcccgcac ccgttcggcc caggctaagt tagccctcac catgccggtc 120
aaaggaggca ccaagtgcat caaatacctg ctgttcggat ttaacttcat cttctggctt 180
 ttgatacata ataaaaaatt atgacaatgt caaaaaaaaa aaaaaa
 <210> 359
<211> 2360
 <212> DNA
 <213> Homo sapiens 🦠
caggoggctg agtgagcaag acaagacact caagaagag gagctgcgc tgggtcccgg 120 caggcttgc acgcagaggc gggcggcaga cggtgcccgg cggaatctcc tgagctccgc 180 cgcccagctc tggtgccagc gcccagtggc cgccgcttcg aaagtgactg gtgcccgc 240 gcctcctct ggtgccagc gcccagtggc cgccgcttcg aaagtgactg gtgcccgc 240 gcctcctctc ggtgccagc ggtgactggc cgccgcttcg aaagtgactg gtgcctcgc 240 gctgcagttc tctcggcact ggtgactggc gagagcctgg gagagctgg agctgctgaa gctctttctg 300 gctgcagttc tctcggcact ggtgactggc gagagcctgg agcggctcg gagagggcta 360 gctgctggaa ccagcaaccc ggaccctccc actgtatcca cggaccagct gctaccccta 420 ggagggggcg gggaccggaa agtccgtgac ttgcagagag cagatctgga ccttttagag 480 gtcactttat cctccaagcc acaagcactg gccacaccaa acaaggagga gcacgggaaa 540 agaaagaaga aaggcaaggg gctagggaag atgcaaatat gtgaaggagc catgtttcg gaaaatacaag 600 gacttctgca tccatggaga atgcaaatat gtgaaggagc tccgggctcc ctcctgcatc 660 tgccacccgg gttaccatgg agagtggt catgggctga gcctcccagt ggaaaatcgc 720 ttatatacct atgaccaca aaccatcctg gccgtggtgg ctgtggtgct gtcatcgtgg gcttctcatg tttaggtacc ataggagag aggttatgat 840 gtggaaaatg aagagaaagt gaagttgggc atgactaatt cccactgaga aggttatgat 840 gtggaaaatg aagagaaagt gaagttgggc atgactaatt cccactgaga aggacttgtg 900 ctcaagggaa acttccatct agtcacacaa accacacca caagagcct caagtgcaa acaagagtgat tcaggactgc ataggggaa acttccatct tgagaagaca caaggtgatt tcagactgca 960 gaggggaaag acttccatct tgccaaaata ccaagagcct caagtgcaa acaagagtatg 1080 tccaatggta tctgggtaa aagaaagcaa aagaaagcaa aagaaagga ccctcctatgcc ctcttatgct cttctgattc 1140
 <400> 359
 Page 99
```

```
39740-0001PCT.txt
 tatttccaaa cctggttcat atttatactt tgcaatccaa ataaagataa cccttattcc 2340
 ataaaaaaaa aaaaaaaaaa
                                                                                                                                                         2360
 <210> 360
 <211> 1433
 <212> DNA
 <213> Homo sapiens
<400> 360
 <210> 361
<211> 1632
 <212> DNA
 <213> Homo sapiens
<400> 361
gccggccgaa cccagacccg aggttttaga agcagagtca ggcgaagctg ggccagaacc 60 gcgacctccg caaccttgag cggcatccgt ggagtgcgcc tgcgcagcta cgaccgcagc 120 aggaaagcgc cgccggccag gcccagctgt ggccggacag ggactggaag agaggacgcg 180 gtcgagtagg tgtgcaccag ccctggcaac gagagcgtct accccgaact ctgctggcct 240 tgaggtgggg aagccggga gggcagttga ggaccccgcg gaggcgcgtg actggttgag 300 cgggcaggcc agcctccgag ccgggtggac acaggtttta aaacatgaat cctacactca 360 tccttgctgc cttttgcctg ggaattgcct cagctactct aacatttgat cacaggtttag gaccaagtg gaccaagtgg aggcgatgc acaacgatt atacggcatg aatggaggag agcagtggg gagaagaaca tgaagatgat tgaactgcac aatcaggaat 540 acagggaagg gaaacacagc ttcacaatgg ccatgaacgc ctttggagac atgaccagtg 600 aagaattcag gcaggtgatg aatggcttc aaaaccgtaa gcccaggaag gggaaagtgt 660 Page 100
 <400> 361
                                                                                     Page 100
```

```
tccaggaacc tctgtttat gaggcccca gatctgtgga ttggagagag aaaggctacg 720 tgactcctgt gaagaatcag ggtcagtgtg gttcttgttg ggcttttagt gctactggtg 780 ctcttgaagg acagatgtc cggaaaactg ggaggcttat ctcactgagt gagcagaatc 840 tggtagactg ctctgggcc caaggcaatg aaggctgcaa tggtggccta atggattatg 900 ctttccagta tgttcaggat aatggaggcc tggactctga ggaatcctat ccatatgagg 960 caacagaaga atcctgtaag tacaatccca agtattctgt tgctaatgac accggctttg 1020 tggacatccc taagcaggag aaggccctga tgaaggcagt tgcaactgtg gggcccattt 1080 ctgttgctat tgatgcaggt catgagtcct tcctgttcta taaagaaggc atttattttg 1140 aagccagactg tagcagtgaa gacatggatc atggtggtgc ggtggttggc tacggatttg 1200 gagggcatggg tggctacgta aagaatgcca aagaaccgga gaacagctgg ggtgaagaat 1260 ggggcatggg tggctacgta aagatggcca aagaccggag aaaccattgt ggaattgcct 1320 cagcagccag ctaccccact gtgtgagctg ggtgaacggtg atgaggaagg acttgactgg 1380
                                                                                                                                                                        39740-0001PCT.txt
   cagcagccag ctaccccact gtgtgagctg gtggacggtg atgaggaagg acttgactgg 1380 ggatggcgca tgcatgggag gaattcatct tcagtctacc agcccccgct gtgtcggata 1440 cacactcgaa tcattgaaga tccgagtgtg atttgaattc tgtgatattt tcacactggt 1500 aaatgttacc tctattttaa ttactgctat aaataggttt atattattga ttcacttact 1500
    gactitgcat tttcgttttt aaaaggatgt ataaaiitttt acctgtttaa ataaaattta 1620
    atttcaaatg ta
                                                                                                                                                                                                                                                                                                                                                      1632
   <210> 362
<211> 2756
    <212> DNA
    <213> Homo sapiens
 <400> 362
atgctgtcct tccagtaccc cgacgtgtac cgcgacgaga ccgccgtaca ggattatcat 60
ggtcataaaa tttgtgaccc ttacgcctgg cttgaagacc ccgacagtga acagactaag 120
gcctttgtgg aggcccagaa taagattact gtgccatttc ttgagcagtg tcccatcaga 180
ggtttataca aagagagaat gactgaacta tatgattacc ccaagtatag ttgccacttc 240
aagaaaggaa aacggtattt ttattttac aatacaggtt tgcagaacca gcgagtatta 300
tatgtacagg attccttaga gggtgaggcc agagtgtcc tggaccccaa catactgtct 360
gacgatggca cagtggcact ccgaggtat gcgtcagcg aagatggtga atattttgcc 420
tatggcagagg ttccagagg gtgcaagtag gggaaatca gcgacaatca gcgagtatta gcgtcaaggg ttccagagg gtgccaaatca gcgatggga atattttgcc 420
gatgggaagg gtgccagtgg gtgacaatca gcgtgaaaaa agttgatgg 480
gcaaaggaagg gaatgttcta caactcatac cccaaaaggt gcaagtca gcgaaaaaag tgatggcaca 600
gagacatcta ccaatctcca ccaaaagctc tactaccatg tcttgggaac cgatcagtca 660
gaagatattt tgtgtgctga gtttcctgat gaacctaaat ggatggtgg agctgagtta 720
tctgatgatg gcgctatgt cttgttatca ataagggaag gatgtgatcc agtaaaccga 780
ctctggtact gtgacctaca gcaggaatcc aggggaatac ccaatgaggg ggcggtgttc 900
    <400> 362
tggcaacaaa cacattgtga atattagatt gctgaattaa ggatcatagt cgggcatact 2460 tatctatatc cataacctct atatctttaa ataaatgtga gaactgttct catggagaag 2520 acttctttgc aacaataata aatgttattt aagaatgaca gggatttact tccggtttct 2580 tcatattgag gggcaactcc agaagtggag ttttctgtga gaataaagca tttcaccttt 2640
```

Page 101

```
39740-0001PCT.txt
  ctgcaacaag ttagttttca agcagttaag tcatagaatg tttgttagct gtgaaaataa 2700
 <210> 363
<211> 2768
<212> DNA
  <213> Homo sapiens
  <400> 363
 cactgctgtg cagggcagga aagctccatg cacatagccc agcaaagagc aacacagagc 60 tgaaaggaag actcagagga gagagataag taaggaaagt agtgatggct ctcatcccag 12
acttggccat ggaaacctgg cttctcctgg ctgtcagcct ggtgctcctc tatctatatg 180 gaacccattc acatggactt tttaagaagc ttggaattcc agggcccaca cctctgcctt 240 ttttgggaaa tattttgtcc taccataagg gcttttgtat gtttgacatg gaatgtcata 300 aaaagtatgg aaaagtgtgg ggcttttatg atggtcaaca gcctgtgctg gctatcacag 360 atcctgacat gatcaaaaca gtgctagtga aagaatgtta ttctgtcttc acaaaccgga 420 ggccttttgg tccagtggga tttatgaaaa gtgccatctc tatagctgag gatgaagaat 480 ggaagagatt acgatcattg ctgtctccaa ccttcaccag tggaaaactc aagagagatgg 540 caggcaagcc tgtcaccttg aaagacgtct ttggggccta cagcatggat gtgatcacta 660 gcacatcatt tggagtgaac atcgactctc tcaacaatcc acaagacccc tttggggaaa 720 acaccaagaa gcttttaaga tttgatttt tggagtcatt ctttctcaa ataacagtct 780
acaccaagaa gcttttaaga tttgatttt tggatccatt ctttctcta ataacagtct 780 ttccattcct catcccaatt cttgaagtat taaatatctg tgtgtttcca agagaagtta 840 caaatttttt aagaaaatct gtaaaaagga tgaaagaaag tcgcctcgaa gatacacaaa 900 agcaccgagt ggattcctt cagctgatga ttgactctca gaattcaaaa gaaactgagt 960 cccacaaagc tctgtccgat ctggagctcg tggcccaatc aattacttt attttgctg 1020 gctatgaaac cacgagcagt gtctctcct tcattatgta tgaactggcc actcaccctg 1080 atgtccagca gaaactgcag gaggaaattg atgcagttt acccaataag gcaccaccca 1140 cctatgatac tgtgctacag atggagtat ttgacatggt ggtgaatgaa acgctcagat 1200 tattcccaat tgctatgaga cttgagaggg tctgcaaaaa agatgttgag atcaatggga 1260
tattccaat tgctatgaga cttgagaggg tctgcaaaaa agatgttgag atcaatggga 1260 tgttcattcc caaaggggtg gtggtgatga ttccaagcta tgctcttcac cgtgacccaa 1320 agtactggac agagcctgag aagttcctcc ctgaaagatt cagcaagaag aacaaggaca 1380 acatagatcc ttacatatac acaccctttg gaagtggacc cagaaactgc attggcatga 1440 ggtttgctct catgaacatg aaccttgctc taatcagagt ccttcagaac ttctccttca 1500 aaccttgtaa agaaacacag atccccctga aattaagctt aggaggactt cttcaaccag 1560 aaaaacccgt tgttctaaag gttgagtcaa gggatggcac cgtaagtgga gcctgaattt 1620 tcctaaggac ttctgctttg ctcttcaaga aatctgtgcc tgagaacacc agagacctca 1680 aattactttg tgaatagaac tctgaaatga agatggcct catccaatgg actgcataaa 1740 taaccgggga ttctgtacat gcattgagct ctctcattgt ctgtgtagag tgttatactt 1800
 taaccgggga tictgtacat gcattgagct ctctcattgt ctgtgtagag tgttatactt 1800 gggaatataa aggaggtgac caaatcagtg tgaggaggta gatttggctc ctctgcttct 1860 cacgggacta titccaccac ccccagttag caccattaac tcctcctgag ctctgataag 1920 agaatcaaca tttctcaata atttcctcca caaattatta atgaaaataa gaattatttt 1980
 gatggctcta acaatgacat ttatatcaca tgttttctct ggagtattct ataagtttta 2040 tgttaaatca ataaagacca ctttacaaaa gtattatcag atgctttcct gcacattaag 2100 gagaaatcta tagaactgaa tgagaaccaa caagtaaata tttttggtca ttgtaatcac 2160 tgttggcgtg gggcctttgt cagaactaga atttgattat taacataggt gaaagttaat 2220
ccactgtgac tttgcccatt gtttagaaag aatattcata gtttaattat gccttttttg 2280 atcaggcaca gtggctcacg cctgtaatcc tagcagtttg ggaggctgag ccgggtggat 2340 cgcctgaggt caggagttca agacaagcct ggcctacatg gttgaaaccc catctctact 2400 aaaaatacac aaattagcta ggcatggtgg actcgcctgt aatctcacta cacaggaggc 2460 tgaggcagga gaatcacttg aacctgggag gcggatgttg aagtgagctg agattgcacc 2520 actgcactcc agtctgggtg agagtgagac tcagtcttaa aaaaatatgc ctttttgaag 2580 cacgtacatt ttgtaacaaa gaactgaagc tcttattata ttattagttt tgatttaatg 2640 ttttcagcc atctccttc atattctgg gagacagaaa acatgttcc ctacacctct 2700 cgattggtc
 gattggtc
 <210> 364
<211> 2984
  <212> DNA
 <213> Homo sapiens
 <400> 364
 gaggaggaac agaaaagaaa agaaaagaaa aagtgggaaa caaataatct aagaatgagg 60
 agaaagcaag aagagtgacc cccttgtggg cactccattg gttttatggc gcctctactt 120
tctggagttt gtgtaaaaca aaaatattat ggtctttgtg cacatttaca tcaagctcag 180 cctgggcggc acagccagat gcgagatgcg tctctgctga tctgagtctg cctgcagcat 240 ggacctgggt cttccctgaa gcatctccag ggctggaggg acgactgcca tgcaccgagg 300
                                                                                                                                                       Page 102
```

```
39740-0001pcT.txt
 gctcatccat ccacagagca gggcagtggg aggagacgcc atgaccccca tcctcacggt 360
 cctgatctgt ctcgggctga gtctgggccc ccggacccac gtgcaggcag ggcacctccc 420 caagcccacc ctctgggctg aaccaggctc tgtgatcacc caggggagtc ctgtgaccct 480
gaaagtgcat taaactgaat cacaatgtaa atattacaca tcaagcgatg aaactggaaa 2580
<210> 365
 <211> 3061
 <212> DNA
 <213> Homo sapiens
 <400> 365
cggcacgagg cgactttggt ggaggtagtt ctttggcagc gggcatggcg ggtaccgtgg 60 tgctggacga tgtggagctg cgggaggctc agagagatta cctggacttc ctggacgacg 120 aggaagacca gggaatttat cagagcaaag ttcgggagct gatcagtgac aaccaatacc 180
aggaagacca gggaatttat cagagcaaag ttcgggagct gatcagtgac aaccaatacc 180 ggctgattgt caatgtgaat gacctgcgca ggaaaaacga gaagagggct aaccggcttc 240 tgaacaatgc ctttgaggag ctggttgct tccagcgggc cttaaaggat tttgtggcct 300 ccattgatgc tacctatgcc aagcagtatg aggagttcta cgtaggactg gaaggcagct 360 ttggctccaa gcacgtctcc ccgcggactc ttacctcctg cttcctcagc tgtgtggtct 420 gtgtgggaggg cattgtcact aaatgttctc tagttcgtc caaaagtcgtc cgcagtgtcc 480 actactgtcc tgctactaag aagaccatag agcgacgtta ttctgatctc accaccctgg 540 tggcctttcc ctccagctct gtctatccta ccaaggatga ggagaacaat ccccttgaga 600 tggaaatatgg cctttctgtc tacaaggatc accagaccat caccatccag gagatgccgg 660 agaaggcccc agccggccag ctcccccgct ctgtggacgt cattctggat gatgacttgg 720 tggataaaagc gaagcctggt gaccggttc aggtggtgg aacctaccgt tgccttcct 780
tggataaagc gaagcctggt gaccgggttc aggtggtggg aacctaccgt tgccttcctg 780 gaaagaaggg aggctacacc tctgggacct tcaggactgt cctgattgcc tgtaatgtta 840 agcagatgag caaggatgct cagccctctt tctctgctga ggatatagcc aagatcaaga 900 agttcagtaa aacccgatcc aaggatatct ttgaccagct ggccaagtca ttggccccaa 960
                                                                                    Page 103
```

```
39740-0001PCT.txt
  gtatccatgg gcatgactat gtcaagaaag caatcctctg cttgctcttg ggaggggtgg 1020 aacgagacct agaaaatggc agccacatcc gtggggacat caatattctt ctaataggag 1080 acccatccgt tgccaagtct cagcttctgc ggtatgtgct ttgcactgca ccccgagcta 1140 tccccaccac tggccgggc tcctctggag tgggtctgac ggctgctgtc accacagacc 1200 aggaaacagg agagcgccgt ctggaagcag gggccatggt cctggctgac cgaggcgtgg 1260 tttgcattga tgaatttgac aaaatgtctg acatggatcg cacagccatc catgaagtga 1320 tggagcaggg tcgagtgacc attgccaagg ctggcatcca tgctcggctg aatgcccgct 1380 gcagtgttt tggcaccag gactcactgc tggcagctact tggcagctact tggagaacat tgggcaccag gactcactgc tggcagctgt tgactccaa 1440 tggagaacat tgggctacag gactcactgc tgtcacgatt tgacttgctc tcaatcatgc 1500 tggatcagat ggatcctgag caggatggc aggatctcaga ccatgacca acctttcta catggacca aggaagatca gcaggacacc cagatttatg 1680 agaagcatga caaccttcta catgggacca agaagaaaaa ggagaagatg gtgagtgcag 1740
  tcctggccac agatgatcc aactttagcc aggaagatca gcaggacacc cagatttatg 1680 agaagcatga caaccttcta catgggacca agaagaaaaa ggagaagatg gtgagtgcag 1740 cattcatgaa gaagtacatc catgtggcca aaatcatcaa gcctgtcctg acacaggagt 1800 cggccaccta cattgcagaa gagtattcac gcctgcgcag ccaggatagc atgagctcag 1860 acaccgccag gacatctcca gttacagccc gaacactgga aactctgatt cgactggcca 1920 cagccatgc gaaggcccgc atgagcaaga ctgtggacct gcaggatgca gaggaagctg 1980 tggagttggt ccagtatgct tactttaaga aggttctgga gaaggagaag aacgtaaga 2040 agcagaagtg ggatgaatca gagacagaag atgaagagg gaaaagccaa gaggaccagg 2100 agcagaagag gaagagaagg aagactcgcc agcagatgc caagatggg gattcatacg 2160 acccctatga cttcagtga acagaggagg aaatgcctca agtacacact ccaaagacgg 2220 cagactcaca ggagaccaag gaatcccaag gaatcccaag aagtggagt aagtgaatcc aagtacacac aggtacaag 2280
 acccttatga cttcagtgac acagaggagg aaatgcctca aggtgaatcc aggtgaatcc aggtgaatccagg gaatccaga aagtggagtt gagtgaatcc aggttgaagg 2280 cattcaaggt ggccctcttg gatgtgttcc gggaaggctca tgcgcagtca atcggcatga 2340 atcgcctcac agaatccatc aaccgggaca gcgaagagcc cttctctcac gttgagatcc 2400 aggctgctct gagcaagatg caggatgaca atcaggtcat ggtgtctgag ggcatcatct 2460 tcctcatctg aggaggcctc gtctctgaac ttgggttgtg ccgagagagt ttgttctgtg 2520 tttcccaccc tctccctgac ccaagtcttt gcctctactc ccttaacagt gttgaattca 2580 actgaaggcg aaaggtgtgg gtgatgaagc tgagttcagg actcggtgga ccctttggga 2640 atgggtcatg aaagctgcca tggggtgagg aaagaggaga cagtgggaga ggacaatgac 2700 tattgcatct tcattgcaaa agcactggct catctctgag acttctggg gcacaactgg tttcttttt gttttttt tttctccag agcactttgg tctagactag gttgaatca 2700 tattgttttt gtttgttt ttttctccag agcactttgg tctagactag gctttgggtg 2880 gttccaattg gttgaata acttctgagg acgacattga acttcttggg ggcacaactga 2940 acgtagcac agttaaggtg aatatgtat gtatcacaaa acaaacccaa tatccagatg 3000 aatatccgag atgttgaata accttagcca tttcgtacaa acaaacccaa acaaacccaa 3060 acaaactccaa atgtgaata acttagcca tttcgtacaa aaaaaggggg gcccggtaaa 3060 acccggtaaa acctggatgaaccaa acctggggaga acaaaggggg gcccggtaaa 3060 acccggtaaacccaa acctggggagaa acctggatgaaa acaaacccaa accaaacccaa accaaacccaacccaaccaaccaacccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaa
       <210> 366
      <211> 1360
       <212> DNA
       <213> Homo sapiens
<400> 366
```

39740-0001PCT.txt

<211> 1412 <212> DNA <213> Homo sapiens <400> 367 cggggtcgtc cgcaaagcct gagtcctgtc ctttctctct ccccggacag catgagcttc 60 ğccaataaaā agttčağāgt tcatīggaīg tč <210> 368 <211> 1075 <212> DNA <213> Homo sapiens <400> 368 <210> 369 <211> 1127 <212> DNA <213> Homo sapiens <400> 369 cacgggcggg gcggggcctg ggtccaccgg ggttctgagg ggagactgag gtcctgagcc 60 gacagcctca gctcctgcc aggccagacc cggcagacag atgagggccc aggaggcctg 120 gcgggcctgg gggccaccgt gtgggagagg aagccagggg tacctgcctc tgccttccag 180 ggccaccgtt ggcccagct ttgagccgag taggaggag tacctgctc cagcccagag 240 catgttccag atccagagt ttgagccgag tgagcaggaa gactccagct ctgcagagag 300 gggcctgggc cccagcccc caggggacgg gccccaggc tccggcaagc atcatcgcca 360 ggccccaggc ctcctgtggg acgccagtca ccagcaggag cagccaacca gcagcagcca 420 Page 105

```
39740-0001PCT.txt
tcatggaggc gctggggctg tggagatccg gagtcgccac agctcctacc ccgcggggac 480 ggaggacgac gaagggatgg gggaggagcc cagccccttt cggggccgct cgcgctcggc 540 gcccccaac ctctgggcag cacagcgcta tggccgcag ctccggagga tgagtgacga 600 gtttgtggac tcctttaaga agggacttcc tcgcccgaag agcgcgggca cagcaacgca 660 gatgcggcaa agctccagct ggacgcgagt cttccagtcc tggtgggatc ggaacttggg 720 caggggaagc tccgcccct cccagtgacc ttcgcccac atcccgaaac tccaccgtt 780 cccactgcc tgggcagcca tcttgaatat gggcggaagt acttccctca ggcctatgca 840 aaaagaggat ccgtggtc tcctttggag ggagggctga cccagattcc cttccggtgc 900 gtgtgaagcc acggaaggct tggtcccatc ggaagttttg ggttttccgc ccacagccgc 960 cggaagtggc caggtttaac cgttgcgtca ccgggaccg agcccccgcg atgccctcggg 1080 ggccgtgctc actaccaaat gttaataaag cccgcgtctg tgccgcc 1127
 <211> 1890
  <212> DNA
  <213> Homo sapiens
<400> 370
  gacctctcat caaatcttcc cattcactca atatcccata agcatccaaa ctccattaag 1680
 gagagttgtt caggtcactg cacaaatata tctgcaatta ttcatactct gtaacacttg 1740 tattaattgc tgcatatgct aatacttttc taatgctgac tttttaatat gttatcactg 1800 taaaacacag aaaagtgatt aatgaatgat aatttagtcc atttctttg tgaatgtgct 1860 aaataaaaag tgttattaat tgctggttca
 <210> 371
<211> 4946
  <212> DNA
  <213> Homo sapiens
  <400> 371
  agtcagccct gctgccagcc agtgccgggt gctggggact cagggaggcc cgccgggacc 60
 actgcgggac agtgagccga gcagaagctg gaacgcagga gaggaaggag aggggggggt 120 cagggctctc aggagccggg tcctgggcaa ggcgcagccg ttttcaaatt ttcaggaaag 180 cggtcggctc acactcgagc agtaaaaaga tgcctctggg gaggaggccc gtgcagctt 240 ccgggcaatg gtggtggtc ggcctagaga ggcggtagtg gaacgcagac cctggtgggg 300 gaatgacatc aagggaggag acgggcggaa ccccagattt ctgcctgtgg gcgatggaag 360 tgaggttcac tggccagcgg agccggacac agaacgcgca aaacgccgtg taggcctgga 420
 ggagccgaag agcaggcgga cccctccgc ggggggaacag tttccgccgg gagcacaaag 480 caacggaccg gaagtggggg gcggaagtgc agtgggctca gcgccgactg cgcgcctctg 540 cccgcgaaaa ctctgagctg gctgacagct gggggacggccctc gactggagtc 600
                                                                                                                  Page 106
```

39740-0001PCT.txt ggttgagttc ctgagggacc ccggttctgg aaggttcgcc gcggagacaa gtgagcagtc 660

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/07713

		1.01/0805/		
A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12Q 1/68; G01N 33/53				
US CL: 435/6, 7.1 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/6, 7.1				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.	
Y	US 6,316,208 B1 (ROBERTS et al.) 13 November 2	001 (13.11.2001), columns 18-20	and 18-24,32,37,38	
A	43-47.			
Α.	1-17,25-31,33-36,39- 45			
Α	US 6,180,333 B1 (GIORDANO) 30 January 2001 (30.01.2001).		1-45	
Α	US 5,563,035 A (WEIGEL) 08 October 1996 (08.10.1996).			
			,	
	documents are listed in the continuation of Box C.	See patent family annex		
•	pecial categories of cited documents:	date and not in conflict with t	r the international filing date or priority he application but cited to understand the	
	defining the general state of the art which is not considered to be lar relevance	principle or theory underlying "X" document of particular releva	g the invention nce; the claimed invention cannot be	
"E" earlier ap	plication or patent published on or after the international filing date		e considered to involve an inventive step	
	which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"Y" document of particular releva considered to involve an inve	nce; the claimed invention cannot be ntive step when the document is ther such documents, such combination	
"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skil		
	published prior to the international filing date but later than the ate claimed	"&" document member of the sam	e patent family	
Date of the ac	ctual completion of the international search	Date of mailing of the internation	al search report	
10 June 2003	(10.06.2003)	03 JUL	ZUUJ	
Name and ma	ailing address of the ISA/US	Authorized officer	0-1 1 1	
	il Stop PCT, Attn: ISA/US nmissioner for Patents	Authorized officer D. Roberto Gos		
P.O	D. Box 1450		ν	
Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230 Telephone No. 703-308-0196				
1 desimile 110. (103)303-3230				

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US03/07713

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)			
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)			
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet			
 As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 			
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.			

	PCT/US03/07713			
INTERNATIONAL SEARCH REPORT	,			
BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LAC This application contains the following inventions or groups of inventions which are concept under PCT Rule 13.1. In order for all inventions to be searched, the appro	e not so linked as to form a single general inventive			
Group I, claim(s) 1-17, drawn to a method for predicting clinical outcome for a patient diagnosed with cancer.				
Group II, claim(s) 18-24, drawn to a method of predicting the likelihood of the recurrence of cancer following treatment in a cancer patient.				
Group III, claim(s) 25-31, drawn to a method for classifying cancer.				
Group IV, claim(s) 32-40, drawn to a method for predicting the likelihood of long-term survival of a breast cancer patient, and an array for use therein.				
Group V, claim(s) 41 and 44, drawn to a method of predicting the likelihood of long-term survival of a patient diagnosed with invasive breast cancer, and an array for use therein.				
Group VI, claim(s) 42, 43, and 45, drawn to a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor-positive invasive breast cancer, and an array for use therein.				
The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: each of the groups corresponds to a specific relationship between a specific type of cancer and a specific set of genes; thus, there is clearly no special technical feature in common.				
Continuation of B. FIELDS SEARCHED Item 3: USPAT, PGPUB, DERWENT, MEDLINE, BIOSIS search terms: cancer, tumor, prognosis, expression, p27, p53BP2, etc.				